0001683168-24-00557210-Q Xenetic Biosciences, Inc. 2024081320240813163241163241163241 0 0001683168-24-005572 10-Q 49 20240630 20240813 20240813 Xenetic Biosciences, Inc. 0001534525 2834 452952962 NV 1231 10-Q 34 001-37937 241202224 945 CONCORD ST. FRAMINGHAM MA 01701 781-778-7720 945 CONCORD ST. FRAMINGHAM MA 01701 General Sales & Leasing, Inc. 20130227 GENERAL AIRCRAFT INC. 20111108 10-Q 1 xenetic_i10q-063024.htm QUARTERLY REPORT XENETIC BIOSCIENCES, INC. Form 10-Q false --12-31 2024 Q2 0001534525 726404 1237221 651005 1256849 0001534525 2024-01-01 2024-06-30 0001534525 2024-08-09 0001534525 2024-06-30 0001534525 2023-12-31 0001534525 us-gaap:SeriesBPreferredStockMember 2024-06-30 0001534525 us-gaap:SeriesBPreferredStockMember 2023-12-31 0001534525 2024-04-01 2024-06-30 0001534525 2023-04-01 2023-06-30 0001534525 2023-01-01 2023-06-30 0001534525 us-gaap:PreferredStockMember 2024-03-31 0001534525 us-gaap:CommonStockMember 2024-03-31 0001534525 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001534525 us-gaap:RetainedEarningsMember 2024-03-31 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001534525 us-gaap:TreasuryStockCommonMember 2024-03-31 0001534525 2024-03-31 0001534525 us-gaap:PreferredStockMember 2023-12-31 0001534525 us-gaap:CommonStockMember 2023-12-31 0001534525 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001534525 us-gaap:RetainedEarningsMember 2023-12-31 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001534525 us-gaap:TreasuryStockCommonMember 2023-12-31 0001534525 us-gaap:PreferredStockMember 2023-03-31 0001534525 us-gaap:CommonStockMember 2023-03-31 0001534525 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001534525 us-gaap:RetainedEarningsMember 2023-03-31 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001534525 us-gaap:TreasuryStockCommonMember 2023-03-31 0001534525 2023-03-31 0001534525 us-gaap:PreferredStockMember 2022-12-31 0001534525 us-gaap:CommonStockMember 2022-12-31 0001534525 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001534525 us-gaap:RetainedEarningsMember 2022-12-31 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001534525 us-gaap:TreasuryStockCommonMember 2022-12-31 0001534525 2022-12-31 0001534525 us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001534525 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001534525 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001534525 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0001534525 us-gaap:PreferredStockMember 2024-01-01 2024-06-30 0001534525 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001534525 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-06-30 0001534525 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-06-30 0001534525 us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001534525 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001534525 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001534525 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0001534525 us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001534525 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001534525 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001534525 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-06-30 0001534525 us-gaap:PreferredStockMember 2024-06-30 0001534525 us-gaap:CommonStockMember 2024-06-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001534525 us-gaap:RetainedEarningsMember 2024-06-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001534525 us-gaap:TreasuryStockCommonMember 2024-06-30 0001534525 us-gaap:PreferredStockMember 2023-06-30 0001534525 us-gaap:CommonStockMember 2023-06-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001534525 us-gaap:RetainedEarningsMember 2023-06-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001534525 us-gaap:TreasuryStockCommonMember 2023-06-30 0001534525 2023-06-30 0001534525 2023-05-14 2023-05-15 0001534525 XBIO:CatalentPharmaSolutionsMember 2024-01-01 2024-06-30 0001534525 XBIO:CatalentPharmaSolutionsMember 2024-06-30 0001534525 XBIO:CatalentPharmaSolutionsMember 2023-12-31 0001534525 XBIO:ScrippsResearchMember 2023-03-16 2024-06-30 0001534525 XBIO:ScrippsResearchMember 2024-06-30 0001534525 XBIO:ScrippsResearchMember 2023-12-31 0001534525 XBIO:UniversityOfVirginiaMember 2024-01-01 2024-06-30 0001534525 XBIO:UniversityOfVirginiaMember 2023-01-01 2023-12-31 0001534525 XBIO:CollaborativeAgreementsMember 2023-01-01 2023-06-30 0001534525 XBIO:CollaborativeAgreementsMember 2023-04-01 2023-06-30 0001534525 XBIO:CollaborativeAgreementsMember 2024-01-01 2024-06-30 0001534525 XBIO:CollaborativeAgreementsMember 2024-04-01 2024-06-30 0001534525 XBIO:SeparationAgreementsMember 2024-01-01 2024-06-30 0001534525 XBIO:SeparationAgreementsMember 2024-06-30 0001534525 us-gaap:CommonStockMember 2023-05-10 2023-05-11 0001534525 XBIO:SeriesAWarrantsMember 2023-12-31 0001534525 XBIO:SeriesAWarrantsMember 2024-06-30 0001534525 XBIO:SeriesAWarrantsMember 2024-04-01 2024-06-30 0001534525 XBIO:SeriesAWarrantsMember 2024-01-01 2024-06-30 0001534525 XBIO:SeriesAWarrantsMember 2023-01-01 2023-06-30 0001534525 XBIO:SeriesAWarrantsMember 2023-04-01 2023-06-30 0001534525 XBIO:PubliclyTradedWarrantsMember 2024-06-30 0001534525 XBIO:PubliclyTradedWarrantsMember 2023-12-31 0001534525 XBIO:PubliclyTradedWarrantsMember 2024-01-01 2024-06-30 0001534525 XBIO:PubliclyTradedWarrantsMember 2024-04-01 2024-06-30 0001534525 XBIO:PubliclyTradedWarrantsMember 2023-04-01 2023-06-30 0001534525 XBIO:PubliclyTradedWarrantsMember 2023-01-01 2023-06-30 0001534525 XBIO:OtherWarrantsMember 2023-12-31 0001534525 XBIO:OtherWarrantsMember 2024-06-30 0001534525 XBIO:OtherWarrantsMember 2024-04-01 2024-06-30 0001534525 XBIO:OtherWarrantsMember 2024-01-01 2024-06-30 0001534525 XBIO:OtherWarrantsMember 2023-01-01 2023-06-30 0001534525 XBIO:OtherWarrantsMember 2023-04-01 2023-06-30 0001534525 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001534525 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001534525 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001534525 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001534525 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001534525 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001534525 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001534525 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001534525 us-gaap:EmployeeStockOptionMember 2024-04-01 2024-06-30 0001534525 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001534525 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001534525 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001534525 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001534525 us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0001534525 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0001534525 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001534525 XBIO:NonEmployeeStockOptionsMember 2023-01-01 2023-06-30 0001534525 XBIO:NonEmployeeStockOptionsMember 2023-04-01 2023-06-30 0001534525 XBIO:NonEmployeeStockOptionsMember 2024-01-01 2024-06-30 0001534525 XBIO:NonEmployeeStockOptionsMember 2024-04-01 2024-06-30 0001534525 XBIO:PharmsynthezMember XBIO:CoDevelopmentAgreementMember 2019-10-01 2019-12-31 0001534525 XBIO:PharmsynthezMember XBIO:CoDevelopmentAgreementMember 2023-04-01 2023-06-30 0001534525 XBIO:PharmsynthezMember XBIO:CoDevelopmentAgreementMember XBIO:InterestIncomeOnlyMember 2023-01-01 2023-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure
Table of Contents Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Â FORM 10-Q Â â˜'Â Â Â QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period ended June 30, 2024 Â or Â â˜Â Â Â TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the transition period from Â to Â Commission File Number: 001-37937 Â XENETIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Â Â Nevada (State or other jurisdiction of incorporation or organization) 45-2952962 (IRS Employer Identification No.) Â 945 Concord Street Framingham, Massachusetts 01701 (Address of principal executive offices and zip code) Â 781-778-7720 (Registrantâ€™s telephone number, including area code) Â Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share XBIO The Nasdaq Stock Market Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:Â Â Â Â Yes â˜'Â Â Â Â No â˜ Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files):Â Â Â Â Yes â˜'Â Â Â Â No â˜ Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting companyâ€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act: Â Large accelerated filer â˜ Â Accelerated filer â˜ Non-accelerated filer â˜' Â Smaller reporting company â˜' Â Â Emerging growth company â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):Â Â Â Â Yes â˜Â Â Â Â No â˜' Â As of August 9, 2024, the number of outstanding shares of the registrantâ€™s common stock was 1,542,139. Â Â Â Â Â Â Â XENETIC BIOSCIENCES, INC. FORM 10-Q QUARTERLY PERIOD ENDED JUNE 30, 2024 Â PART I FINANCIAL INFORMATION Â Â Â Â Item 1 Condensed Consolidated Financial Statements: 3 Â Â Â Condensed Consolidated Balance Sheets as of June 30, 2024 (Unaudited) and December 31, 2023 3 Â Â Â Condensed Consolidated Statements of Operations (Unaudited) for the three and six months ended June 30, 2024 and 2023 4 Â Â Â Condensed Consolidated Statements of Changes in Stockholdersâ€™ Equity (Unaudited) for the three and six months ended June 30, 2024 and 2023 5 Â Â Â Condensed Consolidated Statements of Cash Flows (Unaudited) for the six months ended June 30, 2024 and 2023 7 Â Â Â Notes to Condensed Consolidated Financial Statements (Unaudited) 8 Â Â Â Item 2 Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 14 Â Â Item 3 Quantitative and Qualitative Disclosures About Market Risk 21 Â Â Item 4 Controls and Procedures 21 Â Â Â PART II OTHER INFORMATION Â Â Â Â Item 1 Legal Proceedings 22 Â Â Item 1A Risk Factors 22 Â Â Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 22 Â Â Â Item 3 Defaults Upon Senior Securities 22 Â Â Item 4 Mine Safety Disclosures 22 Â Â Item 5 Other Information 22 Â Â Item 6 Exhibits 23 Â Â Signatures 24 Â Â Â Â 2Â Â Â PART I â€" FINANCIAL INFORMATION Â ITEM 1 â€" FINANCIAL STATEMENTS Â XENETIC BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS Â Â Â Â June 30, 2024Â Â December 31, 2023Â Â Â (Unaudited)Â Â Â Â Â Â Â Â Â Â Â ASSETSÂ Â Â Â Â Â Â Â Current assets:Â Â Â Â Â Â Â Â CashÂ $7,298,597Â Â $8,983,046Â Prepaid expenses, receivables and otherÂ Â 716,381Â Â Â 603,828Â Total current assetsÂ Â 8,014,978Â Â Â 9,586,874Â Â Â Â Â Â Â Â Â Â Other assetsÂ Â 1,018,352Â Â Â 1,018,352Â Total assetsÂ $9,033,330Â Â $10,605,226Â Â Â Â Â Â Â Â Â Â LIABILITIES AND STOCKHOLDERS' EQUITYÂ Â Â Â Â Â Â Â Current liabilities:Â Â Â Â Â Â Â Â Accounts payableÂ $283,586Â Â $240,832Â Accrued expenses and other current liabilitiesÂ Â 1,304,016Â Â Â 568,753Â Total current liabilitiesÂ Â 1,587,602Â Â Â 809,585Â Â Â Â Â Â Â Â Â Â Total liabilitiesÂ Â 1,587,602Â Â Â 809,585Â Â Â Â Â Â Â Â Â Â Commitments and contingenciesÂ Â â€"Â Â Â â€"Â Stockholders' equity:Â Â Â Â Â Â Â Â Preferred stock, 10,000,000 shares authorizedÂ Â â€"Â Â â€"Â Series B, $0.001 par value: 1,804,394 shares issued and outstanding as of June 30, 2024 and December 31, 2023Â Â 1,804Â Â Â 1,804Â Common stock, $0.001 par value; 10,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 1,543,802 and 1,543,385 shares issued as of June 30, 2024 and December 31, 2023, respectively; 1,541,101 and 1,540,684 shares outstanding as of June 30, 2024 and December 31, 2023, respectivelyÂ Â 1,544Â Â Â 1,544Â Additional paid in capitalÂ Â 208,173,105Â Â Â 208,053,935Â Accumulated deficitÂ Â (195,703,279)Â Â (193,234,196) Accumulated other comprehensive incomeÂ Â 253,734Â Â Â 253,734Â Treasury stockÂ Â (5,281,180)Â Â (5,281,180) Total stockholders' equityÂ Â 7,445,728Â Â Â 9,795,641Â Total liabilities and stockholders' equityÂ $9,033,330Â Â $10,605,226Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â Â Â Â 3Â Â Â XENETIC BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â THREE MONTHS ENDED JUNE 30,Â Â SIX MONTHS ENDED JUNE 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Revenue:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Royalty revenueÂ $726,404Â Â $651,005Â Â $1,237,221Â Â $1,256,849Â Total revenueÂ Â 726,404Â Â Â 651,005Â Â Â 1,237,221Â Â Â 1,256,849Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating costs and expenses:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and developmentÂ Â (933,771)Â Â (903,243)Â Â (1,878,092)Â Â (1,498,519) General and administrativeÂ Â (1,130,029)Â Â (945,950)Â Â (1,964,939)Â Â (1,871,693) Total operating costs and expensesÂ Â (2,063,800)Â Â (1,849,193)Â Â (3,843,031)Â Â (3,370,212) Loss from operationsÂ Â (1,337,396)Â Â (1,198,188)Â Â (2,605,810)Â Â (2,113,363) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other income (expense):Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other (expense) incomeÂ Â (21)Â Â 21,122Â Â Â 31Â Â Â 25,642Â Interest income, netÂ Â 63,447Â Â Â 126,103Â Â Â 136,696Â Â Â 180,204Â Total other incomeÂ Â 63,426Â Â Â 147,225Â Â Â 136,727Â Â Â 205,846Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net lossÂ $(1,273,970)Â $(1,050,963)Â $(2,469,083)Â $(1,907,517) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Basic and diluted net loss per shareÂ $(0.83)Â $(0.69)Â $(1.60)Â $(1.25) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted-average shares of common stock outstanding, basic and dilutedÂ Â 1,540,799Â Â Â 1,524,717Â Â Â 1,540,741Â Â Â 1,520,710Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â Â Â Â Â 4Â Â XENETIC BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) Â Â THREE MONTHS ENDED JUNE 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred StockÂ Common StockÂ Â Â Â Â Â Â Â AccumulatedÂ Â Â Â Â Â Â Â Â Number of SharesÂ Par Value ($0.001)Â Â Number of SharesÂ Â Par Value ($0.001)Â Â Additional Paid in CapitalÂ Â Accumulated DeficitÂ Â Other Comprehensive IncomeÂ Â Treasury StockÂ Â Total Stockholders' EquityÂ Balance as of April 1, 2024Â Â 1,804,394Â Â $1,804Â Â Â 1,543,385Â Â $1,544Â Â $208,131,009Â Â $(194,429,309)Â $253,734Â Â $(5,281,180)Â $8,677,602Â Issuance of common stock in connection with restricted stockÂ Â â€"Â Â Â â€"Â Â Â 417Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Share-based expenseÂ Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â 42,096Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â 42,096Â Net lossÂ Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â (1,273,970)Â Â â€"Â Â Â â€"Â Â Â (1,273,970) Balance as of June 30, 2024Â Â 1,804,394Â Â $1,804Â Â Â 1,543,802Â Â $1,544Â Â $208,173,105Â Â $(195,703,279)Â $253,734Â Â $(5,281,180)Â $7,445,728Â Â Â SIX MONTHS ENDED JUNE 30, 2024 Â Â Â Preferred StockÂ Common StockÂ Â Â Â Â Â Â Â AccumulatedÂ Â Â Â Â Â Â Â Â Number of SharesÂ Par Value ($0.001)Â Â Number of SharesÂ Â Par Value ($0.001)Â Â Additional Paid in CapitalÂ Â Accumulated DeficitÂ Â Other Comprehensive IncomeÂ Â Treasury StockÂ Â Total Stockholders' EquityÂ Balance as of January 1, 2024Â Â 1,804,394Â Â $1,804Â Â Â 1,543,385Â Â $1,544Â Â $208,053,935Â Â $(193,234,196)Â $253,734Â Â $(5,281,180)Â $9,795,641Â Issuance of common stock in connection with restricted stockÂ Â â€"Â Â Â â€"Â Â Â 417Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Share-based expenseÂ Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â 119,170Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â 119,170Â Net lossÂ Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â (2,469,083)Â Â â€"Â Â Â â€"Â Â Â (2,469,083) Balance as of June 30, 2024Â Â 1,804,394Â Â $1,804Â Â Â 1,543,802Â Â $1,544Â Â $208,173,105Â Â $(195,703,279)Â $253,734Â Â $(5,281,180)Â $7,445,728Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â Â Â Â 5Â Â Â XENETIC BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) Â Â THREE MONTHS ENDED JUNE 30, 2023 Â Â Â Preferred StockÂ Common StockÂ Â Â Â Â Â Â Â AccumulatedÂ Â Â Â Â Â Â Â Â Number of SharesÂ Par Value ($0.001)Â Â Number of SharesÂ Â Par Value ($0.001)Â Â Additional Paid in CapitalÂ Â Accumulated DeficitÂ Â Other Comprehensive IncomeÂ Â Treasury StockÂ Â Total Stockholdersâ€™ EquityÂ Balance as of April 1, 2023Â Â 2,774,394Â Â $2,774Â Â Â 1,519,360Â Â $1,520Â Â $207,838,756Â Â $(189,956,172)Â $253,734Â Â $(5,281,180)Â $12,859,432Â Issuance of common stock to adjust for reverse split roundingÂ Â â€"Â Â Â â€"Â Â Â 15,941Â Â Â 16Â Â Â (16)Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Share-based expenseÂ Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â 69,389Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â 69,389Â Net lossÂ Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â (1,050,963)Â Â â€"Â Â Â â€"Â Â Â (1,050,963) Balance as of June 30, 2023Â Â 2,774,394Â Â $2,774Â Â Â 1,535,301Â Â $1,536Â Â $207,908,129Â Â $(191,007,135)Â $253,734Â Â $(5,281,180)Â $11,877,858Â Â Â SIX MONTHS ENDED JUNE 30, 2023 Â Â Â Preferred StockÂ Common StockÂ Â Â Â Â Â Â Â AccumulatedÂ Â Â Â Â Â Â Â Â Number of SharesÂ Par Value ($0.001)Â Â Number of SharesÂ Â Par Value ($0.001)Â Â Additional Paid in CapitalÂ Â Accumulated DeficitÂ Â Other Comprehensive IncomeÂ Â Treasury StockÂ Â Total Stockholders' EquityÂ Balance

as of January 1, 2023Â Â 2,774,394Â Â $2,774Â Â Â 1,519,360Â Â $1,520Â Â $207,769,904Â Â $(189,099,618)Â $253,734Â Â $(5,281,180)Â $13,647,134Â Issuance of common stock to adjust for reverse split roundingÂ Â â€"Â Â Â â€"Â Â Â 15,941Â Â Â 16Â Â Â (16)Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Share-based expenseÂ Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â 138,241Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â 138,241Â Net lossÂ Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â (1,907,517)Â Â â€"Â Â Â â€"Â Â Â (1,907,517) Balance as of June 30, 2023Â Â 2,774,394Â Â $2,774Â Â Â 1,535,301Â Â $1,536Â Â $207,908,129Â Â $(191,007,135)Â $253,734Â Â $(5,281,180)Â $11,877,858Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â Â Â Â 6Â Â Â XENETIC BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Â Â Â Â Â Â Â Â Â Â Â Six Months Ended June 30,Â Â Â 2024Â Â 2023Â Â Â Â Â Â Â Â CASH FLOWS FROM OPERATING ACTIVITIES:Â Â Â Â Â Â Â Â Net lossÂ $(2,469,083)Â $(1,907,517) Adjustments to reconcile net loss to net cash used in operating activities:Â Â Â Â Â Â Â Â Share-based expenseÂ Â 119,170Â Â Â 138,241Â Changes in operating assets and liabilities:Â Â Â Â Â Â Â Â Prepaid expenses, receivables and otherÂ Â (112,553)Â Â (762,941) Other assetsÂ Â â€"Â Â Â 362,500Â Accounts payable, accrued expenses and other liabilitiesÂ Â 778,017Â Â Â (201,841) Net cash used in operating activitiesÂ Â (1,684,449)Â Â (2,371,558) Â Â Â Â Â Â Â Â Â Net change in cashÂ Â (1,684,449)Â Â (2,371,558) Cash at beginning of periodÂ Â 8,983,046Â Â Â 13,097,265Â Â Â Â Â Â Â Â Â Â Cash at end of periodÂ $7,298,597Â Â $10,725,707Â Â Â Â Â Â Â Â Â Â SUPPLEMENTAL CASH FLOW INFORMATION:Â Â Â Â Â Â Â Â Cash paid for interestÂ $â€"Â Â $â€"Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â Â Â Â Â Â Â 7Â Â Â XENETIC BIOSCIENCES, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Â Â 1. The Company Â Background Â Xenetic Biosciences, Inc. (â€œXeneticâ€ or the â€œCompanyâ€), incorporated in the state of Nevada and based in Framingham, Massachusetts, is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Companyâ€™s proprietary Deoxyribonuclease (â€œDNaseâ€) platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (â€œNETsâ€), which have been implicated in cancer progression and resistance to cancer treatments. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Additionally, Xenetic has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXenÂ®, and receives royalty payments under an exclusive license arrangement in the field of blood coagulation disorders. Â As used in this Quarterly Report on Form 10-Q (â€œQuarterly Reportâ€), unless otherwise indicated, all references herein to â€œXenetic,â€ the â€œCompany,â€ â€œweâ€ or â€œusâ€ refer to Xenetic Biosciences, Inc. and its wholly-owned subsidiaries. Â The Company, directly or indirectly, through its wholly-owned subsidiaries, Hesperix S.A. (â€œHesperixâ€) and Xenetic Biosciences (U.K.) Limited (â€œXenetic UKâ€), and the wholly-owned subsidiaries of Xenetic UK, Lipoxen Technologies Limited (â€œLipoxenâ€), Xenetic Bioscience, Incorporated and SymbioTec, GmbH (â€œSymbioTecâ€), own various United States (â€œU.S.â€) federal trademark registrations and applications along with unregistered trademarks and service marks, including but not limited to XCARTâ„¢, OncoHistâ„¢, PolyXen, ErepoXenâ„¢, and ImuXenâ„¢, which may be used throughout this Quarterly Report. All other company and product names may be trademarks of the respective companies with which they are associated. Â Going Concern and Managementâ€™s Plan Â Management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Companyâ€™s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company has incurred substantial losses since its inception and expects to continue to incur operating losses in the near-term. The Company believes that its existing resources will be adequate to fund the Companyâ€™s operations for a period of at least twelve months from the date of the issuance of these financial statements. However, the Company anticipates it will need additional capital in the long-term to pursue its business initiatives. While the Company believes it has access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations, related party funding, or other means to continue as a going concern, the terms, timing and extent of any future financing will depend upon several factors, including the achievement of progress in its product development programs, its ability to identify and enter into licensing or other strategic arrangements, its continued listing on the Nasdaq Stock Market (â€œNasdaqâ€), and factors related to financial, economic, geo-political, industry and market conditions, many of which are beyond its control. The capital markets for the biotech industry can be highly volatile, which make the terms, timing and extent of any future financing uncertain. Â Â Â Â 8Â Â Â 2. Risks and Uncertainties Â Impact of Global Conflicts on Operations Â The short and long-term implications of Russiaâ€™s invasion of Ukraine and conflict in the Middle East are difficult to predict at this time. The imposition of current and future sanctions and counter sanctions may have an adverse effect on the economic markets generally and could impact our business, financial condition, and results of operations. Â 3. Summary of Significant Accounting Policies Â Preparation of Interim Financial Statements Â The accompanying condensed consolidated interim financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (â€œSECâ€) and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results for the full year. The condensed consolidated financial statements contained herein should be read in conjunction with the consolidated financial statements and notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 21, 2024, and amended on April 26, 2024. Â On May 15, 2023, the Company effected a reduction, on a 1-for-10 basis, in its authorized common stock, par value $0.001, along with a corresponding and proportional decrease in the number of shares issued and outstanding (the â€œReverse Stock Splitâ€). On the effective date of the Reverse Stock Split, (i) every 10 shares of common stock were reduced to one share of common stock, with any fractional amounts rounded up to one share; (ii) the number of shares of common stock into which each outstanding warrant, restricted stock unit (â€œRSUâ€), or option to purchase common stock was convertible into was proportionately reduced on the same basis as the common stock; (iii) the exercise price of each outstanding warrant or option to purchase common stock was proportionately increased on a 1-to-10 basis; and (iv) the number of shares of common stock into which each share of preferred stock was convertible into was proportionately reduced on the same basis as the common stock. Unless otherwise indicated, all of the share numbers, share prices, and exercise prices have been adjusted in this Quarterly Report, on a retroactive basis, to reflect this 1-for-10 Reverse Stock Split. Â Principles of Consolidation Â The condensed consolidated financial statements of the Company include the accounts of Hesperix, Xenetic UK and Xenetic UKâ€™s wholly owned subsidiaries: Lipoxen, Xenetic Bioscience, Incorporated, and SymbioTec. Certain of the Companyâ€™s subsidiaries require guarantees of support from Xenetic. While all intercompany balances and transactions have been eliminated in consolidation, the Company has $0.2 million of cash collateralizing these guarantees. Â Basic and Diluted Net Loss per Share Â The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted-average number of shares of the Companyâ€™s common stock outstanding during the period. The Company computes diluted net loss per share after giving consideration to the dilutive effect of stock options that are outstanding during the period, except where such non-participating securities would be anti-dilutive. Â For the three and six months ended June 30, 2024 and 2023, basic and diluted net loss per share are the same in each respective period due to the Companyâ€™s net loss position. Potentially dilutive, non-participating securities have not been included in the calculations of diluted net loss per share, as their inclusion would be anti-dilutive. Â Â Â Â 9Â Â Â 4. Significant Strategic Collaborations Â Takeda Pharmaceutical Co. Ltd. (together with its wholly-owned subsidiaries, â€œTakedaâ€) Â In October 2017, the Company granted to Takeda the right to grant a non-exclusive sublicense to certain patents related to the Companyâ€™s PolyXen technology that were previously exclusively licensed to Takeda in connection with products related to the treatment of blood and bleeding disorders. Royalty payments of approximately $0.7 million and $1.2 million were recorded as revenue by the Company during the three and six months ended June 30, 2024, respectively, and approximately $0.7 million and $1.3 million were recorded as revenue by the Company during the three and six months ended June 30, 2023, respectively. These payments are based on single digit royalties on net sales of certain covered products. The Companyâ€™s policy is to recognize royalty payments as revenue when they are reliably measurable, which is upon receipt of reports from Takeda. The Company receives these reports in the quarter subsequent to the actual sublicensee sales. At the time the revenue was received, there were no remaining performance obligations and all other revenue recognition criteria were met. Â Belgian Volition SARL Limited (â€œVolitionâ€) Collaboration Â On August 2, 2022, the Company announced a research and development collaboration with Volition to develop NETs-targeted adoptive cell therapies for the treatment of cancer. The collaboration is an early exploratory program to evaluate the potential combination of Volitionâ€™s Nu.QÂ® technology Test and the Companyâ€™s DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting multiple types of solid cancers. Under the terms of the collaboration agreement, Volition will fund a research program and the two parties will share proceeds from commercialization or licensing of any products arising from the collaboration. To date, Volition has funded $26,000 under this agreement. Â Catalent Pharma Solutions LLC (â€œCatalentâ€) Â On June 30, 2022, the Company entered into a Statement of Work (the â€œSOWâ€) with Catalent to outline the general scope of work, timeline, and pricing pursuant to which Catalent will provide certain services to the Company to perform cGMP manufacturing of the Companyâ€™s recombinant protein, Human DNase I. The parties agreed to enter into a Master Services Agreement that will contain terms and conditions to govern the project contemplated by the SOW and that will supersede the addendum to the SOW containing Catalent's standard terms and conditions. The Company has paid Catalent approximately $2.5 million through June 30, 2024, of which approximately $28,000 and $0.1 million has been recognized as an advance payment and is included in prepaid expenses, receivables and other current assets as of June 30, 2024 and December 31, 2023, respectively, and approximately $49,000 has been recognized as a liability and is included in accrued expenses and other current liabilities as of June 30, 2024. There was no accrual as of December 31, 2023. In addition, approximately $0.3 million has been recognized within other assets as of both June 30, 2024 and December 31, 2023. Â Scripps Research Institute (â€œScripps Researchâ€) Â On March 17, 2023, the Company and Scripps Research entered into a Research Funding and Option Agreement (the â€œAgreementâ€), pursuant to which the Company has agreed to provide Scripps Research an aggregate of up to $0.9 million to fund research relating to advancing the pre-clinical development of the Companyâ€™s DNase oncology platform technology. Under the Agreement, the Company has the option to acquire a worldwide exclusive license to Scripps Researchâ€™s rights in the Technology or Patent Rights (as defined in the Agreement), as well as a non-exclusive, royalty-free, non-transferrable license to make and use TSRI Technology (as defined in the Agreement) solely for the Companyâ€™s internal research purposes during the performance of the research program contemplated by the Agreement. During the second quarter of 2024, the Company amended the Agreement to extend the term to October 31, 2024 with no additional funding required. The Company has paid Scripps Research approximately $0.9 million under the Agreement through June 30, 2024, of which approximately $0.1 million and $0.4 million has been recognized as an advance payment and is included in prepaid expenses, receivables and other current assets as of June 30, 2024 and December 31, 2023, respectively. Â Â Â Â 10Â Â Â University of Virginia (â€œUVAâ€) Â On December 21, 2023, the Company entered into a Research Funding and Material Transfer Agreement with UVA (the â€œUVA Agreementâ€) to advance the development of our systemic DNase program. Under the terms of the UVA Agreement, in addition to advancing our existing intellectual property, we have an option to acquire an exclusive license to any new intellectual property arising from the DNase research program. Allan Tsung, MD, a member of the Companyâ€™s Scientific Advisory Board and Chair of the Department of Surgery at the UVA School of Medicine, will oversee the research conducted under the UVA Agreement. The Company has paid UVA approximately $0.2 million under the UVA Agreement through June 30, 2024, which was expensed during the six months ended June 30, 2024. There were no amounts incurred as of December 31, 2023. Â Other Agreements Â The Company has also entered into various research, development, license and supply agreements with Serum Institute of India (â€œSerum Instituteâ€), PJSC Pharmsynthez (â€œPharmsynthezâ€) and SynBio LLC (â€œSynBioâ€), a wholly owned subsidiary of Pharmsynthez. The Company and its collaborative partners continue to engage in research and development activities with no resultant commercial products through June 30, 2024. No amounts were recognized as revenue related to the Serum Institute, Pharmsynthez or SynBio agreements during the three and six months ended June 30, 2024 and 2023, respectively. Â 5. Accrued Expenses and Other Current Liabilities Â On June 19, 2024, the Company entered into a confidential separation agreement and general release with each of Jeffrey F. Eisenberg, the Companyâ€™s former Chief Executive Officer (the â€œEisenberg Separation Agreementâ€), and Curtis Lockshin, the Companyâ€™s former Chief Scientific Officer (the â€œLockshin Separation Agreementâ€ and together, the â€œSeparation Agreementsâ€) pursuant to which Messrs. Eisenberg and Lockshin were each eligible for certain severance payments and benefits consistent with the terms of their existing employment agreements as described under â€œEmployment Agreements with our Named Executive Officersâ€ in the Amendment No. 1 to Annual Report on Form 10-K/A filed by the Company with the Securities and Exchange Commission on April 26, 2024. In addition, the Eisenberg Separation Agreement provides for accelerated vesting of all of the unvested stock options held by Mr. Eisenberg as of May 16, 2024. As of June 30, 2024, the Company expensed approximately $0.8 million of accrued payroll and benefits related to the Separation Agreements. In addition, the Company recorded approximately $13,000 of share-based expense for the accelerated vesting of unvested stock options. As of June 30, 2024, approximately $0.8 million was accrued within accrued expenses and other current liabilities related to these obligations. Â 6. Fair Value Measurements Â Accounting Standards Codification Topic 820, Fair Value Measurement, defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. As of June 30, 2024 and December 31, 2023, the carrying amounts of the Companyâ€™s financial instruments approximates fair value due to their short maturities. There were no financial instruments classified as Level 3 in the fair value hierarchy during the three and six months ended June 30, 2024 and 2023. Â Â Â Â 11Â Â Â 7. Stockholdersâ€™ Equity Â Common Stock Â Each share of the Companyâ€™s common stock entitles the holder to one vote on all matters submitted to a vote of the Companyâ€™s stockholders. Common stockholders are entitled to dividends when and if declared by the Board of Directors. In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Company, the holders of common stock are entitled to share ratably in the assets of the Company available for distribution. Â On May 11, 2023, the Company filed a Certificate of Change to the Companyâ€™s Articles of Incorporation with the Secretary of State of Nevada to effect the Reverse Stock Split. The Reverse Stock Split was effective at 12:01 a.m., Eastern Time, on May 15, 2023. No fractional shares were issued as a result of the Reverse Stock Split and any remaining share fractions were rounded up to the nearest whole share, resulting in 15,941 new shares of common stock being issued to existing holders of the Companyâ€™s common stock. Â Warrants Â The Company has warrants to purchase approximately 462,963 shares of the Companyâ€™s common stock (the â€œSeries A Warrantsâ€) outstanding as of both June 30, 2024 and December 31, 2023. The Series A Warrants are immediately exercisable at a price of $33.00 per share of common stock and expire on February 23, 2025. No Series A Warrants were exercised or forfeited during the three and six months ended June 30, 2024 and 2023. Â In addition, the Company had publicly traded warrants to purchase approximately 2,100 shares of common stock outstanding as of both June 30, 2024 and December 31, 2023. These warrants had an exercise price of $130.00 per share of common stock and expired on July 19, 2024. The warrants ceased trading on Nasdaq under the symbol â€œXBIOWâ€ upon expiration. The warrants also provided that if the weighted-average price of common stock on any trading day on or after 30 days after issuance is lower than the then-applicable exercise price per share, each warrant may be exercised, at the option of the holder, on a cashless basis for one share of common stock. None of these warrants were exercised or forfeited during the three and six months ended June 30, 2024 and 2023. Â The Company also has warrants to purchase approximately 800 shares of the Companyâ€™s common stock outstanding as of both June 30, 2024 and December 31, 2023. These warrants have an exercise price of $29.09 per share of common stock and expire on July 3, 2026. None of these warrants were exercised or forfeited during the three and six months ended June 30, 2024 and 2023. Â 8. Share-Based Expense Â Total share-based expense related to stock options and RSUâ€™s was approximately $42,000 and $0.1 million for the three months ended June 30, 2024 and 2023, respectively, and approximately $0.1 million and $0.1 million for each of the six months ended June 30, 2024 and 2023. Â Share-based expense is classified in the condensed consolidated statements of operations as follows:Â Schedule of share-based compensation expenseÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Three Months Ended June 30,Â Â Six Months Ended June 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Research and development expensesÂ $(3,804)Â $13,778Â Â $11,433Â Â $27,466Â General and administrative expensesÂ Â 45,900Â Â Â 55,611Â Â Â 107,737Â Â Â 110,775Â Â Â $42,096Â Â $69,389Â Â $119,170Â Â $138,241Â Â Â Â Â 12Â Â Â Employee Stock Options and RSUâ€™s Â During the three and six months ended June 30, 2024, 20,000 stock options to purchase shares of common stock were granted by the Company. No stock option awards to purchase shares of common stock were granted during the three and six months ended June 30, 2023. No RSUs were granted during each of the three and six months ended June 30, 2024 and 2023. The Company recognized a total of approximately $42,000 and $0.1 million of share-based expense related to employee stock options during the three months ended June 30, 2024 and 2023, respectively, and $0.1 million during each of the six months ended June 30, 2024 and 2023, respectively. The Company issued 417 shares of common stock during the three and six months ended June 30, 2024 related to RSUâ€™s. No employee stock options were exercised during the three and six months ended June 30, 2024 and 2023. During the three and six months ended June 30, 2024 stock options to purchase 11,667 shares of common stock were forfeited. No employee stock options expired during the three and six months ended June 30, 2023. Â Non-Employee Stock Options Â There were no non-employee stock options granted or exercised during the three and six months ended June 30, 2024 and 2023, respectively. No non-employee stock option grants expired during the three and six months ended June 30, 2024. During the six months ended June 30, 2023, non-employee stock option grants to purchase approximately 100 shares of common stock expired. The Company did not recognize any expense related to non-employee stock options during the three and six months ended June 30, 2024 and 2023, respectively. Â 9. Income Taxes Â During the three and six months ended June 30, 2024 and 2023, there was no provision for income taxes as the Company incurred losses during both periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company records a valuation allowance against its deferred tax assets as the Company believes it is more likely than not the deferred tax assets will not be realized. The valuation allowance against deferred tax assets was approximately $40.4 million and $39.7 million as of June 30, 2024 and December 31, 2023, respectively. Â As of June 30, 2024 and DecemberÂ 31, 2023, the Company did not record any unrecognized tax positions. Â 10. Related Party Transactions Â The Company has entered into various research, development, license and supply agreements with Serum Institute and Pharmsynthez, each a related party whose relationship has not materially changed from that disclosed in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 21, 2024, as amended on April 26, 2024. Â During the fourth quarter of 2019, the Company entered into a loan agreement with Pharmsynthez (the â€œPharmsynthez Loanâ€), pursuant to which the Company advanced Pharmsynthez an aggregate principal amount of up to $500,000 to be used for the development of a specific product under the Companyâ€™s Co-Development Agreement with Pharmsynthez. The Pharmsynthez Loan had an initial term of 15-months and accrued interest at a rate of 10% per annum. The Pharmsynthez Loan was guaranteed by all of the operating subsidiaries of Pharmsynthez, including SynBio and AS Kevelt, and was secured by all of the common and preferred stock of the Company owned by Pharmsynthez and SynBio. Â Pharmsynthez paid all obligations due under the Pharmsynthez Loan in May 2023, and no further amounts are due under the Pharmsynthez Loan. As a result, no amounts were outstanding as of June 30, 2024 and December 31, 2023. The Company did not recognize any interest income related to the Pharmsynthez Loan during the three and six months ended June 30, 2024. The Company recognized approximately $65,000 of income related to interest and fees associated with the Pharmsynthez Loan including approximately $40,000 related to interest income during the three and six months ended June 30, 2023. Â Â Â Â 13Â Â Â ITEMÂ 2 â€“ MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Â CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Â This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), and Section 27A of the Securities Act of 1933, as amended. All statements contained in this Quarterly Report other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, future revenues, projected costs, prospects and our objectives for future operations, are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning: anticipated effects of geopolitical events, including the conflicts in the Ukraine and the Middle East and associated sanctions imposed by the U.S. and other countries in response; our plans to develop our proposed drug candidates; our expectations regarding the nature, timing and extent of clinical trials and proposed clinical trials; our expectations regarding the timing for proposed submissions of regulatory filings; our expectations regarding the nature, timing and extent of collaboration arrangements; the expected results pursuant to collaboration arrangements, including the receipts of future payments that may arise pursuant to collaboration arrangements; the outcome of our plans to obtain regulatory approval of our drug candidates; the outcome of our plans for the commercialization of our drug candidates; our plans to address certain markets, engage third party manufacturers, and evaluate additional drug candidates for subsequent commercial development along with the likelihood and extent of competition to our drug candidates; our plans to advance innovative immune-oncology technologies addressing hard to treat oncology indications; expectations regarding our Deoxyribonuclease (â€œDNaseâ€) platform, such as regarding the DNase platform being in development for the treatment of solid tumors and being aimed at improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (â€œNETsâ€); our expectations to focus our efforts and resources on advancing the DNase platform into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors; and our expectations regarding our PolyXenÂ® platform, including concerning our plans to leverage the platform. Â In some cases, these statements may be identified by terminology such as â€œmay,â€ â€œwill,â€ â€œwould,â€ â€œcould,â€ â€œshould,â€ â€œexpect,â€ â€œplan,â€ â€œanticipate,â€ â€œbelieve,â€ â€œestimate,â€ â€œseek,â€ â€œapproximately,â€ â€œintend,â€ â€œpredict,â€ â€œpotential,â€ â€œprojects,â€ or â€œcontinue,â€ or the negative of such terms and other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, we cannot guarantee future results, the levels of activity, performance or achievements. These statements involve known and unknown risks and uncertainties that may cause our or our industry's results, levels of activity, performance or achievements to be materially different from those expressed or implied by forward-looking statements.Â Â The Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations (the â€œMD&Aâ€) should be read together with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report. This Quarterly Report, including the MD&A, contains trend analysis and other forward-looking statements. Any statements in this Quarterly Report that are not statements of historical facts are forward-looking statements. These forward-looking statements made herein are based on our current expectations, involve a number of risks and uncertainties and should not be considered as guarantees of future performance. Â Some factors that could cause actual results to differ materially include without limitation: Â Â· uncertainty of the expected financial performance of the Company; Â Â· failure to realize the anticipated potential of the DNase or PolyXen technologies; Â Â· our ability to implement our business strategy; Â Â· our failure to maintain compliance with the continued listing requirements of the Nasdaq Stock Market (â€œNasdaqâ€); Â Â· our need to raise additional working capital in the future for the purpose of further developing our pipeline and to continue as a going concern; Â Â Â Â 14Â Â Â Â Â· our ability to finance our business; Â Â· our ability to successfully execute, manage and integrate key acquisitions and mergers; Â Â· product development and commercialization risks, including our ability to successfully develop the DNase technology; Â Â· the impact of adverse safety outcomes and clinical trial results for our therapies; Â Â· our ability to secure and maintain a manufacturer for our technologies; Â Â· the impact of new therapies and new uses of existing therapies on the competitive environment; Â Â· our ability to successfully commercialize our current and future drug candidates; Â Â· our ability to achieve milestone and other payments associated with our current and future co-development collaborations and strategic arrangements; Â Â· our reliance on consultants, advisors, vendors and business partners to conduct work on our behalf; Â Â· the impact of new technologies on our drug candidates and our competition; Â Â· changes in laws or regulations of governmental agencies; Â Â· interruptions or cancellation of existing contracts; Â Â· impact of competitive products and pricing; Â Â· product demand and market acceptance and risks; Â Â· the presence of competitors with greater financial resources; Â Â· continued availability of supplies or materials used in manufacturing at the current prices; Â Â· the ability of management to execute plans and motivate personnel in the execution of those plans; Â Â· our ability to attract and retain key personnel; Â Â· costs, diversion and other adverse effects of the actions of activist shareholders; Â Â· adverse publicity related to our products or the Company itself; Â Â· adverse claims relating to our intellectual property; Â Â· the adoption of new, or changes in, accounting principles; Â Â· the costs inherent with complying with statutes and regulations applicable to public reporting companies, such as the Sarbanes-Oxley Act of 2002; Â Â· other new lines of business that we may enter in the future; Â Â· general economic and business conditions, as well as inflationary trends and financial market instability or disruptions to the banking system due to bank failures; Â Â· the impact of natural disasters or public health emergencies, such as the COVID-19 global pandemic, and geopolitical events, such as the Russian invasion of Ukraine and conflict in the Middle East, and related sanctions and other economic disruptions or concerns, on our financial condition and results of operations; and Â Â· other factors set forth in the Risk Factors section of our Annual Report on Form 10-K and in subsequent filings with the Securities and Exchange Commission (â€œSECâ€). Â These factors are not necessarily all of the important factors that could cause actual results to differ materially from those expressed in the forward-looking statements in this Quarterly Report. Other unknown or unpredictable factors also could have material adverse effects on our future results, including, but not limited to, those discussed in the section titled â€œRisk Factors.â€ The forward-looking statements in this Quarterly Report are made only as of the date of this Quarterly Report, and we do not undertake any obligation to publicly update any forward-looking statements to reflect subsequent events or circumstances. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Â Â Â Â 15Â Â Â BUSINESS OVERVIEW Â We are a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. Our DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting NETs, which have been implicated in cancer progression and resistance to cancer treatments. We are currently focused on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Additionally, we have partnered with biotechnology and pharmaceutical companies to develop our proprietary drug delivery platform, PolyXen, and receive royalty payments under an exclusive license arrangement in the field of blood coagulation disorders. Â Â We incorporate our patented and proprietary technologies into drug candidates currently under development with biotechnology and pharmaceutical industry collaborators to create what we believe will be the next-generation biologic drugs with improved pharmacological properties over existing therapeutics. Our drug candidates have resulted from our research activities or that of our collaborators and are in the development stage. As a result, we have committed a significant amount of our resources to our research and development activities and anticipate continuing to do so for the near future. To date, none of our drug candidates have received regulatory marketing authorization or approval in the U.S. by the Food and Drug Administration nor in any other countries or territories by any applicable agencies. We are receiving ongoing royalties pursuant to a license of our PolyXen technology to an industry partner. Although we hold a broad patent portfolio, the focus of our internal efforts during the three and six months ended June 30, 2024, was on the advancement of our DNase technology. Â Impact of the Global Conflicts on Our Operations Â The short and long-term implications of Russiaâ€™s invasion of Ukraine and conflict in the Middle East are difficult to predict at this time. The imposition of current and future sanctions and counter sanctions may have an adverse effect on the economic markets generally and could impact our business, financial condition, and results of operations. Â RESULTS OF OPERATIONS Â Comparison of Quarter Ended June 30, 2024 and 2023 Â The comparison of our historical results of operations for the fiscal quarter ended June 30, 2024 to the fiscal quarter ended June 30, 2023 is as follows: Â DescriptionÂ Quarter Ended June 30, 2024Â Â Quarter Ended June 30, 2023Â Â Increase (Decrease)Â Â Percentage ChangeÂ Revenues:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Royalty revenueÂ $726,404Â Â $651,005Â Â $75,399Â Â Â 11.6Â Operating costs and expenses:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and developmentÂ Â (933,771)Â Â (903,243)Â Â 30,528Â Â Â 3.4Â General and administrativeÂ Â (1,130,029)Â Â (945,950)Â Â 184,079Â Â Â 19.5Â Total operating costs and expensesÂ Â (2,063,800)Â Â (1,849,193)Â Â 214,607Â Â Â 11.6Â Loss from operationsÂ Â (1,337,396)Â Â (1,198,188)Â Â 139,208Â Â Â 11.6Â Other income (expense):Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other (expense) incomeÂ Â (21)Â Â 21,122Â Â Â (21,143)Â Â (100.1) Interest income, netÂ Â 63,447Â Â Â 126,103Â Â Â (62,656)Â Â (49.7) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net lossÂ $(1,273,970)Â $(1,050,963)Â $(223,007)Â Â 21.2Â Â Â Â 16Â Â Â Revenue Â Revenue for the three months ended June 30, 2024 increased by approximately $0.1 million, or 11.6%, to approximately $0.7 million from approximately $0.7 million for the three months ended June 30, 2023. This increase represents an increase in royalty revenue related to our sublicense agreement with Takeda Pharmaceuticals Co. Ltd. (â€œTakedaâ€) as compared to the same period in 2023. Â Research and Development Expenses Â Research & development (â€œR&Dâ€) expenses for the three months ended June 30, 2024 was relatively flat with the comparable quarter in 2023. The table below sets forth the R&D costs incurred by the Company by category of expense for the quarters ended June 30, 2024 and 2023: Â Â Â Quarter Ended,Â Category of ExpenseÂ June 30, 2024Â Â June 30, 2023Â Outside services and contract research organizationsÂ $474,850Â Â $731,045Â Personnel costsÂ Â 415,807Â Â Â 126,957Â Share-based expenseÂ Â (3,804)Â Â 13,778Â OtherÂ Â 46,918Â Â Â 31,463Â Total research and development expenseÂ $933,771Â Â $903,243Â Â The decrease in outside services and contract research organizations expense was primarily due to decreased spending in connection with our pre-clinical and process development efforts related to our DNase platform. The increase in personnel costs is due to certain severance and benefits expensed in connection with a separation agreement entered into during the second quarter of 2024 with our former Chief Scientific Officer. Â General and Administrative Expenses Â General and administrative expenses for the three months ended June 30, 2024 increased by approximately $0.2 million, or 19.5%, to approximately $1.1 million from approximately $0.9 million in the comparable quarter in 2023. The increase was primarily due to certain severance and benefits expensed in connection with a separation agreement entered into during the second quarter of 2024 with our former Chief Executive Officer. This increase was partially offset by general decreases in accounting and legal fees during the three months ended June 30, 2024 compared to the same period in 2023.Â Â Other (Expense) Income Â Other expense was $21 for the three months ended June 30, 2024 compared to approximately $21,000 of other income for the comparable quarter in 2023. This decrease in other income was primarily related to fees associated with the Pharmsynthez Loan recognized during the three months ended June 30, 2023. There were no similar fees received in the same period in 2024. Â Interest Income Â Interest income, net decreased to approximately $63,000 during the three months ended June 30, 2024 as compared to approximately $126,000 for the same period in the prior year. This decrease was primarily due to lower average invested funds during the three months ended June 30, 2024 compared to the same period in 2023 as well as a decrease in interest income on the Pharmsynthez Loan. Â Â Â Â 17Â Â Â Comparison of Six Months Ended June 30, 2024 and 2023 Â The comparison of our historical results of operations for the six months ended JuneÂ 30, 2024 to the six months ended June 30, 2023 is as follows: Â DescriptionÂ Six Months Ended June 30, 2024Â Â Six Months Ended June 30, 2023Â Â Increase (Decrease)Â Â Percentage ChangeÂ Revenues:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Royalty revenueÂ $1,237,221Â Â $1,256,849Â Â $(19,628)Â Â (1.6) Operating costs and expenses:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and developmentÂ Â (1,878,092)Â Â (1,498,519)Â Â 379,573Â Â Â 25.3Â General and administrativeÂ Â (1,964,939)Â Â (1,871,693)Â Â 93,246Â Â Â 5.0Â Total operating costs and expensesÂ Â (3,843,031)Â Â (3,370,212)Â Â 472,819Â Â Â 14.0Â Loss from operationsÂ Â (2,605,810)Â Â (2,113,363)Â Â 492,447Â Â Â 23.3Â Other income (expense):Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other incomeÂ Â 31Â Â Â 25,642Â Â Â (25,611)Â Â (99.9) Interest income, netÂ Â 136,696Â Â Â 180,204Â Â Â (43,508)Â Â (24.1) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net lossÂ $(2,469,083)Â $(1,907,517)Â $551,566Â Â Â 29.4Â Â Revenue Â Revenue for the six months ended June 30, 2024 was relatively flat with the six months ended June 30, 2023. Â Research and Development Expenses Â R&D expenses for the six months ended June 30, 2024 increased by approximately $0.4 million, or 25.3%, to approximately $1.9 million from approximately $1.5 million in the comparable period in 2023. The table below sets forth the R&D costs incurred by the Company by category of expense for the six months ended June 30, 2024 and 2023: Â Â Â Six Months Ended,Â Category of ExpenseÂ June 30, 2024Â Â June 30, 2023Â Outside services and contract research organizationsÂ $1,220,522Â Â $1,154,912Â Personnel costsÂ Â 561,612Â Â Â 251,750Â Share-based expenseÂ Â 11,433Â Â Â 27,466Â OtherÂ Â 84,525Â Â Â 64,391Â Total research and development expenseÂ $1,878,092Â Â $1,498,519Â Â The increase in outside services and contract research organizations expense was primarily due to increased spending in connection with our pre-clinical development efforts offset by lower process development efforts related to our DNase platform. The increase in personnel costs is due to certain severance and benefits expensed in connection with a separation agreement entered into during the second quarter of 2024 with our former Chief Scientific Officer. Â Â Â Â 18Â Â Â General and Administrative Expenses Â General and administrative expenses for the six months ended June 30, 2024 increased by approximately $0.1 million, or 5.0%, to approximately $2.0 million from approximately $1.9 million in the comparable period in 2023. The increase was primarily due to certain severance and benefits expensed in connection with a separation agreement entered into during the second quarter of 2024 with our former Chief Executive Officer. This increase was partially offset by general decreases in accounting and legal fees during the six months ended June 30, 2024 compared to the same period in 2023.Â Â Other Income Â Other income was $31 for the six months ended June 30, 2024 compared to approximately $26,000 of other income for the six months ended June 30, 2023. This decrease in other income was primarily related to fees associated with the Pharmsynthez Loan recognized during the six months ended June 30, 2023 for which there were no similar fees received in the same period in 2024. Â Interest Income Â Interest income decreased to approximately $137,000 during the six months ended June 30, 2024 as compared to approximately $180,000 for the same period in the prior year. This decrease was primarily due to lower average invested funds during the six months ended June 30, 2024 compared to the same period in 2023 as well as a decrease in interest income received on the Pharmsynthez Loan. Â Liquidity and Capital Resources Â We incurred a net loss of approximately $2.5 million for the six months ended June 30, 2024. We had an accumulated deficit of approximately $195.7 million at June 30, 2024, as compared to an accumulated deficit of approximately $193.2 million at December 31, 2023. Working capital was approximately $6.4 million at June 30, 2024, and approximately $8.8 million at December 31, 2023. During the six months ended June 30, 2024, our working capital decreased by approximately $2.3 million primarily due to our net loss for the six months ended June 30, 2024. Â Â Our principal source of liquidity consists of cash. At June 30, 2024, we had approximately $7.3 million in cash and approximately $1.6 million in current liabilities. At December 31, 2023, we had approximately $9.0 million in cash and approximately $0.8 million in current liabilities. We have historically relied upon sales of our equity securities to fund our operations. Â We evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued. We have incurred substantial losses since our inception, and we expect to continue to incur operating losses in the near-term. The Company believes that its existing resources will be adequate to fund the Companyâ€™s operations for a period of at least twelve months from the date of the issuance of these financial statements. However, we anticipate we will need additional capital in the long-term to pursue our business initiatives. While the Company believes it has access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations, related party funding, or other means to continue as a going concern, the terms, timing and extent of any future financing will depend upon several factors, including the achievement of progress in our clinical development programs, our ability to identify and enter into licensing or other strategic arrangements, our continued listing on Nasdaq, and factors related to financial, economic, geo-political, industry and market conditions, many of which are beyond our control. The capital markets for the biotech industry can be highly volatile, which make the terms, timing and extent of any future financing uncertain. Â Â Â Â 19Â Â Â Cash Flows from Operating Activities Â Cash flows used in operating activities for the six months ended June 30, 2024 totaled approximately $1.7 million, which was primarily due to our net loss for the period, partially offset by non-cash charges associated with share-based expense and an increase in current liabilities during the period. Cash flows used in operating activities for the six months ended June 30, 2023 totaled approximately $2.4 million, which was primarily due to our net loss for the period as well as advance payments made in accordance with our statement of work with Catalent, partially offset by cash received from the repayment of the Pharmsynthez Loan. In addition, current liabilities decreased during the six months ended June 30, 2023. Â Â Cash Flows from Investing Activities Â There were no cash flows from investing activities for the six months ended June 30, 2024 and 2023. Â Cash Flow from Financing Activities Â There were no cash flows from financing activities for the six months ended June 30, 2024 and 2023. Â Contractual Obligations and Commitments Â As of June 30, 2024, there were no material changes in our contractual obligations and commitments from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 21, 2024, as amended on April 26, 2024. Â Off Balance Sheet Arrangements Â We do not have any off-balance sheet financing arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, change in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources. Â Â Recent Accounting Standards Â See Note 3 in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 21, 2024, as amended on April 26, 2024, for a discussion of recent accounting standards. Â Critical Accounting Estimates Â Our condensed consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles. The preparation of our condensed consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses. We base our estimates and assumptions on historical experience and other factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The result of these evaluations forms the basis for making judgments about the carrying values of assets and liabilities and the reported amount of expenses that are not readily apparent from other sources. Because future events and their effects cannot be determined with certainty, actual results and outcomes may differ materially from our estimates, judgments and assumptions. There have been no material changes in our critical accounting estimates from those disclosed in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, filed with the SEC on MarchÂ 21, 2024, as amended on April 26, 2024. Â Â Â Â 20Â Â Â ITEM 3 â€“ QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Â We are not required to provide the information required by this Item because we are a â€œsmaller reporting companyâ€ (as defined in Rule 12b-2 of the Exchange Act). Â ITEM 4 â€“ CONTROLS AND PROCEDURES Â Evaluation of Disclosure Controls and Procedures Â Our management, with the participation of our Interim Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer), evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act, as of the end of the period covered by this Quarterly Report. Â Â Based on this evaluation, our management, including our Interim Chief Executive Officer and Chief Financial Officer, concluded that as of the end of the period covered by this Quarterly Report, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SECâ€™s rules and forms, and that such information is accumulated and communicated to our management, including our Interim Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Â Changes in Internal Control over Financial Reporting Â There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report that would have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 21Â Â Â PART II â€“ OTHER INFORMATION Â ITEM 1 â€“ LEGAL PROCEEDINGS Â We are not currently subject to any material legal proceedings, nor, to our knowledge, is any material legal proceeding threatened against us. From time to time, we may be a party to certain legal proceedings, incidental to the normal course of our business. While the outcome of these legal proceedings cannot be predicted with certainty, we do not expect that these proceedings will have a material effect upon our financial condition or results of operations. Â ITEM 1A â€“ RISK FACTORS Â There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 21, 2024, as amended on April 26, 2024.Â Â ITEM 2 â€“ UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Â None. Â ITEM 3 â€“ DEFAULTS UPON SENIOR SECURITIES Â None. Â ITEM 4 â€“ MINE SAFETY DISCLOSURES Â Not applicable. Â ITEM 5 â€“ OTHER INFORMATION Â During the quarter ended June 30, 2024, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K. Â Â Â Â 22Â Â Â ITEM 6 â€“ EXHIBITS Â The following exhibits are incorporated herein by reference or filed as part of this report. Â EXHIBIT NUMBER DESCRIPTION Â Â 10.1* Confidential Separation Agreement and General Release, dated June 19, 2024, between Jeffrey Eisenberg and Xenetic Biosciences, Inc. 10.2* Confidential Separation Agreement and General Release, dated June 19, 2024, between Curtis Lockshin and Xenetic Biosciences, Inc. 10.3* Amendment to Employment Agreement, dated June 18, 2024, between James F. Parslow and Xenetic Biosciences, Inc. 31.1* Certification of James Parslow, Interim Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2* Certification of James Parslow, Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1** Certification of James Parslow, Interim Principal Executive Officer and Principal Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101* The following financial statements from the Companyâ€™s Quarterly Report on Form 10-Q for the quarter ended June Â 30, 2024, formatted in inline XBRL, include: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Changes in Stockholdersâ€™ Equity, (iv) Condensed Consolidated Statements of Cash Flows and (v) the Notes to the Condensed Consolidated Financial Statements. 104* Cover Page Interactive Data File (formatted in inline XBRL and included in Exhibit 101) Â Â * Filed herewith. ** Exhibit 32.1 is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended or the Securities Exchange Act of 1934, as amended, except as otherwise stated in such filing. Â Â Â Â Â Â Â Â 23Â Â Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Â Â Â Xenetic Biosciences, Inc. Â Â Â Â Â Â Â Â August 13, 2024 Â By:Â Â /S/ JAMES PARSLOW Â Â Â James Parslow Interim Chief Executive Officer and Chief Financial Officer (Principal Executive, Principal Financial Officer and Principal Accounting Officer) Â Â Â Â Â Â Â Â Â Â Â Â 24Â EX-10.1 2 xenetic_ex1001.htm CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE, DATED JUNE 19, 2024, BETWEEN JEFFREY EISENBERG AND XENETIC BIOSCIENCES, INC. Exhibit 10.1 Â Execution Version Â CONFIDENTIAL SEPARATION AGREEMENT & GENERAL RELEASE Â THIS CONFIDENTIAL SEPARATION AGREEMENT & GENERAL RELEASE (â€œAgreementâ€) is made and entered into by and between Jeffrey Eisenberg (â€œExecutiveâ€), and Xenetic Biosciences, Inc. (the â€œCompanyâ€). Executive and Company are collectively referred to herein as the â€œParties.â€ Â I.Recitals Â A.Executive is currently employed by Company on an at will basis pursuant to the terms of that certain Amended and Restated Employment Agreement, by and between the Executive and Company, dated October 26, 2017 (the â€œEmployment Agreementâ€); Â Â Â B.On May 16, 2024, the Board of Directors (the â€œBoardâ€) of the Company approved the termination of Executive from all roles in the Company, effective immediately, and recommended that Executive tender his resignation from the Board; Â Â Â C.Executiveâ€™s last date of employment is May 16, 2024 (the â€œSeparation Dateâ€); Â Â Â D.Executive acknowledges that from and after the Separation Date, Executive has no authority to, and shall not, represent himself as an employee or agent of Company; Â Â Â E.Executive represents and warrants that he does not have any claims or charges pending against Company with any court, tribunal or administrative agency; Â Â Â F.Executive and Company desire to enter into this Agreement related to Executiveâ€™s separation from Company; and Â Â Â G.Nothing within this Agreement shall constitute an admission of any liability or wrongdoing by Company, which expressly denies any liability or wrongdoing. Â II.General Provisions Â The Parties hereby agree as follows: Â A.Recitals Â The Recitals contained in Section I are incorporated herein and made a part hereof. Â B.Release and Discharge by Executive Â 1.The term â€œReleased Partiesâ€ includes the Company, Insperity PEO Services, L.P. (â€œInsperityâ€) and their respective current or former officers, directors, shareholders, investors, owners, partners, employees, associates, servants, agents, managing agents, partnerships, trustees, predecessors, successors, assigns, affiliates, parent corporations, and/or subsidiaries; and/or any other entity or company operated, affiliated with, controlled by, or under common control with any one of the foregoing; and each of their predecessors, successors, assigns, affiliates, partnerships, parent corporations, subsidiaries (whether or not wholly owned), divisions, business units by or through which Company does business, partners (including partners of partnerships and affiliates), related entities, all of their trustees, directors, officers, attorneys, insurers, reinsurers, accountants, lenders, investors, agents, servants, representatives, employees and former employees (in their respective capacities as such, in their individual and personal capacities, and in any and all other capacities); and all other related entities of any type, scope or existence, of each of the foregoing. Any reference to the â€œReleased Partiesâ€ includes one or more or all of them. Â Â Â Â 1Â Â Â 2.The term â€œReleased Claimsâ€ means and shall include any and all claims, actions, and causes of action, liens, debts, liabilities, demands, obligations, contracts or commitments, suits, debts, accounts, covenants, disputes, controversies, agreements, promises, acts, costs and expenses, damages, and executions, of whatever kind or nature, including without limitation any statutory, civil, common law or administrative claim, such as but not limited to the following: claims under Title VII of the Civil Rights Act of 1964 and/or 1991, Section 1981 of the Civil Rights Act of 1866, the Americans with Disabilities Act of 1990, the Family and Medical Leave Act of 1990, the Fair Labor Standards Act of 1938, the Executive Retirement Income Security Act of 1974, the National Labor Relations Act of 1935, the Equal Pay Act of 1963, the Consolidated Omnibus Budget Reconciliation Act of 1985 (â€œCOBRAâ€), the Immigration Reform and Control Act of 1986, the Occupational Safety and Health Act of 1970, the Worker Adjustment and Retraining Notification Act of 1988, the Doddâ€“Frank Wall Street Reform and Consumer Protection Act of 2010, the Health Insurance Portability and Accountability Act of 1996, the Vocational Rehabilitation Act of 1973 (29 U.S.C. Â§ 701 et seq.), or any related state law or local ordinance related to employment or employment discrimination; claims for disputed wages and penalties under federal or state law; claims for compensation, severance, employee benefits and vacation or sick pay; attorneysâ€™ fees, costs, expenses and expert witness fees and expenses; tort damages or personal injury damages; breach of implied or express contract; retaliation, failure to accommodate; failure to engage in an interactive process; wrongful termination in violation of public policy; breach of fiduciary duty; declaratory relief; injunctive relief; public policy breach; intentional or negligent infliction of emotional distress; breach of the Employment Agreement or any other employment contract (whether express, implied in law or fact, oral or written); breach of implied covenant of good faith and fair dealing; interference with contract; intentional or negligent interference with prospective economic advantage; intentional or negligent misrepresentation, promissory fraud, or fraud; conversion; defamation; libel or slander; discrimination, retaliation, harassment or hostile work environment on the basis of any statutorily protected class including but not limited to disability or age, or failure to prevent such discrimination, retaliation, harassment or hostile work environment; negligent hiring; constructive discharge; disparagement of any kind or nature; invasion of privacy; civil assault; malicious prosecution; abuse of process; declaratory or injunctive relief, or in any other type of action or proceeding, whether known or unknown, suspected or unsuspected, fixed or contingent, at law or in equity, which Executive ever had or held, now has or holds, or hereafter can, shall, or may have or hold at any time in the future, in any capacity, individually or as a member of a class, collective or representative action, relator-employee, or action for public benefit with respect to Executiveâ€™s employment with Company, or the termination thereof, the subject matter of this Agreement, or any other matters with, by or between Company, or the Released Parties and Executive, or by any one or more of the Released Parties against Executive, at any time prior to and through the Effective Date of this Agreement. The Released Claims expressly exclude claims that may not be waived under applicable law at the time the Agreement is executed by Executive. Â 3. In consideration of the terms and provisions of the Agreement, Executive shall and does hereby and forever fully, finally and forever generally remise, release, waive and discharge Company and the Released Parties from any and all known or unknown, suspected or unsuspected, fixed or contingent claims, rights, actions and causes of action, including but not limited to the Released Claims, at law or in equity, which Executive ever had or held, now has or holds, or hereafter can, shall, or may have or hold against Company or any or all of the Released Parties based on any occurrences, transactions, events, acts, or omissions of any kind whatsoever from any time prior to and through the Effective Date of the Agreement. Â 4. Nothing in this Agreement prohibits Executive from: (a) filing an administrative charge of discrimination or an administrative charge within the jurisdiction of the National Labor Relations Board (â€œNLRBâ€) or Equal Employment Opportunity Commission (â€œEEOCâ€) or similar state or local civil rights agencies; (b) communicating directly with the U.S. Securities and Exchange Commission (â€œSECâ€) about a possible securities law violation which Executive is not required to report or disclose to the Company; or (c) filing a charge or communicating with any other federal, state or local government office, official or agency concerning matters relevant to such governmental office or agency. Executive promises never to seek or accept any damages, remedies, or other relief, for Executive personally (any right to which Executive hereby waives and promises never to accept) with respect to any claim released hereunder, in any proceeding including, but not limited to, any EEOC or NLRB proceeding, other than a benefit or remedy pursuant to Section 922 of the Dodd-Frank Wall Street Reform or the Consumer Protection Act or as otherwise required by law. Notwithstanding the foregoing, this Agreement does not limit Executiveâ€™s right to receive an award for information provided to the SEC. Â Â Â Â 2Â Â Â C.Payment and Other Consideration Â 1.Consideration. Â a)In consideration of the releases and promises set forth in this Agreement: Â i.the Company shall pay Executive the sum of $420,420, representing an amount equal to one times Executiveâ€™s Base Salary (as defined in the Employment Agreement), less all applicable withholdings, deductions and taxes as required by law, payable in one lump sum within thirty days after the Effective Date (as defined in Section X below) (the â€œSeparation Paymentâ€); Â ii. all of the unvested stock options held by Executive as of the Separation Date as listed on Exhibit A shall fully vest on the Separation Date and not be subject to forfeiture; and Â iii. the Company shall reimburse Executive for reasonable legal fees in an amount not to exceed $10,000 that the Executive incurs in connection with the negotiation of this Agreement, subject to the delivery of appropriate documentation thereof and provided that the Executive shall submit invoices to the Company within thirty (30) days of incurrence of the expense. Â b) The Separation Payment will be reported on an IRS Form W-2. Executive understands, acknowledges and agrees that the Separation Payment will be paid by the Company, provided: (a) Executive is not in breach of any term, condition, warranty, representation, covenant or provision of this Agreement, (b) Executive does not revoke the Agreement within the Revocation Period described in Section IX below; and (c) Executive first returns a signed and dated copy of this Agreement to the Company. Executive acknowledges that the Separation Payment and other consideration to be provided under the terms of this Agreement is not an entitlement and shall serve as good and sufficient consideration of the promises made by Executive herein. Executive further acknowledges that the Separation Payment to be paid under this Agreement is due solely from the Company and that Insperity has no obligation to pay the Separation Payment even though its payment may be processed through Insperity. Â c) Executive acknowledges and agrees that the Compensation Committee of the Board of the Company has not established an annual bonus target for Executive or any related performance goals for an annual bonus for Executive and, therefore the pro rata portion of the annual performance-based cash bonus for fiscal year 2024 owed to Executive pursuant to Section 7(d)(ii) of the Employment Agreement shall be deemed to be $0. Â 2. Outstanding Equity Awards. The Executiveâ€™s outstanding equity awards as of the Separation Date are set forth on Exhibit A to this Agreement. Executive understands and agrees that except as otherwise specified herein, treatment of the Executiveâ€™s outstanding equity awards will be governed by the terms and conditions of the applicable award agreements and the Xenetic Biosciences, Inc. Amended and Restated Equity Incentive Plan. Per the terms of the applicable stock option award agreements, all vested stock options as of the Separation Date may be exercised at any time during the three or twelve month period, as applicable, following the Separation Date, as set forth on Exhibit A. Â 3. Final Paycheck and Expenses. Regardless of whether the Executive signs this Agreement, the Employee acknowledges and agrees that the Company has (a) paid the Executive for any accrued but unpaid portion of the Executiveâ€™s Base Salary through the Separation Date, (b) reimbursed the Executive for reasonable out-of-pocket business expenses that were appropriately incurred by the Executive prior to the Separation Date in furtherance of the business of the Company, subject to the Companyâ€™s applicable business expense reimbursement policy, and (c) paid the Executive an amount equal to any accrued but unused vacation pay as of the Separation Date. Â Â Â Â 3Â Â Â 4. Benefits. Following the Separation Date, Executive will be eligible to continue Executiveâ€™s participation in the Companyâ€™s group health benefit plans, such as they may exist from time-to-time, if and to the extent Executive was enrolled in such plans as of the Separation Date. Such benefits continuation will be provided concurrent with and in accordance with the terms of COBRA and/or applicable state/local benefits continuation laws. If Executive elects to receive such continued healthcare coverage, the Company shall reimburse Executive for the premium for Executive and Executiveâ€™s covered dependents, less the amount of Executiveâ€™s monthly premium contributions for such coverage prior to termination, for the period commencing on the first day following the Separation Date through the earlier of (i) the last day of the month during the first twelve months following the Separation Date and (ii) the date Executive and Executiveâ€™s covered dependents, if any, become eligible for healthcare coverage under another employerâ€™s plan(s). Executive shall notify the Company immediately if Executive becomes covered by a group health plan of a subsequent employer. If Executive does not elect COBRA, the Company has no obligation to pay any form of insurance coverage after the Separation Date. Executive further agrees and acknowledges that, except as specifically provided in this Agreement, Executiveâ€™s participation in all Company employee benefit plans shall terminate as of the Separation Date. Â 5. No Other Payments. Executive expressly acknowledges and agrees that this Agreement provides Executive with compensation to which Executive would not otherwise be entitled. Executive acknowledges and agrees that Executive has been paid all final wages owed to Executive by Company, and that these monies were due and owing to Executive regardless of whether Executive chooses to execute the Agreement or not. Other than payment of the Separation Payment and other payments and additional benefits provided hereunder, Executive acknowledges that no other payments, including but not limited to those for back pay, front pay, salary, benefits, bonus, vacation or sick pay, civil or statutory penalties, general or compensatory damages, interest, or costs for the period of time Executive was employed by the Company, or for any other period, are due and owing to Executive from Company or the Released Parties. Â D.Survival of Covenants Â Executive agrees that the covenants with respect to non-competition, non-solicitation, confidentiality, inventions and return of property set forth in Sections 9 through 13 in the Employment Agreement shall survive the separation of Executiveâ€™s employment with the Company and remain in full force and effect; provided, however, that for the sake of clarity, â€œCompeting Productsâ€ as defined in Section 9(c)(i) of the Employment Agreement shall be amended and restated to mean: â€œany product, process, or service of any person or organization other than the Company, in existence or under development, which is identical to, substantially the same as, or an adequate substitute for the Deoxyribonuclease (DNase) platform and the PolyXen technology.â€ Â E.Confidentiality and Nondisclosure of this Agreement Â 1. Executive acknowledges that the confidentiality and non-disclosure of all terms and conditions of this Agreement is an integral part of the agreement to pay severance benefits to Executive, and was a material inducement for Company to enter into this Agreement. Â 2. Executive agrees that Executive will maintain the terms of this Agreement in complete confidentiality. Executive shall make no comments, to any person or entity, including but not limited to the media, friends, co-workers, or former co-workers from Company regarding the Agreement, including the Separation Payment. For purposes of this Agreement, the word â€œcommentsâ€ includes any form of communication, whether oral, written, electronic or otherwise. Executive acknowledges that these nondisclosure provisions are an integral part of this Agreement. Executive may disclose the terms of this Agreement to Executiveâ€™s spouse, attorneys and tax preparer/accountants provided that such disclosure to the attorneys and tax preparer/accountants is made for the purposes of the attorneys and tax preparer/accountants providing legal and/or tax advice and provided that Executiveâ€™s spouse, Executiveâ€™s attorneys and tax preparer/accountants agree to be bound by this confidentiality section. Executive, if required by a Court order or subpoena, or as otherwise permitted by law, may disclose the terms of this Agreement without breaching these confidentiality provisions provided that in the event a demand is made upon Executive for the disclosure of the terms of the Agreement, Executive shall, within 48 hours immediately notify the Company of the demand, so that Company may have sufficient time to seek any necessary orders, including a protective order, or to otherwise participate in the tribunalâ€™s determination of the issue. Â Â Â Â 4Â Â Â F.Waiver of Reemployment Â Executive agrees that by executing this Agreement, Executive waives and releases forever any right or rights Executive might have to seek or obtain employment, reemployment, or reinstatement with Company or the Released Parties. Â G.Return of Company Property, Log Ins and Passwords Â In order to be eligible to receive the Separation Payment, immediately prior to the Effective Date, Executive must return to Company all Company property and all Company confidential information in Executiveâ€™s possession, and Executive must provide to Company all log ins and passwords to any software, website, application or program, which Executive maintained and used as part of the performance of Executiveâ€™s job duties and responsibilities. Â III. Warranty of Capacity to Execute Agreement Â Executive represents and warrants that no other person or entity has or has had any interest in the claims, demands, obligations or causes of action referred to in this Agreement; that Executive has the sole and exclusive right to receive sums specified in it; that Executive has not sold, assigned, transferred, conveyed or otherwise disposed of any of the claims, demands, obligations or causes of action referred to in this Agreement; and that Executive has the mental capacity to understand and execute the terms and conditions of the Agreement. Â IV. Disclaimer of Liability Â Executive agrees to indemnify and hold harmless Company and the Released Parties from any and all claims or liens presently existing against the Separation Payment hereby by any person, entity or corporation, as well as any attorneysâ€™ fees and costs incurred in representation of Company or the Released Parties in litigation concerning any claims or liens, including but not limited to any claims or liens for attorneysâ€™ fees and costs. Â V. Entire Agreement & Successors in Interest Â Except as otherwise provided herein, Executive agrees that this Agreement contains the entire agreement between Executive and Company with respect to the matters set forth in it, and shall be binding upon and inure to the benefit of Executiveâ€™s executors, administrators, personal representatives, heirs, successors and assigns. There are no other understandings or agreements, verbal or otherwise, in relation thereto between the Parties, except as herein expressly set forth. There have been no representations not set forth herein that Executive has relied upon when entering into this Agreement. Executive agrees that should any provision of this Agreement require interpretation or construction that all Parties have participated in the drafting of this document and no presumption regarding construing the document against one Party shall apply. Â VI. Severability Â If any provision in this Agreement is found to be unenforceable, all other provisions will remain fully enforceable. The covenants set forth in this Agreement shall be considered and construed as separate and independent covenants. Should any part or provision of any provision of this Agreement be held invalid, void or unenforceable in any court of competent jurisdiction, such invalidity, voidness or unenforceability shall not render invalid, void or unenforceable any other part or provision of this Agreement. Â VII. Governing Law Â This Agreement is entered into in the State of Florida, and shall be construed and interpreted in accordance with its laws. The Parties agree that the proper and appropriate venue for any action arising from this Agreement shall be any court of competent jurisdiction in Miami-Dade County, Florida. Â Â Â Â 5Â Â Â VIII. Additional Documents Â Executive agrees to cooperate fully, and execute any and all supplementary documents, and take all additional actions which may be necessary or appropriate to give full force and effect to the basic terms and intent of this Agreement. Â IX. Acknowledgement of Voluntariness and Opportunity for Review and Revocation Â 1.Executive acknowledges that (a) Executive knowingly and voluntarily enters into this Agreement with the purpose of waiving any right and releasing any claims under the Age Discrimination in Employment Act of 1967, 29 U.S.C. Â§ 621, et seq. (â€œADEAâ€); (b) Executive was given a period of up to twenty-one (21) days within which to review and consider this Agreement; (c) Executive understood Executive could use as much of said 21-day period as Executive desired; (d) Executive was encouraged by Company to consult with a lawyer, at Executiveâ€™s own expense; (e) if Executive decided not to use the 21-day period, Executive is signing this Agreement voluntarily and of Executiveâ€™s own free will; and (f) this Agreement is not final and binding until the seven-day period of revocation, described in the following sentences of this Section of the Agreement, has expired. Executive understands that Company would not have given Executive the special payments or benefits Executive is getting in exchange for this Agreement but for Executiveâ€™s promises and representations Executive is making by signing it. Â 2.Executive acknowledges that Executive may revoke Executiveâ€™s waiver of the rights and release of any ADEA (age discrimination) claims covered by this Agreement, by delivering written notice of Executiveâ€™s revocation of this Agreement to Jim Parslow at j.parslow@xeneticbio.com, no later than the close of business on the seventh (7th) calendar day after the date on which Executive signed this Agreement (the â€œRevocation Periodâ€). The written notice of revocation must state: â€œI HEREBY REVOKE MY ACCEPTANCE OF THE CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE.â€ If the Agreement is revoked in a timely manner, this Agreement shall not be effective, and Executive shall not receive the Separation Payment as described in Section II.C. herein. Â X. Effectiveness and Electronic Signatures Â This Agreement shall become effective following execution by all the Parties (â€œEffective Dateâ€). This Agreement may be executed via manual signature or electronic signature. â€œElectronic signatureâ€ means (a) the signing partyâ€™s manual signature, converted by the signing party to facsimile or industry-accepted digital form (such as a .pdf file) and received from the signing partyâ€™s customary email address, customary facsimile number, or other mutually agreed-upon authenticated source; or (b) the signing partyâ€™s digital signature executed using a mutually agreed-upon digital signature service provider, such as DocuSign or Adobe sign, and digital signature process. Each Party to this Agreement (i) agrees that it will be bound by its own electronic signature, (ii) accepts the electronic signature of each other Party to this Agreement, and (iii) agrees that such electronic signatures shall be the legal equivalent of manual signatures. This Agreement may be so executed in counterparts, each of which will be considered an original and all such counterparts will be considered and constitute one and the same agreement. Â XI. Disparaging Statements Â Neither the Executive nor the Company shall make any remarks or statements, either publicly or privately, orally or in writing, that are disparaging of the other party. The Executive shall not make any remarks or statements, either publicly, orally or in writing that are disparaging of the Companyâ€™s actual or prospective business and/or, in such capacities, current or former employees, officers, directors, trade partners, vendors, suppliers, or customers of the Company, either individually or collectively. For the avoidance of doubt, this includes remarks or statements, public or private, made via electronic mail, blogs, social media (such as, Facebook, Twitter or X, LinkedIn, Instagram or any other similar platform). This provision is subject to each partyâ€™s legally protected rights to communicate with governmental bodies and agencies and to engage in otherwise legally protected activity. Â [remainder of page intentionally blank] Â Â Â 6Â Â Â EMPLOYEE: Â Â Â Â Â Â Â /s/ Jeffrey Eisenberg Â Â Jeffrey Eisenberg Â Â Date: June 19, 2024 Â Â Â Â Â Â COMPANY: Â Â Â Â Â Xenetic Biosciences, Inc. Â Â Â Â Â Â By: /s/ James Parslow Â Â Name: James Parslow Â Â Title: Interim Chief Executive Officer and Chief Financial Officer Date: June 19, 2024 Â Â Â Â Â Â Â Â Â Â [Signature page to Separation and Release Agreement] Â 7Â Â Â Exhibit A Â Xenetic Biosciences, Inc. Â Jeffrey Eisenberg â€“ Outstanding Equity as of May 16, 2024 Â Date of Grant Shares Exercise Price Expiration Date Total Vested Total Unvested Vesting Exercisability post termination Stock Options 12/2/2016 1,917 $ 409.20 12/2/2026 1,917 - Fully Vested 90 days post termination date Â Â Â Â Â Â Â 10/26/2017 1,042 $ 253.20 10/26/2027 1,042 - Fully Vested 12 months post termination date Â Â Â Â Â Â Â 12/4/2019 23,000 $ 13.10 12/4/2029 23,000 - Fully Vested 12 months post termination date Â Â Â Â Â Â Â 3/18/2021 10,000 $ 26.00 3/18/2031 10,000 - Fully Vested 12 months post termination date Â Â Â Â Â Â Â 3/24/2022 10,000 $ 11.20 3/24/2032 6,667 3,333 1/3rd on March 24, 2023; 2/3rds over remaining 8 quarters commencing June 24, 2023 thru March 24, 2025 12 months post termination date Â Â Â Â Â Â Â 12/11/2023 20,000 $ 3.88 12/11/2033 - 20,000 1/3rd on December 11, 2024; 2/3rds over remaining 8 quarters commencing March 11, 2025 thru Dec 11, 2026 12 months post termination date Â Â Â Â Â Â Â Restricted Stock Units 10/26/2017 417 N/A N/A 417 - Fully Vested N/A Â Â Â Â Â Â Â Â 8Â EX-10.2 3 xenetic_ex1002.htm CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE, DATED JUNE 19, 2024, BETWEEN CURTIS LOCKSHIN AND XENETIC BIOSCIENCES, INC. Exhibit 10.2 Â Execution Version Â CONFIDENTIAL SEPARATION AGREEMENT & GENERAL RELEASE Â THIS CONFIDENTIAL SEPARATION AGREEMENT & GENERAL RELEASE (â€œAgreementâ€) is made and entered into by and between Curtis Lockshin (â€œExecutiveâ€), and Xenetic Biosciences, Inc. (the â€œCompanyâ€). Executive and Company are collectively referred to herein as the â€œParties.â€ Â I.Recitals Â A.Executive is currently employed by Company on an at will basis pursuant to the terms of that certain Employment Agreement, by and between the Executive and Company, dated January 1, 2017 (the â€œEmployment Agreementâ€); Â Â Â B.On May 16, 2024, the Board of Directors of the Company approved the termination of Executive from all roles in the Company and all of its subsidiaries, as applicable, effective immediately; Â Â Â C.Executiveâ€™s last date of employment is May 16, 2024 (the â€œSeparation Dateâ€); Â Â Â D.Executive acknowledges that from and after the Separation Date, Executive has no authority to, and shall not, represent himself as an employee or agent of Company; Â Â Â E.Executive represents and warrants that he does not have any claims or charges pending against Company with any court, tribunal or administrative agency; Â Â Â F.Executive and Company desire to enter into this Agreement related to Executiveâ€™s separation from Company; and Â Â Â G.Nothing within this Agreement shall constitute an admission of any liability or wrongdoing by Company, which expressly denies any liability or wrongdoing. Â II.General Provisions Â The Parties hereby agree as follows: Â A.Recitals Â The Recitals contained in Section I are incorporated herein and made a part hereof. Â B.Release and Discharge by Executive Â 1.The term â€œReleased Partiesâ€ includes Company, Insperity PEO Services, L.P. (â€œInsperityâ€) and their respective current or former officers, directors, shareholders, investors, owners, partners, employees, associates, servants, agents, managing agents, partnerships, trustees, predecessors, successors, assigns, affiliates, parent corporations, and/or subsidiaries; and/or any other entity or company operated, affiliated with, controlled by, or under common control with any one of the foregoing; and each of their predecessors, successors, assigns, affiliates, partnerships, parent corporations, subsidiaries (whether or not wholly owned), divisions, business units by or through which Company does business, partners (including partners of partnerships and affiliates), related entities, all of their trustees, directors, officers, attorneys, insurers, reinsurers, accountants, lenders, investors, agents, servants, representatives, employees and former employees (in their respective capacities as such, in their individual and personal capacities, and in any and all other capacities); and all other related entities of any type, scope or existence, of each of the foregoing. Any reference to the â€œReleased Partiesâ€ includes one or more or all of them. Â Â Â Â 1Â Â Â 2.The term â€œReleased Claimsâ€ means and shall include any and all claims, actions, and causes of action, liens, debts, liabilities, demands, obligations, contracts or commitments, suits, debts, accounts, covenants, disputes, controversies, agreements, promises, acts, costs and expenses, damages, and executions, of whatever kind or nature, including without limitation any statutory, civil, common law or administrative claim, such as but not limited to the following: claims under Title VII of the Civil Rights Act of 1964 and/or 1991, Section 1981 of the Civil Rights Act of 1866, the Americans with Disabilities Act of 1990, the Family and Medical Leave Act of 1990, the Fair Labor Standards Act of 1938, the Executive Retirement Income Security Act of 1974, the National Labor Relations Act of 1935, the Equal Pay Act of 1963, the Consolidated Omnibus Budget Reconciliation Act of 1985 (â€œCOBRAâ€), the Immigration Reform and Control Act of 1986, the Occupational Safety and Health Act of 1970, the Worker Adjustment and Retraining Notification Act of 1988, the Doddâ€“Frank Wall Street Reform and Consumer Protection Act of 2010, the Health Insurance Portability and Accountability Act of 1996, the Vocational Rehabilitation Act of 1973 (29 U.S.C. Â§ 701 et seq.), or any related state law or local ordinance related to employment or employment discrimination; claims for disputed wages and penalties under federal or state law; claims for compensation, severance, employee benefits and vacation or sick pay; attorneysâ€™ fees, costs, expenses and expert witness fees and expenses; tort damages or personal injury damages; breach of implied or express contract; retaliation, failure to accommodate; failure to engage in an interactive process; wrongful termination in violation of public policy; breach of fiduciary duty; declaratory relief; injunctive relief; public policy breach; intentional or negligent infliction of emotional distress; breach of the Employment Agreement or any other employment contract (whether express, implied in law or fact, oral or written); breach of implied covenant of good faith and fair dealing; interference with contract; intentional or negligent interference with prospective economic advantage; intentional or negligent misrepresentation, promissory fraud, or fraud; conversion; defamation; libel or slander; discrimination, retaliation, harassment or hostile work environment on the basis of any statutorily protected class including but not limited to disability or age, or failure to prevent such discrimination, retaliation, harassment or hostile work environment; negligent hiring; constructive discharge; disparagement of any kind or nature; invasion of privacy; civil assault; malicious prosecution; abuse of process; declaratory or injunctive relief, or in any other type of action or proceeding, whether known or unknown, suspected or unsuspected, fixed or contingent, at law or in equity, which Executive ever had or held, now has or holds, or hereafter can, shall, or may have or hold at any time in the future, in any capacity, individually or as a member of a class, collective or representative action, relator-employee, or action for public benefit with respect to Executiveâ€™s employment with Company, or the termination thereof, the subject matter of this Agreement, or any other matters with, by or between Company, or the Released Parties and Executive, or by any one or more of the Released Parties against Executive, at any time prior to and through the Effective Date of this Agreement. The Released Claims expressly exclude claims that may not be waived under applicable law at the time the Agreement is executed by Executive. Â 3. In consideration of the terms and provisions of the Agreement, Executive shall and does hereby and forever fully, finally and forever generally remise, release, waive and discharge Company and the Released Parties from any and all known or unknown, suspected or unsuspected, fixed or contingent claims, rights, actions and causes of action, including but not limited to the Released Claims, at law or in equity, which Executive ever had or held, now has or holds, or hereafter can, shall, or may have or hold against Company or any or all of the Released Parties based on any occurrences, transactions, events, acts, or omissions of any kind whatsoever from any time prior to and through the Effective Date of the Agreement. Â 4. Nothing in this Agreement prohibits Executive from: (a) filing an administrative charge of discrimination or an administrative charge within the jurisdiction of the National Labor Relations Board (â€œNLRBâ€) or Equal Employment Opportunity Commission (â€œEEOCâ€) or similar state or local civil rights agencies; (b) communicating directly with the U.S. Securities and Exchange Commission (â€œSECâ€) about a possible securities law violation which Executive is not required to report or disclose to the Company; or (c) filing a charge or communicating with any other federal, state or local government office, official or agency concerning matters relevant to such governmental office or agency. Executive promises never to seek or accept any damages, remedies, or other relief, for Executive personally (any right to which Executive hereby waives and promises never to accept) with respect to any claim released hereunder, in any proceeding including, but not limited to, any EEOC or NLRB proceeding, other than a benefit or remedy pursuant to Section 922 of the Dodd-Frank Wall Street Reform or the Consumer Protection Act or as otherwise required by law. Notwithstanding the foregoing, this Agreement does not limit Executiveâ€™s right to receive an award for information provided to the SEC. Â Â Â Â 2Â Â Â C.Payment and Other Consideration Â 1.Separation Payment. Â a)In consideration of the releases and promises set forth in this Agreement: Â i.the Company shall pay Executive the sum of $342,342, representing an amount equal to one times Executiveâ€™s Base Salary (as defined in the Employment Agreement), less all applicable withholdings, deductions and taxes as required by law (the â€œSeparation Paymentâ€), payable in semi-monthly installments over the twelve month period following the Separation Date in accordance with the Companyâ€™s normal payroll practices; and Â ii.the Company shall reimburse Executive for reasonable legal fees in an amount not to exceed $10,000 that the Executive incurs in connection with the negotiation of this Agreement, subject to the delivery of appropriate documentation thereof and provided that the Executive shall submit invoices to the Company within thirty (30) days of incurrence of the expense. Â b)The Separation Payment will be reported on an IRS Form W-2. Executive understands, acknowledges and agrees that the Separation Payment will be paid by the Company, provided: (a) Executive is not in breach of any term, condition, warranty, representation, covenant or provision of this Agreement, (b) Executive does not revoke the Agreement within the Revocation Period described in Section IX below; and (c) Executive first returns a signed and dated copy of this Agreement to the Company. Executive acknowledges that the Separation Payment to be provided under the terms of this Agreement is not an entitlement and shall serve as good and sufficient consideration of the promises made by Executive herein. Executive further acknowledges that the Separation Payment to be paid under this Agreement is due solely from the Company and that Insperity has no obligation to pay the Separation Payment even though its payment may be processed through Insperity. Â 2. Outstanding Equity Awards. The Executiveâ€™s outstanding equity awards as of the Separation Date are set forth on Exhibit A to this Agreement. Executive understands and agrees that treatment of the Executiveâ€™s outstanding equity awards will be governed by the terms and conditions of the applicable award agreements and the Xenetic Biosciences, Inc. Amended and Restated Equity Incentive Plan. Per the terms of the applicable stock option award agreements, all vested stock options as of the Separation Date may be exercised at any time during the three month period following the Separation Date, or through the option expiration date, as applicable, as set forth on Exhibit A. Executiveâ€™s rights with respect to any unvested stock options are forfeited effective as of the Separation Date. Â 3. Final Paycheck and Expenses. Regardless of whether the Executive signs this Agreement, the Employee acknowledges and agrees that the Company has (a) paid the Executive for any accrued but unpaid portion of the Executiveâ€™s Base Salary through the Separation Date, (b) reimbursed the Executive for reasonable out-of-pocket business expenses that were appropriately incurred by the Executive prior to the Separation Date in furtherance of the business of the Company, subject to the Companyâ€™s applicable business expense reimbursement policy, and (c) paid the Executive an amount equal to any accrued but unused vacation pay as of the Separation Date. Â 4. Benefits. Following the Separation Date, Executive will be eligible to continue Executiveâ€™s participation in the Companyâ€™s group health benefit plans, such as they may exist from time-to-time, if and to the extent Executive was enrolled in such plans as of the Separation Date. Such benefits continuation will be provided concurrent with and in accordance with the terms of COBRA and/or applicable state/local benefits continuation laws. If Executive elects to receive such continued healthcare coverage, the Company shall reimburse Executive on a monthly basis for the premium for Executive and Executiveâ€™s covered dependents, less the amount of Executiveâ€™s monthly premium contributions for such coverage prior to termination, for the period commencing on the first day following the Separation Date through the earlier of (i) the last day of the month during the first twelve months following the Separation Date and (ii) the date Executive and Executiveâ€™s covered dependents, if any, become eligible for healthcare coverage under another employerâ€™s plan(s). Executive shall notify the Company immediately if Executive becomes covered by a group health plan of a subsequent employer. If Executive does not elect COBRA, the Company has no obligation to pay any form of insurance coverage after the Separation Date. Executive further agrees and acknowledges that, except as specifically provided in this Agreement, Executiveâ€™s participation in all Company employee benefit plans shall terminate as of the Separation Date. Â Â Â Â 3Â Â Â 5.No Other Payments. Executive expressly acknowledges and agrees that this Agreement provides Executive with compensation to which Executive would not otherwise be entitled. Executive acknowledges and agrees that Executive has been paid all final wages owed to Executive by Company, and that these monies were due and owing to Executive regardless of whether Executive chooses to execute the Agreement or not. Other than payment of the Separation Payment and other payments and benefits provided hereunder, Executive acknowledges that no other payments, including but not limited to those for back pay, front pay, salary, benefits, bonus, vacation or sick pay, civil or statutory penalties, general or compensatory damages, interest, or costs for the period of time Executive was employed by the Company, or for any other period, are due and owing to Executive from Company or the Released Parties. Â D.Survival of Covenants Â Executive agrees that the covenants with respect to non-competition, non-solicitation, confidentiality, inventions and return of property set forth in Sections 9 through 13 in the Employment Agreement shall survive the separation of Executiveâ€™s employment with the Company and remain in full force and effect; provided, however, that for the sake of clarity, â€œCompeting Productsâ€ as defined in Section 9(c)(i) of the Employment Agreement shall exclude (1) any use of polymers (including polysialic acid or PSA) in pharmaceutical product development so long as such use does not disclose or incorporate the Companyâ€™s Confidential Information into research and development of any products, including pharmaceutical products; (2) work in the field of oncology therapeutics, excepting DNase-family enzymes as a component of oncology therapeutics, including combinations of DNase-family enzymes with chemotherapy, cell therapies, or immunotherapies, and provided such work does not disclose or incorporate the Companyâ€™s Confidential Information into research and development of any products, including therapeutic products; and (3) work in the general area of cell therapies, including CAR T, so long as such work does not disclose or incorporate the Companyâ€™s Confidential Information into research and development of any products, including therapeutic products. Â E.Confidentiality and Nondisclosure of this Agreement Â 1. Executive acknowledges that the confidentiality and non-disclosure of all terms and conditions of this Agreement is an integral part of the agreement to pay severance benefits to Executive, and was a material inducement for Company to enter into this Agreement. Â 2. Executive agrees that Executive will maintain the terms of this Agreement in complete confidentiality. Executive shall make no comments, to any person or entity, including but not limited to the media, friends, co-workers, or former co-workers from Company regarding the Agreement, including the Separation Payment. For purposes of this Agreement, the word â€œcommentsâ€ includes any form of communication, whether oral, written, electronic or otherwise. Executive acknowledges that these nondisclosure provisions are an integral part of this Agreement. Executive may disclose the terms of this Agreement to Executiveâ€™s spouse, attorneys and tax preparer/accountants provided that such disclosure to the attorneys and tax preparer/accountants is made for the purposes of the attorneys and tax preparer/accountants providing legal and/or tax advice and provided that Executiveâ€™s spouse, Executiveâ€™s attorneys and tax preparer/accountants agree to be bound by this confidentiality section. Executive, if required by a Court order or subpoena, or as otherwise permitted by law, may disclose the terms of this Agreement without breaching these confidentiality provisions provided that in the event a demand is made upon Executive for the disclosure of the terms of the Agreement, Executive shall, within 48 hours immediately notify the Company of the demand, so that Company may have sufficient time to seek any necessary orders, including a protective order, or to otherwise participate in the tribunalâ€™s determination of the issue. Â F. Waiver of Reemployment Â Executive agrees that by executing this Agreement, Executive waives and releases forever any right or rights Executive might have to seek or obtain employment, reemployment, or reinstatement with Company or the Released Parties. Â G. Return of Company Property, Log Ins and Passwords Â In order to be eligible to receive the Separation Payment, immediately prior to the Effective Date, Executive must return to Company all Company property and all Company confidential information in Executiveâ€™s possession, and Executive must provide to Company all log ins and passwords to any software, website, application or program, which Executive maintained and used as part of the performance of Executiveâ€™s job duties and responsibilities. Â Â Â Â 4Â Â Â III. Warranty of Capacity to Execute Agreement Â Executive represents and warrants that no other person or entity has or has had any interest in the claims, demands, obligations or causes of action referred to in this Agreement; that Executive has the sole and exclusive right to receive sums specified in it; that Executive has not sold, assigned, transferred, conveyed or otherwise disposed of any of the claims, demands, obligations or causes of action referred to in this Agreement; and that Executive has the mental capacity to understand and execute the terms and conditions of the Agreement. Â IV. Disclaimer of Liability Â Executive agrees to indemnify and hold harmless Company and the Released Parties from any and all claims or liens presently existing against the Separation Payment hereby by any person, entity or corporation, as well as any attorneysâ€™ fees and costs incurred in representation of Company or the Released Parties in litigation concerning any claims or liens, including but not limited to any claims or liens for attorneysâ€™ fees and costs. Â V. Entire Agreement & Successors in Interest Â Except as otherwise provided herein, Executive agrees that this Agreement contains the entire agreement between Executive and Company with respect to the matters set forth in it, and shall be binding upon and inure to the benefit of Executiveâ€™s executors, administrators, personal representatives, heirs, successors and assigns. There are no other understandings or agreements, verbal or otherwise, in relation thereto between the Parties, except as herein expressly set forth. There have been no representations not set forth herein that Executive has relied upon when entering into this Agreement. Executive agrees that should any provision of this Agreement require interpretation or construction that all Parties have participated in the drafting of this document and no presumption regarding construing the document against one Party shall apply. Â VI. Severability Â If any provision in this Agreement is found to be unenforceable, all other provisions will remain fully enforceable. The covenants set forth in this Agreement shall be considered and construed as separate and independent covenants. Should any part or provision of any provision of this Agreement be held invalid, void or unenforceable in any court of competent jurisdiction, such invalidity, voidness or unenforceability shall not render invalid, void or unenforceable any other part or provision of this Agreement. Â VII. Governing Law Â This Agreement is entered into in the Commonwealth of Massachusetts, and shall be construed and interpreted in accordance with its laws. The Parties agree that the proper and appropriate venue for any action arising from this Agreement shall be any court of competent jurisdiction in the Commonwealth of Massachusetts or of the United States of America for the District of Massachusetts. Â VIII. Additional Documents Â Executive agrees to cooperate fully, and execute any and all supplementary documents, and take all additional actions which may be necessary or appropriate to give full force and effect to the basic terms and intent of this Agreement. Â Â Â Â 5Â Â Â IX. Acknowledgement of Voluntariness and Opportunity for Review and Revocation Â 1.Executive acknowledges that (a) Executive knowingly and voluntarily enters into this Agreement with the purpose of waiving any right and releasing any claims under the Age Discrimination in Employment Act of 1967, 29 U.S.C. Â§ 621, et seq. (â€œADEAâ€); (b) Executive was given a period of up to twenty-one (21) days within which to review and consider this Agreement; (c) Executive understood Executive could use as much of said 21-day period as Executive desired; (d) Executive was encouraged by Company to consult with a lawyer, at Executiveâ€™s own expense; (e) if Executive decided not to use the 21-day period, Executive is signing this Agreement voluntarily and of Executiveâ€™s own free will; and (f) this Agreement is not final and binding until the seven-day period of revocation, described in the following sentences of this Section of the Agreement, has expired. Executive understands that Company would not have given Executive the special payments or benefits Executive is getting in exchange for this Agreement but for Executiveâ€™s promises and representations Executive is making by signing it. Â 2.Executive acknowledges that Executive may revoke Executiveâ€™s waiver of the rights and release of any ADEA (age discrimination) claims covered by this Agreement, by delivering written notice of Executiveâ€™s revocation of this Agreement to Jim Parslow at j.parslow@xeneticbio.com, no later than the close of business on the seventh (7th) calendar day after the date on which Executive signed this Agreement (the â€œRevocation Periodâ€). The written notice of revocation must state: â€œI HEREBY REVOKE MY ACCEPTANCE OF THE CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE.â€ If the Agreement is revoked in a timely manner, this Agreement shall not be effective, and Executive shall not receive the Separation Payment as described in Section II.C. herein. Â X. Effectiveness and Electronic Signatures Â This Agreement shall become effective following execution by all the Parties (â€œEffective Dateâ€). This Agreement may be executed via manual signature or electronic signature. â€œElectronic signatureâ€ means (a) the signing partyâ€™s manual signature, converted by the signing party to facsimile or industry-accepted digital form (such as a .pdf file) and received from the signing partyâ€™s customary email address, customary facsimile number, or other mutually agreed-upon authenticated source; or (b) the signing partyâ€™s digital signature executed using a mutually agreed-upon digital signature service provider, such as DocuSign or Adobe sign, and digital signature process. Each Party to this Agreement (i) agrees that it will be bound by its own electronic signature, (ii) accepts the electronic signature of each other Party to this Agreement, and (iii) agrees that such electronic signatures shall be the legal equivalent of manual signatures. This Agreement may be so executed in counterparts, each of which will be considered an original and all such counterparts will be considered and constitute one and the same agreement. Â XI. Disparaging Statements Â Neither the Executive nor the Company shall make any remarks or statements, either publicly or privately, orally or in writing, that are disparaging of the other party. The Executive shall not make any remarks or statements, either publicly, orally or in writing that are disparaging of the Companyâ€™s actual or prospective business and/or, in such capacities, current or former employees, officers, directors, trade partners, vendors, suppliers, or customers of the Company, either individually or collectively. For the avoidance of doubt, this includes remarks or statements, public or private, made via electronic mail, blogs, social media (such as, Facebook, Twitter or X, LinkedIn, Instagram or any other similar platform). This provision is subject to each partyâ€™s legally protected rights to communicate with governmental bodies and agencies and to engage in otherwise legally protected activity. Â Â Â Â [remainder of page intentionally blank] Â Â Â Â 6Â Â Â EMPLOYEE: Â Â Â Â Â Â Â Â /s/ Curtis Lockshin Â Â Curtis Lockshin Â Â Date: June 19, 2024 Â Â Â Â Â COMPANY: Â Â Â Â Â Xenetic Biosciences, Inc. Â Â Â Â Â Â By: /s/ James Parslow Â Â Name: James Parslow Â Â Title: Interim Chief Executive Officer and Chief Financial Officer Date: June 19, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â [Signature page to Separation and Release Agreement] Â Â 7Â Â Â Exhibit A Â Xenetic Biosciences, Inc. Â Curtis Lockshin â€“ Outstanding Equity as of May 16, 2024 Â Date of Grant Shares Exercise Price Expiration Date Total Vested â€˜Total Unvested & Forfeited as of May 16, 2024 Vesting Exercisability post termination 12/31/2014 122 $ 550.80 12/31/2024 122 - Fully Vested 90-days post termination Â Â Â Â Â Â Â Â 9/6/2015 127 $ 550.80 9/6/2025 127 - Fully Vested 10-years from grant date (9/6/25) Â Â Â Â Â Â Â Â 1/1/2017 1,459 $ 516.00 1/1/2027 1,459 - Fully Vested 90-days post termination Â Â Â Â Â Â Â Â 12/4/2019 9,000 $ 13.10 12/4/2029 9,000 - Fully Vested 90-days post termination Â Â Â Â Â Â Â Â 3/18/2021 5,000 $ 26.00 3/18/2031 5,000 - 1/3rd on March 18, 2022; 2/3rds over remaining 8 quarters commencing June 18, 2022 thru March 18, 2024 90-days post termination Â Â Â Â Â Â Â 3/24/2022 5,000 $11.20 3/24/2032 3,333 1,667 1/3rd on March 24, 2023; 2/3rds over remaining 8 quarters commencing June 24, 2023 thru March 24, 2025 90-days post termination Â Â Â Â Â Â Â Â 12/11/2023 10,000 $3.88 12/11/2033 - 10,000 1/3rd on December 11, 2024; 2/3rds over remaining 8 quarters commencing March 11, 2025 thru Dec 11, 2026 90-days post termination Â Â Â 8Â EX-10.3 4 xenetic_ex1003.htm AMENDMENT TO EMPLOYMENT AGREEMENT, DATED JUNE 18, 2024, BETWEEN JAMES F. PARSLOW AND XENETIC BIOSCIENCES, INC. Exhibit 10.3 Â AMENDMENT TO EMPLOYMENT AGREEMENT Â This Amendment (the â€œAmendmentâ€) to the Employment Agreement dated as of March 23, 2017 (the â€œAgreementâ€), between XENETIC BIOSCIENCES, INC., a Nevada corporation (the â€œCompanyâ€), and JAMES F. PARSLOW (the â€œExecutiveâ€) is dated as of June 18, 2024 (the â€œExecution Dateâ€), and effective as of May 16, 2024 (the â€œAmendment Effective Dateâ€). Capitalized terms used herein and not otherwise defined shall have the meaning set forth in the Agreement. Â The Company and Executive desire to enter into this Amendment to the Agreement and hereby agree to the following as of the Amendment Effective Date: Â 1.Section 2(a) of the Agreement is hereby amended by adding the following immediately following the last sentence: Â â€œEffective as of the Amendment Effective Date, the Executive (i) shall serve as Interim Chief Executive Officer, on an interim basis, and shall continue to serve as the Chief Financial Officer of the Company, with responsibilities, duties and authority customary for each of such positions, subject to direction by the Companyâ€™s Board of Directors (â€œBoardâ€), and (ii) shall report directly to the Board; provided, however, that in the event that the Executive is not selected by the Board to be the Chief Executive Officer following the interim period, the Executive shall continue to serve as Chief Financial Officer with responsibilities, duties and authority customary for such position, subject to the direction by the Companyâ€™s Chief Executive Officer and shall report directly to the Chief Executive Officer.â€ Â 2.Section 3(a) of the Agreement is hereby amended by replacing the Base Salary referenced therein with â€œ$400,000â€, which change was effective as of the Amendment Effective Date. Â 3.A new Section 3(f) is hereby added to the Agreement as follows: Â â€œ(f) Retention Bonus. Executive will be eligible to receive a retention bonus (the â€œRetention Bonusâ€) totaling $100,000, less payroll deductions and all required withholdings, if Executive remains employed with the Company on the ten month anniversary of the Amendment Effective Date, or March 16, 2025 (the â€œRetention Bonus Dateâ€); provided, that in the event the Company terminates Executiveâ€™s employment Without Cause prior to the Retention Bonus Date, Executive shall be entitled to receive the Retention Bonus. If earned, the Retention Bonus shall be paid in the next payroll period following the Retention Bonus Date in accordance with the customary payroll practices of the Company in effect at such time.â€ Â 4.A new Section 5(c) is hereby added to the Agreement as follows: Â â€œ(c) Retention Option. The Company shall grant to Executive on the Execution Date a stock option to purchase 20,000 shares of common stock of the Company (the â€œRetention Optionâ€) under the Amended and Restated Xenetic Biosciences, Inc. Equity Incentive Plan, as amended from time to time (the â€œPlanâ€) at an exercise price equal to the fair market value of the Companyâ€™s common stock on the grant date (i.e., the Execution Date). The Retention Option shall vest one-fourth on the grant date, one-fourth upon the first anniversary of the Execution Date, one-fourth upon the second anniversary of the Execution Date and one-fourth upon the third anniversary of the Execution Date, provided the Executive remains employed with the Company on the applicable vesting date. The Retention Option shall be evidenced in writing by, and subject to the terms and conditions of, the Plan, and, except as otherwise set forth herein, the Companyâ€™s standard form of stock option agreement, which agreement shall expire ten (10) years from the date of grant except as otherwise provided herein, in the stock option agreement or the Plan. Executive agrees that he will not loan or pledge any securities of the Company owned by him or which he may accrue in the future through Stock Options or other equity awards as collateral for any indebtedness.â€ Â 5.The Executive acknowledges and agrees that the change in title described in Section 2(a) is on an interim basis and further acknowledges and agrees that any further changes to Executiveâ€™s title in the event the Executive is not chosen as the Companyâ€™s Chief Executive Officer after an interim period, and any related changes in duties and other actions of the Company, does not and shall not constitute â€œGood Reasonâ€ as defined in the Agreement. Â 6.All other provisions of the Agreement not amended hereby shall remain in full force and effect. Â [Signature pages follow] Â Â Â Â 1Â Â Â IN WITNESS WHEREOF, the parties hereto have executed this Amendment under seal as of the date and year first above written. Â Â Â XENETIC BIOSCIENCES, INC. Â Â Â Â Â Â By: /s/ Adam Logal Â Â Â Â Name: Adam Logal Â Â Â Â Title Chairman of the Board of Directors Â Accepted and Agreed to: Â Â Â Â Â Â Â Â /s/ James F. Parslow Â Â James F. Parslow Â [Amendment to Employment Agreement] Â Â Â Â EX-31.1 5 xenetic_ex3101.htm CERTIFICATION EXHIBIT 31.1 Â I, James Parslow, certify that: Â 1. I have reviewed this Quarterly Report on Form 10-Q of Xenetic Biosciences, Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: August 13, 2024 Â Â By: /s/ JAMES PARSLOWÂ James Parslow Interim Chief Executive Officer (Principal Executive Officer) Â Â EX-31.2 6 xenetic_ex3102.htm CERTIFICATION EXHIBIT 31.2 Â I, James Parslow, certify that: Â 1. I have reviewed this Quarterly Report on Form 10-Q of Xenetic Biosciences, Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: August 13, 2024 Â Â By: /s/ JAMES PARSLOWÂ James Parslow Chief Financial Officer (Principal Financial and Principal Accounting Officer) EX-32.1 7 xenetic_ex3201.htm CERTIFICATION EXHIBIT 32.1 Â CERTIFICATION Â Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the â€œExchange Actâ€) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Â§1350), James Parslow, Interim Chief Executive Officer and Chief Financial Officer of the Xenetic Biosciences, Inc. (the â€œCompanyâ€) hereby certifies that, to the best of his knowledge: Â The Companyâ€™s Quarterly Report on Form 10-Q for the period ended June 30, 2024, to which this Certification is attached as Exhibit 32.1 (the â€œPeriodic Reportâ€), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and Â The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Â Date: August 13, 2024 Â In Witness Whereof, the undersigned have set their hands hereto as of the 13th day of August 2024. Â /s/James ParslowÂ Â Â Â Â Â Â Â Â Â Â Â Â James Parslow Interim Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial Officer) Â Â â€œThis certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Xenetic Biosciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.â€Â Â Â EX-101.SCH 8 xbio-20240630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995513 - Disclosure - The Company link:presentationLink link:calculationLink link:definitionLink 995514 - Disclosure - Risks and Uncertainties link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995516 - Disclosure - Significant Strategic Collaborations link:presentationLink link:calculationLink link:definitionLink 995517 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 995518 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995519 - Disclosure - Stockholdersâ€™ Equity link:presentationLink link:calculationLink link:definitionLink 995520 - Disclosure - Share-Based Expense link:presentationLink link:calculationLink link:definitionLink 995521 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995522 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995523 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995524 - Disclosure - Share-Based Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995526 - Disclosure - Significant Strategic Collaborations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995527 - Disclosure - Accrued Expenses and Other Current Liabilities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995528 - Disclosure - Stockholdersâ€™ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995529 - Disclosure - Share-Based Expense (Details - Share based expense) link:presentationLink link:calculationLink link:definitionLink 995530 - Disclosure - Share-Based Expense (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995531 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995532 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 xbio-20240630_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 xbio-20240630_def.xml XBRL DEFINITION FILE EX-101.LAB 11 xbio-20240630_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series B Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Treasury Stock, Common [Member] Counterparty Name [Axis] Catalent Pharma Solutions [Member] Scripps Research [Member] University Of Virginia [Member] Product and Service [Axis] Collaborative Agreements [Member] Transaction Type [Axis] Separation Agreements [Member] Series A Warrants [Member] Award Type [Axis] Publicly Traded Warrants [Member] Other Warrants [Member] Statement of Income Location, Balance [Axis] Research and Development Expense [Member] General and Administrative Expense [Member] Share-Based Payment Arrangement, Option [Member] Restricted Stock Units (RSUs) [Member] Non Employee Stock Options [Member] Related and Nonrelated Parties [Axis] Pharmsynthez [Member] Co Development Agreement [Member] Interest Income Only [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS Current assets: Cash Prepaid expenses, receivables and other Total current assets Other assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Accrued expenses and other current liabilities Total current liabilities Total liabilities Commitments and contingencies Stockholders' equity: Preferred Stock, Value, Issued Common stock, $0.001 par value; 10,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 1,543,802 and 1,543,385 shares issued as of June 30, 2024 and December 31, 2023, respectively; 1,541,101 and 1,540,684 shares outstanding as of June 30, 2024 and December 31, 2023, respectively Additional paid in capital Accumulated deficit Accumulated other comprehensive income Treasury stock Total stockholders' equity Total liabilities and stockholders' equity Preferred Stock, Shares Authorized Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Income Statement [Abstract] Revenue: Royalty revenue Total revenue Operating costs and expenses: Research and development General and administrative Total operating costs and expenses Loss from operations Other income (expense): Other (expense) income Interest income, net Total other income Net loss Earnings Per Share, Basic Earnings Per Share, Diluted Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Diluted Beginning balance, value Beginning balance, shares Issuance of common stock in connection with restricted stock Issuance of common stock in connection with restricted stock, shares Share-based expense Net loss Issuance of common stock to adjust for reverse split rounding Issuance of common stock to adjust for reverse split rounding, shares Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities: Share-based expense Changes in operating assets and liabilities: Prepaid expenses, receivables and other Other assets Accounts payable, accrued expenses and other liabilities Net cash used in operating activities Net change in cash Cash at beginning of period Cash at end of period SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation

[Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Organization, Consolidation and Presentation of Financial Statements [Abstract] The Company Risks and Uncertainties [Abstract] Risks and Uncertainties Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Strategic Collaborations Payables and Accruals [Abstract] Accrued Expenses and Other Current Liabilities Fair Value Disclosures [Abstract] Fair Value Measurements Equity [Abstract] Stockholdersâ€™ Equity Share-Based Payment Arrangement [Abstract] Share-Based Expense Income Tax Disclosure [Abstract] Income Taxes Related Party Transactions [Abstract] Related Party Transactions Preparation of Interim Financial Statements Principles of Consolidation Basic and Diluted Net Loss per Share Schedule of share-based compensation expense Stockholders' Equity, Reverse Stock Split Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Royalty income Research and development expenses Prepaid expenses and other current assets Accrued expenses and other current liabilities Other assets Revenues Offsetting Assets [Table] Offsetting Assets [Line Items] Labor and related expenses Share based compensation Stock, Class of Stock [Table] Class of Stock [Line Items] Warrant Outstanding Exercise price Maturity date Warrants exercised Warrants forfeited Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based compensation Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Options granted Other than options granted, shares Stock issued for RSU's Options exercised Options forfeited Options expired Provision for income taxes Deferred tax valuation allowance Unrecognized tax positions Related Party Transaction [Table] Related Party Transaction [Line Items] Payments to Acquire Notes Receivable Accounts and Financing Receivable, after Allowance for Credit Loss Interest and Other Income Assets, Current Assets Liabilities, Current Liabilities Treasury Stock, Common, Value Equity, Attributable to Parent Liabilities and Equity General and Administrative Expense Operating Expenses Operating Income (Loss) Shares, Outstanding Increase (Decrease) in Accounts and Other Receivables Increase (Decrease) in Other Noncurrent Assets Net Cash Provided by (Used in) Operating Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Accrued Liabilities and Other Liabilities Other Assets EX-101.PRE 12 xbio-20240630_pre.xml XBRL PRESENTATION FILE XML 14 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover - shares 6 Months Ended Jun. 30, 2024 Aug. 09, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Amendment Flag false Â Document Quarterly Report true Â Document Transition Report false Â Document Period End Date Jun. 30, 2024 Â Document Fiscal Period Focus Q2 Â Document Fiscal Year Focus 2024 Â Current Fiscal Year End Date --12-31 Â Entity File Number 001-37937 Â Entity Registrant Name XENETIC BIOSCIENCES, INC. Â Entity Central Index Key 0001534525 Â Entity Tax Identification Number 45-2952962 Â Entity Incorporation, State or Country Code NV Â Entity Address, Address Line One 945 Concord Street Â Entity Address, City or Town Framingham Â Entity Address, State or Province MA Â Entity Address, Postal Zip Code 01701 Â City Area Code 781 Â Local Phone Number 778-7720 Â Title of 12(b) Security Common Stock, $0.001 par value per share Â Trading Symbol XBIO Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 1,542,139 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 15 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) Jun. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash $ 7,298,597 $ 8,983,046 Prepaid expenses, receivables and other 716,381 603,828 Total current assets 8,014,978 9,586,874 Other assets 1,018,352 1,018,352 Total assets 9,033,330 10,605,226 Current liabilities: Â Â Accounts payable 283,586 240,832 Accrued expenses and other current liabilities 1,304,016 568,753 Total current liabilities 1,587,602 809,585 Total liabilities 1,587,602 809,585 Commitments and contingencies Stockholders' equity: Â Â Common stock, $0.001 par value; 10,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 1,543,802 and 1,543,385 shares issued as of June 30, 2024 and December 31, 2023, respectively; 1,541,101 and 1,540,684 shares outstanding as of June 30, 2024 and December 31, 2023, respectively 1,544 1,544 Additional paid in capital 208,173,105 208,053,935 Accumulated deficit (195,703,279) (193,234,196) Accumulated other comprehensive income 253,734 253,734 Treasury stock (5,281,180) (5,281,180) Total stockholders' equity 7,445,728 9,795,641 Total liabilities and stockholders' equity 9,033,330 10,605,226 Series B Preferred Stock [Member] Â Â Stockholders' equity: Â Â Preferred Stock, Value, Issued $ 1,804 $ 1,804 X - DefinitionAmount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -

Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20 + Details Name: us-gaap_Cash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-

1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -

Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount allocated to previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 16 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares Jun. 30, 2024 Dec. 31, 2023 Preferred Stock, Shares Authorized 10,000,000 10,000,000 Common Stock, Par or Stated Value Per Share $ 0.001 $ 0.001 Common Stock, Shares Authorized 10,000,000 10,000,000 Common Stock, Shares, Issued 1,543,802 1,543,385 Common Stock, Shares, Outstanding 1,541,101 1,540,684 Series B Preferred Stock [Member] Â Â Preferred Stock, Par or Stated Value Per Share $ 0.001 $ 0.001 Preferred Stock, Shares Issued 1,804,394 1,804,394 Preferred Stock, Shares Outstanding 1,804,394 1,804,394 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Revenue: Â Â Â Â Royalty revenue $ 726,404 $ 651,005 $ 1,237,221 $ 1,256,849 Total revenue 726,404 651,005 1,237,221 1,256,849 Operating costs and expenses: Â Â Â Â Research and development (933,771) (903,243) (1,878,092) (1,498,519) General and administrative (1,130,029) (945,950) (1,964,939) (1,871,693) Total operating costs and expenses (2,063,800) (1,849,193) (3,843,031) (3,370,212) Loss from operations (1,337,396) (1,198,188) (2,605,810) (2,113,363) Other income (expense): Â Â Â Â Other (expense) income (21) 21,122 31 25,642 Interest income, net 63,447 126,103 136,696 180,204 Total other income 63,426 147,225 136,727 205,846 Net loss $ (1,273,970) $ (1,050,963) $ (2,469,083) $ (1,907,517) X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as operating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_InterestIncomeExpenseNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingCostsAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAncillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RoyaltyIncomeNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 18 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) - $ / shares 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Income Statement [Abstract] Â Â Â Â Earnings Per Share, Basic $ (0.83) $ (0.69) $ (1.60) $ (1.25) Earnings Per Share, Diluted $ (0.83) $ (0.69) $ (1.60) $ (1.25) Weighted Average Number of Shares Outstanding, Basic 1,540,799 1,524,717 1,540,741 1,520,710 Weighted Average Number of Shares Outstanding, Diluted 1,540,799 1,524,717 1,540,741 1,520,710 X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -

Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 19 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($) Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Treasury Stock, Common [Member] Total Beginning balance, value at Dec. 31, 2022 $ 2,774 $ 1,520 $ 207,769,904 $ (189,099,618) $ 253,734 $ (5,281,180) $ 13,647,134 Beginning balance, shares at Dec. 31, 2022 2,774,394 1,519,360 Â Â Â Â Â Share-based expense 138,241 138,241 Net loss (1,907,517) (1,907,517) Issuance of common stock to adjust for reverse split rounding $ 16 (16) Issuance of common stock to adjust for reverse split rounding, shares Â 15,941 Â Â Â Â Â Ending balance, value at Jun. 30, 2023 $ 2,774 $ 1,536 207,908,129 (191,007,135) 253,734 (5,281,180) 11,877,858 Ending balance, shares at Jun. 30, 2023 2,774,394 1,535,301 Â Â Â Â Â Beginning balance, value at Mar. 31, 2023 $ 2,774 $ 1,520 207,838,756 (189,956,172) 253,734 (5,281,180) 12,859,432 Beginning balance, shares at Mar. 31, 2023 2,774,394 1,519,360 Â Â Â Â Â Share-based expense 69,389 69,389 Net loss (1,050,963) (1,050,963) Issuance of common stock to adjust for reverse split rounding $ 16 (16) Issuance of common stock to adjust for reverse split rounding, shares Â 15,941 Â Â Â Â Â Ending balance, value at Jun. 30, 2023 $ 2,774 $ 1,536 207,908,129 (191,007,135) 253,734 (5,281,180) 11,877,858 Ending balance, shares at Jun. 30, 2023 2,774,394 1,535,301 Â Â Â Â Â Beginning balance, value at Dec. 31, 2023 $ 1,804 $ 1,544 208,053,935 (193,234,196) 253,734 (5,281,180) 9,795,641 Beginning balance, shares at Dec. 31, 2023 1,804,394 1,543,385 Â Â Â Â Â Issuance of common stock in connection with restricted stock Issuance of common stock in connection with restricted stock, shares Â 417 Â Â Â Â Â Share-based expense 119,170 119,170 Net loss (2,469,083) (2,469,083) Ending balance, value at Jun. 30, 2024 $ 1,804 $ 1,544 208,173,105 (195,703,279) 253,734 (5,281,180) 7,445,728 Ending balance, shares at Jun. 30, 2024 1,804,394 1,543,802 Â Â Â Â Â Beginning balance, value at Mar. 31, 2024 $ 1,804 $ 1,544 208,131,009 (194,429,309) 253,734 (5,281,180) 8,677,602 Beginning balance, shares at Mar. 31, 2024 1,804,394 1,543,385 Â Â Â Â Â Issuance of common stock in connection with restricted stock Issuance of common stock in connection with restricted stock, shares Â 417 Â Â Â Â Â Share-based expense 42,096 42,096 Net loss (1,273,970) (1,273,970) Ending balance, value at Jun. 30, 2024 $ 1,804 $ 1,544 $ 208,173,105 $ (195,703,279) $ 253,734 $ (5,281,180) $ 7,445,728 Ending balance, shares at Jun. 30, 2024 1,804,394 1,543,802 Â Â Â Â Â X - ReferencesNo definition available. + Details Name: XBIO_StockIssuedDuringPeriodValueReverseStockSplits Namespace Prefix: XBIO_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -

Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionReduction in the number of shares during the period as a result of a reverse stock split. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 20 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Â Â Net loss $ (1,273,970) $ (1,050,963) $ (2,469,083) $ (1,907,517) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Share-based expense 42,096 69,389 119,170 138,241 Changes in operating assets and liabilities: Â Â Â Â Prepaid expenses, receivables and other Â Â (112,553) (762,941) Other assets Â Â 0 362,500 Accounts payable, accrued expenses and other liabilities Â Â 778,017 (201,841) Net cash used in operating activities Â Â (1,684,449) (2,371,558) Net change in cash Â Â (1,684,449) (2,371,558) Cash at beginning of period Â Â 8,983,046 13,097,265 Cash at end of period $ 7,298,597 $ 10,725,707 7,298,597 10,725,707 SUPPLEMENTAL CASH FLOW INFORMATION: Â Â Â Â Cash paid for interest Â Â $ 0 $ 0 X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pay vs Performance Disclosure - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Pay vs Performance Disclosure [Table] Â Â Â Â Net Income (Loss) $ (1,273,970) $ (1,050,963) $ (2,469,083) $ (1,907,517) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 22 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 Insider Trading Arrangements [Line Items] Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a + Details Name: ecd_InsiderTradingArrLineItems Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration XML 23 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 The Company 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â The Company Â 1. The Company Â Background Â Xenetic Biosciences, Inc. (â€œXeneticâ€ or the â€œCompanyâ€), incorporated in the state of Nevada and based in Framingham, Massachusetts, is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Companyâ€™s proprietary Deoxyribonuclease (â€œDNaseâ€) platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (â€œNETsâ€), which have been implicated in cancer progression and resistance to cancer treatments. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Additionally, Xenetic has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXenÂ®, and receives royalty payments under an exclusive license arrangement in the field of blood coagulation disorders. Â As used in this Quarterly Report on Form 10-Q (â€œQuarterly Reportâ€), unless otherwise indicated, all references herein to â€œXenetic,â€ the â€œCompany,â€ â€œweâ€ or â€œusâ€ refer to Xenetic Biosciences, Inc. and its wholly-owned subsidiaries. Â The Company, directly or indirectly, through its wholly-owned subsidiaries, Hesperix S.A. (â€œHesperixâ€) and Xenetic Biosciences (U.K.) Limited (â€œXenetic UKâ€), and the wholly-owned subsidiaries of Xenetic UK, Lipoxen Technologies Limited (â€œLipoxenâ€), Xenetic Bioscience, Incorporated and SymbioTec, GmbH (â€œSymbioTecâ€), own various United States (â€œU.S.â€) federal trademark registrations and applications along with unregistered trademarks and service marks, including but not limited to XCARTâ„¢, OncoHistâ„¢, PolyXen, ErepoXenâ„¢, and ImuXenâ„¢, which may be used throughout this Quarterly Report. All other company and product names may be trademarks of the respective companies with which they are associated. Â Going Concern and Managementâ€™s Plan Â Management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Companyâ€™s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company has incurred substantial losses since its inception and expects to continue to incur operating losses in the near-term. The Company believes that its existing resources will be adequate to fund the Companyâ€™s operations for a period of at least twelve months from the date of the issuance of these financial statements. However, the Company anticipates it will need additional capital in the long-term to pursue its business initiatives. While the Company believes it has access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations, related party funding, or other means to continue as a going concern, the terms, timing and extent of any future financing will depend upon several factors, including the achievement of progress in its product development programs, its ability to identify and enter into licensing or other strategic arrangements, its continued listing on the Nasdaq Stock Market (â€œNasdaqâ€), and factors related to financial, economic, geo-political, industry and market conditions, many of which are beyond its control. The capital markets for the biotech industry can be highly volatile, which make the terms, timing and extent of any future financing uncertain. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Risks and Uncertainties 6 Months Ended Jun. 30, 2024 Risks and Uncertainties [Abstract] Â Risks and Uncertainties Â 2. Risks and Uncertainties Â Impact of Global Conflicts on Operations Â The short and long-term implications of Russiaâ€™s invasion of Ukraine and conflict in the Middle East are difficult to predict at this time. The imposition of current and future sanctions and counter sanctions may have an adverse effect on the economic markets generally and could impact our business, financial condition, and results of operations. X - DefinitionThe entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic

275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent + Details Name: us-gaap_ConcentrationRiskDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RisksAndUncertaintiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 25 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Summary of Significant Accounting Policies Â 3. Summary of Significant Accounting Policies Â Preparation of Interim Financial Statements Â The accompanying condensed consolidated interim financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (â€œSECâ€) and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results for the full year. The condensed consolidated financial statements contained herein should be read in conjunction with the consolidated financial statements and notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 21, 2024, and amended on April 26, 2024. Â On May 15, 2023, the Company effected a reduction, on a 1-for-10 basis, in its authorized common stock, par value $0.001, along with a corresponding and proportional decrease in the number of shares issued and outstanding (the â€œReverse Stock Splitâ€). On the effective date of the Reverse Stock Split, (i) every 10 shares of common stock were reduced to one share of common stock, with any fractional amounts rounded up to one share; (ii) the number of shares of common stock into which each outstanding warrant, restricted stock unit (â€œRSUâ€), or option to purchase common stock was convertible into was proportionately reduced on the same basis as the common stock; (iii) the exercise price of each outstanding warrant or option to purchase common stock was proportionately increased on a 1-to-10 basis; and (iv) the number of shares of common stock into which each share of preferred stock was convertible into was proportionately reduced on the same basis as the common stock. Unless otherwise indicated, all of the share numbers, share prices, and exercise prices have been adjusted in this Quarterly Report, on a retroactive basis, to reflect this 1-for-10 Reverse Stock Split. Â Principles of Consolidation Â The condensed consolidated financial statements of the Company include the accounts of Hesperix, Xenetic UK and Xenetic UKâ€™s wholly owned subsidiaries: Lipoxen, Xenetic Bioscience, Incorporated, and SymbioTec. Certain of the Companyâ€™s subsidiaries require guarantees of support from Xenetic. While all intercompany balances and transactions have been eliminated in consolidation, the Company has $0.2 million of cash collateralizing these guarantees. Â Basic and Diluted Net Loss per Share Â The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted-average number of shares of the Companyâ€™s common stock outstanding during the period. The Company computes diluted net loss per share after giving consideration to the dilutive effect of stock options that are outstanding during the period, except where such non-participating securities would be anti-dilutive. Â For the three and six months ended June 30, 2024 and 2023, basic and diluted net loss per share are the same in each respective period due to the Companyâ€™s net loss position. Potentially dilutive, non-participating securities have not been included in the calculations of diluted net loss per share, as their inclusion would be anti-dilutive. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Significant Strategic Collaborations 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Significant Strategic Collaborations Â 4. Significant Strategic Collaborations Â Takeda Pharmaceutical Co. Ltd. (together with its wholly-owned subsidiaries, â€œTakedaâ€) Â In October 2017, the Company granted to Takeda the right to grant a non-exclusive sublicense to certain patents related to the Companyâ€™s PolyXen technology that were previously exclusively licensed to Takeda in connection with products related to the treatment of blood and bleeding disorders. Royalty payments of approximately $0.7 million and $1.2 million were recorded as revenue by the Company during the three and six months ended June 30, 2024, respectively, and approximately $0.7 million and $1.3 million were recorded as revenue by the Company during the three and six months ended June 30, 2023, respectively. These payments are based on single digit royalties on net sales of certain covered products. The Companyâ€™s policy is to recognize royalty payments as revenue when they are reliably measurable, which is upon receipt of reports from Takeda. The Company receives these reports in the quarter subsequent to the actual sublicensee sales. At the time the revenue was received, there were no remaining performance obligations and all other revenue recognition criteria were met. Â Belgian Volition SARL Limited (â€œVolitionâ€) Collaboration Â On August 2, 2022, the Company announced a research and development collaboration with Volition to develop NETs-targeted adoptive cell therapies for the treatment of cancer. The collaboration is an early exploratory program to evaluate the potential combination of Volitionâ€™s Nu.QÂ® technology Test and the Companyâ€™s DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting multiple types of solid cancers. Under the terms of the collaboration agreement, Volition will fund a research program and the two parties will share proceeds from commercialization or licensing of any products arising from the collaboration. To date, Volition has funded $26,000 under this agreement. Â Catalent Pharma Solutions LLC (â€œCatalentâ€) Â On June 30, 2022, the Company entered into a Statement of Work (the â€œSOWâ€) with Catalent to outline the general scope of work, timeline, and pricing pursuant to which Catalent will provide certain services to the Company to perform cGMP manufacturing of the Companyâ€™s recombinant protein, Human DNase I. The parties agreed to enter into a Master Services Agreement that will contain terms and conditions to govern the project contemplated by the SOW and that will supersede the addendum to the SOW containing Catalent's standard terms and conditions. The Company has paid Catalent approximately $2.5 million through June 30, 2024, of which approximately $28,000 and $0.1 million has been recognized as an advance payment and is included in prepaid expenses, receivables and other current assets as of June 30, 2024 and December 31, 2023, respectively, and approximately $49,000 has been recognized as a liability and is included in accrued expenses and other current liabilities as of June 30, 2024. There was no accrual as of December 31, 2023. In addition, approximately $0.3 million has been recognized within other assets as of both June 30, 2024 and December 31, 2023. Â Scripps Research Institute (â€œScripps Researchâ€) Â On March 17, 2023, the Company and Scripps Research entered into a Research Funding and Option Agreement (the â€œAgreementâ€), pursuant to which the Company has agreed to provide Scripps Research an aggregate of up to $0.9 million to fund research relating to advancing the pre-clinical development of the Companyâ€™s DNase oncology platform technology. Under the Agreement, the Company has the option to acquire a worldwide exclusive license to Scripps Researchâ€™s rights in the Technology or Patent Rights (as defined in the Agreement), as well as a non-exclusive, royalty-free, non-transferrable license to make and use TSRI Technology (as defined in the Agreement) solely for the Companyâ€™s internal research purposes during the performance of the research program contemplated by the Agreement. During the second quarter of 2024, the Company amended the Agreement to extend the term to October 31, 2024 with no additional funding required. The Company has paid Scripps Research approximately $0.9 million under the Agreement through June 30, 2024, of which approximately $0.1 million and $0.4 million has been recognized as an advance payment and is included in prepaid expenses, receivables and other current assets as of June 30, 2024 and December 31, 2023, respectively. Â University of Virginia (â€œUVAâ€) Â On December 21, 2023, the Company entered into a Research Funding and Material Transfer Agreement with UVA (the â€œUVA Agreementâ€) to advance the development of our systemic DNase program. Under the terms of the UVA Agreement, in addition to advancing our existing intellectual property, we have an option to acquire an exclusive license to any new intellectual property arising from the DNase research program. Allan Tsung, MD, a member of the Companyâ€™s Scientific Advisory Board and Chair of the Department of Surgery at the UVA School of Medicine, will oversee the research conducted under the UVA Agreement. The Company has paid UVA approximately $0.2 million under the UVA Agreement through June 30, 2024, which was expensed during the six months ended June 30, 2024. There were no amounts incurred as of December 31, 2023. Â Other Agreements Â The Company has also entered into various research, development, license and supply agreements with Serum Institute of India (â€œSerum Instituteâ€), PJSC Pharmsynthez (â€œPharmsynthezâ€) and SynBio LLC (â€œSynBioâ€), a wholly owned subsidiary of Pharmsynthez. The Company and its collaborative partners continue to engage in research and development activities with no resultant commercial products through June 30, 2024. No amounts were recognized as revenue related to the Serum Institute, Pharmsynthez or SynBio agreements during the three and six months ended June 30, 2024 and 2023, respectively. X - DefinitionThe entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 808 -Publisher FASB -URI https://asc.fasb.org/808/tableOfContent + Details Name: us-gaap_CollaborativeArrangementDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued Expenses and Other Current Liabilities 6 Months Ended Jun. 30, 2024 Payables and Accruals [Abstract] Â Accrued Expenses and Other Current Liabilities Â 5. Accrued Expenses and Other Current Liabilities Â On June 19, 2024, the Company entered into a confidential separation agreement and general release with each of Jeffrey F. Eisenberg, the Companyâ€™s former Chief Executive Officer (the â€œEisenberg Separation Agreementâ€), and Curtis Lockshin, the Companyâ€™s former Chief Scientific Officer (the â€œLockshin Separation Agreementâ€ and together, the â€œSeparation Agreementsâ€) pursuant to which Messrs. Eisenberg and Lockshin were each eligible for certain severance payments and benefits consistent with the terms of their existing employment agreements as described under â€œEmployment Agreements with our Named Executive Officersâ€ in the Amendment No. 1 to Annual Report on Form 10-K/A filed by the Company with the Securities and Exchange Commission on April 26, 2024. In addition, the Eisenberg Separation Agreement provides for accelerated vesting of all of the unvested stock options held by Mr. Eisenberg as of May 16, 2024. As of June 30, 2024, the Company expensed approximately $0.8 million of accrued payroll and benefits related to the Separation Agreements. In addition, the Company recorded approximately $13,000 of share-based expense for the accelerated vesting of unvested stock options. As of June 30, 2024, approximately $0.8 million was accrued within accrued expenses and other current liabilities related to these obligations. X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 28 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements Â 6. Fair Value Measurements Â Accounting Standards Codification Topic 820, Fair Value Measurement, defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. As of June 30, 2024 and December 31, 2023, the carrying amounts of the Companyâ€™s financial instruments approximates fair value due to their short maturities. There were no financial instruments classified as Level 3 in the fair value hierarchy during the three and six months ended June 30, 2024 and 2023. Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50

-Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholdersâ€™ Equity 6 Months Ended Jun. 30, 2024 Equity [Abstract] Â Stockholdersâ€™ Equity Â 7. Stockholdersâ€™ Equity Â Common Stock Â Each share of the Companyâ€™s common stock entitles the holder to one vote on all matters submitted to a vote of the Companyâ€™s stockholders. Common stockholders are entitled to dividends when and if declared by the Board of Directors. In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Company, the holders of common stock are entitled to share ratably in the assets of the Company available for distribution. Â On May 11, 2023, the Company filed a Certificate of Change to the Companyâ€™s Articles of Incorporation with the Secretary of State of Nevada to effect the Reverse Stock Split. The Reverse Stock Split was effective at 12:01 a.m., Eastern Time, on May 15, 2023. No fractional shares were issued as a result of the Reverse Stock Split and any remaining share fractions were rounded up to the nearest whole share, resulting in 15,941 new shares of common stock being issued to existing holders of the Companyâ€™s common stock. Â Warrants Â The Company has warrants to purchase approximately 462,963 shares of the Companyâ€™s common stock (the â€œSeries A Warrantsâ€) outstanding as of both June 30, 2024 and December 31, 2023. The Series A Warrants are immediately exercisable at a price of $33.00 per share of common stock and expire on February 23, 2025. No Series A Warrants were exercised or forfeited during the three and six months ended June 30, 2024 and 2023. Â In addition, the Company had publicly traded warrants to purchase approximately 2,100 shares of common stock outstanding as of both June 30, 2024 and December 31, 2023. These warrants had an exercise price of $130.00 per share of common stock and expired on July 19, 2024. The warrants ceased trading on Nasdaq under the symbol â€œXBIOWâ€ upon expiration. The warrants also provided that if the weighted-average price of common stock on any trading day on or after 30 days after issuance is lower than the then-applicable exercise price per share, each warrant may be exercised, at the option of the holder, on a cashless basis for one share of common stock. None of these warrants were exercised or forfeited during the three and six months ended June 30, 2024 and 2023. Â The Company also has warrants to purchase approximately 800 shares of the Companyâ€™s common stock outstanding as of both June 30, 2024 and December 31, 2023. These warrants have an exercise price of $29.09 per share of common stock and expire on July 3, 2026. None of these warrants were exercised or forfeited during the three and six months ended June 30, 2024 and 2023. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Share-Based Expense 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Share-Based Expense Â 8. Share-Based Expense Â Total share-based expense related to stock options and RSUâ€™s was approximately $42,000 and $0.1 million for the three months ended June 30, 2024 and 2023, respectively, and approximately $0.1 million and $0.1 million for each of the six months ended June 30, 2024 and 2023. Â Share-based expense is classified in the condensed consolidated statements of operations as follows:Â Schedule of share-based compensation expenseÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Three Months Ended June 30,Â Â Six Months Ended June 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Research and development expensesÂ $(3,804)Â $13,778Â Â $11,433Â Â $27,466Â General and administrative expensesÂ Â 45,900Â Â Â 55,611Â Â Â 107,737Â Â Â 110,775Â Â Â $42,096Â Â $69,389Â Â $119,170Â Â $138,241Â Â Employee Stock Options and RSUâ€™s Â During the three and six months ended June 30, 2024, 20,000 stock options to purchase shares of common stock were granted by the Company. No stock option awards to purchase shares of common stock were granted during the three and six months ended June 30, 2023. No RSUs were granted during each of the three and six months ended June 30, 2024 and 2023. The Company recognized a total of approximately $42,000 and $0.1 million of share-based expense related to employee stock options during the three months ended June 30, 2024 and 2023, respectively, and $0.1 million during each of the six months ended June 30, 2024 and 2023, respectively. The Company issued 417 shares of common stock during the three and six months ended June 30, 2024 related to RSUâ€™s. No employee stock options were exercised during the three and six months ended June 30, 2024 and 2023. During the three and six months ended June 30, 2024 stock options to purchase 11,667 shares of common stock were forfeited. No employee stock options expired during the three and six months ended June 30, 2023. Â Non-Employee Stock Options Â There were no non-employee stock options granted or exercised during the three and six months ended June 30, 2024 and 2023, respectively. No non-employee stock option grants expired during the three and six months ended June 30, 2024. During the six months ended June 30, 2023, non-employee stock option grants to purchase approximately 100 shares of common stock expired. The Company did not recognize any expense related to non-employee stock options during the three and six months ended June 30, 2024 and 2023, respectively. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 31 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income Taxes 6 Months Ended Jun. 30, 2024 Income Tax Disclosure [Abstract] Â Income Taxes Â 9. Income Taxes Â During the three and six months ended June 30, 2024 and 2023, there was no provision for income taxes as the Company incurred losses during both periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company records a valuation allowance against its deferred tax assets as the Company believes it is more likely than not the deferred tax assets will not be realized. The valuation allowance against deferred tax assets was approximately $40.4 million and $39.7 million as of June 30, 2024 and December 31, 2023, respectively. Â As of June 30, 2024 and DecemberÂ 31, 2023, the Company did not record any unrecognized tax positions. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Related Party Transactions 6 Months Ended Jun. 30, 2024 Related Party Transactions [Abstract] Â Related Party Transactions Â 10. Related Party Transactions Â The Company has entered into various research, development, license and supply agreements with Serum Institute and Pharmsynthez, each a related party whose relationship has not materially changed from that disclosed in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 21, 2024, as amended on April 26, 2024. Â During the fourth quarter of 2019, the Company entered into a loan agreement with Pharmsynthez (the â€œPharmsynthez Loanâ€), pursuant to which the Company advanced Pharmsynthez an aggregate principal amount of up to $500,000 to be used for the development of a specific product under the Companyâ€™s Co-Development Agreement with Pharmsynthez. The Pharmsynthez Loan had an initial term of 15-months and accrued interest at a rate of 10% per annum. The Pharmsynthez Loan was guaranteed by all of the operating subsidiaries of Pharmsynthez, including SynBio and AS Kevelt, and was secured by all of the common and preferred stock of the Company owned by Pharmsynthez and SynBio. Â Pharmsynthez paid all obligations due under the Pharmsynthez Loan in May 2023, and no further amounts are due under the Pharmsynthez Loan. As a result, no amounts were outstanding as of June 30, 2024 and December 31, 2023. The Company did not recognize any interest income related to the Pharmsynthez Loan during the three and six months ended June 30, 2024. The Company recognized approximately $65,000 of income related to interest and fees associated with the Pharmsynthez Loan including approximately $40,000 related to interest income during the three and six months ended June 30, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies (Policies) 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Preparation of Interim Financial Statements Preparation of Interim Financial Statements Â The accompanying condensed consolidated interim financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (â€œSECâ€) and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results for the full year. The condensed consolidated financial statements contained herein should be read in conjunction with the consolidated financial statements and notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 21, 2024, and amended on April 26, 2024. Â On May 15, 2023, the Company effected a reduction, on a 1-for-10 basis, in its authorized common stock, par value $0.001, along with a corresponding and proportional decrease in the number of shares issued and outstanding (the â€œReverse Stock Splitâ€). On the effective date of the Reverse Stock Split, (i) every 10 shares of common stock were reduced to one share of common stock, with any fractional amounts rounded up to one share; (ii) the number of shares of common stock into which each outstanding warrant, restricted stock unit (â€œRSUâ€), or option to purchase common stock was convertible into was proportionately reduced on the same basis as the common stock; (iii) the exercise price of each outstanding warrant or option to purchase common stock was proportionately increased on a 1-to-10 basis; and (iv) the number of shares of common stock into which each share of preferred stock was convertible into was proportionately reduced on the same basis as the common stock. Unless otherwise indicated, all of the share numbers, share prices, and exercise prices have been adjusted in this Quarterly Report, on a retroactive basis, to reflect this 1-for-10 Reverse Stock Split. Â Principles of Consolidation Principles of Consolidation Â The condensed consolidated financial statements of the Company include the accounts of Hesperix, Xenetic UK and Xenetic UKâ€™s wholly owned subsidiaries: Lipoxen, Xenetic Bioscience, Incorporated, and SymbioTec. Certain of the Companyâ€™s subsidiaries require guarantees of support from Xenetic. While all intercompany balances and transactions have been eliminated in consolidation, the Company has $0.2 million of cash collateralizing these guarantees. Â Basic and Diluted Net Loss per Share Basic and Diluted Net Loss per Share Â The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted-average number of shares of the Companyâ€™s common stock outstanding during the period. The Company computes diluted net loss per share after giving consideration to the dilutive effect of stock options that are outstanding during the period, except where such non-participating securities would be anti-dilutive. Â For the three and six months ended June 30, 2024 and 2023, basic and diluted net loss per share are the same in each respective period due to the Companyâ€™s net loss position. Potentially dilutive, non-participating securities have not been included in the calculations of diluted net loss per share, as their inclusion would be anti-dilutive. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Share-Based Expense (Tables) 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Schedule of share-based compensation expense Schedule of share-based compensation expenseÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Three Months Ended June 30,Â Â Â Six Months Ended June 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Research and development expensesÂ $(3,804)Â $13,778Â Â $11,433Â Â $27,466Â General and administrative expensesÂ Â 45,900Â Â Â 55,611Â Â Â 107,737Â Â Â 110,775Â Â Â $42,096Â Â $69,389Â Â $119,170Â Â $138,241Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies (Details Narrative) May 15, 2023 Accounting Policies [Abstract] Â Stockholders' Equity, Reverse Stock Split 1-for-10 basis X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 36 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Significant Strategic Collaborations (Details Narrative) - USD ($) 3 Months Ended 6 Months Ended 12 Months Ended 16 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Jun. 30, 2024 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Royalty income $ 726,404 $ 651,005 $ 1,237,221 $ 1,256,849 Â Â Research and development expenses 933,771 903,243 1,878,092 1,498,519 Â Â Prepaid expenses and other current assets 716,381 Â 716,381 Â $ 603,828 $ 716,381 Revenues 726,404 651,005 1,237,221 1,256,849 Â Â Collaborative Agreements [Member] Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Revenues 0 $ 0 0 $ 0 Â Â Catalent Pharma Solutions [Member] Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Research and development expenses Â Â 2,500,000 Â Â Â Prepaid expenses and other current assets 28,000 Â 28,000 Â 100,000 28,000 Accrued expenses and other current liabilities 49,000 Â 49,000 Â 0 49,000 Other assets 300,000 Â 300,000 Â 300,000 300,000 Scripps Research [Member] Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Research and development expenses Â Â Â Â Â 900,000 Prepaid expenses and other current assets $ 100,000 Â 100,000 Â 400,000 $ 100,000 University Of Virginia [Member] Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Research and development expenses Â Â $ 200,000 Â $ 0 Â X - DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAncillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RoyaltyIncomeNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=XBIO_CollaborativeAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=XBIO_CatalentPharmaSolutionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=XBIO_ScrippsResearchMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=XBIO_UniversityOfVirginiaMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued Expenses and Other Current Liabilities (Details Narrative) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Offsetting Assets [Line Items] Â Â Â Â Share based compensation $ 42,096 $ 69,389 $ 119,170 $ 138,241 Separation Agreements [Member] Â Â Â Â Offsetting Assets [Line Items] Â Â Â Â Labor and related expenses Â Â 800,000 Â Share based compensation Â Â 13,000 Â Accrued expenses and other current liabilities $ 800,000 Â $ 800,000 Â X - DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_LaborAndRelatedExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_OffsettingAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_TransactionTypeAxis=XBIO_SeparationAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholdersâ€™ Equity (Details Narrative) - $ / shares 3 Months Ended 6 Months Ended May 11, 2023 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Publicly Traded Warrants [Member] Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Warrant Outstanding Â 2,100 Â 2,100 Â 2,100 Exercise price Â $ 130.00 Â $ 130.00 Â Â Maturity date Â Jul. 19, 2024 Â Jul. 19, 2024 Â Â Other Warrants [Member] Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Warrant Outstanding Â 800 Â 800 Â 800 Exercise price Â $ 29.09 Â $ 29.09 Â Â Maturity date Â Jul. 03, 2026 Â Jul. 03, 2026 Â Â Warrants exercised Â 0 0 0 0 Â Warrants forfeited Â 0 0 0 0 Â Common Stock [Member] Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Issuance of common stock to adjust for reverse split rounding, shares 15,941 Â Â Â Â Â Series A Warrants [Member] Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Warrant Outstanding Â 462,963 Â 462,963 Â 462,963 Exercise price Â $ 33.00 Â $ 33.00 Â Â Maturity date Â Feb. 23, 2025 Â Feb. 23, 2025 Â Â Warrants exercised Â 0 0 0 0 Â Warrants forfeited Â 0 0 0 0 Â Publicly Traded Warrants [Member] Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Warrants exercised Â 0 0 0 0 Â Warrants forfeited Â 0 0 0 0 Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of non-option equity instruments exercised by participants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionReduction in the number of shares during the period as a result of a reverse stock split. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExpiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=XBIO_PubliclyTradedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=XBIO_OtherWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=XBIO_SeriesAWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=XBIO_PubliclyTradedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Share-Based Expense (Details - Share based expense) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Share-based compensation $ 42,096 $ 69,389 $ 119,170 $ 138,241 Research and Development Expense [Member] Â Â Â Â Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Share-based compensation (3,804) 13,778 11,433 27,466 General and Administrative Expense [Member] Â Â Â Â Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Share-based compensation $ 45,900 $ 55,611 $ 107,737 $ 110,775 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Share-Based Expense (Details Narrative) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Share based compensation $ 42,096 $ 69,389 $ 119,170 $ 138,241 Share-Based Payment Arrangement, Option [Member] Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Options granted 20,000 0 20,000 0 Share based compensation $ 42,000 $ 100,000 $ 100,000 $ 100,000 Options exercised 0 0 0 0 Options forfeited 11,667 Â 11,667 Â Options expired Â 0 Â 0 Restricted Stock Units (RSUs) [Member] Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Other than options granted, shares 0 0 0 0 Stock issued for RSU's 417 Â 417 Â Non Employee Stock Options [Member] Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Options granted 0 0 0 0 Options exercised 0 0 0 0 X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionFor presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNet number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=XBIO_NonEmployeeStockOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income Taxes (Details Narrative) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Income Tax Disclosure [Abstract] Â Â Â Â Â Provision for income taxes $ 0 $ 0 $ 0 $ 0 Â Deferred tax valuation allowance 40,400,000 Â 40,400,000 Â $ 39,700,000 Unrecognized tax positions $ 0 Â $ 0 Â $ 0 X - DefinitionAmount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2 + Details Name: us-gaap_DeferredTaxAssetsValuationAllowance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrecognized tax benefits. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 217 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B + Details Name: us-gaap_UnrecognizedTaxBenefits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 42 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Related Party Transactions (Details Narrative) - Pharmsynthez [Member] - Co Development Agreement [Member] - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2023 Dec. 31, 2019 Jun. 30, 2023 Related Party Transaction [Line Items] Â Â Â Payments to Acquire Notes Receivable Â $ 500,000 Â Interest and Other Income $ 65,000 Â Â Interest Income Only [Member] Â Â Â Related Party Transaction [Line Items] Â Â Â Interest and Other Income Â Â $ 40,000 X - DefinitionThe amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business). + ReferencesNo definition available. + Details Name: us-gaap_InterestAndOtherIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireNotesReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=XBIO_PharmsynthezMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TransactionTypeAxis=XBIO_CoDevelopmentAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=XBIO_InterestIncomeOnlyMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 43 Financial_Report.xlsx IDEA: XBRL DOCUMENT

begin 644 Financial_Report.xlsx M4$L#!!0 (!.$#5D'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO=;=!P4)B0-!2L+(/>QLOD&1#+LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/
!47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " 3A U9PVB3:N\ K @ $0 &1O8U!R:W!S+V-O&ULS9)1 M2\,P$,>_BN2]O385T##E9<,G!
<&!XEM(;EM8DX;DI-VW-ZU;A^@'\#%W__SN M=W"M#D+W$5]B'S"2Q70SNLXGH<.*'8B" $CZ@$ZE,B=\;N[ZZ[3E9]Q#4/JH M]@B\JN[(2FC2,$$+,)"9+(U6NB(BOIXQAN]X,-G[&:8T8
=.O24H"YK8'*: M&$YCU\(5,,$(HTO?!30+<:[^B9T[P,[(),=DE-0Q#.31S+N]0P_OST^N\;F%] M(N4UYE_)"CH%7+'+Y+=FO=D^,LDK?EM4]T7=;'DE&B[XP\?D^L/O*NQZ8W?V M'QM?!&4+O^Y"?
@%02P,$% @ $X0-69E&UL[5I;<]HX%'[OK]'X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(]J;M-
O=5H1I;*$81V1@?5XL:$#05%%-;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?
C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4QO?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-
AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-
Y;&O%"N@GL!_]':-*K^(M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-
'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-
GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.*7YRM)Q%4XOT4SMA*7&+XC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>PF\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?
-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" 3A U97Q1W+,L% #*'@ &
'AL+W=OU>@OR'N9Z%5*)DD@@I?Z#K2E;!#;-^B:H8:_9LDY<9TSPAS6 MM;3'P^7C;'E.G(%-_J(Y;MD_;N[GHOWSU_@AU0J&W-^V'BHECQI46 M*GHB=V(ME;;QX59:958\5-40KU_B]8\#E
M<8"W0H4R,',G@=G;>LOA3N5L63M=HOJ&G(.2NC!G?[MR&Q\J*8A'W6JIZ?SGPB_"*[J^0Z8U940ES5E?)80*-HL+U/J-2(V8@_8M=N4 MM5UJ!46534%9!HGX(P$F67Q@U!6/-S$<6C;
[0_9GWTQGWKD5^A21 MAE:9AN*I9 ?MP1!6,'RGD%,?R6_BR8J-6SE0W)[;[;&>E?,4.8=608?B267' M><\?R30 V' 1^CQ_=B)C&;?L]MILT&.#"^O,BXN;\E89B.+)9<<[37RI(!OD
MJ&=DKF%6(E(13V9O<*B[#.PC''>??;(BGR(6T2H743S,[)#'00#NZ=E^@[R# MZ\B'Q,Z)6PZZ/>@BTX_E-K$RXW8W MBL.;]'+%8ROK*1(3K2(3Q5/.:]9R0-\JN0D3WUYDW//]V IZBNCJNC\+3S
M&O16IAKFYS_#=>T]>\#1H7W'FBMP75/2*D"Q P$JYU2"UX/A!OU+.]8IXA*K MXA+#D\X[F6?ZE4RPN'3 I-^_;/?[S+'RG2(M2L2HM,3SDW(<:@J!<$,I^>/B1 MS(6?
:BD%1)W\F0P0.8\G*7Z0D94=-_@,&='*=8JTQ*JTQ/!HLZ\FF3SZ*YXL16T4 M/F T&_?CJV?O7!A4\(J'[&C\M'^[:WX@)*7$IXH]O?3 XY?K!^(/5S5E+,* M1>RH4#1-
M%#%HH!Y,^5[<"LG[EC'>8H0Q^H0Q(X*0>;M%-(MA(*E5/;"/>9 MR:3-?5^ #9@$A:&5]Q1!B%5!B'T5A.8QCR)RG:5P.K6/6MRG[@LG+FN(YU;Q MQSTJ_DQBH9;FKOP9'/0*$D*\YHFUK@<,:
[]TXKJFH%7Z]1'HY>/^'F^FD8^9!HR;6(>H%;B_RG?[/JA<.OE;F;U=C.B MO2ZC[F#8V3Q'[#Q;+32C+U]$38EO7IB+AAU]7Q<)IL:/E.E[]?)!:RSC?7 D>"&4N@/,+*?5^Q_Q N7P]^A=0 M2P,$% @
$X0-6;Q!F]E@!0 NQ4 !@ !X;"]W;W)K4*O]33)Y/E@JM3H; MC62\I"F1IWQ%,_W-@HN4*#T4CR.Y$I3,"Z"2#S-"7B^9(F_.E\@ 8O'WQBCTME/AA-QBOR2&=4?5[="3T:55'F+*69 M9#P#@B[.!Q?H;
(I=XU!8?&'T26X] T/E@?.O9G S/Q] @X@F-%8F!-'_UG1* MD\1$TCB^;8(.JG<:Q^WGE*B_%^0UF0B1?S1!9_P=/&%@Y G$O%TXVS1I"RK/Q/OF\F8LL!N3L<\,8!^K@;!R< M@FB)K*!U1129C 5_
L)8ZVCFH9B;PENS89E9QID2^ENF_=1D>OOQZOKC[/H* MZ*?9[?N;JXM[/;B\>'_Q<7H-9N^NK^]GX/7GC.1SINC\#3@!GV=7X/6K-^.1 MT@!,F%&\>=EE^3*\XV5_Y-DI<.
08(A=B_NTW_V*QMH=%>Y.TWVD:5?<<<4= M%_&<7=QS(6BF)&2*GEFXU,&<.T!S!$[DRL2T_.!/D.2BC4=3'[]!?GPK8W= MD8(UN#H55Z3
$>A%P7CT7H;>]50IX:8LC5Y2*@$))L#KI94V)"7@;UMY,AW0M0" MWC7SH1/BT([;JW![O;CON2*)/-J_;&\@&TNN\/83(C8*PA;)K%WFA'P-N':9? MP?1[8=Z:R>N!YW=>BR *'0^WX.VW:\ +*GC!
;.X&U[0G17HZ!_8@M>U0]"' M'L8[=F=8X0L/2A)(P\L88I1>Y8(CYDECA2L03BJ"$>]"W(1QSS/E 0K\FR. MH(ULU)ELK'="Z+?6Q&+FPM#9L6,0K.L5W =1Y+3.&'62J([CUG)9:Q3L;A>= MR2!J4[
8>OI,>LX.#ELU%_U]M@'%W7A>F'@P_8AM1B&4*<1;P?P%V9=X=">$L?3E"DM,56Y*6*>*98]TBS>!;DWGOVH :ML^>^! MFISK\HGK2D*]=;A'\U1QXK69%T77]1??
0HATRA)@39*1%X6IXPP]UQF&$!<&Y<@)O9>@3,K\1P(:<2-7M&A2Y;ON4[K%)KERM1U^_(+F8 MZRY"MV\ZGQ2ZCV4@)BNF\XL5:E=W8!BBP$'0:^.UFD+/B9Q=B:56*:A?INB2
MDZ=Y0G3[8SI$%C-E1=N5(2C=# NZF, M/-4'<6FZ[S75DZ['UMJ^"=R81<\)G,[NV&O7A%[K#]0O0.X%)3(7S^79MD+L M"HL3#X<(A6U5>
(AELV^L10CN%R%E1926Y&MM(KLZ(G!=+\#M+L!B& 61Y[MH M!^!:<>!#%,=6"2^RQ\$$NLK"+L0MAOU*'&_UZOTB9$:%@7T)=,NXH%HYS4%1 M_,!?'XH,^+<5^"[]_^C@<>UOL'.
<6H]_@DYTL/Z2-&:K&N%@_?>$@%PO]Q!\ M,35^"&Z*XFNE[W;N*O21;Z>P?58EW-'6S9JYUOQ Q"/+)$CH0KO!TT!O=5'> M%)8#Q5?
%9=L#5XJGQ>.2$KUDQD!_O^!DCCE/2T48GZNZ]P/(2&\0>)0RC=3RA(B M9)7-=#YG0()YF@H@'G)8G%/EY=0)M14?CZ->?Z/ED5LNZ,A/^.")J58$B11 M6CS)2SD0*P+#WB(P2X%YJ,
J!5:>:$&6IS4D@KA=1I>(J6CII@KYV.1JF4V4 MJL_H"2;?1E(GW,'=[7!TZXV&2):\N^NK8?]!5B[ZU_W;P0AYEZ/1@X=.'E.2 M!9& X!2=C F#5(0@(I_$I^@S^HATQ$/9RKNZD$S*6??
]!5>:!?.?$[\NF8 ^ $H[N Q7$O2DTW=8T@!@ GT_SYZ\]'*5?N(.%[KM*0Q5L4NM@MT6SY@ST'Q$J.&4RI@0C.\\TCR?>?=`. ...
M$Z>]&D4T/*O4K-.J5,;U/YDK@VPQQ*IQ,[Z/X?AY'!$?S MZ5^WT>@)'_)-'?-S%]X]S,KTATUG\,'J\10?RZB.C99HI2%^35S_J@*DUJ"RA M^6OREOQ!;"+7:)4#6V%V.H=-)F,ZTR\$YETR1U'
,DEBED)JP$?
G\?TS>!M5 M:7QGJ09>V<)Y2L0[K.&^(YGF_(9W(YO&LJY_>BQ_\[^H$8W7:?="N^[@F^ M6Y;P_\[M?Q$%+0OP((>F),'V>*JSPY0NW[[PSZ?R<9-
%SDL7/1':P(GZ[(OXY]C"F@F5L)W6ZT" 7BM [Y<% MB+*\5,;38]R[2 *CUT\D,&!^E,#H=$J"?BM!_ZP$GZI[$%(RVH+ :YW#+6A!)IJ62BK(4A3JS/>HHO;WDW)[O!,>53DQ^GA^XP9$B)_A\]T@4(Y\3
MN(Y9EJ"5)7A.67YYG=WQ>5YOJX6:2;N"E*N ME\ND^/VC6.2O%R,Z^OZ+S^G3Q%147U9WA3P:[RGS="FR,LTS M4HC'B]$5_1!S7B=L(OZ1BM?RX#.I3^4AS[_6!]?SBY%1]T@LQ*RJ$8G\\2(F
M8K&H2(?_]M!1_LVZ\3#S]_IX>;DY3._ECT_!S?V4W(9D$E_=1,&47-_(/]Q._A;?_N8' MGZ=_)L'?OUS?_XO\\B5+UO.T$^O-?R1GY,O7)+W_\]7Q5)RAB4+ MD\[,T(Y-DE5;&,-]-#/HI*W%'F205)D:?
94ZECAD0[>3]D]5545Z<.Z M2AX6@E2Y[&HALDI'C?34>WD3+-?%[]OK]X[LKJ8&&!\YO*2M=/&4J=[L;*] M6-F&8_9P/HJG-*NOF;Q=+9)L)MZ1EV2Q%B2IB"]F[PFG[P@S&(.TMT7;&W1]
M1W^Y9(YCGH]?#F75#:(6,]I!/D R',?V/$/!!=W(,^IZAN?9U&V'A@#4X@Y7 MB?%) M)A+J:MT,@;.A-NF0P^(K3'@^S'@0\>@?)**T\:A"W;4@:!>^HX=..H M13UNJT.A[6N]
[G\H5\E,7(SDPEZ*XD6,+0:T\V;?X'F+28LQ(1%F+ 8"=92 MC[E7CZE5S[26REF]V9@3\4UNP$H!R40+@;M(H%4"B>.;73EREYE4F>Y(S85(MG B)$Q\]_986K+T6+*T6;N3.?)&7)20 ;>8
2!Q?"1.8'6NY!GU#,>BCK(< M(#48(7'B$SK>$H&]%X&M%<%U6:[K583DCV2VW6>4FUV;W,@D__*#3"1!9JL MDEY$40I2KA9I18I\G(? MY[3DXNSEXOP\N7S?J4"RT38[<(6=.,#NQ5-7"Q^SR0
3%F+"(DQ8C 1K:<_= M:_5:B_8B @H/?ZZSN2NU]CL>CDD+O>4TJ,;1"VNWG+<[O[9<#S#IQ_3 M=*1O-Q&.CP8]<38#@;"-H._NT/F,2@M1:1$J+<:BM674V(%4[P>>Z";H*0-J M
BR0OP,="M/VN*NNX5CMA5B@" L4'[T";4DT[B35VY,Z4T&?.D0'2" ?"Q30 MKF%Z1@W+\&RNKA-(3498H/B4OK?5T+B-5&\WHKL+^O:&2,@\[B_0KN_6-1BP M>A1B@2(L4(P
:NNF<2:IWIK\:3:#OMVA/@/MNG*0T8#::(!*"U%I$2HMQJ*U M1=@XHU1OC;[=;Z!=>\Q(J5P"+L^LXT*[+V6R9T M-])S/,ON^W]'VOB(5&\DGOP, SP8@$DH!P.8TI";'+N6NJ0H-J)J+00E1:A
MTF(L6OMAI,929'I+L7>7F&;R.,MVCV>^IM6SW"J659'.*C'?QH!/*&F&U!< M8(%\+%" !0JQ0!$6*$8 M?77N*A,[Z+^B/YT18J^V:%%"NN:L*;ZN(./VF2 M2@M1:1$J+
<:BM15X\#PFB@&KIPRYL6$9L*QK/U)9JCC*'B3 :C#$ D58H/CX M)6B+HK%@V=LM6'WJ$"5@6;!8H(!-B8S;5DIJQ8L5I,1%B@^I>]M-306+--; ML">Y&"':H%<
B[18]4%2WZ&%=*U46/=3AU%"+'B!4%CV68W#F>.I(ECPJ6V MV?/8=C?2,4W+83TF!FL\3:;W-$\S,>"1 'Q&L.*! F7%XQI,'0]42Q*5%J+2 M(E1:C$5K:ZBQ))G>DCSU(0I818#?",QGR)7LSF?
(E72IG,Z&ZDH"H7(^FR;S MN!H;0EAP/I_L2@*1KNTXMM'S# 5K3$FF-R5/?H8"'@S ;H2G-.1+0B:&OKN# MIS2J+XE*BU!I,1:M+:/&EV1Z7Q+=Q- V-V2'AP3RL4 !%BC$ D58H!@!U-9? MX\4RO1?
[TTP,3*=QPKI6+F!BH-JXJ+00E1:ATF(L6OM]QL;&Y7H]T030T\9 M<&/# OF\^X"FR0SU?V8"K/9"+%"$!8J/7H&V)!IGE>N=59V%H4\=H@,DD(\%
M"GC7JCVCS.&>ZHN%6$U&6*#XE+ZWU="XG%SO*ZI8\0%2? MA0&$?]EH8$!8J>2 F7/(D5H+@Q^\>JYW%G_ PN# &^5@O0,%@A:&OJ^#WSW' M??D<]^USW-
?/4=_'Q]\J]G]93NR\]5E<4D6XE'BC?>.',AB^_TUVX,J7VV^ M#>4AKZI\N?GX+)*Y*.H ^??/*^^']1?L++_%J'+_P-02P,$% @ $X0- M68OUA$ $!0 [!< !@ !X;"]W;W)KLT%MO6G5JN_MSA*C< G%)K-
W__A*@B!AIO>,7 M@?C>)3S/KSDO?Z>9#_H!F,&7I,XI8/>AK'MC:+08(,31+^0+4[IY/RN2)8CQ MQVRMT&V&49@[);&BJ:JE)"A*>\-^/C/AGVR8W&XGD&Z"Y)4/;K%L=D/^C! MWMO
8[3>,#&@#/M;M,8+S)ZW\XP_*15*&"4XI1%)0897@]X(WOC0$@ZYQ;<(M[VGM'HBE+ GY(1XFX:"GBC?",0Z8@$#\\H+'.(X%$G^/GR5HKYI3.-;OW]#O M\L7SQ2P1Q6,2?
X]"MAGTG!X(\0KM8O9(]E]QN2!3X 4DIODOV!>VMM4#P8XR MDI3._V2*"VNZ+4DHN; <>0.6NF@-1V,,PYZZ:!; =.C=# ^.H-9.N1+5XJU MY\1YB*%A/R-[D EKCB9NQ^ MXHV>^,/BB5\>_.G3
LSNP'BT^ KN[F??%^#3%!S[]_KFO M,/XJ E)RFEOBVFU,]/JX(&D$.!GX8XE/&B[[?Y6B[_"*:AXT-YXN-5: ?_> MI5^ KEX!3=4,R?N,/^ZNRY;S_V;W__/L1V3HE2CT\$_)XI#O.\>9P]@-O<&_XQV_04O^4
M,=XEF-7J MCMM0[:D5A"YL?@6^Q$QW- /*%6M7Z[7;D^<&I6M,&S*D%',%HS0$<82647Q MDG:7DNP2S.L2S.\(["A$3A4BIU62\PQO453)D5Z)O(*C%[2,<1$DPC8XDT6G M%?
C2Z'0)YCDG:KZ&4#/-9J:6V-F6YIZ3O5MQZK9R.A.,E3J7$=?J?2EQ78)Y M[@DAS41Q:J%;FJFJCA[JZVT"6M5#GSWU/3N"4%*:RON MQ;1VB>:5:,>?O.48AN$VB958:KH-
3=,YPZQV8%9[G]E\RQ.T"HZE-+:"7$QC MEVA>B?81&B66[30>*B[86C0,QT*UB/CLM MM4JT.DN.Z^BJ837I/#6$NNK:FF6>H?-0),'V*NF-3BS29RN1IX6+K;F.Z39R
MTUAB"%5;,VVU8>F5EN9[D+[$\ 3R>/V'J@FVETV+Y_G\/F_@C.X/[1LPF=[- M'A]X*3^;2L^>L--ZJ%,TKU,TORNTX_@<:B+87A3E^LS/H"N2\<3),)^%24/2 M"G1Q2+I$\TJT^C?
1/#]UFA3D*;7N98*S==XVIB _&A4]JVJT:DV\H9L8_P6 MWHRA9-P3K>R\6WJ + _K@#RCCZ9:"&* X5.H7FZLB*UK+Q0,CV[QWNB2,D22_ MW6 4XDP8V]7A+"W!S%!U> ?_@M02P,$% @ $X0-
65.&I96(@ Q < M !@ !X;"]W;W)K?[82,HA2AKF^('^[_.]_9W(5; MQN]%!B#10T&HF%B9E.78MD6208%%CY5 U5K6Y0<<&I$!;$]QQG8 M!SVY2B>6HP\$!!*I M"5A]-C #0C1('>-/P[1:EUJX/]
[1/YG852Q++&#&R,\\E=G$NK!0"BM<$7G# MMI^AB:>O>0DCPORB;6T;.!9**B%9T8C5"8]\IT/R'.\H.,\L]/E M?EXH@DK)U]94)T_OEJ MQ, @=" 81.>N-_1'0R>T-_LY[C)T^LYHX#\UC#L,O6 PD'
B6LHK)^JNUJVW(N3:4]6)^ZXYG;L1ZK%E5WE'_XNK]= M8[[.J4 $5LJ5TQNJJLGKGE%/)"M-45PRJ4JL&6;JS0+7!FI_Q9C<3;2#MG%' M?P%02P,$% @ $X0-685Y7"U# @ D 8 !@ !X;"]W;W)K) M-
7\$VUG&O\=VTE!0FTF]2?QQWM?/.9%/EHU4C[H$,.B9,Z%C7!I3+8) IR5P MHJJ]E!<+NY%)Q8NQ4%8&N%)N%,BS@+HC"I>,C1;KN8OW M=\H-/IHC%PF>RD?W623Q3AT0, @-
XVESW1<"/9=YJ9,L9O,%^RCW M1ME=:G4FV=CR9J#0@R(9%05:*45$;;L1B\#8T]P<4':N:U;M^B,VQC=26%* MC3Z(#+)_]8$EZ_&B]XZ&C3\7(MK- [?H"B,)@-^XS[=L?<;7Y N^G%KH]'& M -
<_3^7>6D].6[O;L] 522'&]GIH4$^ D]>O1K/PW0#XI >?#+DGNYH!&H7[MZ=7H&!]M,EF9_TO=X@X;YH1I& ";]F#309\04EQ>= #=L^A+;752U!U#V M+I$S;.>+['->[;YQ84;YAOV/4_ %02P,$%
@ $X0-64JB!'Q(" R!(!D !X;"]W;W)K&ULE5AM<]LV$O[.7X%9SKM#W(BIMDXI-9.R]UVDOJ MQO&U,S%W 2A(#F"08 !0LN[7]UD)*5$$=N^^2"0(([L,NSN\U8R]+*HSP
MT"CMSB>U]^VKV3XTF_\$E6M:>%W<59RRMQ^_Q=>V-Q M-QNDE+(1VDFC17K\\GE\:NK$]\ H3-OQ3BHW;N6;DR=*8>[IY7YY/YF204*+P M)('C;RU>"Z5(%,SXDF1.!I5TZE_XN^ Y?EMR)UT;]
(4M?3I>3E8IKQ3 M_I97/ODST\DKS#*A5^V27OG$$U9TSILF'88%C=3QGS\D'/Z7 XMT8!'LCH]" ME6^XYQ=GUFR8I=V01A?!U7 :QDE-0;GU%D\ESOF+S[5@KTW33SCOWKW%?
6=$#E3Z&%EP6[DL854NA"N)R]U\64 M_?#]=R\7B_EIVA'NCD\S8YF'J/0P24P/?R9U(6QK;% M,1-V.L(7X+\HUCS MDH=H4'6%#=\L1ZI7-6]R]H$[QXNZ<\)
[F"$=XVPI35MSU&0A.IB!R:3HMC@PL4J;.,B^*6M.E%!!59 D+!N#S!R[_C%]6.M-:V5PH/2V!MA'K96+HWN"B7@3M8C]N8C[GI(M6*NX)T(E=TKA9*5%4"<;2(.98$]X!), D'B0SI--P9:0D@%2U97!.?
+(%++ M6TF!6LL(K;BL1F5@ !/MJJ3+Q0$D,^NL41[RPW0WQ_/CVLQOCM:EE40,"&+(4 M0I-5"BBGZ$4PR.TJH)5*"=>PDYZ1(VG3:/*TSZH,+A>=M5A46W8X7B@ZMW6H M/R1A "YJX\!+4U
0A0+IC*<<4:.C_^ETH'<6@2#!,!'RR #L*[B%:-/$1%,& M.:.V651)ZBUK$$%*2FP.),%\UQB*^6592N^(.I$/M5%#<\NMU\B+B_$;ZFK)R M2*=MT",P22G3%IUNB(+3F;
[:90:;L*#Q6[QIAW6B&8+"321@)QJLS,.HB^8\3$:%+ M:;*I#<)R9#940*Y;.EE*#BCW:S5GI;08 ^ W])%G\2Z'J:"\J@Y1>%16SJZ% M:X65#^QV>CFR8+\ZE#4_3)[LA[OIK],?V3]D(ZF(OF)1=O?K& >
(R B_1XTA M2A@/YA#:F@?DQ>==)OM:4]HTJOG6R@#L2--DQ^VV04Y#<,Y^;I;7@[1A?90' M.]D:]IG.L3L==(<..E+,W?1V.@"U$B7*5!$+E1@R[3UB7DGJLE1I+@#)V\@Z MM)!Q94
,H&PAL$Q@#/48"48**SLLN2R\PPLR50"AI+K]>6GS[#HY.7B M-&>_P.EK2!T64KWE[*U%J?P9P M/,E+TONEVEA)C-GP+PHQUF1(+1'ZX/L$K
MJ*I0;GWSBI1A3=D5,)83_2>).UXB^I0>EE(O,%XVLDJ)YJ"/9!G!0C2&0PT M\'G*?C8$!:8@4',D[0]<8_(F@A[:V8T"H8[K#.U9=2&2FUH$<^E'D""HUI$; M'=45""WT)JPB6T-
X4K/G%5I%!2%4<.BGEA/#%4%:C87@:MTK3+3WCRXC7MTV6 M+Z62?AM:"T9.J3L1N^K@D]%\HD0@$ZC!=L*=#F^\M%@5M*X$933W6J8\]PX MYQ%!+%
M\%9%R0[;HY0>*@VSCV!TLV_#$@T!^+KH NGJQX(,J6 Z6X3X(Z60+DB6+UWP MU[5#72'$$T&4.RH5W)&5&9*2C!HH.$%4&V$0D]MXI"_LJ89L8R)F!%@H>G' M>W<8VRF-AO8;_-
=6QCA6,@V9)?TT7XMB'V&GHO.W4J/_X0/\4# AYQK.XMP M903'LD,8J(-A+$!PJ#*@]0\/F)/Y0 D]%%>5'0J3\4CGGUS:!$AN82@ MMEN"DBC7T:[7A * 1EIF9H6.A6 @^TN!1$X8A(6!5'&E%%
(\P9Y#2?DPI<2W/$ M-D0*)W(2'WFA$5R[;U*>[:5\ #0C0"#02QJ'&_)YJEZ*IB;9OR-B-"M70J\ MVI>L:Y&PCJ(#[U=XS\'8L\N=H8*+FF!KDLQ^*^*.HI $FL%8::L*V-+1*+]7 MP. &N+.*?
(=+8>-8!VCI91\:!P1"1P#;8]"SENM(24EB#TJ9J30@FY@B&!A+ M_@7]QQ3W8#)[+_PXZ(9G>^VV=WD(!U5-G\Y$]!C,(CFK!+FJ,5H&(8Y JC$ MZ[D=;F1-5^4,28@[N!O# *A(RDY'?]W AON8Z_]W-
G242IY+/3WT4CK;^;K0"+Q9T*<4O$N#U^XT$T*HF<5F*%H_/IBY\FS,;O)O'&FS9\]U@:[TT3 M+FL!/K.T <]7!F"D&U(P?+RZ^ M02P,$% @ $X0-60XD5IK9 @ 1 8 M !D !X;"]W;W)K&ULE55-
]LP#+WG5Q NT%% 7 M.T[Z@38)T^U@%BG3=#L,_.BDW'0'8T%D"6D_7P!I%]H6D+(HI4:;%C>9 GE_5!%_*U_,#(D&#JT]BY%N_$-7=F:\CC%+G#"/X+2M_U/B(2QF!J *F!#*PD9%FBT@G,KYA7Q1^,)
\N\DF4>$*H,'> M0?!GC3>HE =B&G^VF%&7T@?NKW?HGX)VUK(0A#=&_92Y*R?!1100Y%1;FXV M7W"KY]3C9491^(5-ZSL\C2!KR)EJ&\P,*JG;KWC>UF$OX")Y(R#=!J2!=YLH ML/PHG)B.K=F
]=Z,YA=!:HAFYO8_J.N:1:9#N"4[(]JCZ?*1 MX"RY.L!XU#$'>'4)_S]T<*X580)[(N2P*F7%K@3/ M87M3K:)N]VNQ%YW4Z&^[M?+T7=BE9L<*" M0Y/^.4\DV\ZLUG"F#G-B81Q/G;
L>&PO=V]R:W-H965T>RV[MH71$'FQK8-6ABZ=\'59 M2G=W3MJN3_J3_N;#1J4/G\8G1Y7W48N2]Y&5]8(1\N3_MGD M\'R?Y\<)ORE:^\ZS8$S<L6UE[SR]O\I#]F0J0I'XP@\7=#%Z0U X'&UP:SWV[)
M"[O/&_37T7;8LI">+J$^K/0G/1?]$5.2UGK\N&NWU!CSS/&RZSV5>LT]S] M65]DM0^V;!:#0:E,^I>WC1\Z"UZ,"U@P;19,(^^T463Y4@9Y>NSL6CB>#31^ MB*;&U2"G#
=E'AQ&%=:%TWD*AK!+,5*/LX4/#LGRYRZ&$$][^;CPNH$-?R8Q.^J@03^Z& M^J=/GTP.QD>/L-UOV>X_AOX_0_4X]FPH_CV\N'1422=C66'Z6Q/(J5*\5D::
M3$DMYD$&0ND&W[LJ"*67V;*2YHY1,HML,)YR?O* S#$W%RJ!)8MB&])QH< MB2KNBJF+Q> I$P154[7S/58.-W5VMPE":'*QJ'6EZYLF#<\IJIX)J9KRZ
MS0II5A&L5#Y*S8]/G[R83L=\U<7\6ER]%,/@&"%LI4QC2D-E(LY\FBF MZQS&:BT,"X9N.&!#QX;+_ OJ.1ED*"/OV=T@'7,%_)=2.9ULPQ?(2LMZXYP*
MOS;WPA=VC5*X(!>@NQA.ZAQE#GLNK0W&!A*Y\IFVO@9>]=:RD8* M8M7O081[R@4Y,M$W9Z!A@9X2Y%C#I /TB$!IFG2_B#RDF7$X.$S9)46TX,T M/!2_\HH[,7F60 ?W%
(&62S1]SDIX)Z^C3P8]+@XQV0/'O4^AV('Y'&065B4_OHK7;U];5Z\)R ME:'8L-FO%U[E'IE&_E'\5Y6]);-%.5?60YU1J8/>6X.J17B8;+E_*Y<*'M% MV58U[O-M]^QN _=]K142?55#[U$
R4^^KF+LE\Z6F_V'KG.!P$;YBZ722'YO M(37+1\HT=%;C998D>:L.*&B<;9H^T'$UQ^V>4POIQ0_CX135JG4CPIGT!=9H M2 6KDOJ+10B+?)?V4)PCX%DD\5+IFK?Z!6?>]]9[+FDQ+
[B@KSI[L0$U%\8B MKH250F]F>Y[=0R/*U8UBS=@.RZI"FY0+'84'("5HXAR772.8.3F_Z5_K>&*D M?]N<- V8>I8*.Q@AO>. [TT2<@DG MBA6L2JT:J4!-IV_:US,"I>J+-)-3*H8UJ3*C-6A)KZC-
A!TR[T#.<[-/XG?MNOU1O 04+6W83%D]8FPH7!$,;Y>W8HRG3R3?N#<2.VY MD7MYHQF+-B4>\XA+->RA1IR=),'4<1'"T5C#@RDC8>^C=<6U'K%/AKB*!6@
M&8I[:&]CRN!Q^V.U<,.)%?.M2&=29]VSSL,&00^BUBN70.*9)SJW]YUS=YU: M1YW+1DEN%:]4G)00N'3O:+^VM[:%=%G93D]7/FC^2H&OIB66CH?/G_6%2]>H MJ]!)L%:\N"QMP$8J/!=H=.9Z
<3[H;%YX@_8N>_HW4$U#!!0 (!.$#5D2 MQF[])@@ ,L3 9 >&PO=V]R:W-H965T"CFP>01_%$P5,^$^%W<&3\-&2R)SH:S4BAFQ..F=C3^<3TG> M"WR18FT[OQF=9*[U-WJX2DYZ(W)
(9")VI(CWTIZ6SUYBDC=W? MM?:/_NPXRYQ;<:&SKS)QRY/>^QY+Q(*7F;O7ZU]%=9XWI"_6F?5_V;J2'?58 M7$YJG\VHS/,BE"O_Y8Q6'?)A4FV8+^(>_E)7?\]-CH-3,D#6WTPQ_5[X9S
M4E%29L[@K<0^=SJ3J9(+&7/E&-:Y$ZF,&AX,!TOP-4:Q]LP6-QTBO(EEF)WNF//XS?CHY>.-ZT.=[T M)>W_.JLO:YT.V]1S![X-Y%=P=K?D*)M8E [R&80&[-HE_;:Z52XI3#16KHE MDXCD>@HD-
FP.]5B(!/RM3"0W4M@^^_&'JY/)Z"CH] _CH_^P*\5N8Z?GP@ 1 MXW=]!GVPD!=<;5AJX!X4.5VY$M%;0_5):_XUXTQI=2 >XZRTX 6RFLD8;"-(M)A;&@=%8@1-2JHW(>*6R8XG<&;\
[LNQ.9YL_A&).Q$NE,YUN(,8=6PLC&/*[MDKJTV29]S&4;5EGKN,E@,-9*583EHU,8G93Q4P\<&-@1# F=\TSKQ.-VG@F1 M2)6R1%IM$F!L@-WK#<_-Q&V,$+*'Z48%5RY14;#=Z!7;*,[(X'D^;W
M]OIA\QMLGDJNV!>4C7=V=G9_S:YE+LG'UU72ZK=UVJ(MH+!;Q<[*%!S'KZP M]MIY$KI4L70QF5"#?Q,J)#)@(!U(4_?;RET8>L\0FAJD39IU\>[('C!L C M?8DNJ!D@S5E&-@TO
#:&'OCU.S2C9/'TZ=R\#N0/WXW/6(7H/6,? GU MQ&8Z*T.=75]?-*&NI9H*07!!FJ(FS9W80A+03(X.,E;4B-L?$4;19%"NM(] MN_W;J41;ES"YJK1^^VI4 AEQFR,H8$.1AT9AM'%2:;O(5H8&1-

"B]+8D@":,"0(S^$\7OMXB\" 4_W_AW2((' M?ZO8EC@W""3$GB>)4$F9U^&!?&V:XE#']B?+K(,>;I*]'H5CU[%=RG1]SB5?Y:LJ8C;/MMILOMR'*J36K6E=DB:']JF"GZ^\QV9W0>1
MU[".&5PJG]UM/Y$DO%T3Q5,VMOM]GYG0%@\6$._[EYAGE%T(8SC::-1Q-$=[M]B I\?PPN[_J^O2B"PQS)778NK/L\I D9"JDJTDO<%5H"RY)/('YT:7B-VI$
M=2Y;^:K9[..,QH\!NPQT2*M64+FS[R6X#;F%0AJJ=\H(NQ("[U)$'5(#_3TB M_$GHDL)XMJD'L<-Q&,]#CU"$SD J.-ZBJC0C/#:29VCF:8'LT$VW,KH\,QI, MF]^?%?)KK,3(0[U5FA0EP1MF^?
SEK$LFER(6N9\CQ_OXI$L=T3/4<0/O#+7U MAPI '1,QL8#)+3JAYR>4TM9S(/2= M8EKM(;M)M! 4#/;?JH(B1I146PK]#5_OJF^"GC;/G>23W7"K%=2E06F+61[9("&CV)X0 X:V=C(/R69L?VO7V"
M:IY9O3ULK7!N7 8:J_VHD^A^$S[R% V^ '?P5KU'$Z8-M/FV92(*5P!CB_ = M@;9GW?TVNPACI-W@>B[^:K9T%YMIW??2C3J7>FO4#$NM5EY=W]C.]$/!?&7]^;^Y1;&EVFRZTA&1?
<3WK?]7O8^< "3:G_C$0^ELJ%;RW-:O.E MZBQ\H&G%PV]$*_JQ^<+OSGFKEV3N?^YU)PX)$$\'ZA M,:Y6#V2@^7YW^C=02P,$% @ $X0-681O\9L*! * D !D !X;"]W
M;W)K&ULK5;;N,V$'WW5PRTQ:(%4DN6G4L3VX"3 M9M'=KC=!@K8/11\H:201H4B5I'SY^PXI2W8"QVB!OM@B-7/FS!P.1].UTB^F M1+2PJ80TLZ"TMKX.0Y.66#$S5#5*>I,K73%+2UV$IM;
(,N]4B3".HHNP8EP& M\ZG?>]3SJ6JLX!(?-9BFJIC>WJ)0ZUDP"KJ-)UZ4UFV$\VG-"GQ&^UO]J&D5 M]B@9KU :KB1HS&?!8G1].W'VWN!WCFMS\ PNDT2I%[?XG,V"R!%"@:EU"(S^
M5GB'0C@@HO'W#C/H0SK'P^<._9//G7))F,$[)?[@F2UGP54 &>:L$?9)K7_! M73[G#B]5POA?6+>VD\L TL985>V\XQ#N'V/-N WF6 M/S/+YE.MUJ"=-:&Y!Y^J]R9R7#I1GJVFMYS\
['R1IKK!#.XW)+-! TQF\&!+ MU'#7:(W2PE?.$BZXY6BFH:68SC-,=_BW+7(\#OX%+)6TI8%[F6'VVC\DKCWA MN"-\&Y\$_-+((8RC,XBC>'(";]P78.SQQN_@/;(M2\0N<5\-)S\N4B,U71D
M_CJ6GT/\'P4[CGP_A MOX6 !PDD"L+HIU:4,R!3N%-5S>06R!HU@7%I%3!(EA M$2L'[8(5*%$S05TOD%J.>L*6@"PM0>7P!?-&>&Y0)ZN)5S(\?KN+1 MY8T!=V5TL7)Y;^(_9QRES*%/1]\0X)]
[,';V#ZR504Z'=J0.^]CA$W'&.I& MFX917:G\ZY)3"9=HC#8'Q?/0/8#*Y)&I@@U MV_I0WCTAQ7)."Q+8<&.=DEXU1Y1.0&6<=+3@&G!#!EP6@%4MU+95O6<.S-"U M:E+-
$SHV#5T;NA>IM]^7Q[1A5*/A&ZO\J7VCS8+<,A_TFQK"R!5F M(26U/3QAK;0%*]2[\6$4_?AKN("<"X)-MJ^.=9<;'9>TT6TCN#K<;]*2R<(;
M5MSXV>6$J347$%^T'3*$SW3BLXP[T5HM]V('6L0LP/)A>U#*%G]'N M(#72MH.LW^T_ Q;M]-N;M]\02Z8+3HD*S,DU&EZ>!Z#;N=PNK*K]+$R4I&ULE93!CM,P$(;O/,7(2)Q6
M39IF2U6:2&V7%2!5JK:P'! '-YDDUCIVL)WM\O;83AJ*:(NX)!Y[YIM_;(\7 M!ZF>=(5HX*7F0B>D,J:9!X'.*JRI'LD&A5TII*JIL:8J]THI+D/JGD0A>$T MJ"D3)%WXN:U*%[(UG
G<*M!M75/U)!U96QDT$Z:*A)>[0?&FV MREK!0,E9C4(S*4!AD9#E>+Z*G;]W>&\1XT"=C<)7LI7QRQL<\(:$3A!PSXPC4 M_IYQC9P[D)7QHV>2(:4+/!T?Z?>^=EO+GFI<2_Z5Y:9*R(Q
C@5MN7F0AP_8 MUW/K>)GDVG_AT/E.8@)9JXVL^V"KH&:B^].7?A]. F;AA8"H#XB\[BZ15WE' M#4T72AY .6]+\H4/%+>(FR0ZE:AW7&C%X&Q M<.<29#UHU8&B"Z I;*0PE8;W(L?\S_C
BAJ414=EJ^@J\%,K1C);R *H_@* M;S)4.O&\R;\KO6,ZX](5J^';OQ]/PW17!\2 XOD;_GZ.Y"CHOO MQ8:JD@D-' L;&H[>WA)070=VAI&-O_5[:6P/^6%E'RU4SL&N%U*:H^$2#,]@ M^@M02P,$% @
$X0-69;-? &ULE59+;[5PQ4H">O7G:<1VT#29IB4R#=(,FVA\4> M:&ED$:%(E:3L^-]W2,J.$SA!>[%%CY5G15X#O'N=G[!N?)0JE'M[@N9U'J"*' PCH$1G\KO$0A'!#1^-EC1CN3
M3G'_>XO^Q?M.OBR8P4LE?O#2UK/H)((2*8]>Z?6?V/OSY'#*Y0P_A?6038G MBT5GK&IZ95HW7(9_]M3'84_A)'U#(>\5JN*Q5])$;3Y^.,FSXT]P];/C=C--+.$[J:3HL2X"
M5OX&U@1NE+2U@2M98OE2/R%>.W+YEMQ%_B[@UT[&,$J'D*?Y^!V\T<[9D<<; MO8$7'(/_SA?&:JJ'_P_Y&"#&AR%QCF-X&PXN5=-04W@>N&)%#:9F&D%58&MTQRV3FU])#(H@;KPX
M2LNM0.,E SQ8!4HBK)0E#&HV(:A*K27#U.^+AM-GZ818+W+03,#O"<=;CON; M \>QM^_Q2K[B)^>3PS_2+AA
M&\@RWS6CX0O%BCMC#"Y16U[Q@ED<$/9ES>02'8E#23DGV<*EFR2O9:%TJ[2(M!'EN:Z]RCX7&$+>*:HJ%#'_#%2N9@\6JHK![T3L*N#;85]Y]*[B-X:'&P8$#
M6#/3Z]+H!F8AR_2#%C&!+HFA*SKO]U'P.X9O"BK7Y$24B1!= M*A*D&%/Z.A<&0Y&@39K?VP#W' ;['%Q)N=AI='<<);K/U!:\!]6]GD.A#!/9TW$&/YC63%*:'YZC/ZB)WGI[0(AMIPO:HRBT
MK59/G+H+J4[&DWQX.AG!:!2G*7S>A>Y<&ESB*0Q*+@I4Z*PL>:C=_6JH64FP M"T'9I3;1C.@/?L-D/LS(5#9*G<6OG=@,LM,PHLD:S8"'_4H51L%ONG)"[NY?$>;A G\7# M,^2&Z26GI JL2#6-
CX\BT.%]#PNK6G^=+I2ER]E_UO0:0NT$Z+Q2-.#ZA3.P M>U_-?P%02P,$% @ $X0-6>TYQSV2 P &@@ !D !X;"]W;W)K&ULC59MCJHX$/.[K[#257654O)* EM 6MJ]MB>U72W;
MNP^G^V"2@5CKV#G;%/CW-W9"ECVQ:"5(QO;,^_C3'=2/>H*P)!]S86>>94Q MS740Z**"FNJA;$#@R5JJFAIK*1\M(NOY+K%WP$SBT0FO%O MA^GU*JW@*7U$_]WYCKZLJ(:/DO_%2E/-
O+%'2EC3+3?W*18JN-K#MAM*!FHGW3?1>'$X%Q^() W G$SNY6D;/R$S5T/E5R1Y3E M1C1+.%>=-!K'A$W*K%O%%P#^V8DB2T"=Q&*<7\)+>R\3A):_P
M\HX>L*@,N5&*B@TX^N^;E38**^2^<\ZWV.EY;-LUU[JA!Y$:<&UT82K,#BD4%&2^^7/MV_&<91_T&1'-:%-H^2>88< /Y"K-/;#,"26\RH<1EBTG-O^ MPP%"3 7X5P"D;@L&;,$03#?
TZ7:22"0^FJ$;<&W+#[[;?Z9K\ S_K$*@147D MVBG6;/\:M<=8/8\(TZ3@5&NV9KC+A$,L).((RX:4EIR5+FK:X,O6E1Z@:IR? MBKKH$0S66G*<@_IZL,3Q6FXY6.M.4U#(VFIT$D?
M@P<7L],F>S)^B6Z=/1DX MMZQ+I*<&]UBA5&%0K+LE8&1EXUJ@4Z7)%?DM\<=A2MXA&25+MU=B%,X)6XI?)8-OA JH% MYWZ:98//(- MWB:EQ,'$; /95#TAI2-_@I4P&OE9%)$HS/T\R1$I1,S1X(K8
M2IEDB)E-_&0\<5HF?I2'3O'8C].(W-8-EP=T?NGJ\$?31?)_=?AIJYC8G-27 M97@QX2XR-NVN4K]+^^O*]K2 3NDTRBT7AB'+\E9$O'_!N(<*%)"=?0AY;@8$ M)_.Z!K5QMQ(6F-P*TX[N?K>_^&[:>?
_$WMZ:WZC:,-3)88VBX3 ?>42U-U&[M,+)QTW\E#=XECJSP\@9E&?!\+:4Y+JR"_G-@_A]02P,$% @ $X0-6=\ MY5]5 @ . 4 !D !X;"]W;W)K&ULA53);MLP M$+WG*P8P8LT)-AR9*RN;8 +RV:
&,I,NAZ(&6QA81+BI)1<[?EZ1LU04VRTU3 D5CK!)[L%,@F.R^=+?OPQ'@)GX#D.P! M2=#=;114+JFE^42K%K3/=FS>"*4&M!/'I#^4)ZO=*G,XF]_)0@F$;W2'9A)9
MQ^CC4;%'SSMT\@;Z"AZ4M)6!S[+$\G]\Y)3TYGK54@-2018/,W?_./>CE-X.KWMG9D!M>A+H2998 MH%BCAG0TZ!@OO)"%$C65KU"RTO&>:EET=)L%ZFV860.%:J3M+G8?[9^%63<-M_]*[-
^6!ZBV3!CAN'#0>7E\2T-V<=HY5=9B-M;)NTH)9N:<-M4]PZQNE[,'Q M&_2/9?X74$L#!!0 (!.$#5D^UN4/CP, .(' 9 >&PO=V-H M965T^F*+Q_N^^^Z.1\ZVVGRT#9&#SZU4
M=IXTSG5766;+AEJT0]V1XIU:FQ8=+\TZLYTAK *HE5F1V].L1:&2Q2S8'LQB MIGLGA:(' [9O6S2[&Y]Z.T]&R;A4:P;YPW98M;AFI[(_=X]&%YE!Y9*M*2L MT H,U?-D.;JZF7C_X/'"H*T]^@:?
R4KKCW[QOIHGN1=$DDKG3@#_-G1+4GHB MEO%ISYD<0GK@\?R0DNW6OXI*M?,D\L$*]JQE^Y1;W^F?3X7GJ_4 MTH9?V$;?,3N7O76ZW8-902M4_,?/^SH< 2[SKP"*/: (NF.@H/(.'2YF1F_!
M>&]F\Q\AU8!F<4+YICPYP[N"<6[Q2!(=5?" QNW@@T%E,=3+SC+'_-XK*_=< M-Y&K^ K7%.ZUG*._1L[=);K9:6C? AG*O.A(;C5;8=J!PU:(.7(L*M03L,&C=^"]!4^&IFS2 M044;GO2.Y]:E($$7)\TN
JN*Q[SJY UP;(K]K^:2[!I[(]"V\5]8)U[OH^M"@ M:>V.SQ+]DP)AV0!RB"BQ"Q*WC6;>8/,J&]$%<4H[G@X6*%#W:!L4*T94QO=M@FO0025L*1GJ];/ED-KK5Y?%Z,VUA:52/4HN2*>-
[XW_/##*/_Q5^ K,$!V MG"J7@<\XW%%)[8H,C$?AE(ZA%I+M(37O^_3V=L D]]XX4$2G20HL%=M(P;O+ MS@@)Q33N#N&N-T*M [[6O6&J3SUG36:@:W89_90>2S_M"(+4J+Z4.4HYKBA\
M[\$^X2*_/MGXC9'!/KK^(86N-[9'9F#6;2/*YCCH *L-JI).FP4A,H=>B5A]WWFZ^ BS],\ST_1'8IJP(T#O9)B'3L+54_0A^&DX/4I#[8O&B!B7:VWH_WB&L&2_ 1]DOL]33S*]" HG4>A+DYP=
MW;LMF75X72R4/FB\@@_6PP.VC/V%_?X^O$!60O.5E+-T'SXYB(!$U^4N'"Z M"[?X2CM^$\)GPX\P&>-_^[76[GGA QR>]<6_4$L#!!0 (!.$#5E]%+@N M;P8 @0 9 >&PO=V]R:W-H
H965T;1HDP!)VF%=VRVHVW7 L ^T=&VQI4B5I.)DOW[GDI*LMHZ M8E]L220/SWV=2YYNK/OD"Z(@;DMM_-FP"*%Z.IGXK*1^2^K&MR&!D95TI U[= M>N(K1S*/BTH]F4^G)Y-2*C,\/XW?
KMWYJ:V#5H:NG?!U64IW=TG:;LZ&LV'[MX:U:%X$_3,Y/*[FF!87WU;7#VZ1#R55)QBMKA*/5V?!B]O3RA.?""7\JVOC> MLV!+EM9^XI>7^=EPRH1(4Q880>+OAJY(:P8"C<\-YK#;DA?
VGUOT7Z+ML&4I M/5U9_4'EH3@;/AF*G%:RUN&MW?Q*C3W'C)=9[5>.OV*0*2YQT=#D=4^V+)9@ :E M,NE?WC9^Z"UX,KUGP;Q9,(9Y/FILQOA>#;0^"&:&E>#G#
(9$O+$F%%Z\,#GE7ZZ?@'+'>]ROISO!?RM-F-Q.!V)^71^M ?O ML//#8 0O =OE\%_7RQ]<,B;?W89G/".=N-Q+3WUE1N:'C^\,'L M9/IL#]NCCNW1/O3S:T>5=#+F-2+WT@1RJA2_*"--IJ06BR
#H7:"WT5]+_AN MZC^PX^!=0:BVS):5-'?LT[LTQ-Q7!!6>U44,V,%[=9(&#)_/Y]-GBQ55\FCU[-,#<$2A&"%LITUA>2@.Q8HX\FNDZA[%: M"\,:H1L.V-"QX3+_B!).!AG*R'NN-
9".C@7_E51.)]OP!4K2L6Z=4^'7YE[X MPFZ0\E?D J06PTF0H[)ASY6UP=A (E<^T];7@&LX ;\ARBX7.[W=.5J9&#J7 M8PY!BT(AWH\7X\&:#+F(A6&J.'QR6S(5K,U4Q4$HY V)9'I1=TZ84L5>%$_
MB&_" 4,D3_].TL)0NHU&ADL&(MWO1!@?C\&HHT!;\'KVE J?3=0)H=DUM$$,5TA[?069' MO.DO92$&L[H/G M<$^Y)"<.9U&?!#T%# [RCR#$'R!OID #S-.EH%'G),F+P\ 6R2HOY21H>BS]X
MQ9V8'2?0T1>*0*L5^CQG);R3U]GHP7AY@=<@./!;,K=6WFQ1WZ/._D]_H[\ M=NF.F%]U#L>>N^1V+]A]B[MRJ>P[RK;2]B7?;L_^-HCQYUJA&M3O?EXB<3.HAW/ ME:Z9[>\XSK^VWK-
TB44!X=J5F/\?-29VZV;;VRLHPKX7ZAVJF>9P_0QG-U MHUAQM\.RJG#@DDL=91L@)?R'@V_V"5F6D_M)_]_$(S;E:XB/0V<0IHXRPY%G M>']ZO0Q]6XF* [#' 9Y[9]@-
!H_WFU0WCC@6Y.$7"&Z8@VKTD$'.4K-.:DY MG,3%W!^21D6ZB4D$\RWU-,;J41/?4!L)NN7.B^+CHU%LGL:: _1MI+FJ9.S$ M?GO8V;3M IFF#EH68];N"!L*1Q3CZ]6M*-/Y/*DO3M?4G:
[Y)-0H[K)+D7B7> M<4EX3.JL?U*\WR (5>R4RB60>&*,SAU\X]Q=Q3SIWET_!BMQ:5[9WH)MHIWO:4-N#G& MQP*'!7(\ >-\3&Q?(/N\G_^'U!+ P04 " 3A U9_1*%L[," #\!0 M&0 'AL+W=OAY&4-
7)6"$PG+L3/QKZ:1\;./TK8J ;F$H6COR:C%%=\[%%!#%@#N#$S-525 4(:?W:83!?2!![:>_1;6SO6LF *KD7UL\QU,78&#LEAR=:5 MOA>;+[KIV_P,E$I^R6;UC?J.R1;*RWJ73 RJ$O>KFR[^P\'
0/Z1D"P"P@L M[S:19?F):9:.I-@0:;P1S1BV5!N-Y$IN1)EKB;0(O)G>"Z4.2&YY"_CO>064QXEOL MZ#BV:9\KU; ,Q@[VAP+Y]:[$[Z_IT?TX\GF$<=\"\@4>CK'=LS7%1"Q),I6L;!5 M9*
(VJC'[QJ%5\!CWD^C'N?]/RMY#(0%>R4]0/+#BSD=5H&Y+.ZMUC M?B:S@C"?>8X,]X>!HK#B[5(J.A M&PZ&-LO0]1-J$P_<(/+),7&]@XZL0:[LW%XY]9U&B\VJT)HG!;6+'
\@S0.>+\40N\W)D$W\-._ M4$L#!!0 (!.$#5G"WLD.#P(%0$ 9 >&PO=V]R:W-H965TBD^?M)HUB/L-2Q72I7\E@ETLE1KUN) \MUSHU&L0N7OZZ*!ENH; MV8$PGDJJEJ(Q5>WK3@$M'*CE?
A0$"[^E3'A9XLXV*DMDCYP)V"BB^[:EZK0& M+H^I%WKG@RVK&[0'I9TM(8<\&>W4<;R)Y:2M2 TDX(HJ%)O%2[7L8UW \8 M'/7%GMA*=E+NK?&]3+W M(@.!5H&:I8#W
'GELC(>!HYO2FE!5[NS^S?7.VF MEAW5<"?Y;U9BDWJ?/5)"17N.6WE\@+&>6\M72*[=EQR'V$7LD:+7*-L1;!2T M3 PK?1[OX0)@>.8!T0B(G.XAD5-Y3Y%%FB9)'HFRT8;;5ZI#&W%,V$?)41DO
M,SC,\N$QB*Q(SFK!*E90@615%+(7R$1--I*$S@H$F[^\!*>.:_*!*47N9'Q(? MC0;+Y=!COO60+WHAWR,7TR8H\W'P"P"Z"P9S.ZN=1F6> M^^^]?1,N@B*O](TGM?
%K[%F.LM@WDI>@ M]#OR]:EG>+HB6S&8&XCSDKSC#*>OTZ=7IL!O0X#VZ),SVGU++K%3MLC5343 MFG"H#-&-P\DT\G!IZ>\#!0=JYO=A)-%[/]NV%&:PO=V]R:W-
H965T5#QK[E:THY^I'$:7XU6'.^ MN1@.\W!-$Y*_RS8T%9\L,Y80+F[9:IAO&"6+TBF?J@PG&%'HGOPNRR?W;+9 M9;;E<9326X;R;9(0]GA#X^SA:F .GAY\BE9K7CP8SBXW9$7O*/^\N67B;MA0
M%E%"TSS*4L3H\FIP;5X$W+2HLO&Y8W(J)ZY1\2KW6?:MN'N!F\H818H8M#H3$-> M((CXLZL-S&L+?3<-%<3C>PT!N72WD6_Q,M^/J,!F@J%?V2
M;:EMC@),D8/MSK.Y:@=<+=#@^U!VQR@W<-YQ+=5/^!F]%K!L&J&N2N9R.6 O-^-MV^C.T#B%@]?W!F#0'I;7@ÉVHT+H@?=%B;PN9%!%I?J=:1\^Q%RW2B2Y=*`

(B%>\X$Y]&PH_/[J)5&BVCD*0>$TU44(B%L M3.XS<2O2)4=O7,I)%.?H;**9SOZ%OV&/M^YZ,W/;R^'7+2CH W#.N9-%1,? MB6FA#UG*USGRT@5=*/Q=O;]SRM_7^YOX%" X
="U8"@4:&3 3S+<8"WQSVWZ M#EG&KP@;V%8T:'Z^NZ7JT)%]UX6W=>[NS04[N91]^#9C9>DL)H1894\ZPAO
M+_=W%%V+A$]75$R^')%T(=U_Y&O*$%^3%,E.7_\23/2>TR3_5$4\J@;8Z@84 MB\]%OB$AO1J(U26G;$<'LU]^,AWC=U5F0,)<2)@'"?,A80$03,HON\DO6T>? M?
2&),\8$V"CM[.AF9A]IH M7[BO-D P21NGT<;1:G/+Z(9$BT:*4J.LG&_#+6/E;)SGE"LUT4,K\@82XDS(.$^9"P @F MY9=IM.4$X]G+0NVZ/T,;!TM";>(<-
W%/4[S3%%_&GW['(HF=_I>#0=)<4)H'2O-!:0$43Q%W_)KMB3 I-/]JM^5E /-*BO"&HJ,BTX MV3A9IK9.9NH+9==AR+94*U,*IP7U0.-ZI\9-3AM)XO15L=, M?
7GL+F319I.C9MW3]LAU20)S4)H+2O- :3XH+8"BR1G3%O/,R:OOQ$&+?Z T M%Y3F@=)\4%H 19+VB(8U;5)2&8%%#KBM
MVF%]U>Y%&W'I9'_!%]7*(O$5M%:42TNPL]L>_8!:6YH#0/E.:#T@(HFIPW;9T/OWJ= M#X%6^4!I+BC- Z7YH+0 BB;G65OGP_J#4_DV/E.@-:YE-$
M[2PQH+6[X=X1XH2R57DZ/$=AMDUY=7:R>=J<0+\NSUT?/+\Q+^:FXKEK7GC5 M^?(67QUW_T"*12Q^,5V*4,:[L5A=676"O+KAV:8\P'R?<9XEY>6:D@5EA8'X M?)EE_.FF"-" MYP
"/99%Q>=6+L3VPK9YFD.)^3G=0B?7K"DKL9!3MK'YE@'.M%)9V)[CA':) M265%,[UVRZ(9W8F"5*#+$-5)68_+J&@^[GE6H%+%V23"[5@1[,MWL =B*_;
M6R9G=HN2D1(J3FB%>&*SGUL*]2*9*7@M\([#G1V.D/%E1>]\FG[*YY:@-00&I M4 A8/AY@"46A@.0V_FLPK=:D4CP>'] _:-^E+RO,84F+[R03^=R:6"B#-=X5 MX@O=?
X3&G/"2VG!]3_:U[+CL872'1>T;)3E#DI2U4_\V/!PI"!Q^A6\1L%[MKA"\H. W"OYK+02-0O!:"Z-&0;MNU[YKXF(L<#1C=(^8DI9H:J#9U]J2+U*I M/+D33+XE4D]BS1E.\A0\B@SCP-
'N,K0C6.,:@$NB)X10HBB'Q[%H/ MI.#H;\P85C%^A_Y$7^?]B=/;[NYDMY(X4KITVUB]KZJX+UGUT32N1*KD7? M3F%N%K&@3V %?WQFQLZ_51;1(L-@F6&
+K!"5H@Q(,H4=W.6:@V.&4EJJKG:K MDML7CAHIIU&CJP'B[L^9AC/[X9CG4ZEPZD"F7:GX5,IUI^[8Z8HE/6+^Q O< M5JSC]AU>C3L-&PQTVZBQ88!R(-*9>,UE"M@O9DXB/?
63#0)%IL$2PR!=8(2 MMD$)#9>'T&103(+%)L$20V"=H(S;H(P'OYOKO*),'^(,"BQDD8#F9.\+R"#6 M6P-B$$BRNP49'=63BJ-^S+)"=&N?\JS(9,= MGJ8W9
MAE0<%;"6IISSLY"5E3(GD8/<]G7 E,"\OV:4G&8* -MIQS] M#U!+ P04 " 3A U95!S4*S & #L-P &0 'AL+W=O[(^]"TW^;BR"+O];;B\%L@-9\ MX\:!_BR>?
N/%@,8ISQ.!ROZBI]QV:@V0%RLMPL(YR2#TH_S1_5%,Q)Z#[1QQ MP(4#?NTP.>+@% [.:X?1$8=+3J&F%<.(R[1I@4#I.N#M/"89H5*Y_=K#0K
M5[O+A11/2*;6"2UL]DM4W\TXJXD=I*]YIF;SJ)WYZ>:>%]VTK@C67ZNV;&;:G M[Q'Y'OOZ&?V\XMKU X7^<*5TTX]Y!?V*?D)#I+:NY&HQU$D"*6;H%<&N\F#X M2#
'W8A(;Q4BT9JO&_R)V7]B\!\F R]'CU]&?XF-P!OW&=GV.X0M[#0-Q^S] M,8[.D&-E[J,&]U5W]J;HY+3H]+3HS.R^XE[BWCAUM4HX91\Z&6]TA'<WP>^
M%SRC/Z6/U!9]27LNT@]I[O<'A/9?_-1X[V4]N4TJ!'W.LZ(\#O,RQ<;8*VOQD]'@QQT*ZRDXV][@EG!PY!93DE.ZQ3ZMZR@5JMVWQ;@:>7@EGM;^/2>:T=-&6!()X70[FC29YNWF+Z#N%4M87V!
M%ISNFXsd=...

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function() {Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 45 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 130 120 1 false 25 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://xeneticbio.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) Sheet http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) Sheet http://xeneticbio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 7 false false R8.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 8 false false R9.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 9 false false R10.htm 995513 - Disclosure - The Company Sheet http://xeneticbio.com/role/Company The Company Notes 10 false false R11.htm 995514 - Disclosure - Risks and Uncertainties Sheet http://xeneticbio.com/role/RisksAndUncertainties Risks and Uncertainties Notes 11 false false R12.htm 995515 - Disclosure - Summary of Significant Accounting Policies Sheet http://xeneticbio.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 12 false false R13.htm 995516 - Disclosure - Significant Strategic Collaborations Sheet http://xeneticbio.com/role/SignificantStrategicCollaborations Significant Strategic Collaborations Notes 13 false false R14.htm 995517 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://xeneticbio.com/role/AccruedExpensesAndOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 14 false false R15.htm 995518 - Disclosure - Fair Value Measurements Sheet http://xeneticbio.com/role/FairValueMeasurements Fair Value Measurements Notes 15 false false R16.htm 995519 - Disclosure - Stockholders??? Equity Sheet http://xeneticbio.com/role/StockholdersEquity Stockholders??? Equity Notes 16 false false R17.htm 995520 - Disclosure - Share-Based Expense Sheet http://xeneticbio.com/role/Share-basedExpense Share-Based Expense Notes 17 false false R18.htm 995521 - Disclosure - Income Taxes Sheet http://xeneticbio.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 995522 - Disclosure - Related Party Transactions Sheet http://xeneticbio.com/role/RelatedPartyTransactions Related Party Transactions Notes 19 false false R20.htm 995523 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://xeneticbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://xeneticbio.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 995524 - Disclosure - Share-Based Expense (Tables) Sheet http://xeneticbio.com/role/Share-basedExpenseTables Share-Based Expense (Tables) Tables http://xeneticbio.com/role/Share-basedExpense 21 false false R22.htm 995525 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://xeneticbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://xeneticbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies 22 false false R23.htm 995526 - Disclosure - Significant Strategic Collaborations (Details Narrative) Sheet http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative Significant Strategic Collaborations (Details Narrative) Details http://xeneticbio.com/role/SignificantStrategicCollaborations 23 false false R24.htm 995527 - Disclosure - Accrued Expenses and Other Current Liabilities (Details Narrative) Sheet http://xeneticbio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetailsNarrative Accrued Expenses and Other Current Liabilities (Details Narrative) Details http://xeneticbio.com/role/AccruedExpensesAndOtherCurrentLiabilities 24 false false R25.htm 995528 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://xeneticbio.com/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://xeneticbio.com/role/StockholdersEquity 25 false false R26.htm 995529 - Disclosure - Share-Based Expense (Details - Share based expense) Sheet http://xeneticbio.com/role/Share-basedExpenseDetails-ShareBasedExpense Share-Based Expense (Details - Share based expense) Details http://xeneticbio.com/role/Share-basedExpenseTables 26 false false R27.htm 995530 - Disclosure - Share-Based Expense (Details Narrative) Sheet http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative Share-Based Expense (Details Narrative) Details http://xeneticbio.com/role/Share-basedExpenseTables 27 false false R28.htm 995531 - Disclosure - Income Taxes (Details Narrative) Sheet http://xeneticbio.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://xeneticbio.com/role/IncomeTaxes 28 false false R29.htm 995532 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://xeneticbio.com/role/RelatedPartyTransactions 29 false false All Reports Book All Reports xbio-20240630.xsd xbio-20240630_cal.xml xbio-20240630_def.xml xbio-20240630_lab.xml xbio-20240630_pre.xml xenetic_i10q-063024.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 50 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "xenetic_i10q-063024.htm": { "nsprefix": "XBIO", "nsuri": "http://xeneticbio.com/20240630", "dts": { "schema": { "local": ["xbio-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["xbio-20240630_cal.xml"] }, "definitionLink": { "local": ["xbio-20240630_def.xml"] }, "labelLink": { "local": ["xbio-20240630_lab.xml"] }, "presentationLink": { "local": ["xbio-20240630_pre.xml"] }, "inline": { "local": ["xenetic_i10q-063024.htm"] } }, "keyStandard": 119, "keyCustom": 1, "axisStandard": 8, "axisCustom": 0, "memberStandard": 11, "memberCustom": 12, "hidden": { "total": 75, "http://fasb.org/us-gaap/2024": 60, "http://xeneticbio.com/20240630": 10, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 130, "entityCount": 1, "segmentCount": 25, "elementCount": 308, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 402, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://xeneticbio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "b", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "b", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } }, "R2": { "role": "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets", "longName": "00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } }, "R3": { "role": "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef":

"AsOf2024-06-30", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } }, "R4": { "role": "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations", "longName": "00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "unique": true } }, "R5": { "role": "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical", "longName": "00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:EarningsPerShareBasic", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:EarningsPerShareBasic", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } }, "R6": { "role": "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "longName": "00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_PreferredStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_PreferredStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } }, "R7": { "role": "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows", "longName": "00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "unique": true } }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:NonRule10b51ArrAdoptedFlag", "span", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:NonRule10b51ArrAdoptedFlag", "span", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } }, "R10": { "role": "http://xeneticbio.com/role/Company", "longName": "995513 - Disclosure - The Company", "shortName": "The Company", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } }, "R11": { "role": "http://xeneticbio.com/role/RisksAndUncertainties", "longName": "995514 - Disclosure - Risks and Uncertainties", "shortName": "Risks and Uncertainties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } }, "R12": { "role": "http://xeneticbio.com/role/SummaryOfSignificantAccountingPolicies", "longName": "995515 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } }, "R13": { "role": "http://xeneticbio.com/role/SignificantStrategicCollaborations", "longName": "995516 - Disclosure - Significant Strategic Collaborations", "shortName": "Significant Strategic Collaborations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } }, "R14": { "role": "http://xeneticbio.com/role/AccruedExpensesAndOtherCurrentLiabilities", "longName": "995517 - Disclosure - Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } }, "R15": { "role": "http://xeneticbio.com/role/FairValueMeasurements", "longName": "995518 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } }, "R16": { "role": "http://xeneticbio.com/role/StockholdersEquity", "longName": "995519 - Disclosure - Stockholders\u2019 Equity", "shortName": "Stockholders\u2019 Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } }, "R17": { "role": "http://xeneticbio.com/role/Share-basedExpense", "longName": "995520 - Disclosure - Share-Based Expense", "shortName": "Share-Based Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } }, "R18": { "role": "http://xeneticbio.com/role/IncomeTaxes", "longName": "995521 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } }, "R19": { "role": "http://xeneticbio.com/role/RelatedPartyTransactions", "longName": "995522 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } }, "R20": { "role": "http://xeneticbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "995523 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } }, "R21": { "role": "http://xeneticbio.com/role/Share-basedExpenseTables", "longName": "995524 - Disclosure - Share-Based Expense (Tables)", "shortName": "Share-Based Expense (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } }, "R22": { "role": "http://xeneticbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "995525 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "From2023-05-142023-05-15", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-05-142023-05-15", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } }, "R23": { "role": "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative", "longName": "995526 - Disclosure - Significant Strategic Collaborations (Details Narrative)", "shortName": "Significant Strategic Collaborations (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30_custom_CollaborativeAgreementsMember", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["us-gaap:Revenues", "us-gaap:Revenues", "us-gaap:Revenues", "span", "span", "span", "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "unique": true } }, "R24": { "role": "http://xeneticbio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetailsNarrative", "longName": "995527 - Disclosure - Accrued Expenses and Other Current Liabilities (Details Narrative)", "shortName": "Accrued Expenses and Other Current Liabilities (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-06-30_custom_SeparationAgreementsMember", "name": "us-gaap:LaborAndRelatedExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "unique": true } }, "R25": { "role": "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative", "longName": "995528 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "AsOf2024-06-30_custom_PubliclyTradedWarrantsMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_custom_PubliclyTradedWarrantsMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:ClassOfWarrantOrRightOutstanding", "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "unique": true } }, "R26": { "role": "http://xeneticbio.com/role/Share-basedExpenseDetails-ShareBasedExpense", "longName": "995529 - Disclosure - Share-Based Expense (Details - Share based expense)", "shortName": "Share-Based Expense (Details - Share based expense)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "unique": true } }, "R27": { "role": "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative", "longName": "995530 - Disclosure - Share-Based Expense (Details Narrative)", "shortName": "Share-Based Expense (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30_us-gaap_EmployeeStockOptionMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "unique": true } }, "R28": { "role": "http://xeneticbio.com/role/IncomeTaxesDetailsNarrative", "longName": "995531 - Disclosure - Income Taxes (Details Narrative)", "shortName": "Income Taxes (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["us-gaap:IncomeTaxExpenseBenefit", "us-gaap:IncomeTaxExpenseBenefit", "us-gaap:IncomeTaxExpenseBenefit", "span", "span", "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["us-gaap:IncomeTaxExpenseBenefit", "us-gaap:IncomeTaxExpenseBenefit", "us-gaap:IncomeTaxExpenseBenefit", "span", "span", "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } }, "R29": { "role": "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "995532 - Disclosure - Related Party Transactions (Details Narrative)", "shortName": "Related Party Transactions (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "From2019-10-012019-12-31_custom_PharmsynthezMember_custom_CoDevelopmentAgreementMember", "name": "us-gaap:PaymentsToAcquireNotesReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2019-10-012019-12-31_custom_PharmsynthezMember_custom_CoDevelopmentAgreementMember", "name": "us-gaap:PaymentsToAcquireNotesReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "xenetic_i10q-063024.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsAndNotesReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsAndNotesReceivableNet", "crdr": "debit", "presentation": ["http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Accounts and Financing Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable." } } }, "auth_ref": ["r560", "r580"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": ["http://xeneticbio.com/role/AccruedExpensesAndOtherCurrentLiabilities"], "lang": { "en-us": { "role": { "label": "Accrued Expenses and Other Current Liabilities", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": ["r28", "r30", "r33", "r570"] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued expenses and other current liabilities", "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r28", "r434"] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "presentation": ["http://xeneticbio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetailsNarrative", "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Liabilities and Other Liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r7", "r8", "r45", "r88", "r301", "r322", "r323"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r1", "r3", "r8", "r249", "r252", "r279", "r318", "r319", "r543", "r544", "r545", "r550", "r551", "r552", "r553"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r497"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional paid in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r38", "r434", "r612"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r336", "r550", "r551", "r552", "r553", "r571", "r613"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r503"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": ["r503"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r503"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r503"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Share-based expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [

"r22", "r23", "r185"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r468", "r479", "r489", "r514"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r471", "r482", "r492", "r517"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "auth_ref": ["r503"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "auth_ref": ["r510"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "auth_ref": ["r472", "r483", "r493", "r510", "r518", "r522", "r530"] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": ["r475"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r64", "r71", "r84", "r103", "r131", "r135", "r140", "r141", "r146", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r244", "r246", "r270", "r295", "r370", "r424", "r425", "r434", "r449", "r564", "r565", "r577"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r81", "r89", "r103", "r146", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r244", "r246", "r270", "r434", "r564", "r565", "r577"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": ["r475"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Exercise Price" } } }, "auth_ref": ["r525"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Fair Value as of Grant Date" } } }, "auth_ref": ["r526"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "auth_ref": ["r521"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r521"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method" } } }, "auth_ref": ["r521"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered" } } }, "auth_ref": ["r521"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r521"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined" } } }, "auth_ref": ["r521"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative", "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Securities" } } }, "auth_ref": ["r524"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": ["r523"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": ["r522"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r522"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://xeneticbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Preparation of Interim Financial Statements", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r73", "r298", "r347", "r365", "r434", "r449", "r539"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash at beginning of period", "periodEndLabel": "Cash at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r10", "r50", "r100"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r50"] }, "XBIO_CatalentPharmaSolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://xeneticbio.com/20240630", "localname": "CatalentPharmaSolutionsMember", "presentation": ["http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Catalent Pharma Solutions [Member]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r501"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets", "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r78", "r85", "r86", "r87", "r103", "r123", "r124", "r126", "r128", "r133", "r134", "r146", "r153", "r155", "r156", "r157", "r160", "r161", "r165", "r166", "r169", "r172", "r179", "r270", "r327", "r328", "r329", "r330", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r348", "r357", "r379", "r401", "r409", "r410", "r411", "r412", "r413", "r538", "r548", "r554"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://xeneticbio.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r85", "r86", "r87", "r133", "r165", "r166", "r167", "r169", "r172", "r177", "r179", "r327", "r328", "r329", "r330", "r426", "r538", "r548"] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://xeneticbio.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r180"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://xeneticbio.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrant Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "XBIO_CoDevelopmentAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://xeneticbio.com/20240630", "localname": "CoDevelopmentAgreementMember", "presentation": ["http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Co Development Agreement [Member]" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure

Amount" } } }, "auth_ref": ["r502"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": ["r502"] }, "XBIO_CollaborativeAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xeneticbio.com/20240630", "localname": "CollaborativeAgreementsMember", "presentation": ["http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Collaborative Agreements [Member]" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": ["http://xeneticbio.com/role/SignificantStrategicCollaborations"], "lang": { "en-us": { "role": { "label": "Significant Strategic Collaborations", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": ["r74", "r75", "r77"] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": ["http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r243"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r34", "r65", "r297", "r356"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r440", "r441", "r442", "r444", "r445", "r446", "r447", "r550", "r551", "r553", "r571", "r611", "r613"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r37"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r37", "r357"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r37"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r4", "r37", "r357", "r376", "r613", "r614"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common stock, $0.001 par value; 10,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 1,543,802 and 1,543,385 shares issued as of June 30, 2024 and December 31, 2023, respectively; 1,541,101 and 1,540,684 shares outstanding as of June 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r37", "r300", "r434"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r507"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r506"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r508"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r505"] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": ["http://xeneticbio.com/role/RisksAndUncertainties"], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": ["r54"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://xeneticbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r24", "r420"] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r105", "r106", "r162", "r167", "r285", "r287", "r293", "r417", "r419"] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": ["http://xeneticbio.com/role/IncomeTaxesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Deferred tax valuation allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": ["r227"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://xeneticbio.com/role/Share-basedExpense"], "lang": { "en-us": { "role": { "label": "Share-Based Expense", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r183", "r187", "r214", "r215", "r216", "r428"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": ["r463"] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": ["r461", "r463", "r475"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r462"] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": ["r450"] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": ["r463"] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": ["r463"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r496"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype":

"textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": ["r453"] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r96", "r112", "r113", "r114", "r115", "r116", "r117", "r121", "r123", "r126", "r127", "r128", "r130", "r239", "r242", "r256", "r257", "r291", "r307", "r421"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r96", "r112", "r113", "r114", "r115", "r116", "r117", "r123", "r126", "r127", "r128", "r130", "r239", "r242", "r256", "r257", "r291", "r307", "r421"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://xeneticbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Basic and Diluted Net Loss per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r11", "r12", "r129"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": ["http://xeneticbio.com/role/Share-basedExpenseDetails-ShareBasedExpense"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": ["r456"] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r452"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r452"] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": ["r537"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r452"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r534"] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": ["r475"] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r452"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r452"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r452"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r452"] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": ["r535"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r4", "r79", "r92", "r93", "r94", "r107", "r108", "r109", "r111", "r116", "r118", "r120", "r132", "r147", "r148", "r149", "r181", "r229", "r230", "r236", "r237", "r238", "r240", "r241", "r242", "r248", "r249", "r250", "r251", "r252", "r253", "r255", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r306", "r318", "r319", "r320", "r336", "r401"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r504"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r468", "r479", "r489", "r514"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": ["r465", "r476", "r486", "r511"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } } }, "auth_ref": ["r510"] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://xeneticbio.com/role/FairValueMeasurements"], "lang": { "en-us": { "role": { "label": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r259", "r261", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r289", "r431", "r433"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r472", "r483", "r493", "r518"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r472", "r483", "r493", "r518"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r472", "r483", "r493", "r518"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r472", "r483", "r493", "r518"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": ["r472", "r483", "r493", "r518"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "negatedLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r47", "r381"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://xeneticbio.com/role/Share-basedExpenseDetails-ShareBasedExpense"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r47"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://xeneticbio.com/role/Share-basedExpenseDetails-ShareBasedExpense"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r150", "r151", "r152", "r258", "r260", "r264", "r316", "r317", "r386", "r415", "r432", "r582"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://xeneticbio.com/role/Share-basedExpenseDetails-ShareBasedExpense"], "lang": { "en-us": { "role": { "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r151", "r152", "r258", "r260", "r264", "r316", "r317", "r386", "r415", "r432", "r582"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://xeneticbio.com/role/IncomeTaxes"], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r104", "r218", "r221", "r222", "r223", "r224", "r226", "r228", "r231", "r233", "r234", "r235", "r332", "r430"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://xeneticbio.com/role/IncomeTaxesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Provision for income taxes", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r72", "r76", "r119", "r120", "r131", "r138", "r141", "r220", "r221", "r232", "r308", "r430"] }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "crdr": "credit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses, receivables and other", "label": "Increase (Decrease) in Accounts and Other Receivables", "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Accounts payable, accrued expenses and other liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": ["r547"] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": ["r472", "r483", "r493", "r510", "r518", "r522", "r530"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": ["r528"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": ["r464", "r533"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r464", "r533"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r464", "r533"] }, "us-gaap_InterestAndOtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestAndOtherIncome", "crdr": "credit", "presentation": ["http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Interest and Other Income", "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Interest income, net", "documentation": "Amount of interest income (expense) classified as operating." } } }, "auth_ref": ["r290", "r556"] }, "XBIO_InterestIncomeOnlyMember": { "xbrltype": "domainItemType", "nsuri": "http://xeneticbio.com/20240630", "localname": "InterestIncomeOnlyMember", "presentation": ["http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Interest Income Only [Member]" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r97", "r98", "r99"] }, "us-gaap_LaborAndRelatedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LaborAndRelatedExpense", "crdr": "debit", "presentation": ["http://xeneticbio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Labor and related expenses", "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit." } } }, "auth_ref": ["r546"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r6", "r29", "r30", "r31", "r32", "r33", "r34", "r35", "r103", "r146", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r245", "r246", "r247", "r270", "r355", "r422", "r449", "r564", "r577", "r578"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r42", "r66", "r303", "r434", "r549", "r561", "r575"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [

"http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r31", "r82", "r103", "r146", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r245", "r246", "r247", "r270", "r434", "r564", "r577", "r578"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": ["r502"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Name" } } }, "auth_ref": ["r502"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r521"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r529"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r503"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r50", "r51", "r52"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "verboseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r46", "r52", "r67", "r80", "r90", "r91", "r94", "r103", "r110", "r112", "r113", "r114", "r115", "r116", "r119", "r120", "r125", "r146", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r239", "r242", "r257", "r270", "r305", "r378", "r399", "r400", "r448", "r564"] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "XBIO_NonEmployeeStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://xeneticbio.com/20240630", "localname": "NonEmployeeStockOptionsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Non Employee Stock Options [Member]" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description" } } }, "auth_ref": ["r502"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r500"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r499"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r529"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r529"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Total other income", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r48"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "auth_ref": [] }, "us-gaap_OffsettingAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OffsettingAssetsLineItems", "presentation": ["http://xeneticbio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Offsetting Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OffsettingAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OffsettingAssetsTable", "presentation": ["http://xeneticbio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Offsetting Assets [Table]", "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements." } } }, "auth_ref": ["r43", "r44"] }, "us-gaap_OperatingCostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingCostsAndExpensesAbstract", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating costs and expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total operating costs and expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r70", "r423", "r555", "r556", "r557", "r558", "r559"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": ["http://xeneticbio.com/role/Company"], "lang": { "en-us": { "role": { "label": "The Company", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r27", "r62", "r324", "r325"] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssets", "crdr": "debit", "presentation": ["http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "Other assets", "label": "Other Assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": ["r63", "r83", "r294", "r425", "r449"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r83"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Other (expense) income", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r49"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount" } } }, "auth_ref": ["r502"] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": ["r463"] }, "XBIO_OtherWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://xeneticbio.com/20240630", "localname": "OtherWarrantsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Other Warrants [Member]" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r470", "r481", "r491", "r516"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Amount" } } }, "auth_ref": ["r473", "r484", "r494", "r519"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": ["r473", "r484", "r494", "r519"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": ["r498"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireNotesReceivable", "crdr": "credit", "presentation": ["http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Notes Receivable", "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics." } } }, "auth_ref": ["r9"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r501"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r501"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r500"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": ["r503"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": ["r499"] }, "XBIO_PharmsynthezMember": { "xbrltype": "domainItemType", "nsuri": "http://xeneticbio.com/20240630", "localname": "PharmsynthezMember", "presentation": ["http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Pharmsynthez [Member]" } } }, "auth_ref": [] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r500"] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": ["r457"] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": ["r459"] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": ["r440", "r441", "r444", "r445", "r446", "r447", "r611", "r613"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r36", "r165"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r36", "r357"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r36", "r165"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r36", "r357", "r376", "r613", "r614"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r36", "r299", "r434"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets", "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Prepaid expenses, receivables and other", "verboseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r542"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r142", "r288", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r416", "r427", "r435", "r436", "r437", "r438", "r439", "r562", "r563", "r567", "r581", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative"], "auth_ref": ["r142", "r288", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r416", "r427", "r435", "r436", "r437", "r438", "r439", "r562", "r563", "r567", "r581", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610"] }, "XBIO_PubliclyTradedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://xeneticbio.com/20240630", "localname": "PubliclyTradedWarrantsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Publicly Traded Warrants [Member]" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": ["r498"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r498"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": ["r465", "r476", "r486", "r511"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r145", "r182", "r283", "r284", "r296", "r304", "r350", "r351", "r352", "r353", "r354", "r375", "r377", "r408"] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": ["http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r145", "r382", "r383", "r386"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r145", "r182", "r283", "r284", "r296", "r304", "r350", "r351", "r352", "r353", "r354", "r375", "r377", "r408", "r576"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://xeneticbio.com/role/RelatedPartyTransactions"], "lang": { "en-us": { "role": { "label": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r280", "r281", "r282", "r284", "r286", "r333", "r334", "r335", "r384", "r385", "r386", "r405", "r407"] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative"], "auth_ref": ["r105", "r106", "r162", "r167", "r285", "r287", "r293", "r418", "r419"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations", "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative"], "lang": { "en-us": { "role": { "negatedLabel": "Research and development", "label": "Research and development expenses", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r217", "r415", "r424", "r579"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://xeneticbio.com/role/Share-basedExpenseDetails-ShareBasedExpense"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": ["r466", "r477", "r487", "r512"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": ["r467", "r478", "r488", "r513"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement does not require Recovery" } } }, "auth_ref": ["r474", "r485", "r495", "r520"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r39", "r60", "r302", "r321", "r323", "r331", "r358", "r434"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r79", "r107", "r108", "r109", "r111", "r116", "r118", "r120", "r147", "r148", "r149", "r229", "r230", "r236", "r237", "r238", "r240", "r241", "r242", "r248", "r250", "r251", "r253", "r255", "r277", "r278", "r318", "r320", "r336", "r613"] }, "us-gaap_Revenues": {

"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations", "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative"], "lang": { "en-us": { "role": { "totalLabel": "Total revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r68", "r69", "r95", "r103", "r131", "r136", "r137", "r139", "r141", "r142", "r143", "r144", "r146", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r270", "r292", "r424", "r564"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Revenue:" } } }, "auth_ref": [] }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RoyaltyIncomeNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyIncomeNonoperating", "crdr": "credit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperations", "http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Royalty revenue", "verboseLabel": "Royalty income", "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources." } } }, "auth_ref": ["r48"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r529"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r529"] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": ["http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r243"] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": ["http://xeneticbio.com/role/Share-basedExpenseTables"], "lang": { "en-us": { "role": { "label": "Schedule of share-based compensation expense", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": ["r21"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://xeneticbio.com/role/Share-basedExpenseDetails-ShareBasedExpense"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r21"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r25", "r26", "r382", "r383", "r386"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r184", "r186", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://xeneticbio.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r13", "r14", "r15", "r16", "r17", "r18", "r56", "r58", "r59", "r60", "r85", "r86", "r87", "r133", "r165", "r166", "r167", "r169", "r172", "r177", "r179", "r327", "r328", "r329", "r330", "r426", "r538", "r548"] }, "XBIO_ScrippsResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://xeneticbio.com/20240630", "localname": "ScrippsResearchMember", "presentation": ["http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Scripps Research [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r451"] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": ["r455"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r454"] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": ["r460"] }, "XBIO_SeparationAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xeneticbio.com/20240630", "localname": "SeparationAgreementsMember", "presentation": ["http://xeneticbio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Separation Agreements [Member]" } } }, "auth_ref": [] }, "XBIO_SeriesAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://xeneticbio.com/20240630", "localname": "SeriesAWarrantsMember", "presentation": ["http://xeneticbio.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Series A Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesBPreferredStockMember", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets", "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": ["r540", "r541", "r566"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://xeneticbio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetailsNarrative", "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://xeneticbio.com/role/Share-basedExpenseDetails-ShareBasedExpense", "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "Share-based expense", "label": "Share based compensation", "terseLabel": "Share-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r2"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://xeneticbio.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrants forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r204"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Other than options granted, shares", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r202"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r184", "r186", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": ["http://xeneticbio.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrants exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": ["r5"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": ["http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Options expired", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": ["r198"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": ["http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Options forfeited", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": ["r568"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": ["http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Options granted", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": ["r569"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative", "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213"] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://xeneticbio.com/role/SummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r53", "r101"] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":

"SolicitingMaterial", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": ["r458"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets", "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r78", "r85", "r86", "r87", "r103", "r123", "r124", "r126", "r128", "r133", "r134", "r146", "r153", "r155", "r156", "r157", "r160", "r161", "r165", "r166", "r169", "r172", "r179", "r270", "r327", "r328", "r329", "r330", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r348", "r357", "r379", "r401", "r409", "r410", "r411", "r412", "r413", "r538", "r548", "r554"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r4", "r37", "r40", "r41", "r79", "r92", "r93", "r94", "r107", "r108", "r109", "r111", "r116", "r118", "r120", "r132", "r147", "r148", "r149", "r181", "r229", "r230", "r236", "r237", "r238", "r240", "r241", "r242", "r248", "r249", "r250", "r251", "r252", "r253", "r255", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r306", "r318", "r319", "r320", "r336", "r401"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets", "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r107", "r108", "r109", "r132", "r278", "r288", "r326", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r357", "r360", "r361", "r362", "r363", "r364", "r366", "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r375", "r377", "r380", "r381", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r401", "r443"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets", "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r107", "r108", "r109", "r132", "r145", "r278", "r288", "r326", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r357", "r360", "r361", "r362", "r363", "r364", "r366", "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r375", "r377", "r380", "r381", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r401", "r443"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r469", "r480", "r490", "r515"] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Issuance of common stock in connection with restricted stock, shares", "verboseLabel": "Stock issued for RSU's", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": ["r4", "r15", "r37", "r40", "r60", "r163"] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://xeneticbio.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Issuance of common stock to adjust for reverse split rounding, shares", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": ["r4"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://xeneticbio.com/role/Share-basedExpenseDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Options exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r4", "r36", "r37", "r60", "r196"] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Issuance of common stock in connection with restricted stock", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": ["r4", "r37", "r40", "r41", "r60"] }, "XBIO_StockIssuedDuringPeriodValueReverseStockSplits": { "xbrltype": "monetaryItemType", "nsuri": "http://xeneticbio.com/20240630", "localname": "StockIssuedDuringPeriodValueReverseStockSplits", "crdr": "credit", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Issuance of common stock to adjust for reverse split rounding" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets", "http://xeneticbio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Beginning balance, value", "periodEndLabel": "Ending balance, value", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r37", "r40", "r41", "r55", "r359", "r376", "r402", "r403", "r434", "r449", "r549", "r561", "r575", "r613"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Stockholders' equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://xeneticbio.com/role/StockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r57", "r102", "r164", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r181", "r254", "r404", "r406", "r414"] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": ["http://xeneticbio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Reverse Stock Split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": ["r61"] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL CASH FLOW INFORMATION:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List, Table" } } }, "auth_ref": ["r509"] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount" } } }, "auth_ref": ["r501"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r508"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransactionDomain", "presentation": ["http://xeneticbio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetailsNarrative", "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": ["r419"] }, "us-gaap_TransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransactionTypeAxis", "presentation": ["http://xeneticbio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetailsNarrative", "http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Transaction Type [Axis]", "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": ["r419"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Adoption Date" } } }, "auth_ref": ["r531"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } }, "auth_ref": ["r532"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Expiration Date" } } }, "auth_ref": ["r532"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": ["r530"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Title" } } }, "auth_ref": ["r530"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Termination Date" } } }, "auth_ref": ["r531"] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r19"] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r19", "r20", "r40"] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change" } } }, "auth_ref": ["r527"] }, "XBIO_UniversityOfVirginiaMember": { "xbrltype": "domainItemType", "nsuri": "http://xeneticbio.com/20240630", "localname": "UniversityOfVirginiaMember", "presentation": ["http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "University Of Virginia [Member]" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": ["http://xeneticbio.com/role/IncomeTaxesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Unrecognized tax positions", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": ["r219", "r225", "r429"] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMaturityDate", "presentation": ["http://xeneticbio.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Maturity date", "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format." } } }, "auth_ref": ["r572", "r573", "r574"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r122", "r128"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://xeneticbio.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r121", "r128"] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": ["http://xeneticbio.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": ["r536"] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-4" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards

Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-

50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r195": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-

40-65-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-

65-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r380": {

"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r417": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r418": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r419": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r420": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r421": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r422": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r423": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r424": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r425": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r426": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r427": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r428": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r430": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r431": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r432": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r433": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r434": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r435": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r437": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r438": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r439": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r440": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r442": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r447": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r448": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r449": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r450": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r451": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r452": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r454": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r456": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r457": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r458": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r459": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r460": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r461": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r462": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r463": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r464": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r465": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r466": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r467": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r468": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r469": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r470": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r471": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r472": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r473": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r474": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r475": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r476": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r477": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r478": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r479": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r480": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r481": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r482": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r483": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r484": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r485": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r486": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r487": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r488": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r489": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r490": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r491": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r492": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r493": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r494": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r495": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r496": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r498": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r499": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r500": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r501": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r502": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r503": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r504": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r505": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r506": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r507": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r508": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r509": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r510": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r511": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r512": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r513": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r514": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r515": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r516": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r517": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r518": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r519": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r520": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r521": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r522": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r523": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r524": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r525": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r526": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r527": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r528": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r529": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r530": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r531": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r532": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r533": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r534": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r535": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r536": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r538": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r602": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 51 0001683168-24-005572-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-24-005572-xbrl.zip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

[RN]Q18G(QZ>U;3C"GPKIM^+>UA7R %@Q"-#4-E;]$U0JV5 M)QU-TK0,DGN\S8A./GV8:]7(2 [%TL6 THB$F%(:%1958$^*^,\R('3&DNR, MHA"0KG6AH#J4Q@
&2AUR;DJ!M'"_&N&KJ3PRCE$D(M3Y=$-!5IAZ#'"@=*(@ MIYZ2M'B_2ED\XB1AH4B"U-R@R,"NU:(F/-2+B 2E&"4]I6:X!:I-X,CF^HF- MSNDPR3*S';Q/\0BT=?IIP6 E-
&1HJ2)NAIB=)R5UHM,;-"0@7:M'076HFP$, ME&+DW)1:J>"(X_V+Y#J-K"32XOP(9$!3+H\:!% ASX33!C>BT@N2T)ZK-4]CAKJ;%/60+;=GU7@0 C%0$[8M:W@/:%X
MZH&NTR(N=NR:M;M2XM,AA[C2AHI MK5@,M/N:48 !24?/4*$@ M:H3Z5CZ%Q!Q8R3;KN#OPN,UD=YE%ZA&*P6U@20P&QX*F36,BVK M?
%)0QJYWY@D@EH(7Q4VBB'ZHO/[?;9SBM\K\2[%NU:6AV]>4! A(26IV"OW4 MR+/F#XC9H%D*133O1F3UG7_1O+,5S3O0HGEWB&B67S(@HGD_(JOO_8OFO:UH MWH,6S?
N#!$,+WFM;<\GBD9-E]D7FG*U$>I&,2%4JF#T,GEP$;B:Q, ,VGF$F M/F7"!U8S,B?94YR&ZB&S"NY%, K24M4,L"/D(R=HTD\[(&[LO+8UU:#<6$D: MF)]6ID]2WL14&'@BZ1,S-
BX5VJ!,G_C;?:B;@<[$4>4L)2D?20*0B MHV<23&6#J)&/B74M5[:A(3U*-GCN[@BPA-;^"'#G(0@1R!A)+S4CU=Z1\W-B M;,@S(3A0M C]Q\X*64*J+>/.,QA%+!(22IC7:XKQ49%9
-9D_IBE:@*J MI%7DFM(>/(@=1X@I2PU+G,,1QGE;CGPMVJZNT^>X\<]:S#^FT'7GS $3I#MD(MW73SW'%I_DSB@KZ9W8E:IO4NC\QO4(%S5R M6&1)',9%G*X_T,DGB0-
9KF0@5X)0$VS4(") 2$%)2XBQV@)1@W0L@CG!3(28 M%@0_!(C3")/9:B7M[75@5Z(P$V[$H4:"$(F1GGB-(#X/.Q:H,D' M8C)*/!(33Q)2DE<(20Q"%+F,D
MN3NT4]:>FOSKY_"173"@.) @A[EN^F4DA\U_%P-" AIBXNV0%10U6!\'$O9= MUMH\"%A[&P2L#8. -<1!P-IV$+#V-@AH7EN%"*'MTNPAB=>!(CBA%NU:%!K*
M0WU(H*"DHN:G;#-:$[2W<1W1DHXZY@?^[%Q9>7IB&6!V7T1\1."HJ@YJ;,KPKN^E"ECO3P-*4,"TA" M6H+*\Y.M#0L5Y$@+2BXWB)#U#N \
<(%,78,2T$D#QDO#019 AJ ML%ZTL-@$27)1YG&*M'"]0:3->W> M?B+9E^*QCL^JS)L"[58;6LI]C4BA@+2BXZ?03&."*ILFI*X?\3SO XI741;5 M.95 '1J!L)ODK'
MUTTC8<@.1%2C\C0*B$Q".K#S6T>4A(6[1P0D""$9Z:GO(6DM4&/B6#4SJF'2 MG<=Q$M,";Y2G':XF;]R34W1,S29S2C;G![]1"O M!W(\,I80'
R,.P@0&E'24@V+NW<%^(F=5SXD<7B39(%ZE:6'<1PQ3Z0W"):W M!P!2@,A*%2*/ Q%'>BG_BR#]3,IM$>[F) LQ9EY6>=M:F=;?+*W=:F94EOIJ
MLC(%I+,Q?!4*W">!.FF<=7HLGXMYS&F<17/+PL^+QX!^P%E9Y*P'I<34J^!: M(\?;"Q89&&PR:"P 2<^"IFK#@5LB;GJ&*F/4L?8T/\OW40!Q=+&[QRM,V+F#
M)7XN+NB+/FMF&!:VKF=0UMD93N:,AB!$.):M:JJ7HVX"Z('YB-5)H%]8(HBG M;GZR#85LK29WO^PE6O_P:^L]L@P>!(=3%A"$0E8JC1<$3R)":1B0,RJ?X
MN7^E3/(<%_GD@07P#X>#>17(I4+D!+OJZ"/ *$-*2W (7"RNEPL@*J@'\U9B M$+#N-:&@*TIC 2F$#D[U>T[;?YT;MB+H/\49&MZI%+/73)=(N?_0ZFM#MD
MA,*EC[R7Z)S@;1!'U\];G.9XDD9\=;JG447.K"Q=ZF%$5KIRL3 #HR9[KI)S M\\P2X_E2Q6I7Y*8V_N4BQC,]65 MDZTMF#9F)&$A[N1T7=\O?H>N__/C=/D/
M2"JUFVKK##PIT6+2K49#5-NXZ7>R-_0_!Z\]T?)YL&.#=\-060%VVOUI">Z M0RD2C'ZT](0UOAJ,MA4:FF[:R6,8DA)'8MVP^P@6R7C4FG4F-2HTI@%5G[;$ M)W-NW4YUE?
QNF!M8SZ2PE %6/.I#>-&,0! M5A5:.4"2 ?,ZB@ON\D&;RLN,>_?C-%3+0FOA=.O#3+VW(Z*&@^F\S!S%VT1: M"]Y%A5T;[^H:O1P!90%BW)+#5[#(,'I9H6OP.X2YB?]YWYPP-
S2"JV623T%2 MJGR^I$C'.W$JJH.=MR$,C&C4W"0[:Q6R\5_EX+,J',]Q#XD=VLO57KDZS8@P MU_V9C.2P^MBPA%04S6764IRBN1_,\WW[UY\Q9M X*>F-&?T-LW9V_>\']1 M7GE
!V7QF)'XGU1:0 @F0=Q-$TO@VU<"+>-&-%.USWTE'O+&W(HF.JD MYR3UA=K1A@V^S M/+_#Q6RU#)[5:XGC4G&\RGM(%@>+O&.2 "/5PWCK=%NO[';3H:TH2\B[E)<$
M!WE)=GQL58V?=&-8-=RE.$VDNRI48=W([8=*;BE>,R'HEO<,/,6[&2IX-=CU M+B-Q '?>*FMK!" U6=A*)M&PADPT26'W6,&6LK MWQI31)FQ- &M-G.<&97D3A5CYH4;=2,
[72M+3]MY8[I;"S,P.K3GJM@'_"IZ M62&DDW'JH;7PI$&;28<&#E%SEM,-:6 M0',-(4?:(9P2[557ZL&; @I73]IA MFTQ+$+U<;$=L_F,"CB&OU17$@=H!T0#E"H,T1JLVV-
J@3@:/3B7:I;@,E+NZ M4D#!2$K/;ZBF"HTZ$;@: __QM^[Q$TY+;(K)<+V)@>&HQL!0D$^%1Z22 MD7\5U:HW5 H_[8BN_8"UK3A@)=\^A%+FLT:CEUG.S\[4T:%,G8N%G=.H.;;9
MZ$70,1F!:5ELF0J1=1H[%#)#OE'=',P%T&OA'-,/^DCST(B0T+Y-H$Z:T8KEVJSS$)7;P83:(JSHSO47&W%)1?T[+RKKFU]F];:U+KO<5[ZSB%-
M:5_9@'RH9VD:>JE8RL=@F:9WA".>O5NV*=-=I!6@B?2J'\I;V+E4DW4VNMHR&H$9RMLRE0?)K(Y6H&_J M9NI;_X-XSDN9*55-,Q@Y#[AJS(0>55I
49I5C3E,FOU!>4LSS0M,/T^12\+ M=UB]=Z*"N]T\T9/N[Y[(L6#49" H[I]4\%I 9RC%_J>!8YLI("W4J,8)?KLT MMDFJ!^N=_L^_D'\'A')8/,$X%(Z/7$TD7 &L0+J,V5
3%H(0^]JZ#YLAWX[1W M$>1QJ,B8 NM2%UJZ77U(@6 :$!T[X8[(&KMWBSQ#']..U=Q4A9*[S4EVJ=^ M!I1U"JJA8#74YV>CHMK"NXY^QO'ZD1*9/-$^=8VK&^!G*\%M2M8.
MREY7B:,2 *//0U@/5=ND@>I$4)4*"ZLDGF" TBPJ,E[7-EOWS-&I)"T*8L6 MHE8E 5W6!MXO%+9%2WW"TCXX+,[IZ5&9V1Q%BV*@!2ZX;F&Y["4+O Z3EFW MB1X"^B"D?
28/5N>]B;%M1#PW$U8-@=^J;BL:RWHM44P5&-"_9)CLJ],*5R6A M#.<\Y_S$U666TF8HC[-TMJK^7,0/"5[@D"(U8<)?F*;ST#(OS;[0W!V:()C> M[!BY$!9.:7),^JPS"SM!/WELPBQ-
69Q+^MN7N'AD<2\+$H>L)P04*TG\(%7] M/W(]L4X40$49^0$L:HIEBM"KRKAL'+.N@.E:)M%_E7D5B'Z9*<*7\L_T$.0X M8A'[<)ISEX-[%F4HCPOZHT M[P13=QUE5
BDSY(\YVDV;EF>IG C]U/<3MRT6VU27J?:3GE^B#/>OKWYP_LW MO(W[^\5TIATEL;,2),?50<]M$@LWKQZ4@HN6YP598\HYP-R[J@[G;-UQ%QD*
M>&N#5AGAAV1H>BAG:2&2E3#.\6K',D9%'YP*F'&L7MD')N%=W2_C?52%VXQ- M(:Y8OO>P^'2=:@\5:%@*FWS5O1/VBY7PUOY\+!F;"D!)TO3]@3[U=J-
1Y0"VTD*5[*U<1QH.TQ,T+<"E)4!SH*9\3F M)'N*(QQ=[#[2B<\T;0\E3-@%-U6P8H,__P$).?9..S"C@RG7R%3 Z/=@ZD+(MF\GBK^CF=O;S=MVDR.X[T3_,J;PM91_Y8RL6K([T'3
4[8>;$&Z3:5[&A/6E>QOS=^:(*^Y7] M.62=3LG6LN*T<_(P:%_DOZ(VSI3]-3S=N$X"=KY#KB0L#)4%I%/!THG>0Y9C MXUA9Q?*%RZ.N(IRQRUOP%:[^3VL4<]O?5ZL\QSQ^1>?
J!5HMS9'07I:JXXAI MQ_@$@\AJ+TD23+-\G'P(@Z!'^C=V-66O6>5)\1/=G8LZ_#>QXB>8A&%65M=6 M\Z]!NRL 76[:VG] M\X-0 (7<'#<-2T)8?$5> \>U!*
(U@)9;E26+%GIH"E^P.MKRH\)52PM0CTW= MFP<[5GE86)DP)"7N]BXZ^C*[(^,1A-K4V&[=I<74J 1Q4CZ$NNMN2F:%O9GM$) M&C=M&^1]&]P=67C70_V:THL7I:"N%KYLE1#
<*=AQO&4^'<8E!^^J97ED_[*= MN:<@8:LH]ZV?'GM ZV[_APZRVI<=5O_KYS I(QX"*N0S@WO:"UZO5E@YO71- MPFEP>"\?N!=NWBD#6+782]ZE+0&'5M?;YX]?=[4_Q;?
^BBKET>L8Q -#Q\B0 ML$[$>L.@0_M(:-LA2H^GIP\@.D H//(<3*D4@)F(WD;#;C9?2FWVX3[* 1) MX]8P35<9V?!=)/+B:VUT_V9<5G];=C8F8*9A8[C*^SE?)S/;Z_7-\M)[>H
MW=5'T[N;V?V'R7(ZNX.P=%U%]&)N_^;(:RW*1\"U 459G+4: D8_7N,PJE411GLQT+_\.G_:+MG:R" G_40U?Q7F89'E),/J%FQ[7/\U8Z'0V\-SE7Q:VDV6I""0 A#QTQPCVVPJ &C7QC>I>
[+*59N*/*?UH;NADUU-D$R4"VG1=UM.L(:F%#REIJ,L4)8&#$Y::HXV^^LKJ=7+^^K4V>Y:]FQKO MM(\ST>[U="HP"W9,-30%G6UUM.8I\ZO"K7%@@)6[D]Y7FZV[$]7\6J%"::E
MJQ?:V 2<.1P&-&C3/^5\', C M+%2QX^X+_;+2R 3<[98%R5) MO8NV#7 S3JHR,W\"56="+4O1!J@8E41'2I"=Z9D>_RK40T0G[&B.$Y_.W)\(
MS9E2BU%M"U241L(CQ:G:MW8L54G#_REO-RIT*K6V="70D5EIM&EI!D*6X[C* MKX@6NV3T*>]L-'EO*WG$C(.:286EOQ92FQ5UXR@U R' <5Q'-HE5J!1/[6#P
M4"8!N8WSPNCQI\$Z:^M,=-O6304$(2<3.Z$%]_"(&?AQ)2TP/*59A708V\H M65>6HV!H0T?-NFOSM&7>],BV.C%:.'?8LM./ 0Y"2'8<-C@J%O&/!;WP[?
\OHKAWES]Y;45!D&1/74$+/V]?;2RO/A M*CN3G(I3F^ M!>W0EOFHEH\365GZ$QULUMRNTS>W_'[_YMW3_FRJWC?,:-N3&!)?S]0,!B 4)8M2W%(MT=@A:OC-T[>=T\:N!Q-
IGEZDJR*GPQS#*3\5TME@0T^U'7S(82 $H^0YUTD'004V"RB=-*(,S03\23+OLN)<;(D%D1[D,M*M(RV0RQX/2C M(#A.2*X'Q>MU43>6B@6P
<#9<%=*K!W;]IZ"4(*4DC!J7:\)O\,&M=T.@)-9 M#6TZF-[E<:X]PZ"$.AZ7*,D.QB8"#H18#.248Y2!6&ISQW)9%)_G))R194ZN M\R*NH@%_P,5C%NFD8V?F2D9C,M%
(RL8&A+Q&$!5O%:?/T)S$(4890BVFWDJ(@-F=@)&WM[/(+9S76R<9<5 M_\#MB UKVRT[,P_C(F,F)*,EI0T(S8T@.GID11-$-$6T3]*Q_&[H-Z#$FN6$ M:1HI]JY40%<2TQ-M1"5'0?
%;,C($L-TUX'=5XF5V75W)-UM=LXL60CY+E/=T MHZP]2<P7V",2LS\(^I4V#TNG70\>4K(LODISA+> MJ,Y6?\TV^)+1(KO;X(N]4O5)^)2K3>9TFM79@Q6N!6E;];9),?VRQ%"=&J+)
M 1+Q59S_5@9)O(K#.N?+X+G9)K(7LCD9GV*VS:1.T*8TP(K:DKBML(?),7W3 M!-NM11C.IT'S4V=W^EFRVYHHH3YI;X[W33GP'0\]7M<-A7RMDL$HKY',3<) M_ QUDF.J'B;H;
[W'/%G2@3VL^!@F36HDI(F3D26 R9.$H]6JH #V*!+SNN M":(I,M+3'R3VT4=V=VDSG-]EQ3W^K8Q)VY[J.L8QQC[VT.TR)-M1UUN"$-MH MNKK=]HBF@-
*L0*1*H^T!72]$,S>C_#*A3? R^Y!N8^:ZJ/("TX&=+3H;";=+ MS4HD"#D9Z0G+RMP <0MVU_@RWO#)P(>[^;3C<9I[<@[C]):;=9L5W3Z&&NM4
M1SJZ/1G)@'!4I&$G%1&3#ML;&RC'EV",V_5*I'.QZ#?E%3!80K':>N_+Q,=. M>\-W3G!4D$T:W23!6I.O !DH>4FKEKNAB5@6O%Z(D/E2-' M@U*0EJ).26>(FGJ64SNXHB/NZ";C3B&?
@D31ZFC1S1[_FBFWYX'54! 2,O,3 MKG[MCVOY3"E"JXSTW7!8O&PO@U[IK,_8/FL,_]0V5W@2$U.QY'CHY]Q-\ M3IHO]4:&'NY59XK-#!T6TG:&!4\ &Q]{BQ@I'! W6J5!T
M='LJD0'A-#X:=D-A4"BF6#;:WL-]*.7ZF83<2U^5J0[ ]28$8CTAM$_AE/Z0 MDG#XYAF3,*8]# ?Y*.N?2% =3[T)8L('4\J%R!.2U]-M2<#$09'#TIN@A\% M?5Z-9U&0,[\);NGC%&>_
=M]^%QPK5X^INMY*.M 3 :N-&-'O)&.'@U"0584 MS9W*#GT(R&=QJ@N&'8MJ6DW\ER3@9X (N8U3/"WP1A9_0 =V)28SX49(M:B0($1GI#054&Z#: E$3)A@>Y03]PJP1-W>]/?
FA(,D2DTT^6RU)1%GIYMLZ ML+,5'"/A=@%'B00A(2,]8?F&]EHD#A+$K;AO]R@FU^:.7/UE'GWP%FP=AFM M-D9[]R&D6;",&(!I;TMK&1=2_Y?O^6TIM$V;
JKU#)=*97YV>:NM$)X>!D(&>F^->1]&(P<_?=AMZ5%NZ M#P!J+Q8=V&'3TO)J)$@5&.D)POL"4L\5?O'WZT.@24#N>U19 3[O4H7 4(< M2EIB4,YLZRN255>^2[])"YM.I@OTT<>
(1&5=S!X%0@Y::K8=S+*.>^:[C]%* M18/UU,.H!:,$@M",B=V8[L6;=)J9M"G.H@+GMI]1T.QW-4N (15US(3IC-_H MB175Z^=M3,QZ&,+]T?F61*',<[G)
MOK3=*%%9^=DRT69!OG4A-0*C(MGJ=I,Z6Q14$:(98 CJH37[?>]E7:S$7=C.F72RQLG,O.1%\0G,@ M631GP_/)0UZPH">#;WGDM%QW,\CH_"2?HWM5[5$2]EY+3I$;
(29N)^TSU$N]KDC[M]-F6>_L&M'\%^J5YR7%'&]CR$;Z M?F+OE>H^SC_G-'L?J;)($<0I]T#7=T<&&Y=RMZ+?U:[6 (P0;5@*>QW,AC?L M/2M(+?
@E*]"T]!9,&%_[5MG.U*7TOF2FJT ,:S!"'$'64H_>13@)0Q8$K+,N M8VCN= 8N!6@VKF)0 MTZ;:OH4\.#4/8\E#LRP9:(Y-"HR@7\9?,D1EMLTU*I7H9\4C)NBR)(1Y#'32
M]2[]]I1Q)V")H7'5F[@4L0WYKE)U>#!RM""I.0K>"PH+IX659%7?]6QL7.T'0-02XU)"?8%4T? 48E4EJ" M^R,'06IR^%6RCUD289)7[.ZR
ML/XT;8.UV2&9NMWJ],K3$8\8UE++U0N+;_M7__VQW=O__>?4)6:=X'N,S%;=8,4WN.$G2ZXS/(B7SP&!#\$.8[HZ-3&4*2E MB;JH3G<$^0%??
+TL1C.B/D@VA)C"#\PMF@6J3WKD60$VW=?XONODW-->@O3A5D MW=!_@H,JASS)KZ]V:/.AJQ[UF/9BF8;;!R^!YGV5#\Z^U<*E?"^I=;6K@ M8'1GYBBZL3(+?
DUC)S0QH(96DB53*ZHW\2PQ;?NGPT,6F=E9NE$9@/7$NA&> M!Z38+>G@(FI!N0_67'*0M\N)&>O? NT9X+O)TP]2:.W7.-Y =NN4H\ M&.E9D!0%%U-A;9G_!=5;+P'O
KL.2$KK3S['A,^_]31FM'*ZK6.7A=X^C]X$ MC-CL> [UQEK'D'L]7,5)R3K?.UR@VRS/T183Q%/R+KQ%^(BC,AFL(+&EHYN, M"(M'W8#&DX0SXH>
]I:A*OG%;DZ_BO:6'\]Z+@QD(5;EW_UB9%?W. ML6 &1^;67'6[Q;^K]XG/4&V-^%/$[?TKLE.5Y4[@S$'WCNI!;@I%Y9=_G[*M%_GJ>H[[H53]RG'>
](),G:+^W=H%)3OE,GFV"Y)B5VV* MT2^3T4EGP!,H(OB*O"O[Z!T6%4DFV9 M@FH'"_D^A<;<;'H]R9L>(K[$945KU+1WJZ9Z6C7?$]83'Q5.HYJ^C1/O(I/
M\AP7>7UL1598%F;P:M(8TM+5^SAJBXN78\:;P[_^W1/PA+P/0<0S3$U..S\I MOI"EK>/S:O;9&9Q.,QM"D^@8TJH#:!J)H .H'4JG^)C]!!.0VF)U'I1L/:/ MH>E'I";$AN.",+=5)QT:/.&TE-
?:YAFH#G] 2>S;*X#_*K5:T6)E8\-* KKE M'076:373T>U5.!D0C#YT[(3:UV)1!0:SL(SO:4(9?7!:=69,(P\%UNE.AHYN;TM"!@2C M(AT]89-@(!Q(PXPZ'S\';*NBF)'[>/U8S,HB+VB?
UMD!D&=?8^9!4\9,2.2E MM(&F-!/1H>AJ/.H@88KM^AF3,,]QG,0A;A_F]=/\I9C/8D[+NRQMLVO4]BDA MV
V9"_>&%>9H2VS\R[HAC:;+7#>G=KV(2A$A<[R0V#X\U=RG9LIKI*M;4% M(\Z1A(=Z;" H.O;]A0=--*03IHX7PL5.]%C]$A#F#3'CUT!7[GO3-"](R5TE MF@H7C9JC'>N53J>?
HG/>]5X.,]D8^.0(-\"OMUX*F>=;4,O'H/XX M^4U&5C@N<#1-YYC$V=&KZ2$,OHI:>_BG/4HE^ZK[I.'YQG915?-0;^JWB] MJG2]V2;9#N,%)D]TC*KX6IVS(?JWSOM-0+=J)-
YT)F8"DO0]@; MEJ:Q7]X:[%EN;[XT?4;HAN\UA]QW=-C%'#SLD M;3?9F\",3@Z>7ID&),=(^*N8VFN"2]/%4X%.U96=(,+56TR5";+P07L&E4O
M2_S$%QM.M<*F>,E74=.T'^@HM4[ZAJ^_!NJR)3BJ5EBT9F (2UTG6_\];44; M_?JOH@H>^%'=+&+_JU7;PS(L/T?$CX)G_;]5H7U\>8[S/S3IGE>XNBJ)"Q(
M(\\&_Q;Y99:RD"Y\R:+ZZJ3%2J#U,4@DL]?D]C\GK:\XJU+RFBN\PH3JF6:E.D:-KEMI]B_!&FHV@6TLG1Z M?YQ]5GIWQ)G.P,C.GNM0@HTEDQUZ:JQ0T)AY%^+'E+2.%#1[=852;88IT2X%
M9Z#<%9D""D98>GY#,7717%#;+(IY]^A=1OM=:]5-.A>[WA,K/X=1:?GQ:3@@ MNW+_A1$)@9'O2]A;WY\$QL5 D<=;@P.!V0S W5Y")BPN]+H%M]5O272$]&X! M;8IM1DJ M,E0;
(FZ)]];>U5??059%@>[EZ@ZKIK\&&\=1/'^$HP,"49P6GKB?<$5F"NMVK^?^@P1;HPR[3.>M+::6X6,KE!G],9Y M_37DA("->ZAO_1]B?'?#8H/\U#;?V-.G
M71((RVRSR5*VDBKM!U580!_=2'%8 HT!:F+C<9LSQ*U\>J_UKC!3 M.NGT4+]^#Z8<-.2$2$CU16N3HB#Q0UFPX2Z;=M&I/X@6APZK[K$9 .HFEA3 MU318? 19P3T5TD\XQ21(:
XFT29.X[RH;B+21.PUF J(ENFPQ*J]:IKFWJ6 MS4E:3Z4U:^XLJFG(HW,/08!*1,U-I)"HD7 ML%-_5@/OF'P;WT>"\\-3\!b./#X$:G(BDWZ4D[.E&PC-)Y6M\:-J;#5[CZ
M_S3MK,CQ%8_]LIJT-HQ*%]_8RWN$!46:-OFG2^17&*>BN4U;I1)S4P1N*#TA1T\>H96Q9L59;[5)#7)98[7%P&^2-W$XMP=+'[F+,@6FVS M/@GI2$:Y$&!O#:A<#R
]+%J:!&)IH"81=J;Y&Y8.+>%0T;Y3W*?EJ7P92_8O MFS<\!0G;8KO'=(:AP6.V -^747WAPZR\DH=UH/KYS I(SXL"Q^9L^M]4.#K MU0J'TN4YMPP ZO-JU$%81W-
X,>^1<4]2=HU%C2H M9H8::HAQ0Q6YKU'\1]VKHC)($+/T4 J=N8RA)-1((*5A05"82N]- M0)4*/[227R99CI?9AW0;7\5YJ"@7'19(R5A1%+9!N1'B5FP0OXPW?.W\P]U\
MBE@"]$')Y^/^RVM)H@DAB@+J/012(G).XL91P*M&+U:AWZ_=\4 ZY77)_DOI M,+ZJNY*'>QK5C-C_UNR(&XCA%(F,E3QLB'*=H?O3+?T3_;GYB?Z'19FDO_Q_M4$L#!!0 (
!.$#5ET^Y#39R@ !* @ 5 ->&)I;RTR,#(T,#8S,%]P M&UL[5UM<]O(D?Y^5$$Y5:O-!MB6O^^/=[*4HBO*]HN,2'N3^^*ʻ M@"$U,0AP!Z L[J^_&0 D06!>>D #GYV]_?USXO02?"
M(AH&O[PX?#8 M?6\5-T^QCL74NT.IJ0E4^DEF-%,W8 ^*.H:^Q0HBZ@1J@FGH 1*3TA?W9:>Y)%$X(SUD%KN+((L$[FHVE/I*9(EW]-(^Y$_*=[O+-&J$:T'&P&^$C6>G&PR]:I$!(2L@LI[G$IY:^+S.@HG;#2B] JH,/=*,K7F[4AQ-G%3@.(1B@O$%?0/%5%2(8-'%
FUGEESTY (this line unclear)
PL72)S'AOT@_%/O["'[>'NU;?<^CI?13Z]> M??WZ]640/CA?0_8E>NF&"UB#D]B)5]&VM=>/K[/_I>Q_\VGPY2?QGSLG(CV. M5Q#]!C17UZ([V:?_
KF9OSY]]:\/UQ/WGBR<$QH(W%SR8L,E6I'Q MG;Y[]^Y5\ML-:8GR\8[YFV^>;419]LR_RW5T.A/42+>=>@Z<6)VXV=Z M2@KQMY,-V8GXIY/3LY,WIR\?
(^_%!OP$01;ZY);,>N)/;KWM5Q^YG\34O:.A M,-DK\>M7@Y"[)]B];_M$<4KY?<-2,J/.M% M[]4!7PX\$D3$XS]$H4\]]R;>N>.+\";WA,2162QH"^W)/"88">)]P>GXARL@
M,;Y1;40?0O^T6@T&RW%N,(=MYHI$TA:'&X<2S;:4V_P;T3S$ET%ASBT/UR M_H>'N'OZ]HO#HWY81T*M_]>GI1/>7?C<&A[SMW(?!PA+=0E\P<%;8BWO!Q*?]!,.^(#TI]L
ML&)BH+JFSAWU*<0IK!NJ2X-+A]DF?B!.-&*I3W7)*V6J39_L!YEFOJ\)D_=\ M!CH1*".J8PR*3GJDNF*VX69.H\FKU,0EK;F$A\?KS&3\3YD31(X+ZK,F
MOG9'QGI'R,9&RI)/39T]'R"U@:]=K"\(GP7]Z,9A8G!^,/>D@UIM;Y:RU]MR MBZW/8K:J'=QPL:U%=FVG4KRBPA;1-R7_#A%7&]5(/QP_*"1]X?BC7DOIB; &B)48@N?DAT M2.27ME*?
D$/&Q#:R!D&5+=4G;/^KP[PI7?)L0:!M:W5)_15$%&^K'+?$&^"&;AUA(;FZR*?&W:S\6NC6)+VM2)_Z2D8BKFJP>H@P_[+&0QY@$'O$V
M#0D5X('KF,:"/#M-..V=B*.'E0"6_YA29])LA/%#=*_[O@C1APP C4=H"@W_M80<-_\OGY$/]NXBOEMQXTQ)?+O$_:?\SIRF0O&I']@T24]ZB7*A]B]),>;/U
MF=L+&7Y>\8JGUQD%*^629CTQ+VG_M;,,Q8N5.AD2(0*0?- \4^T M@V:??]\3,ESZSEP.9X$$B.=-W;OD^3L@K1-G&Q/7C@H(%"/P;S)%"]RV2?!I'+\6[(,F0'X?4H@WM]C
MXBW3=W#(6R*L^GXSH$P?PU!ND0,!/LM)M@*#9'P3O9H5. #;Q;#43\]2%AT)' M),@I\3WL\-$".@R>B#L/V+"KM:S \/'\3\S]<6./8Y%B#\?^T*_"5MD2PP M)HR&XE"? ; O$0-1?
X>)ND)#5+R'@0=%>TL*WO_@@UU0#Q2QJYCH*=;G_M+=+#+2&'0HZRYS2JB0K[OXG#P*#GB*&0HVQ##2]V#'AVS+831CNJ]*FAD*-L M0$U*MHSY,
(AIO!9)X3>KQ=TN<+J/=9D*BC'*IE.E% JVFTA#$(M<=QV^14HH MQBA[39UR*#@/N#[.\:"CSS^@ZQU0)=(H4BC[#&UZ]% /6949+9.J&L>-.JT
M4+!1=I9Z!5'0GCJ/5Q[7*LFY$2"905>R0+%'V5:"U$4Q@B#0N MMAZ$GG9(-S!"S8&RW[10'<4H?<_C<$79'] ;0J-D1V,_L M8#^#PXZR@S6JV1'8W]C!_@8..I>U*@F)NP#_N.
(3<.OBA-H)3$41Q& ML>/_'UV:5J>RCFB!M7G:)M!QA3NXN@A2]5J$ "Q1=EKRI5IVU(A849<=3N MNT\!!1E RI3IF4\KT-Q]G$?!MIX;)D*BBO*3E*E5-L#KT@ECI1=/_=K<-8;
MRK!:5*-E&'IC-.82#,+%8A5D,1K%]9B"% HORO9=BNLBL8^SC X*,LIF3ZU8RPB/&1&6)GS9G>1QB;L&;#2;J49>'3T4<92]GEE1
M7.2OHFA%F"W^$BZH%5"V?5"EVQYGB+OBP]ZI.QN*F[,*$:9$A44:Y0MGTJI MEK&I";-K49/UXB[TU==#I(10A%$V>!K56@9Y3PXYO 42*+ H.SNI.DACPO#1
M36H]];,7Y)10@%%V<CKET,>.6CLG5N.O2@F/I522-BFN>&\1XWN?#IWU#?) MM S@>S:8B&M4;?O^7G+E1Y3Y9(M$CDO^@QOV!2D4<)PKDCKUVH9ZY=&8>*E(MES1P
I=OJ7:5[12H&[F@!L"Y0PE4&B&_QOQ_7\$X==@0IPH#(B7+O5U$7XE M"]0*B&>(!G513/]]%<<)98D@C)%'U"00B%'/#M4](>3>YDF-6_GGK2>LPYO
M%0<4>,1#1+VR2/EI,1$RTP=RX<1.)]$.?Q4'%'_$ T6]LFCY\VP@2]&%^C/S M B$4;<146*EJ*"!/%HH]OGZB&&I(.[84"*$@(^.\2E5# 7FX(&S.![7W+/P: MWQ?
J$>7K_38N\A!IBCOJO4JUHBTOCGQ35S*^?$*E&N*+*^T+E_1@YH): 66["E4:9V[-W>37 M3]UI=%"\$3>F,L5PIDRMIGSJ7OJAHUV7[Y%!\47B MZB AXO@DVO8VP(8(V #4)(C[4RLH<,
(%K6(1IB^'),5RH]\$J3IZWXO)I@P9: M/JAI,"]Q A1'6@5%NXM>Q@M?WY(982)-84H>XW/^H2_Z11& '6H?U(I"8!@D M9OK;JY)>U_P?&]UU"G[H:J\0ZEGOI+<-E(M*J*.;B^'-9'@A?
IJ,KJ\N^E/^ ME_/^=?IF,.Q-?AT.IY/>=O\#)XVY_^7PJ]DS)[I+[+B*3N:.L\R]RQIQM/F7 MG9]F__!Y*_)HMHWWC\-T*Z$IKYJQPJ[@/IW,':98\<-#0(:S]:F2K];:L;R0
MW>]S"H7R17^03<&]Q'+#LKR#F%6O=?5670D>5#W]*AFW>%-N]3[7F#&G@0,_9D +:+!13H9@,:])HIZH_^'C0:24!? M;B;LZU1EI7B);'$8.WY"B66NG"?
=A(%K,IN"'U2O*WYM.IVI.^8,@UBF?AJ MO>4)=)/<>XA\^T_.&A>AL%;0*M&;VM=6U#0^U=.8/#R6<=>#5KC^ $MU=2&= M96Q$0$V6T,>(B)\,'(",<\7H$9#?,XOP'&.P)6$KD0=
X.6_GH\,@3)(22>!J+:=E MPJOY;QU/,NN./A!66O.<+;"T% M1P+=:#G1DGV:R)9GY%$4&'P@(AUR0:[#*+HA\6@V=1ZU>UJ[AO">/ZBPI:V"
M$;IMIXPXT8JMD_$['/$UCO!6=N';>7K/_FT&3] MWG=[7WE.WF]*L^?D_>?D_>?D_>?D_4;-\)R_YR\WT9H/;VBVU_%]R&C M?^R6?:8H>YGO6)+[8?IWS$Q\<3MBB8I>LLL?

$Y9(#C67FO]HK@/8 =(Q^Z5N MEA2,M.QB&YZCN4M@5KR3MM&79]#H5J4^_X)/1 "=%/ECN;LQT 0\]'<0+" MHDMF@Z\PM$Q'<], H'KWS&.:F90,1W,CP:!R]TP"FI]J1:$?^9?
L6901X+= MNW+LH]EH25CA.;6]0/?WL$#W9,K_^#"\F4YZH\O>:#R\[4^O. %^?9KT('BK M@CFJK63 2M]X(,&* &ZOERF1M[@&Z$O9&7)%T4>ZVW#M^*+$M=#F)@S"M,OH
MACD-"_;^U=(H)MWQK9.YC,E?X.I)JW6QW# /M]XS2",DA3K[(8X8%0#L&)O M8NW,"L:B UTK(OSS]US&"^Z+?K@4ZF7BZOJ;E@U[_VK;"0$8"7NTGN^;&2. MSQ7L>PL:4
&'>,?!:&7%S1'ZN1-15RV]@ORH3@:T*J,/E$7I+JB_BG5GTTJ&XSH:,.B-;I?? M")W?B[>H'_AP-R?I@UZC6>F\UM"!+)LYKB.&2AAUU;*9 UID(U@W=%PG#15Q
M.H[$A<&]$\Q)=!5H+BKNK61^J+*2&?S:OWD_G/2N;O@O1H-__#JZOAC>3O[L M+,/HY]]PGQ^OIO_&SW'(71>K5B4(Q/Y\D>^@BWR *D;/-_E:MQ3D'?,(#IG*VX*Y
KECLZ<(/"=+GO MH%M]S=\\LK!'IV_VY,)H31:1D&+OM*J80ZDQNBT45^7JM@(A 2Z MO8JUS$R&4M%C9V-5L9!>=W33 J2&;L5O GL)*M*7%L]/(M_YQP2>SU2 PK?
M3*\J7JP8UVR<");<^AV$P0-W66Z,T2S].:9\JS\A+J?4OQ!P8+.=68>"NO:A M\'5C)"YKD7I]_5X ;K8%?]Y@(H0=<.TE?>]G_P[QXR=1H& MR"7D#]CY6MBP
T\12L5OR(9=3%QRHOM+/_RJ*+CR8Z4TI?[DU][E]>BW#A1< MR:6\;%6URD&2<*$M*(4L8Q8^4.X"Y^N/W*Q7P?8V8M^-Z4-;+]\8Z]"6UVI M4*HQ9'F-6A$Q]%FTV?LNW;)1_?
N(>D,%8HL9N-0G>[).P]IZ8S-?ZTSX&>X, M3<*.[E,;RR+[40W#NDI"WYGH,=RN>M4K+[/X'N@NC CJ0IE[ICB*)!+YYZ9P/;H0^ MB-12S>QNV4QG8L"'&!P U%'7O%&X^ V?
ZM)7UE,?MQX7R@UT)I1\H 8$.?7- ;TOKV,!W*.3=Q,[] MX$4D?N4EH;GXOP@A/SB^V/W<$@X/=?D8)7[!W7G_'W*4Z;E L4<,'UU_Y275 MQMSD9N(M-\%P-B.Z%6?;S()?5WT)YOS
MKBZ%7@16^FF<=*Z62S!SO$WR%T%LY M'."[L] &T*M158GU)D3 M^62@RGI;0JAUFHNK6D(M+[!74+S]ZAD"@(BX+^?APROB>FE7'S\L+VCD^F&T
MRCVSE)XTOWOW]OO3U[V3WHZ"_X7OY'H/48^OF1($ I?D?G_X47)>PM2M7&_G M3?POG]D GZ+P= @X>EJDJ%$'/[6^3[W5#(]MU^3X-Z M:U&8D1T^$G'[M?>4]-\ZBY\"'7.LV.?
SU>M3Y0+'9"E>!1Q^HMW)\M8\7:?"1UCAW4=C<,7A+ M7KV3P.3-$DI\;.4>L>^^$L';==N^]Y]I* Z;U5Y;(,$'5N.T!5ES1_PM^>Q6 M
(/'ENCP896ZPKZ[EJ1NUUD_)'>9B=I5]PCP$=4XZIZDN0R#-M>[4[Y!.><- M?M$O?'-DX%2I^@."!Z]^2]K6N@K21'LQEU"8LN X/7]C =J@_0&7$.+11!,4N8T+8>Q:NELF= M'8!%M
Q@6]0?CK*P!4#GMD>CY AM)YC1"EH&L!7]3Z*SL) Y];[0I@\2Y6L MNA:R*&SB/ 4B,-KU9[!9^;Q4M_81[KLQWU_Y;Q'Q-0$MI07C77^*F!W>&DU; MACW9*'")A!3&H45)# ;^_J0K"^
-NK;][D#+LL-=X:'N7EL45.#L:_'0]X MV#1IB@A\(DFN,X+PES*!S5!_]D\%,VCTQAB MJ+!AR$U"]02#23#6*_<0M5! ML4IZ^5L474AAXZOAQ5+\=$%G,\(A<(G13+9M@.W6R*
[9WF[5,&H]F+&ORJ1U&4^.! M;JK2"M7:9+H6P*9K9%-?A^G,^+1L0LD ("+:63S"8#TP,]APC<0'[UGB0IZ
MMTON6E7M<0IFL,T:B3'4T=FTJ^+>SYR[E>^P:QK%D),N#3G8+HV$("KT)9/F M^".>NSAYT,&4^OC&Q@DRI2BER#<6ZUXXZ_$6PH"$]\A?]_I? M'6X)K[=7E:\%+]O(,YJ5]"F9:-
_E8)RMG/FFW]\(I+EI*:?$3^.WL4+^(%>J M3MM7,$5A@NPV^P7_4WUW0DJ(#[[.?7)@2Z5O^2+F<5X!! +\?!WP6[@.F.]& M)"9L08,$(M&GS,-
&F0/WPE#%@1L"0MN;@OD\SG10AVD*-+C7A4 @ADKA45#> M",!W&^N(1J9$-"4U[@4A!92EA8E2S991G\1?QLP=L6G$AE%,TRHN'TA\'WH& M"\ X<:\(&:UAHW[;0?C=8R^0
4A#CGM!R&@#HZ)XP_U-&/^;;(=08NH2,$[< M&T1&<]BHW(]E+KFZ84 V*PN^8%-'IU6TN/>)C.CK53RB]N"(AU\ MM;*9OA7%>FZK!
MIE"P<.W*!Q#?"3(!KQ9+47>1"YQ4DE\;5BH5F*]AG60]906MX,1;Q, 6O7H MZ"O8M5D/#,@1[1&DB@#W>.5Z'$O:#5G7=R]8'XR"4G$-T3) ^]LJZEAG+7A MQ[VM59,%[0'KR)EU?
6[\IGELGG+V4M>7ROZG0BT3B:_V9M(*T ME8"*^'0TX+!PG_H0+*F007,4K:/'/TK28IZ/HVBT;/L<^C@/1\U^8SXB;;$. M\/,1*<:EC;0[\@\H/'OS:.L^&3[<<.>6:U!K"D!]+\7V&1-
UOI+7<<_7.YJQ MLTX"7$*)G2:!-^9[+[%ZOP@7#K5^9_;0KR&[@=RR4NLWHW_+Y8ZSF7/K[8;3 M%##4Y;F:#U0I IV_;!UL;>2#'NTIBW,P&:^P[<9;
[D6;,B!>S1>!=^LYL'CXYOKHK:!F04Q> A@#HC-$H(M]2,\P,2*G-!P< M#\'N(U+)M,@[D9(1#['&\9RF).A\#C_GK^82X*Y8\O*S.UU63XZ8D6)E/ MIR]&)OH^,G?,J*OK-
CD:W$0!*Z1+FF'_^Y[O|L,:-I<.9;)I0YG&3'N^;T5 MX&I=6T9^OX^M/WR)$S\8W ?SL?3%5WL-M')"4Q"_9)CB:8V:OI5]1T,37<$,>WY?8=2Y[?INB13:E6]!! AU(\..%=92U8YH.;J5?RI&
M'8-M,AKP0%$"!2D0^D:":A4& M'(6]*+ /'Y>4@5 O4@)!;R2^5@%TN:(HF%^L4D%T:.]HP/NJC@!=U*Z309QQ MZ%.7DFC,PFWJ53Z(\Z,IB+-IH.
<$7D^T0CQ.B!#/R6MB%=A1,+:3,YP)XN6% M,*[T 6R=B?=HS;*76PR$HN612B[731AGHAEB[=Z>ENZ=3.]);T./D@$\8G,GH'\DJ@_"(.(X>ZE' M!-
XX!\MH=LE74H%+'7^RN1P4]>^B6%RUE+AFUGY-S>-D1Q\D/*SN;!TP'5*J MMJFRV+6Z52&-NBFS=&+PN*71EX@K\C%P"8L=&HB,-E0\GVI]*K@3%9)^[PH M74>JAGFX,+#A#
/KO6MML6G.Y75LO<]W0\2+>3 M='8"=#TH/W+G,QNK>(_("I=N]+V=R!,Q9) Y=0>ASVT6I@.(M-_]4.IWN0%
MI\&*"4"O:5JL1S$!EZ*$66N]37/)NC=IL)>UV,LWB>+V8V#F&KKERY0>1N#3!H\;[W8=!UHN-NSEWX4^9AO M3_].[*2"LY>PIO9X4;QXJ\9.1$!WU'/A]$>93(!>9V!#
[EL0\Q0Z%PB'3G2A M2B)$:VVI-TGK/22U0I6U))8[-* MQ.DU.ZE&LWS=CUOB\R6_-PBC.JOVB],KP5+G:Z! IK>#&T;N MP?6X2:"UX1V)\:!])G5J?,HW2*>G983201]+V5 \?
6MQ#NYS-U:RX339R4B M 3JDG@NYMP%,4^A*$! ZT4^ROCUV6+R>,H?W>%<58#T[*[_?F##W$N[>'CO. M.:)"& M=YN?_O)\\%A="[X:HM%H5A!LG?X7T#VA_=V\&B'2ZV)E!43-
W9'+V#CZ;G0 MDBBKV@P" KJEA@X+N$KB+>UD.P(VEI$1[3YN57L!H>C&7%<*S22UH*2S6BE? M31*@Z7V7\B--7L^1FKWXJ7M/O)5?D%D(>QFR)BJ?
MKT4I6V,%M4WP$D>YTQN=, M0MB:1)X&)Y)S;L+ 5?PZ'TE2O5XCF27K^E8WWBIH,CVQ"=3J?6FGS@Q6"UVN M-5>&#:F=U;[2#5]KKL<"\V*K@;=[?*)6EXM8G',W_K>=J_&_?
$X>GB5L*6+> MHF::XCD<3BJG_%9,K@2@U@>CH%:[)PEZUCH=.#S-8]\ 9F8X_4/;UXG)OG7^=7H\")'9]_=&
M\/X84+'!XSN]T>P397,:4$<+NHX!>M91_V"H=";86CFR,,P4XQ9Z*W<>,0F MA#U05S._RRF_H?E=#D S#^;!K":4RH2)=/.YAAQ__M9Y8!E]F0X-S==[KK+I M\(;Y6L\#';WJ+PNK!U
R04.41S^CO0W7CA^OTSPXWKO#)1$2!![:4IL<'C4+ MT;-C9%6VX!00X M],X^9F3IT,VI_N:R;C^*2!QE%VS51@8Q8R=FM&!J"Q")>BPHWVG=Z"]YUBT] M282PHU5Y;\]AK(
\:I?)]03-456>"*W"?'OFEX!RU$86A\W!2M?U=Q1HT;4V M9_Y]_#IQY XNRP$Y>3^P3$=WSN"?2NF.T6S&1Q.QZ4B^%<.1MX*\&V$G^^H; M"G7PCY.+@I5&#K-IKKMVT*MU-8-
AKAL_>+4P3FY(G_+/*&*T&;64^/@,(E6C MF@(%6'0-VQ$;I(WLG<4:-T0,N MUV)UR:>V++';&$A3T6-7OC/-; 6GUZN-;A5YCKLF9U!!C]U+;,VBUQO=+)T* M.#46H;0U&F;TJ LUM2
[U%*-.G6-K>]L1H^L[M8V/2#!]GPI\)T(GFPM8>K& M2@Y68DNG!_[&,Y$FDPVPZ520=\,> #\KI@C+U<'?>&I9C-8]& M)?2M:%XDTUY41MLL]FYC\3--A;MJ3UG
58[$(@T0DY:9U&],OD6(OQ-5^5+K. MH%"SJ41=PL2"\3>QU#" Z2TV.ME,[8:X1L%=[RZ\ZGKBSI&?(D+PEC/@O=4 MI176$+WQ-Y-?'>:9([T%LHX,Z-:3;$&-9A)]#XZPY]@S]?
ED@1"B9TF@2?* M#6COV6CC&H=^K1N^(/5C4%SG4/V;"5/7/&A^/D.\2M(H_';CKL"AT>&Z (FLNH8]2.C&S73,7&_$;NG\AZMXBAV D^;SV_F[-+^RF0_* [=--CP
MD3"71F3,J$NVOXRRWT:GEE8T-]>E[5TETT(10[?W1C)Q+I](EG/*#T[,QYIX M?>'$FG ZO 7TK&H+J]KB@FY(XU)"M9*X"8/14M"FAPY7012S5;+VV#BQIYES M&_TJ>AZVS0S=
O['ZV0EW9(5Z?3>R72/+D,V(S0FWE60+FT:\+DJ0J#GBK?A M@M6MTXF\\G)IV.PT_62GKN8YG_);6+)JL9L#^NS7O>1S/9+^^KF(;*<*M@T7 M2S]<$Y)=AU;TBUQ]T5OBAO.
L&52=P[T1"<1E#KY[H1X&NX%FRMB.G&G.M2C M3FEXEV3=U/VA;GA;HSVW6/.\;@CQ4SK2:;_?K3'3]&9.6Z=MS"RT"],%MU)6M$6W7!E$<"8L:.?(+.)-[S309S?"[
MSUO0@(I5CAET.?RR.IO S M^%4A ET&_QO(0[_=2=U_C@8HK@94/F2'7R0X]!/=6(HUO.L_&"7\G7[E$"M@ M86VL//" M<7Q+"RS^.'3@HBY+,5ZQI)38\'%)L]>2FU]W
S[=^:TXUEH<:+:C=]!67?(0 M)_SAFW-".[=K/_L@S;29.H^@TO9O3HMI!RE_+VF@_D&6ZUVLIJ3":1,F,F5 M7*0LH^.<6W!&(3H4&9 #-@"#2#,IE:JCC]D7V:Z,V>]%#9/7&9.
[#PWE83GZ[W?0'/:K)KK1FX! MU+K*##4KG?&ST13BEI;;8&^^[FXF607O+ITQFW3&SPF#::E/&+-IXYNQLE1[M]+2RO$BFI# 9;3?,9^^T&ILU7.COWF&+:!W$]^0/?
7D_"2'V7D'M+7I%^90J MHF\'GLIS5W6.5[KGL/!*I3X_AJ7(\#,(/;51 3CD^E(^/;YK;>-.R[OZ\H(S=A+$K'NH0^Z$-"9D[D95O'18T$U"?CPBKA>>O@Q?LA=>,Z)\OPQ]X\-&1-
9&^U],+VB0A3>T3&GZWXVD92 I!%PX?,>Z\/AW3PO X^$BR M.Y=>GX[I &!LHV&O<1>Y5T%$N21B/>^=@:'K%9/IRAH;XCR@GQ/_E_P%0 M2P,$% @ $X0-639'901.+@ ?RT! !(
!X96YE=&EC7V5X,3 P,2YH M=&WM?6E3V\J:\J>^\]J7M24"4,AH0LY*:&@)/#?0E0P-EJ:CI(4AOWB2SY M;(%X?OW[+-VMUF*VF#6>N?GG[VK3_\>OIU_^/BPH=?>]NI*?__MP
MNG>ZW_OX897_A*>K^O&'3X>[?XF3T[_V>_]^4CB_+WHKHUS<:I&A,'\D(<_M)R,_]O@'3YS(5 U>P(?PZ9'Y;N2G9RI^+]:V1"Z_YRM^Z,]@GZDZ&^8O/G]X
M?'AP:EZEYWGJQ]D@24?O13$>RS3P,PGO??K8^SY4?97#$CK=#ZN?8,'X+?QQ M-&W&%Q]?QOULO-5\Y;J;V1)V,'AUC=;Q8>_CA]]@-3(H99O#GA]7?
M8"WPC)8VLPFG[<"%92#C7*9;XJ:3K.3)"R:/R_/23/$[\&!]OO],>/.X<'G_=V M>P>G>OJOX]1WV\?J;IW>"""VOQSW>E_A=_'2'XVWQ)?>0>\87CGN]?>3VWH,
MCAF"@O^W_JUBF=^KE74_+O(B9@"E,6%*Z BEEY& MX3]%L@6 W3Y+I1S!V BJERG]O"Q4!DL+I?#C4-"QRE"H:L]$?T*_]65^(64L M_B,'@U1.3$]E,N[+]$PLB7)LC9WGTAW;6US
$?Z4L(CK CTVKT*\)/I0B2*)(!/HHF(I4#F>+:8>5#V(2* MA9\)9_PC/\V5S#IZY SC!2,5RI1\EP;]CF%UOWT\EH"*_2B;.7DU MH'&Z_6F_)W9Z^_M'V[N[>P=?_OUB[07]^^1H>\?
\^X^]W=-?__VBN[;VRXO; MKN]-G1Z;$8^EX T@1^9XX4/4=Q\.-TU;Y2@I1,&H;;[L>WQ*WJW\N,T:TJ0NH,"L#K.<92 ;P#W@Q@#WY0![;P I"&3*-'LLL]W.8ND=S\
<0EE]X=5Z @[;2 MI2="&N4PR!/@$6)]TQ/K:]TW=4IOF\4E^RT&T^KI,4'[&N=AL8G!6_OGI=!V M7[W!C+?#@$_7PX##6'SU)Z)+\%M_Y1'(/R5^&N(YIJH4&%^29G6XTAL5]DZG
M+DN^.1ZGR3FR28T7*O91J5A<@!?+(QVDR4CX@%!I$@$]J=@=Q!,@"ICQ"C4: MR5#!F4?P,R("+"P9,68QNI6#YOAK*H: H:G,8+\T,\]EM_=\3W]GAK3_LWP M"#,1^5E.=(6"*4O*
3BZ.%+'A1,Y]E,&\2Y_'.0U^Y-&:P?? .O%\GP3&:, ML(S[@,K^ B$,+,&2L]!ZB%H&7$B_"(?)JG*)[#)H1L"/2SN! GP#Y3.0:, MOS,;JE$FHP']D]L"V-4.'@TV%?X;/X80UE3W?,^K=]{PL^#*"
[(6?@LF6Z^." MXPD3B6<?_=>'UG*D*15XJ@B%(e>'@\!N"<Y<6%"Y4/^9ND M2.&L\E3UB]B/Z$Q"X(\]R_'L<60XHN '9\SG&O./HY&'P-)!*0>5@ZP(MB%R M9/96PL-
!1J0>P),FF\M*(D,27%PPA(#3/%N8?[D>S \2^"6@+V(K2>,*7(G7 M (#8]N\R"6IA("[&?H)D*?@ 47*]ZL(611@]D6:Q&=A@D.6RB38:V .!$,A MOR/!91&>:@Q&TV7?=TI P?
^@#M_J';E4Y[Z^)^'IV%"N$?4%+. 46,H1Z%X* MS^0>S*F9NC].@/C[/#Q4SL^1M+/6 O851EK6BA.*L[IX^I-_'PW8$DZ1I! D2RN(V MNV/DZ3,(#7=VK#PDEJ@(95:UW??
B;"S)4CGJ'>)^SQ4Y9/<[1QW76VS?J[@3 M*QA.)4N+H"&,-9> .VB0L4 RF@_26# 0R;PKBA\55XJ*:D"U%8/\,\#1XE]@U9&>"H;!+1E^@T*;#+M5V&16]#;5
M*C\%B&_I'Y$/@6H$P$E1]9Z4F#<= !+9%K."$IC7_"C@OPD MZ$-#V-]BINVAMM)L=+7O&WEAC# A1.'!$P+TO0H"T_TH$9C)'$ M[-DEL-!IEF\M;]4>&?/-0--8%OED+&&/ 2
Y']S\#B8SAGD\!K25NK*;.U1HZBCV8G]5K9_/\+E>R:W8)!_"CQ_F$NLK.C\@_^[>[^W*0:;+8K!)JL^UU+"])#]) 4R MM2-
\BOS@F^C"\K,D4N&6T,\QN.B/,UB.^9L5W*C&L3RDJG_DPRHJS2P*FQ0 MVK]H4;DV-GYY,<558=YX]4MU*(]%PV .= UAU4XS)9S[:?2_[;2E\@0W@,31V2X
MWEDWDR[&N8O(E1G=W>&N&-CW=G^*Y[BB>8HK>N;BP0ZY65^\<23_.2A^X MX=H56<,.6I2@I68%HJ?(M%2AGT&F*HD/0]DG":L]4"3(0PG@"U%>]P$^6D-9
M7"!U"3J/M/8U4OE(R^!"Y>586G1GJ'^=RYA%.*M(&6(M:YSS+0AK<&XVDB/ M3$8]D[QX>C73CFGY?0S+)?$:^B/-[TO:5)W2+L 6(,4A:'%-SA$TI[\!0* M3Y0J#BI[29'#CF']]!-
%Z&&,M@#-M3$ $1\Y!DE,?(OFOYJ 9"F52_(>H) M?1@1-34:E=VP+)71@0/3OC=^2?!WIX-(N*S%GOWW=LNO &R?=JG;S.M5XMD'\L< M]$!RJ>[% %J,_(!M@[J_>J-
#L8>T+'@Y#3!,>I&>.3EFQNOI?C_H"IVY#N# M;&YX&B[P!DS2(\[<=O7[MVVL[AI^/M2M8-M3;H'F'^FW>G'R&='VEO/UD0YV*9>R6$0%&.SIQ-_(.&\:_2C^!;ROUKX/Z1 MI-\
2;9#YL,LXC.0#' 0-OX@* MEYWD0&AY;<59@2KQ49KD&K7T:.MK7;T8O<@|U,Q]%&%'29H;=S6.LJTU=?U3 MB2H; W]/ K/W8SGDUW1@O-SYAEA:?
R=^ZYQT=CKB90:+V1)OUKKBP]Y'6',F M_^E@/MXRV7 ^Z;>L+U-JA:%18,447 (ZIY4Z,1$GMIND[K^ +P6I,K'Z+4W8 MZ'I-#<_"L-B9MB& "P$XD'B8D =@!Z8EFR)Q\TM]M M@+
(O8SE0FL=X%)&H 1%>A/8Q_#-,91@BS8; M!SH(RC]5QM/#-;=$"8XW Z(N(Y1E(1B>W!QV,MB)9>)0G]L"$,-6%2?TK.%1K7"/;!1$?#@#AHYV4 MTRI\G:% %7 M>D0N5A
R/,=!ZA*\!,?L:).YP6IJUUHT2 $%U< M&#-319!',*"C&K0H"Z&1RQ.=L, [*VD&X'.\4A4.*Z_L6%:1O8)GZSK\BYL,PE+#GYX;H8'JPZ^#,/.UI*]4= M4D*'/GT\!'O@P._H(P6PJF(M&I\':
43H8)T&(AK9ZV-@*=AG(N]/LX+3F$ MP*8Q26.#PBBWG&7!]J6)Y]BI(L8G$ %@.XSZY#Z&OQ-&>DZ:+T&DZC^SE@*) MT21=,1*+A3!#&46<9IM:CC'1:X=:>SJ"P^7H9>M
1XC4LN=PHQAS8ETB*_I_MX! VCGOI1JN]ZKLE%_+M#>8?:,FT=%E(:N:\,8CV<73>1KN:DZB(M'YM MDV&<=P3! +!>1/M]6=W++"RT,V_I#R)]6^D6FN$4NE=)YD_+:Y8')
M]KFI0! WD ?5;#>O+^%R7_>)" [Y]^I=V>B0!AQF,V\FAV;,=EQSLV.4\"-%.5A:7==:G' MB//Z'9_.P?]QIVH6?Z]]2(YU=C@>@XV,$55*X-.8O[C@C-/K'>[4Q\E@,Z"T M:D^ =4BP#LSLAQ-
=*,:]U%\F'R-,@S8_(LCH\! M)L#:*(O3)"(Z*SOI51<&$ %.YH-9^Z^BJ,_*\9!QE29UG6-#%;[4!*=ZV(=LIO*H?!;&JP'W
M4GYCO3>08U;DK",;_9HA.;.13YIX+AHI()$0O\IQM:L%SGB)W%B(%#A\'?1: M"I,(M=*\MB1>RG)#X;99VD84AVQGD,YGK872."IEGM2GNO%Q?>K:\;PD5?Y4KH115)Z56S:?
Z*8X,@G_8]=/X3N,'66F@O48#3[!/&[E#WCL#C+T]Q MTY@D4J.;U92[#)0?8!.@T#4,KAE7@70?2$YV[PPEE4%)\GP8OPB[M\;^Q"V7 M)E?R")70?[U:7_/POZ7WV]BM(PQKHT<'C
50X]#KFQ,PFHKA)TS6/_$C##DN M@4X:@AK,51;LT&Z+_"UC7FN6D;O&<<<2BPHH.'E@%I=2$A>.OROWOG)=:4W4Q
MFW="GP/:X$*C8C2F+995;6D^P>292>94W]9\,=6EVW23/T&QCY*+Y4O*H#7G MK%5"WS]:/2^$5K/SXY1.05%0$C4E3\"J1#)F_$*O9,6W3\;5H*U*&Y]$BL: M7ZA'#?
=SHFP937+D-18XE4@T&32& 936<0D3V0%"_XWD(J#BE2?.D>C'T2C M&>*1V_&"SSF5:M0',]_-]AJ0!\!'7P<%E^09\%!*1>&D#\U;\>PQ'^0[NA/$
MO[HKWMK:&H>LJMEC*@Y@!F*G($UCS9>LFRP&BSY73ABD&A-T< O?#F4$8V)<- M>WAEKI#FCNC:$(:T2?@XK/$RP:$E6G MI6I6-BZ6-M65!K!P3.V+CQ#?4JE-]IM?A\
("4&=6<5IF?EI:ZL9#4 M7E43EQ%[QR?B,_J__EA9=[V2Y, C9Q8%9ISN&A0L0X3/2@PKYUM9Y\JP>GG=C ,3S7;9%'< 1)B+T3@E3U*PK-XL*>5FFX M#
>]U0]O4@!C3<9DM4M2Z!-9SP><4QZ1TPB 93YIKKE%LI;M:HQ'*M//!272M M4"6VBSWC9.E4Y.AJK?]493'IX+ 1"E841=(.K]F-3%G 4PH8_5Z04YW,W]; MLK51J""XHBAPN;"
[Y4&1TC:NVKHE!;U#Q$NS.TPZJ.PH+"3ZK; GG>UL5 TH M^[E3A*G[QY1])]1'Y4^F+0%#G@*3P_^LHS?)5^'_F@./=M=J(L$S;L7/?, M:I\9HPUFQVBG$%T;?]QQ,G,YRI?
GTLI0VQ#,13+&*, 48,* 5=F0^ +\)T8; ML9_$!:!LCM$NLN(=>]BE+0/64*P A?99@I7Y QW^=(;J#0%[\%@K03^B(4D! M2(RQO=0E51YE<<&99H4#_X&?#9W1!RK#$-
M$^BDWNDHN:CUDVB(XXLU2N+RD ME&V!UIK8RHRF#Z9XB+^$FL3_M?9S$,O=N=[69Z?-@\@_+'(;'^M1]HK8QI 6
MU1UQLEG3WYS\X'W'*"\?!LLMLQE0Z[JV*W0A\G@S'1ENC*=I/@Y[1@L"HK!L- MO'BH&BC;S0(S7*2?FQ36O&UCBPO3=V9T)PXB2ZL_E0E75@>R,'#\.APG+*N= M;
I46P]7T%"PB:ON(RF];21Y5? "BG8 S%'D@^P]:FH$E?E=8[^O&"[>:G,+ M+"Y,/U',2>]CN2'30"%W<3,W15&>==)*TV E:=W==SP*=MZJ0M1PK>C?+4P< M_E-?
>@D!#KEQU8UG#;*6TVEQRCG,K"?C%7\C#-?)QMC8YZ- M\0#9&!OS;(SG3'>/.JD9VWGKJEO603Y/43H;/8F-$2 !!I1,"S*(:PV*-IT M>RBI0"Q=ZW7=VESG(&R,
8KA0JM30XE0(SI0G&# ?AP0@HWM0#2_B_8'>#L M"O(I"35@DR+1,0"LJG17#H/(6'?#@I70P#0)"\C6"%U*G.!KMD19;UG6"QMG MLG%#8=@ZN;E=V86I*,=X3!,#7?
%L06K%2],;>=#DHU87%!;)V5CD%N'W^R+_(.M.F+/;:XNL9PM!=EP853 M/.>5:V9O.#>0#Q#1=?TJ>[M#0*QIAA?KA5JC92R1?AHIKK];4LOTONZD/C&J
M%MMXCA'($[D68';%E*0)*CT^-6FW8*H5YUT*;J(+4"S[DMI.6,H=4+E- QU, M:5SL5F3+M"1I()FES+T]!7"5D";&K@R5F(K;PQ_746(++Z9<,%9P^AI=8;C0TZV'G K-B)4"XVIG=I;O?
WL MDJ'(9\S[SE>&NV:"2@3WO*/1LJ3=QV6BJ WNZPW50"S@C@<'Y"AC$LR&WXR MD^ .Q/3KF8IT!4Y#U,';2\=CB^+?R]PN%?KUU"E,LJDITZ')0Q 3*1ZW49
M%TD1<$>XZ@/YX6XK".LJEX M&?6"Q63$5K&JA]P!&"RC<"+S5W>$M-7C4CX/ADF2<0Z"+OKE8L)*TP] 04>? M#55_F&A9DZZ:P4W]K@9+R$Y35\Y;EN#4K;C,OQ%51-96&?
K*2D[8(8F OL]- M5CS4J1 U*\9N7$\NR"/8R9>Z5A %XKISZ);1IDF,-1&]NP4XPE=(VN:EA*"-M):E30$1-.V3&Y>O<]*HFN!&]Z%6MZ7/ZUJ+%A7HLG]O%.M55UMMZ.6J07NF4
ME+;5Z#X"GGW>>6[3H+T29&>]W/]E8*7D.BF:$\IF_P&)^5PP&K$M4S_R!HU M:W$2KQ!MY#]!']KTB@3.\74('"F=2?J2[7)QSXQCF(YRQH9N(8 ^D236; M6@FN+>HH":/-
X01@FLP%)^XN MT!<$4BKNFS]GA@"\]S!SL=WYVAJS/QOY);%]B@$!IV/N\/O \N[7A>2A,@K:M M7=N3>M\M%[LP1=5HB3>R9;@EA1QJVP M3<805T%2L61ZYL?]_TQF?"E-
LP,Z^I-X]NRB7,(P(F2,>N)+=!QC.&!.0= MYJ]*V$-8D:+)X!NA^N?9>2WZ0;/KAFDXH39?)] C87/LZ ^[$O[1[M'\NHG.>VC1]^>I1$DS\Q?40&PSB)DK/)S&]#?
((\L%I+&WVB/C]5PUW0?N+*6L%;QI MP@2PW?0Z-%=M!]U26705&%:)+[CA$=!UJJBO', D'@5)V_#CR^Y3>@XZSK/)
M4FG7*&I.692K=(G%FI6F,6G@D.R;;BSV1BAIXP35EI&V*73$L11@9/A- MKM$VAOQ :&,H2>F(0;)R06T^,Z.LCRCKT_O.U<398J/F!I7<5W?B=JL+?=O8 MHBL=)[K335L4'28-
C10WNVUTAG<\10P3W+-B#1?'+==?#55IP)V(>?=7Z"RAIB)6,]M>/R=C6H%+[Y0!\% M=2,)^:X,4.+&"5@87J,UQ!A=?WE>%LQAEY!K(H7I&,UI[YK4LJ8@="'T"DC-
ME+B!HZ_;YNC75PHQD"NS3!#73&J179-[^7EF8SX5V_!AJ"Z&<<-W>*E-LVB M>&&@-2>\;O/<IXJ<\1UDSC=%P5?BND^%)_-9K+.@QK\H5NALFIL.3.X6"% M6FTLG
);E38>DY\V;KCG;P!&S'076?+]B&NDE_I*;BMN2$ M) -RS<@DKF2H\"T65!?191@#S[="<:4]-13]&P59U.)5IK1./OI(^W(K-B.V!BTP?)0T;[J32&S8I0YU6<8[FL?$-
V$,&!H;@W%H'!U8>;E>?I*BPFWM"F- M943.A-HX3.7ZUEI+Y%JCBYW M.\G=*19[O\TSPHOF4;TX;3.?7T,W&3FC*@-0(^!-1E%'0D!Z">&3UC<4:_U
MH9^.*%WJYNWK]34,V,T8+]P3F@-&.I&:;U?F3N]M*@_W[@7C05\^P=S1JUR$ M;"\2IO+("XD=Q=A?WWIQE*9$3#.R96]KG7K$(Z:RB9 2S=YO((R%EGE)8]
MF,L>Q.76KPB2M'S!*4QM.^"SH2W,V<9-V,9LN48OQDO]'%?Y2W\TWL*: 7T? M-B+(GA;5SYZ7-$O031B :1A+T*N(VB MW,0J$M:Z'WHFZ=X!-=N. $KV]N[->V)?N%[N[M<_79N!
(JJ7L,7)-O4*?6 RFW#;"]8:EC8'M$]MU>UK"?R[3/:9;V M"#QF;+K!/77/(*.304B9.\S*/+S@QIP@GY:36VP3RPT2;=6)SH1&YPY3?T "S$OF&JCIE!"2=<5HK'5-'<$VTYF0 M=?
F1%H/8OA(G-[4X:.S>/!E*&BBH!Z.4&AR.>PY4AN1+$FW%%4"5LD&O6H:3"=^V MVV>;_74OW&:V[.8+-=A!^;#O7SOS?G/:2(4D'8 O=S5N&8EW;/-569^C?)%6A M7]/<':
(G@M<27K:6WV+*))?.GI;JC]").2;)DQWBNI+/Z9$*[*-PVZ1P-R&@ M8SPNW92OG6%=@PG@:K\J0)B57L_/B"CG,]\^P^/U/;/C 3(\ M7L\S/)XHW=V/ C!;#6"[+ G=U>;A[&/ACTL1:'-

%!PD*84J(U%>PNH$5U\N< M%6 DD\"E2^\-S'2!,.:QDR5=@M5<@LH18]W(STWAK'1&A[6<4>%M:\V:]1#Y MF0J<6]?[#[7KG\PT//G;$FK3+ K+TE-=+D!E_KXZ M-
Y$9#EF7&6;DUHQ\<6I%0T(A[KO-M]X8OT=W5BZTQ$O M,RIFW5SO>N+#WD>)#M%_.N+#ZMY'YZK2[=W>=N7*F,6%:N-W+.1"SH.72Y:5 M\,686,X%S#]907?
ATGI7WX>@,]^9K5%,WF*N\9@TXMS5]N_;Q9PDH1OW#LA9 M4F34.F14PA4#1")U^#KJ9 M5%9IH2&FH3F7IP.FWU&'@SMFZG")/(Y6J/F5 &5(.@;]DH=)E#9<%N1 *@
M@IYW=LO6\,E!._8VM08!<#4#M"+1VZ4[ZP^66ZK]<$'1+K*& M$W>AF@RH\[\I-K(]_6VA0-E("-WPU$/7RAU3\-RLFT ?/(/SVA:H^%*'439 M_(-\XHR8#BW3VC'OPX_*%A?
88L\4*E9@?2;S7-^L+/65OKKVH^IG*V]]Q,MD M,].0GPFY$H-P<9<*3;Y1V'5B3UC=M1A^2-Z]WFFO+].91M7",'VG1!.^E(B;
M&KPQ]S>7-;G&2XI<#+CVF:S=:+ULV*G3Y*F69^3A;_H^&KH2F0OGJ$AG6D)> M20GM!6S_42/TZF1 $-B0^>_.F/_QW1^YT71?)9T@&0%/B1.![>B=DGLNAH)A
MRX:O<4F2P)&6WN1#V)/MT[W# SBE+\>]WE=X(+8/=L67 MWD'O&-XX[NWWMD]ZIKP?&W%5V J2&Z,4>]^H4BK"(JHXYF8.+?XQ?0F6-#FL MM>Q1I\.8N#Q!EIL]-
*\\$6"A@5C6%W7,%? ;:&VSU;]MFK)5MGMEC>P)@-" MB\^>L;6[V>+V-DYB[(FWN&"IP!'KNG("$+G/.=-.Z%XX&KF4U"[S.02]3EMWK MT9P&W5IARP"Z?
B,SYT"U$4X1LWW0,2RFU_+0L 9LCL*MQHF%:LF+\:>R0W9] M1NIS@U[!LG6W_I +G4E)'/A!!F(FHFXHV-T@R]/)"M\'C]T/U9G"[$PJUEXR M'41]T1F' U"\(E 468P1)PG+RW3:EQC
\'#X*,;7\U4$&F 8IM3:I7Q2KB@N M1GU=W\GQME&1%]1^A1P;X0]GEQ3PC!JUT(T#H NC#Q*^0?U_^E+,SIP#LN=7 M9%QJVCI?XT/;DT;GZ*1EJU5T.2$EXG*VPZ3/BV&6W!Q']
[GI@,;%EV(=F3.J M2SNU7,G:4,5E7+8.&E5$4NE;<,KC5IA\QCHSJ.4UJLWGVJETVIS6Y7BFN69M M502"MG&S,I!#W3ZIB!PS2LY1%2 3L(])"))VDLN2DNJH(T-!$2M8*N"4N5J,
ME0@#HS+U0BW':?G0B9-3GQ]*-#&)G-P6Z*$\5)M/6T#. MUOF["XL"K>8,J?G$E*0]=X%X(%7>O/8BIHL:&MV)J3$)MP6!^;YEIO&@R8/3 M8XV+?J2":,+)#D"I6#3E48L._A$=):!1
Z!UCS%J#NB 7YL^Q$JT^*G=".3H MKS=<5?M"+EU'HW&V'R"KU\DFE0L+173-U2_+T!! M?P>(G,+L'L,&O/1HPNU:J+,'YK&8LJPP*?JYMAUL/Y9V.,,Y$82=4_>XAP@J M.
YO1UD.]F>4X#W364)>"ZJMLRJ#)SX#G?>3Y!N@^06:7M1EXT]/[*L8[)L] M0/\]+!O%ZC-SQ1G+'5(&_)3Z[U*G-*-_.9E56_R+(L+),VX3VJ0 9HXUI\L>9/C($EBA/M?G
)-61_M58EQFGOO;[F:[7W9K'B MUGFO_'&6L+J0C.>"LQ=^>RKU4T?9J\;S^X:TE*'\E-!\,?F9"L8 =9$HL+-UWO MW:WIU8N/IWBCS7LWU8CL3-4TLTN.F0?&1P>LYB?3[@
MSS#@+-6E>]A8TSUR$Z-VVM:]N]C[^#\V^8%]A7DBW)NS.?>8\ZYL0%$[#V>O MWUWB6GLS=ZT]&@&OMS=RU]D@8X'27_V\?>]^'JJ]RL7U7T=J'\+=?HKD__L^85"R3Y==UMEI
ME1&4//_';? KS6XF_ZE.O?<8*IR<+/$[C1.>6GD$FAN5Y>%?_B$"NT7;*?(M9*>#B9=8O&]_L7LE1M98G'ZH59!ICPW/:SR_U7Y.ACXE/UYO"^\>XQ; 0DH# M#/;RF1RE8
D]E@T9NQ:%.J:>K%."3R4?966MTVW6/[5Q=*RSG=_B\RLV5&>8CW)+>"J NM<]EO7-Q[@)S1M,$YMQ@ET? MRPM-ZIO3?HH;BQWK+7E;MR5NNUO]G/G&%6SE=>?-;]KOE9U$K]
]>@UYUKK.K7'EHQ;U[;+)S?<-;6WL0 MM>AV:EQWH]-J*EH?SS[6X'Y3H&ZO=MRC1 MNX]-=G;7GI86M[[9>9CEWOK,-Y[BF<^UN+D6-]?BGI$G<_GW^NQ?VP1%\G
MO\SE<;QF.=L=2--I0'EN^EZW^V1BKQH[-IXP=FQZFYN71XX?]?(WO(V-C2>A MDZUNI"&VAO_JI\%0K+^BZ]&-+;&.#S*!/?7T_:A8;_16_%/X*5UO@OWWL+$>
M_$HEW^93D0_3HCKG\KF"^F0$]'S^^?P__S/0D'MK]]VNZBA7BX%'[40 M7W]B&NI&Y^W;]Z&@&NRX0D=ZU-AQN9?P42_]%HCIT.KIK@PD7E\!9AC7M]],_M0V5U5'_[FE54&-+\[?
R"6OWU].O^Q_\/4$L#!!0 (_!.$#5E2U9;2[2T (M M 0 2->&5N971I8U]E>#$P,#(N:'1M[UK4]O(FO!WJO@/_6;/24&5,-@D M)(2?EI<^_MK=/8#_"OR?
C^>]\\/NIX_K_%]XN]X??]P[/OA3 MG)W_>=C]UZM!$NY M_):O^9&ZB#^(5%T,\QTQ\M,+!?_<>/?]IX^?CH_/*]WGJQ]D@24RS3P M,PGO[7WJ?
ANJOLIA":W.Q_4]6#!^"_\YJE7;KL99ZWPZ@:M MXV/OT\??8#4R*'*5Q.)WF6;PWX_KO\%:X!DM[<$FG+4#%ZR!C'.9[HB[3K*6 M)V..R/]03_(\&=%OO-??/NT?"WWN"72/SGN[A^*L>[)
[NGO>.SX2N[^<=KM? MX'?QVA^-=\0OW:/N*;QRVCWL[IYU&U?\F" K^_ZVW;U7\X.;?(UQP_E5DN1L M]\(J#B4.:]8^_[5W)F8 97GI!JB(E==1^>1[!@=R]2*4FI>A7A)]* M$211) -
\%U*@P UB>GPEG_!,?%B^SEA[YAYSC7%B#R\U"E8TC M?_(!CB]2L5SK1W!6.^)*A?F0EJ%B(-DH\6&Z2 Z "*^&*I=KV=@/Y(W#:FH+&^>[>85?L=P\/3W8/#GI'O_SKU<8K^O?9
MR>Z^^?+=5?Z$!>5Z5U(2D&12 UW$.."Y'XRB9 (X#71I" &'@ MP__F<,91)/I^!E^,BS0K_#A'6D * (H>92(9P#_@Q0#VY -Y=&DT9 ; 0@Q? M\.HTC]\WDJ G0C^'M?S;CPL_G8BV)SH;
[7=UFBYG$8W,9X0M MWC @;_^\%[JNJW>8\7YGO7>[LSZ.Q1%\.N\\0CB>XF?AGAB!RH%%I>D M^OADR0#'XS2Y1'ZG#UC%/JD&\%YY7H,T&0D_BI:7TB0"PE!Q=1 X3GB*WZ@\
M$UG1SU2H_%0AR0#[A$DB $D_DIZ0@P$S6Z%&(PEOY)S M)B(_RXDT$*JRQ'Z@2_>0P]#0.HX$7Z1#Y-4Y1/8@4=?9T.BDC@!#IC*<2HS/+.A M&F4R&A IQ(;]PL&FPK_YW#"FI1>
[AEU[WI&%GP90?,*3\&ZRO5QP?&$B<1# M@+]]DB@3$42^0@&5BF (\A@>CV45X]C@R'%'P@@_F\YV)Q]&?0YF!9$$%@11^5O?S(3 I*Z7A M(".2\/!DFLUE)9$A"2XO&4+
:5XLS'^Y'4*3\OHJ010%F7Z5)?!$F.&2I^H%U!<# U*EEZ.U%('I&V: 8\4_8-61G@J&P2T97H,BF\RZ==BDZ]38T3\B#P+% M"(^3HOZKM:3 N-0 ELBPG#E"4N4\8G4INIW1!^?
A1P4@%'TZ J:G'PMKI22Q M-(X; +:\0!5LA_WL?C!<7N)G*KW'AAVX-6[?W;=8N1I*VBVL&$VO*SA9T!?Q M+$-TTX=*:SJ>Z!<9X'Z6P<[0]0GT.3#-
"DNAH(53FM$H"5GWB\7)588D_&@ M[6^P4W?1VF0W.UKUC+6QO$0'PAXH=DTQA$KD<+"T1%T?.$\:RPDA:U:D]"/* M&_.W'X#)(**\"Z2\11B&YRT>(MDHTU9LBA=5*?U;_HI?
UQA_QJLUB4X']@# M[0BU+SC:H2?L>\"/ /1A->HFC@B8ER5HSI8?Z2 *QC- M##2-79%/QA+V& "2X\'*;V P8TC&(W<5(.44OK;$;JSC*_@BL+3$C:O4.=H4 M-R,:2,4(QB,KW1]JZ.%$?
B/+?QS!\K)FL>/_[G/&U\5G)*/P !WLA=V"0OPL\ M?YA+K*WI0/[^@]]O34K!5H-2L,5JSZT4,]UD/TF!3.T(>Y$??!5M6'Z61"K< M$?HY!@+]<09+,W]9H8TJ"*LB:YGZ7/F NDGJ]L(&)?
VK!G5K<_.?KV8X*LP; M;_Y9'8]#YC"8 UT#UQUQ#J3Y0>RF8+@'.^+('TF&_5&" &^['ZV;K_#)K-DW M:[-3)L2TP\2H>!_7X3 ;SK6?2O_K6E\B0_@ 3!R1X79G/9T=,L -UZ[(&G;/H@0@-
2L0/46FI0K] M##)527P8RCY)6.U_8@D62H!?B *[#P R*@JI2_!YIK6OD8$D-:@W&TD1Z9C%0F>?&XD"#)M%]:?AO#>DF?\$> M;WI?TN38D'8!L 8I"D.+KW"
(I#WY.2@4GBA5%VVDB*"4Q,B_L5OREU-4":5;XAZ0A1&1$V-1F4G+$ME=-[M!^,UPY5 MT'.51U+\WNO9."'.*4Z1Y#.Q&U"LHKVI]+HQ>WMI3; PYCK[>WW[6L_?;^U
MQ:')75!Y@%\"UI"6"X:D/>ARGNT-?OFS/U(18[(7&2*;%8<2W?]NFX"O]"JH M0X<^L'1Q!EI:Z*>A,^#F>Z\6BCZ5.>B!Y%@MQ0!:C/N ;8.ZO/WJG0ZG'M&Q
MX.0T_BGJ1GC$SOAO]3*Z?Z,N=N(]HVQM>CI]&I/<(;WJ>!0K4'W%7&:X!R= M(4D/$F!7 M<#RUQ;_70#E(PO U'$DVW/F<^O%7\0?RA;,<""W7*];1!5"W424^29-<8Y8>
MK;/1UHO1B^RA9NZC"#M)TMPXJW&47:VIZY]@ #*4 %?T]GJ/ K/Y4SGD]VI+ M?[(#8,446@(Z]TGU=4(B3F@W2=U_6,*4F7B\3N&3@%(AF=A4.O"VQ# A < M2#Q,R .P U..9]FE5,9
*Q48%PT.QY,A=_))@;?QR;Z,Y4!]/G?IZV/%$17H M3V.?@S3&7-(!'9B766F&;-/P1LLH4\POR1^YJ4/#'P551PK H% ?!0I, = M]W<97Z#&P,Y%C&5)' >Y! @ M*1W.
0R**)*K@0859P=\0<)0<[M->89B4\H=\J ^KQ=FB!L49@ M%"GR H0BY0C$ WC1K$:.$OU2B&*"ME$NB9A50W*-06@R \&:+E\Q\"V] 1KR MGCT-%1O4'\"+2!R\Q"O@J[#FU:83-#(9?
[M(DA /AMP?]!<@/= [NCV6E^A@ MM!G)TJ.\\FM@4O\(SM0:U\AV0<0'($W1:"?E=.90H JX%CW1#VL(&1[D(/6+ MD!@"_;6#]JOD1%L\\0$@,5-
TI/J2*33RD6AW:C3O51%X")B29>9LAD!B"F3U M%?!D0-Q+!8C)25@))^=P#IF1,H5>,;^(R/ BE$)2&)$"ZV[7\#V4RN-\L 7))- M4H=:-0%[_&M).^0J*15I M;_PK(CZ,0AEW?
FZ(#]8'NP[.S-.>ME+=(25TZ(>TC"&821Z<^!4EM-"91*1= MIQ1,X528 "T6TNKIP0A4&LJXT*_CM.00 IO&Y(4-"]/<NU0 M:TQ&J' Y>MMZT)-T*D$NYW@3JQ)9T?
\+AP72SGDKU6"]5V&G^K5,>X/9-VJS MHVU87D]:]XP12[2+IY$IV7)2=9$-9GRL4V&< =P3!/K :1/M]2=WK=9H;>+> M@UNWH1/L"L_LW;=Z".S;YNP9D>WVXN7)&C]"C^$6F
M4AT*DB9/4RZJDV(,.\<.BE9%7L2_*$)C\ W:8$Q\#/2R:(#>,B:$XCY:7 M+CC[@E+ZT78G=H&HZ3&J\< V?.FFLC;2C4X0+-T9=^#7RTL-#-OZ0\B?5OI% M9KA%KI72^33E-+\^3@:;
:55>P*L0X)58&8_G.9*L>V5_BKY&&$:-/D!6!PI M!59*2A'N"QTBQE%6JB0 $V!ME,-ITA"=E9UUJPL#B G\\&JA5=1U&?E>,BX M2I.ZSK,4)_ZFR-1TK1:HB 9PK"&K*;RJ'P
M6QJL',*M73..+"1D+7A]U)^9;TWD&-6Y*PC&OV:(3FSD4^:>"X:*2"1$+_* M<;6G!MA=(V M*F6>UR#T/'H;T1UWA^13,:NT[35$TK4F -D2)-)I;9).Z^7E[8['4.XZ*I<
MF^FDU)KY3#\E6C:\@BL 38FH #G [!;Z21$X&3]H<:.50#DY2RL4X,37!;8H<(])LNV[-O;<.A;,&W)S3)NM%$,N M+VD0(J0>/D5\7F!JSPE(_NH,9XU))34:6DW%RT % F8!:MV4V?7
=2#M'R0M MVZTW.X8U%M M13SM8$.T T5Z 3P'X&7+XLBKB.)5*I1'XPT-U=G0/;;CY8JA0;D!1P.)1*H MV*$)M[&QP0&':NX/V)
,E1E;F)6?I MJVXZY33;TJU6I'9?&0>XZ)V>B<_H:/ACK>.Z?\A30EX#\H [30PH*H&XF97(M,&.^Y268<.PKXLX.-G@"6+-!*63(I#"=G/[
MM;+"_P#404#L;S(9]E7Y9>&@Z'UIKO5;5AX]).!$(Y(V+T]S)E>4KTNY=30]P5Y M*74JSW2@SFA]Z*\,]X5]NO;2W=J@2,D>N>T6A=XAXI_977U#82'1#X#]N+@I M0+W9#(U?
5K7I=AQE4C EIOB364O &)+ ;-N+(36L&>O?,9;5M\E>T@; RZD> MUU?VHY3@^5EGG8+ &S.BYRZT+M4H!3[*+7,VLA^Z\A&EE.'$^XJ@HNTI) M<=4D4-
<7L0:YM'W@5VI51U&FY27*Q!53?2]F\.UI3@V\-#?Y2_D=EVSD!P<0 MT*&N>7H9;;=\V>[.4>?925RFNMOX]^QF>[LC+'H+=>HOQ41" WUX ;D0QL=. M(A_XQ,DT]ZK,G^6
12(9<[I[;3%%=9106[YYW5%I&I;?9!HH"G&XZ4D[MD1MJ; &A;WL5H\-P"1GRN5PUJD=*OA?1:K>&53V8S!5SJN",(=5]S'/I98P2E MB)LADI^/) 4'BF[;#5!:GD)-_3H?O\7Q\T>,&L&D.
(SIK&@C J&$@Z60ZJ< M&\UH<@KV3AJ254XE)5*"N"IJ/Q;Y3BE3I9$OY2R]$:6LEMI&U*)<1160A'5U MGH%.ZP
S.BW0T"]RPQZ3591YVXWAWA$E0=05D)M(9@TQ(<:Q"8Y%HR6!O# M00*GMN7'-@>==G<%^HMKG9%/@0P=JPV[P5:%:JJ)E$W[$+3NXSM&DIVWVF=O
MREJLN1I@D!5A$Y"YS+C%!Q;3B=!O_0]&$5"%*;UH_JTDRNNF 53RCS M!5C%GJ[,8+[P^7JQ5:*%*T18DP(R+@ O."&M:*)3+:0'0V%>3U+]ZP((M> R& 57CF$ [0(R;!W
5&GPX(*"U/UO"_GE #5CT2[6K U'MW MY3"(C'7+'1;TL@TRS58*\[P+5O&HK>]?[(O\I:HN=VV928\IRY87S:I3FA4_YX*;%6*^# MZ?BW])VA?B6,'Y5K
P8ZC6&,&9+%2%130BI9QO:T:5Z)5C7VUI.Z"T*6\3(T MTW%[A]HOS=QF-JK94'TNDJ2Y]6YY8V6BGI-T[95K9HT-$W4:OTD^Z_,3&XQ8JBHS^RE\#U/6F99D#E2TDE5:9#,:Q5C-
5W$1 MN3U;<1WE%[R8VI]N,FKP88::4EU!X="F;,N0(-'S1TJGR,N,"&6) M.,^.GAY-@W_K))8<)C0R+U':4)F-+CE/KFH-?:L- M9:V/'A:3D7:$2=UD?*-O'Q]K-'9!\%
<"QKO76)*ONX28NG_J'%(V!_"$+HNBXD*+ M54GJ](U3H;3,N&21^YS4E&X$)3I3:^:9QD.7)2CJL_&! MS$2GC*BI+NLE>";FGTMXX";%%>FENJ0Z P"N]H/GS(([W!0#IF63(]#B;8%
MT)23/4[B-2*-7(>S\O?4A@)5AK'C@<*9E!_IPN9+[A7 O(-CQ[IN'-M>3"JI M<[9?3B:VK1W:WC3ETXWM&$P^!QZ>3A$K65FCP5TO9JX%4;$X?X07N) C$_E[MD@;Z\B:*'NQ8SN>)
(3#\2V1\?%F"]L;_TJ.3ZR()S#H%*]]AA[0\TF:8(:8 M[>972SXSX?CME6 5#>_K^E$P $P5\4I[E:,ANCP_B>#]6L](^"W# PJ 22LJ M<#PYVUVEB<=#/QT!A12DE^)&
<9FPMDL9)6.>+Q%1@KEVW&R19K)FJ2DRXNI* MVYRXT:6[IR"+Z)6U&-9(_GT]F?33@!U.[@)T=H5>FRM%1//RL7:KL\H-%4PE M/FI[.%("BXR2"V+-P!+H2VQDQ28LCGEP!'Q5.R-
!+NOW34DQQO'183$&CKL34+CH."2:-+2OTS-DL*RK,3YS98/HSRF8Z'= MWN=I07C:M7,0Z^(ML0/5P!:HOQ90+(^"LMUH"===Z_(2%.\7DPO5J.?6 W"H[-&-?=>F$\8D[B.9
M3^'Q=(!@A/I?G& [S)&V='6DF>N)2L;]46_1?*"BR@X.LDI;<&R=H5]1O, MC DYH@[IYM>J>/X!MCZ(#=-C38Z;VY,'LT0*YH<)JJ8/1G M!K^8E:"&L5FK0ER"\V7.
(V3(I-.\W13#8+!/NPJGZX[;=-UXJ_-6[>=P_1. M-#!<;C![Z:SU450.\K;#F#4AFG!9@8[IX@=^B/^,#?134%B'DIOU9T1\G8/=Z4S7]8XPE
MY=Q&:7DI\J^\VR.%:5W+:>&:U+)]0>C@:!60FBEQ)SE?<)M?L(_TV19@?M02 M?RB"6E..FF&LYL*>29C_.U[L&R!!,2):TZ'/6U5""^,='%:M^$^M@F.DUO-
MS:IT@P9*:.+&7SJ&V=N#3"LR3==^;CC&?D8.?KMG) -%$H*$]*&];UU%LU" M6;O$$]]2658\NTA@J8DV:?KS4<<_/VB6SA_8)(.2"DYEZ8R9H\K^"";1]SK? MD"OIWM@LJV>$Q]T.
(]86U?3]*CN48 H@I\HZLHR>$#DZ_5&2/ND^Y3E@<8KS M+_*(TT4?F+HSU0+PY__/QZE_?*@E'9J_;WFN$ZTW]43A\D%UF\0)IWX68:: MW#S]W4^+"NQ%OZL43B9?
^C_Y2RS9KW8JPC%,AMKJE..2[6CPE9.XQD MM%B/N&ZD5R:ON>I"I6F-BIOR9[(,>$)&RG4E>8H7H16,^BJB!-L*Z;)V@PW: M:EE>RI)!?N5CZ](KV<\49?-
S4I^)L\&PH%./IANK&NM*5T90=+CR]I;^2/C:&5IB,S8P/],DX4Z8Q_DM@-HN9K_@') >] M620'/5.Z>P1UIN?<_/LPI@-74)-*H]MGE[X7.<< P--27VZ\#EY7+94Y-S7'
MH^UD"__!+K>4Q*PS7(S;P33B;;I=B))@:LUX^1([W7A2Y_@N+]DCV6E*I:)P M>1+I^#H&L3/:5;UQ7U:,;#8Q9Q"KY@'1@PH#AN9F1XS24Z=<7AK=411?R@FW M'2Z]"
(CO";7:Y6B>UDT> @;" 8') %M>FH:#[G,9.'A=%LB*\O8DU^G47,GZ M$J,1C\&M?G]09H67 "ZL/*ZL*_CT-P8_].P)N/>0$(_^HGA$],?J1\VIFI03N/= M6XSK5OG8<18O11.:
T:ZCHIOP.5NV\TV'/=7[4_,!0'.;W*9;7VLE):HP_7$LFZ"24/'.[PD!LA95V^4?7++/K'EUF^(M'S5\P3F'33O@LZ$M+-C&7=C&PW*-;HP7KSE1A-?^"#3_,WMG,2)(3XOJ%]+
M3"&1X^[7$1*F8157DHYGIY!C61VR! ZH,(S+' %SR4BU[LQM!^5F0I*PYI[5 M>$.8T_M/Y9[38P9#58K;4U"HADLGG5B>[;_-04A,3?,RMQ2,3\LI_+"
,ZLBUS3EUL=)C7%]O,QEK7U,%],YV)YIA=L\++OY MA;J>H3 X]*]>.+\YGTH))7F/5$WR7LO5?;H<^H[+[@%=O=^ -A\&P H[C'B1?]Y6#%>%C28NL+?DP@S MX%-N?
$BWW#A7'0[HZL1+!8-SUUG3X_N%"_]YEL$YS4.F"TR]?=_Q*2CJ^H;= M2W-4Y)N@^PP;'(YER;DNR*"6'KZZ- $>CGR7Z;V4#NS$<GM[ZYTG.MMT.>5^2[S.J(AI]]/VQ,?
>)XE^U;];XN-Z[Y-S*^7N M07?7O7V$[K]TH]98*H=:#O;/*QM@%&-2;ZY@_LD:WKVRTFGKRQ-T;0&K4!3: MMYAK?#%3X?)J WKMJ4Z2T%U(0&X8+$.'%8T*[K^?87>63GL-.]7IU?
EN,G0H M,RP&@1G"U7K#CA@-*^"%H=.\]]>$S(K(M$%$]V\B4X\:*3?TIKZ*3:-2F$2N M5MO"A3*@*@]]]4)>A"TD]"W8#&P 5=."S?[>"3P[:L1^K,9: JOF@28J^-%UY M/5AMJ*?
$!7%#&^KU8J(7<:XBW5P!3MR%:C*@NP=,.9>]5<"68I2]_]";3OVS MK8YK^AQ,5Z:@*Y\Z2%>;]+@-PRN5)F6C'W*M,V(ZM$QKQ_01OK9&WY23EK6@ M%5A?
@%&K+]&5^O96;017/7A%7FT.62;AFINAF) KH0P7=ZF2YRM%;R?VA-7/ MIO+/LXCT6GY>+?33=VA,G^:5+5A!-#(7 Y<5&,;;BSP39,2%K%V5O&J8M^X"
MJ;O15TL\X"=]50[=M6\YZT;"H;-\?1]+EWT#TZ[^T>BK/N MR>]I[GGO^&AY;?>7TVJW"SP0NT<'XI?N4?<4WCCM'G9WS[HM4^[:JS$Q)&Y& M*78<4N5;A$5Q<\C!L![!5!+4*
[4X=0Y2F;2\&@,=A:#)*VP!$6.#^,R< Y7!.47I M]D'+L)ANPT/#&D82F].B]4 L5,MYC*.5W6?J,U(W+723E*WC](= [/D5&9<.-\XW]2'=![5"1"<6I65[=G2F M(R7B
G9BSJ@N[=1J)=5$E;>=V;]V5$C)@&C M*8];9?,9ZW2FAM>HUP+?1]8;>SDDH(Q9:X4]^]0K MO1RGX4,GWJ_R@C05:;-/,W_D)(8]MH#<>MX"\F'#6@>P*-!J+I":STSU\4L7
MB$=2Y=/7U\1TX8K3-!-,-M7F"^KYEI;VJ2]_18XZ(?]2":<-(&4"]6KGK4 MJ]X@Y^NL=5]6\D&O7,=6RS@^O MU>ND%,K3I-
Z[QG;AIB64M\@,@DLL*$/17&Y1]M(QO>6QV@/;5E!/BE"!E.3L MRSS%YAL(A)@>@0H7X@.\?0.K8DUK'A:*Z BL7WJC(8#>%1 YA=D]QE%XZ=&$ MV^]0IQ;,QS'%L6%2]'-
M.]C^.LUPAG,B"#NG[G'?$%1P'-Z.LASLSRC[]XNS MA'PD5.%L509/? 8Z[R?)5T#S*S2]J&O*SQQJ&*P;WHQ7H(&D 0L3 6ST+R=#+'-O 2*V7Q7V)&3X @'L!0*L7]Q@Y)0S[81T0@9?
^:9K M:?I)J&P[9IP0PZ2Y4PNO"S35 2?*Y.+IF3#R>_GH-QS.51(L9OX!,]L@)$BN MWJ?_X53&D+U*8\9##/]3N@'>1!/Y\=?_AS[Y>9>,O9Y+;1.NW%M'Z M'Q"MWUI$ZY\6-=5QI
J5#0VM?$_C%NY^A?KSK3E/6= M2ZC1\YN-*K^9]=[;6[Y6>^\A5MPX]XT/B2LKI<8KSZM9^MBOX"Q05<^3(^O MV5#%MUBN&7Z,>9/QA1V_/6Y@]-\+Q'NI[\'7<$
1]G\7L13M;4]T-CIO]KT, M+5\>B+__.;=:KUOD'$U8?8R5C.+F2_D0A/#9QFO?_P%?OCS"8B(6[+^S=N* MB!\G22I FWDQ_8_@C/<2<7.7>XV":6_RH?
G@;B,E_^TCN>DD<=INP)^W[7!-5WT?OT__8?"#V%>>)F_%N?^[A>OSB3"+V7&?WSYUOPU57^5B=UY9##\B'G*-Z?'\ M-\>.)F'\3.)U'/K9<$<<%[GIF22Z?Q=TGU5&25=?
(EH;QG%\3$A4#)/MF6F5#90<\#M="-9K,&WNU'DHLX&2"2,GTN,2R^C/8.3:N3/K,7+BV4\-[]'/ M6V+-OKI=2J#]2(@]LA,P.#MQSW<\2_8=94)FM.7&NV^&P#Q_F'@\- [/1OZ
ME(C\?9MK;SS-W8'%F0:8^\$'>9*"9?F]>]V>^U:-!X%Q?J/5F;YA86VCU9XN MKVD&P5AI79*3I9_Z[N]UT.<)9@3Q*?\NLUR&-VZT2;MO5 @-CK?GLO72Z?3Z MO]YW-
K=W;K=7WLYO\25M5O>1_)RD TE]7DA[?7 M>2 Y-2<.ICM[\:[&"3;_+:^\JN_]-EXS7N?L .+]D/@F<7UW$+0[ZYOM]M;8+^#0OK/+$5_4.\?;O1>K\QSV7=_P [BP.\:45KC[>>
MM\B8;EK/9^K%:,3I_)8VBS7?G;&;V04CV\:;C^Q8-1K"_@-&C#4XKU-8 MS+*8?S'_7>9WV&_>;C^Q-8"'U]YJ;3PU?QP=X W* MT>(%_ZXA3_N>4F9Q?R+^7_F^5^4EM59?X-
JUE.3B-O>QGSUF7NI6>W-5ONI M:5E\@)W% 2[4K(6:M5"%O,OYG\9J^(L.?F>OL]BN?VLPT1O;U1D#^ER&?G M1C_8DPE\!M38?,FH\917?[?
8)R5H/["*^.86WLKUS33$2Q"^^&DP%.WWE&/= MV1$=?));%.I;S3&&J+WXN_"3^G:(&QIB;TJX5>N0M>?BGR8%M7AYHPN5 ^ MGZ/P7U=;=TTJ>A?
W;>D,*X>0_]TWSJZI_ZM^MS/Q?ZYT+_7,R_F/^GFO]% MZ)_MSGJ;L:#>>$X:Z&;K_?OGH8 :U'C&.MSU_L,GO/)](/6/5C\/9"#Q M(D#1;K/+\FX:J'9W\K=O606(=[.[=
)\OR..QW3G]0=Q MZ,/&%XT']\QX/M'/0PXQS9]%N/6]XX/_D3B6/_U_OAI_\/4$L#!!0 (M !.$#5GP#(/C$@E .&5N971I8U]E>#$P,#(,N:'!!M[5OK]K(M%O.Q/\P%VVK1"(\DK;W*E
D7FVI4A(%]G:KU?TPV.-XML;CSM@A[%]_SYFO MC6U,0M.FV>VF4@K8<\Z<.8_7Z[^8SGK52?2'N#^"5X+_NO/)_&S[@/_I1$X:?SH;OZXYP@I]/2;L5A&3.ETR1*5N12[&D?
MU9TL6+ABS">_C:?C^61(!I/SV7 RG@I'LSJ93(>-J&@AVMJTVK% M$C(0DH9<^$7V0[$,]+_,Z>^3=Z#B\W(FP:YZ%_SLX_%@G'-\R*0GJ-LJ0$
MU)0]V0O(9Z3]'SS9\8MJI9P%"#4"FFT1F.,P"I#=(%:4F[5>&V4X,D(%*5>5:3: M($,.\!?_B>SP3Y.+A6)%%CK,LFXKS?U14@$\)8KKABQF<-I6*I9RT+4)L@.HQ!
M4SHP<@$5A\HF/I '&F4!/[/!BLL(1GB=6]'KC$IIJA^E^.P(FF/<'9V,R)*5>3= M?71*H\GTJ>MJ;Z8_SR[ZP^3SO\EH_NYUK=UJ/-3RX3S-9,AMZB7G
<(,8UVYZ-DQ8K;H6LR9G,^ZI7<,8=M-XKW2_14Z\W0 M*!#EQP?T,#5::FIPA,32;$@(-GQKVVCDO,GYQF,&I<_,<=D5"M8"C4
M329*@I(<,,8TA23AL4$%#),OR=#ES,DL/7<<;ZS:M(=\2,3"Q[:(.7Q;"N(Q"(E%]!A?"!$G#GH|8ZE[3 M,[M'CDV& #K@)@W/CW:%ZPJL M-C!:]!@EKIA):J&!A4WW]&C7Z)M-S*#$4F&#T"PYC=#"Q?KDIJC[ZX<$?;(HJ:CZ]T
BV8!!V@NK M%7"OS+[/I4)U*C05-K/9:27"JG(P2:_Z+O>X J[#YJ4#!$EB-G]L#,$ 12"-P;12[U:<<6*7-B0Y@GL$&YEM.,_@RM_M$@@V7MI8N7C]Q5D8\OPOV@0V@K^OW]KL1P
$B%#P\3TH8QU^7,$V3QA@9(]:B8,/HTC,^JADTGFP&I("S;>MTG6>]M8XMG]YT6K56ZU6;(];PP7+P24ME_I7C*S Z8MUZ&U%1\Q<,!ES
M^[E/G_@@^\):)G,,,LS]CH,=L%IXHQ4OTCJ@?4":2D2P8%D]20/B1PLS4R-:N M*P[X":F%% 1>\'0N !1E.A;@74*]0.IB2U;"/.T30X%M&$3K+VT3?G7B,;5(M0--<2S !]EQUI\GD4:T8'\2

8;..GQ=X6&%"$K@61"7;$DY$#'==,=KLWD#_MRQC\"**1)6C8!?X^4$J%6'%'<_,X0,8R_7KAV*5!: &P$QC85 M\FT('I">,\E^U0K;3!<^PE%%%$*3"STM"2"UR\3/RX2J;V5\-
#2L"CT3((FA M2Q@TR,2!JDM":ZQ+RVJEN$/*,:#<3@[G@T>F)C;%1Z$R*1,4J:EE"6E#T<$V M%MW4$2E+2<%8%@.]Y(M+9&%0G("J=M;"1-X3V"LDQNH!3G@5".7S(5ZN'@;\QG
MX&5DP(6R.-9FH+N);T'N 8B'%@'>(W_,G3;B.O(;-P M8PH<>U8K![S!&O42.QQ]*Y*B?6-K7H-F@!T[MN[%8H&%J,RW>C(--HU$O]2$(M^&MKU;P2^>]-PB&Z$T@<
Z,9U(>B$^$;L) MI$ 5*IB#=NN0K"$1JS@NL&-&DP%3XSQE8B:F2*34:M$>42H'$3(]?*8Z- N4 MJ5Y' +T@CH1$*XX\#! ME ,V6P 2^5!S/A4!#U@$O-RO8YOG\
(!:GWVQTMX3SXXRGJ8K/!.;HUM@M0K= M@K(D7S!=:.FS5!FY.:6U8H>7&#N]#J93HINVPZ])5EHME6YK)M&M9%DJXK? MFN!9KE
,@#&9CNX[SG)"/=0JSNZ,P#Z..3R=6Q,A09+,]W)TW@++#=YK59L MP8QTFZF9EA46P[FB,.W\X7 /$Z5\..PP0A+OB4K^1+L:1CR4*U:L]A"-C2
M6%_#OLHZP*;:UK;/*ZRX+D^&IYB;T;).Y&D M5CFR]E'MO"]H?H.@/OA] M!A^ISD !Q0@S[7R+][2!IDZ.C M^'FD[FCRWS)7?57B&:],*.\%*C'+A9#0"*4=4@<[
A+)D".%/^3&3W=A2AYU7C,T11%'#DY>;8Q2BG2G+QXMD/+&>TF M>NV0^3H ?N2+KC5(5/ $Z/[J4"%M[-$S80*[^S;_;2PNWZ@*R]R%GBZ33!F MB5T7DM'/1PL&V
4"!=H9]K/U]D->09CUX]R.V=/AJ8V3_3VC*DRGDQ_ET M/)N1C^_&E^/S-Z:G":C4M07F"BB'](,Q3!Q85^?@OB^_]SY)! E,J?&WHHX/B&"X3 M./$E,CQ'L:>O:\>UWLY'R3:A]@V[%X+

~~M$"Q4(B2%DCFOV'8R_%,?MUKCR_LR'R=*O-B.H8/Z:JM0PGF>^WMZ\D$Y"[68 M,89 1*,XE?$RG_&KL.J;XR)&YLMOM[_^/G2ZGP\O">B1TYWKRWV?~~
~~$10@Z=RN:]7,@YWHL4.LXSX%Z+ M*1==V! *;X,+^1E^SY'85M'E;8,W*4[;&%WK[YA(UNQK0;D79*FJEH2A; K* M?$23N_OQ_1[<71O7G1U=)0D:[LS IW~~
~~W,5FE1&L'>V47'ZR&T/&1N8:E\RDF MQT$%OVG-\@'@SML$1+\)!W%'9[A4@8NQWMN[1TT#F(*L JDBZ"];REH4Q=%@ MI*#8L RZLBB;\R+XX_KGI?&]_/>2]1]~~
~~[L\,Z%A>X$*$8WBTSS:?57+,>GR&$ M+T0C P/"^.]I>DEW%S*I',VEV%PA B=]/DA<>@MCB)MHOKB$>.3X%%.(BL5551&X!;S3!]P*QW6\+[O'1>L?2H-*[] M 4]14GY;-9~~
~~N0;5O6+HW!@TFVME^%7XXS->78R;RF0$+C4"..U!?-0Y\>LHR M$SDK'P\^UY:-MW0@&"-]C/UTRV6W_.U:EN2VP/#$=COQ0P[_O6@FW^B>+2; M=<,-*KK.;JQD_@'?~~
~~*5EC;ORH%D+0(X>DF12;9U),/GQC*)\[)DO#(3XHG;P5 M2.2H9EMT6GO4MWP'P+XA:&L2]Q7!XM_'$=MX;G[O9_;95=*Z+6AXW!4X8-Y< MS9K+5 JA/"*W~~
~~!ZZ^=MIQ/QQJ>2M.B(WERND-LA1%B<33>M)UTQ@GLJ/HDD/N?+B.:"&42^0F'J1EY:X(MYZEOV.CU9CMJ9ND,;D[<)$GO^6FM/J $$24?!'6,3LU4S43J18=_5BD9/M33 M<19?-~~
~~RFM>P(#5P- S-HSUQ#=)-0K"O^$#1!..71E55!%&?L[=F6<<9;HJ:-[M7'7%]&F.3)^VOK&?Z=,Z7QCKLTP7'O"-N@7@W^JU0=/$>8;^Q%I5Y..MS@]=#8L ME[-~~
~~F&:-6OZZIQH_UQQ>YLF58"'7*:^=?0O%]3-0ZUBS;X.D#M8 M.Q@XV4AH5A^WC8+MS7^.@D$V;@O:X\L3QRG;V"?W0?9)Z+E+\0ZZ[]@-Z(=8 M=^V$A@9X!>H(S~~
~~]5O[NDU>OO_=P3)\9ZS'5AOXUTM"+ Q-E8,.=F:&TL*.;8 MJH*I.:HV!+J FOJU!T)CDLN,VY-B\>GO\(//RP]QW< 8\=A_&(.*88R$7M+ ME&Y)CT_^B/DGA&$):$S"C?(.NMKBX?~~
~~[R:**%'KA/BNHC+38G+>1(W^M3E#).B U35$^)N57(9^(^I^JO0R*Z27VZ-")O)IO+\^GK\SO5V4OLU:$^>>]7:Y>O[;%3>35?9E45D/C[%T50D.;2(XB5PD4=* M!/422-786AJM,?~~
~~9T"B('*VVV=P&5V2#VFQ"IR"RM-+T1KY6&=ST M[GB0PT*PGMR\!@'F((!9>YN@[OB^)_4KEZ_]89[570T6 MF,(%]8)A3[MPAC.2="P!)DYYF#]?,("@BWTH"65HFA1MB~~
~~IH;*%HRS5\:4^H M5R;?Q]GV),O71_4R*S$W409"QWX'W@$>2XLT W_+A%A[>7L%2J/$.7SD.*? M<:E<;KUOMN(6W:'@<$T.0PJHB0"_?I;G$>!P;9S ;Q GY'/Y%%V(,OGR~~
~~MX/"XQH_G-_#C^4(^E6$V:&FQUD/Z#E3HBBAPMT5I(*LRTO71;<9MC;PR9#F-O@ <><:SAX#4DCV:3()W1,BN'H%,W&%HL>\87O M*(1;9P@CG[X5^$RJD"'W]+]-~~
~~_*U5M(%,6.9R+'EFR*SJ*^R<0@Q$6J-98[LT';USQ?2#&QZY&/2ZJUUCH3.5*& M,L5S*9J+[43MPQ-KG7V.'(YS*2Y'IU@FMN'UJ^QSSLL^SYK)6<4LCE$>"#7X~~
~~MTZ_F0WLB_]}SG4X3]%&?J/V5LR 8J2XDB&.M-?4CV.89@2)9YQCZH*8X+I?B M G3N).HD*-76>H8.JY":YU/.?G8&EL1J@6PV2$B;!^ZL;CS3)XA3G<K;* M?&=#A-~~
~~>^5&,8:,NS6XRS264, 29YE0#N/GGNPG!+(FVG>JXR1B[\D:Y^]/+O M4KQ7#U=4QN">V5:7;.]3G=;Y3&IB"#!Q2H+[?@#F.%]QP+%59=*MW+Q<:W=^_NTFHA[%$92HCNVDMO\~~
~~[*KT1FE* HNWE0%*!<>?=E"+'C<4V8DHU\ M$LC"\(2-4LFQ$YVP#7Y<'3AD(Q_-!-+>A.J M!3?DT:M;\W2*W2R?7Q+0G:&L=O585VNT< M2SSD+U/ G.Q-FOJ~~
~~M//YZ>GA_Z%15H:/LTGFTQPI!R"@% K5..),]A6C-J<,<^J,XB_D0*1[?&AXV MQZ4*N1CG1ZVM!CERHJWQ%O,ADCR^1*,S=*H0H12$$"UJW54^1);'MX*'SQ92~~
~~M=)Z0+4Y96^DMADCS^,I:@JW;DZ\XEN)R,Z]):W>P);"0G-NA@ MY6KMRD=+WV,(C'6)"!]<1 (Z:)HV -#TF:='L/0'/-=M^I^/Z3 LLGHAD/@L M3?@JFKW^0!?~~
~~L]%97C,74'R65GWDNG]_W%R."K>Y&,5G73@1-/F4_%9!W30 MU&L@\"W0JB"[$#0+N6L+M!+HH%FX0.+C>82[5?$A MR0,"3 *!V5_R($A%L34'_C>>0PBDM !A0V/"<5K!H+0NU".#~~
~~=0ZAJE!4Z"- M3,,45/3]% 1W(3.Q)RL6XLP^M"G+N,R.@Z2BA:/::- !>KUKJ;SZ##,K,V"Y7>QZ]|E:_>E5WJ_31*_YRKO?>U-66=%0FTM2G*@$/2H -N6 MJ4D)9@-#~~
~~(BL2_$&SYM[P,ZD,3Z=RA=U%9<$*: Y0(OF-)'(I07&E5/L-5MY M[WFD/>@-)7+L?=O@_S+]^+C926_?9%GQ_S9;,Y^QEXR6[^G @FI%<>-N-/GF2GJXS';FP$RNY)H41~~
~~M*G6Y'SNY9@>A\A^EI+WNE])Q#*46%YM:"D7$BFO\I4V[OS@.K\SJP\(HEG* MA;=URK\Z=?-[ZY+I[,12KDB,L'2H=.A^+.5*^$/E13TM)11)S]Y(VQ=))WS^ M8@J0\2].3KX-G?~~
~~6ZFFI'L%1+'L!PM0;>J(8V$-24]8<4U02ZW/U*#02])\/E MT:/T;/UA',O-;T ZK6Z46K#RA!A,$S1,08;N"3%*(<&!#_50-_NA MH])LPRCXQ^\ $/7"2)+1&3\DLH3JP?~~
~~%/N,I<0'_NRJJ@BC+\(N0'$Z!Y!L99 M3/N(&2UDN=B6^Y]TFKJ2@2*=4_=017R%WWD9 54$YQ3_E?HE*"/X$TNETI9- MDN17!P!KV;2I#<^I+!(V^P^."&:14?~~
~~N&10NRKJ+8(HJKO]#O4(Y%Y_> ER'L MST5-482A 2%S?H-PZ7I?[Y2"#=I0YX)PFU(D,&X??2$R[=8B_-C(XE>]!E6W182:AO#-N[_TQ?D6^L3O[9SW M(.!%C>>HNV]?~~
~~(#&7R=K1@?"<[@"HU2$\0\P4P4@]G.<,S'!N=G_T+TWM&?. M87%P]?.](V=BZVJ8?BFQTJMTJ]6J,MJO5FJ5FEZ2C-%56NEL^V_?.HDO;!M~~
~~MFD9NDVT8.Q>E>JUK7%QD60=U)>.@[M:593W'-HO:'>4V050.M_W.A4J+MZK77=1"J0TF7]YJ%6H3@Z1:' :>H@;9F M.T#+W"N"&1(G;.!HOLTP?'OR9-~~
~~[<%\V7(?/$0S,S&L#7CO$C4!,[?@Z5IL+(M#.4C,Y2+H4_G$9)?CX]@MNWTXF2[ISWSQSJ9Y5,=_* MWUMU=#;]3B[0=P*^)G[XIY?"+G/M:4 [Y<'*RT@VQR7HU&LJ^Q>~~
~~M!UV@ZS!H0V=E=P %L,POX2@\$)6%,718*2@9 =N58>> MTT$?J(:\"JR+3P[.)AFIR%>;1:U0.":^%@P&C9$^QJK)TE(.CK*_\P;/ MI]*OU:-24)GVY(K.9;*%K-GM";O9& F6+<<&() MA-~~
~~(.'X46^*? /QN!YFLIZP'PLS6H26;W[%DS? 1C)TCB)/+'2&21"1I)YL/ M6B\Q;?R&Z9PUQ?\VL_$^N_K6N;!.WD^TKI65M?"?IQ\A8^?3S[]ASZC:>8SX2^BO8CV.CKN(MJ+\-HNU=Y+%~~
~~<@3<&I0RZLBB;1QN$'Y"LXG.9A(CI MW/%0*'FMV@WXB:QN+*O.^=,'R#H?D)CB:1,)$5/,%'U(6Z ;_PTEIM;)YR[$ MU*LS-%?TO%@-7">TLXU9H+;E9GO2N^T-WS3N>?*2VZK&~~
~~@F(7Z1=\SWZA"M[B29]EW>/TPO:F4K[C)MW07"5+/ MB^)!S^37%8/=L]=&F:4+O_O/IY0IFV@#EP"*%ZH&@:R D9ZRNR^<+B CYUTZ MOEKX5MX]6G.[J&C4N]8U/R[-,~~
~~<[>VEY;F[]PQ&QZX2A/RFNX#51:#7?Q<0M M"6+Q_Z>F.0\L\L:328F(*.OHD-\0/A!?6]K;R;E2;1R&D^<9=3:Y40=8+AZO7 MEO:UH-1"M>QIE/97.Y5)9F]Z(,/(?L%1?3IE7#& &I/-~~
~~*AT;P'NJQ) M^#"^I*FO$%<0UGK7^MF4.PIH A$^:J]_=5-[D_X*$=*KL=ZR78,< MM$><1UULI"JKB M4@(F"07F3S3Z%GGKLHA:O1@>!RF;RDV<>CZLF/S?_^99~~
~~MA@FR6E3(#AD[=P(G:6W\NLU MB)5L6:]"MI8(^Y7)OS:N;B9_+YEI(BR8$O!6 $LYLRU8I\AH#-9(-V@VA=TL MO\9[=O(\;MG8MK+)?C1ELVV$Y@A"XT5HGB~~
~~T7H06"$)C12A+$X3&BU!F9PCU MC&/=AZQ%Z6EDF+@+9TOS.2/ _DE',("$_$B@&KA;6 - UI* @6@3Z*^R""R_ MJP%$K:?B57 LW)XHVE4^\[,Z,@O25BJ)MA+UXBVG\9XI\(IV#~~
~~(Z(44D@&XL8 M?[A EK#;/MF-A#)QY NV;?!"9A1"',NSD8_5>#9%%[(DMQ"S0)+(+6:$DL@M M7H1R)'(I'L,Q;PRXH/7I>S<&GB&H^R"D!DRKEN16,XSVY-=KX?)F4)K\Z'2W~~
~~M>30:_L8-A)-2((B[N+AE?R/,9:U-92;,NS;W^CTOTL6Y'4*.B#:#"V@S" 6) M0'UD<@06*)X(U(%3,&BBCU!PQQ1<4](ZYUF&3,P$J8GG8JB)3[$Y+E7(!2YJ MC8/'_,I;"7M%5!!!BR*~~
~~(@D@J!8/F\@@%#U[%+^CP$!7]R=7AGJT_LA%:?U3: MDP%3KVB5+*W_SFWEP!!Q9+4/(?=8U;BZ@& PM"YU,U+!\A2SU02R1R=O0PS7 MC5>.K]YX^3I]9:N=0FHO^A^A>WU;0I,~~
~~[[$+B"GZS[W7Z3:9&1TKM!KYF/^<; MKN\4P6\Z0CQD^Y# M;CML9UZ]>HT/I,;7^S(=J6'(B>77/=(K/Q4'B>@P(1^(8A$8BC4;)K.(MG M=1(6A3#4T3!4B#HN/G(7,=Q>!8::#!VX!1-~~
~~AL7VP6&RM%D*GI/D0#9U\V[1D M4CF:2[&YP&U:XN&RH&EIPF!;TF'1VKWPT=M%A6OW0G39\>BR@&UC^,U/V$*W MC2"*[("5V0+[1"Z9SZ5X'II!-K]WY>2D]K^8 L0N&N"[:0?~~
~~TV6N&"5S.IS]] M9QYQ^!E(/TW'A;;GD'R0013H'IU>-*N/U%V]UKIN4I5:N5*F;AYJE>64/UQQ MFQ#^/(073#GZD*#:?8)9#OT-@1.?W.3#RZZ&P95'4%$48&I"'G)]F(Z!I^I_3 MW3-~~
~~D)GI<*]G\;B6+3'T^?F;Z@)O?Z=3G/0CK+LR@ M/0/5+E5Q1H8>NZL1/XZG+KWEJ*=-;7B."7[5V=]>IWCAX;&VI#'/S"4B@M, M?(N0FHT G4),>(;~~
~~(9:)P3.1R3W*Y,P99S0WQIHI6YAK)I-X/J7@"!DMD4F^R M9)5,ZB6R.@<1F=2;1#$EDWHCITIFUW4XNTJ8"3>I5WI.?]\5V?K?@7P4DWIO M!'4DV)^^+-~~
~~ZL\$&6C);N8%3O.Y^U\W.Y<.X=S@S+;DTPX8;RYHELWKC8N>D M#A<*SQ09,JMWRZKMJS>/22[YVRS68X2VC]0]7KZVY@I ELWH_FE);=]V) MS.K](P0XC))9J-~~
~~9O72&2Q4XHB,2/&]SD3>"7 +)Q#&KEX/Q()B@K<*)>.V M]ZHSHEW>R)!9O4EDD>WHCH"7+C)D5FJR.2-.QE@@>^19O854KI!)97DF.;-Z M^?AF]?8N>Y?~~
~~UAO1T^Q.06;UAY"9./1]OL]PX(#MD[,Q]N*(M7O;#C3C:XJS> M+23"[M67C#KFKQL/G8\[JY>)-*LW1V;U)DW9D %7,2.4S.J-&:%DXE/,""43 MG^)%:(Y,?~~
~~(H9H7N>U9O;Z:Q>^=4LOKQT=>XINY5:HJU$O616+Q'CM6+\X0)9 MPF[[9#<2RASRX$6?C$*(8_E>86C)?UXOWZTW#5/F'[ID7N\A#UHBXT4318[M9H/,ZTTH!8E~~
~~)8H<@06*)P)UX!0D\WH32L$XACGZ)&>"U,7G-Z^+9U-\MI"B M\@R9UYL\]@JL(,B\WD.G(QG7FU *QJ7B5^12-I_8FP MJMD"A(G0 J32GOQ0 M;G-~~
~~R];8_,1_Z)S4/S(EN_K"!4>3:;U$PVYE6F^!3.LE M#+6M-;T%,JWWV%EL?!-Z"V1.[T=@L"1-ZRV0:;W'S&I[G=9;(--ZCY_#MC>M MMT"F]>YKO&ZK#RA!A#8#[F2,A-~~
~~P>W+*&>+BC44-!-2NN>0'MC M $@#803]:("ZUZ.6^Y]TFKJ2 M@2*=4_="#TI)$[R,@"I"RF>^4K@0&#(-E4[;LBW)KPX [I%!6<14"T.#LEB(M0@T$7G=&%VP.L-V^W>)?A"~~
~~$AN^L/@B_ISS,9,A>FN/^F2%O7LJ<)_A_O+G. MC68'P5^IUG@(2SJ0D<6OU(U]%XL(M0TA.^,^TM?G&^A3_S>SGEWV7*#C*36 M$=EO7R QE\G:@2;P.=T!4$%!>~~
~~(:8*8*1>F&8%&8X-[NY7^C>&]HSYK XN/M; M9_K&SL6V)W4_5FJ55K5$75;KS5*U4BM5FBFJ6BN=[>+EI7JM7*DU*V4*_M2L MWU;+Q1;\I=F"_[FKU%I-~~
~~JGY%E:Z+M>^5YDFU!C^HEWYZ;"R<9%4U&11_TJ.@#YADBET0N MCULN9]G;A"',&Z#5_!)OSFCE$=5''_+NE>K_B+HJ8!"5B*GO1+Q#2-/'G@M/ MQ/N@!L4?~~
~~*X;1T'<+B([^Y8)REW[@N[FYK].1ZCO%O.?52AY?Z>!HWK[2P06; MKOEY WQ<:.KV6J_2/8KIZ<:C+BFNV.N=#FR1,SUIWB2?0 .)%BL=U6=)D?S3^ M#!~~
~~[%^E/WD&80TURH,=HMNYNZ MR6AUEC#"X3!"\)M_'+W!:/5<*@]=_EQF!\.S/R)KQ#4>>9XW MS8@X9V\QM[M^4*JD,FFF%S@N^QD.O)>=4:DFW8<34:K)Y%%MJ,~~
~~[@MV0XV@R6CVYG!$G8RR0 M/?)H=89-Y3.%%,_MP%8$'0; MX$X,DQML'JT>@.@>;X /I(<*K)IM">#IO=L M_;7*_>SE#G66NJE1 IXQ@<& 5*5T:Z.4@39)88CAFQ;~~
~~(LZFDQ*G9X^UD'@=D MAXR=N0_]>Y9RS(>;0>?3;VO5%' /I;&U5-?[.YTSQG^K@TQF_?3TJ=BO$/E[MCD]?1[QG=U5HGGBK@387KGT7NV'2+),J\ R9:K8)'SQ>5NM^3.!C<>/E 29$~~
~~M\+O@Q@1.A'QTTON$)]NG?8C,&!,BLO5+@FR+(19CED/FA<">!1EN&#-"R7## M>!'*DN&&,2-TSW/I"SN=2\]>W96J+V_-IU&>S*5/!J.2G$ L8OSA<@*$W?;) M;F0N_<'.&(XE~~
~~BCZ79M3$(.Y.>*;T*?VLY^>&F0V;2'_P03)".U'D"&PSR$SZA%*0"%2B MR!%8H'@B4 =.03*3/J$4W'A@L7]B)LB% BZ&"P4I.D.G"MFXIQE_)JP3D_"3 M>?.'3D$R;SZA%(Q??~~
~~2_HY\VGS6]+/X>H@_)LB<)&:(E2:4_N&G^:K4S_I5^7 MCWW/U1[%L)32=.S'G=<],KD)?NDE^MJY\B4[)J[M"IF-Q\USF11'![ZR0J3A:#3L&L[B-QDWSP6^]T~~
~~8ZF@8*D2!%K_!N/EA";WYEDD5G#Q\],'W#S9 SQYG)+ MQIV2<:>'/^[T,'F&R"61R^.62^MA,J=T=7J3C"%>H,T'U54!XRLRAOC0Q)N, M(2;BO1JBI(TA)I(=3)KP<..$2+;~~
~~[(/2_H23;&;^\!\GVO'&4LPN=F7!#F*\9 ML_K_3>^LD>Q/SAZK4U M%RFR9 [S1U-JZRYMD3G,'X010ER)R6PTASF7+:0*-#%V"9ZENL@;0:ZR9.*9 MPTP7"JDL$[C4EXQ2W:O.B'9-~~
~~)4/F,">11;:C.P)>+\F0.Y'&\0]A[G3YW)W5Z/'21Z0.F><6,T \UAUEN M#08O+XQ:*@AD#G,R&)7D!&(1XP^7$R#LMD]V(W.8#WFHYN:16RYZ?RID/$D& M)W:))*%;S~~
~~@EH5N\",V3T.UX,.:\-NP[W M[)V2C] [I=*>_!Q>TN\5;O0]%,BTYF1/7EE7O)T)-D5T.XU6&L90?+\I9ALO M'V]:Q_4UK+B1[6G,L.6G"8(F:Z%P@~~
~~M$YV/F=7V.M&Y0"8Z'S^';6^B=^06;%>TU0L!_GB.$WU.^9C)I+\UQ M_)R0-R^USA/\]Y,[$:S@^"O5&L\A 6=:$CBU^I&M17%A%J&L)WUOVE+\ZW MT"=^;^>\&YZY049:P%$!W[Y~~
~~8BZ3M0-MZG.Z Z#&@_,,5,$(_7"P#',&XV M<[_0O3>T9\QA<7#WM\[TC9V+;0^'?ZS4*JUJB;JLUINE:J56JC135+56.MO^ MR['Z1U;JA6W3=/9T:E Z%Z5ZK5RI-2ME"O[4K-~~
~~]6R\46_*79@O^YJ]1:3:I^ M196*S6OJZK;^N[D+1'UZ<#3RYQA?MUW5&$QS.;E[CBZT&89M3_C^H]#\H^7H M,NIO-QK 5XSQ(U#T'5M#!F01*)<&#P-O\]@BO/TXB3,X-~~
~~MY7>C^U7,TS[2> MH)!'9Q?\!!2#QZ<8D^_C]\&DE7GCV-43@OU?&PX*MNUQEC+)7%5^T*+TE[X5 MHD*!7:T-,!FBOH$9SBOXY2UGXYXYU93?]3OX:-~~
~~^@*M"WDJ9U$(&*4Y9>LFR? M0HY?WB+N8[_7A9@]#C0=P#ZY1+!#T'W'KVXO'R;-\5M[,KB]9']UWPV-%>.[$6G[#]FL9[?AV5U'SYB% M_<=;-UL5907,(;*E15'ODRN5 M?_ZE,~~
~~(V1,A#KMZ<<@5^LIS?"9BF3&\I,BS6=I6L1R@ MVFP)7=$L Q.]%(@ID)BE6%CJR@E4:U/QS:GSX>-_Y=:/6BIWL5M1X,#DL M]06U!XP%/8S!IP15HI39!HA.CI]MBJ(J8I9!7,0]!.~~
~~-(IRD49;KK4EN3TP M7 I;'G"L_JNO_7%]:NF/ET_Y\I66VX&*]Y-<#*^MT_?J(1$932Y9!W> _1\=H$KVLDDPWAROJ@EH,BFJ$W]6D]Y30?R+;>"V.DF:"N~~
~~M@G_11\#ME"W$0UQ/+VM5,+F6=MQ$+$B,S5DQMKTK^"'>5@H5S*!=32WSS!B[MO;< &?]5V:+PM\&]N3O*3>^(UFD5X2,JF,G;&[<'1-/(M+D=HHJ[3<"%*D?~~
~~W2N#23R@=P0@+2=I5G4HYT.M266^V!.5-T Z%4]C1*$]FX M;T_H>T[Z+OTH_^6C*+THZ41/-JT%20L>+\,')V9$S15'_CR;YU,\[W61:!-& M)^0,K,VGRK+IK@<~~
~~\-1KUKEF+36I@Y4G\'UQ/6LV'%\UQY5U41H@KX \X@=@03%#I=@'*;2);X[(O M]P-%'O!F[X\4Y1PZO'VQ30D&"]D19%3VFS_9+0&BV0?T^\[L0^(R7 F@T!]5~~
~~MSX7HWK&QR@_GDU;BTC5MN=F>%-6\U*T/NN6K+9Q)SCD6Z.V48%(=T)-5=#L6 M]7D:8(F>L&.R14;WN42U//^-4&]!MKS7.3$~~
~~M!P.I6BWY/FD[EV$PJ1V^)K,0F),TFN,_IFJ/A4,'WX@0% M,=^5HKU558N3(O,E4C=O TN;YZ-1N]ZQOJZ=Z3(]U[DBUZ&S;XH7;=X2?G[O!3J[9TP6>NZSU! ME2^7X7M/>/D99-~~
~~D1%,T8Z:$&X+A5-?,;B MY82\>9IWA;QQOZH]J5[J*DDC(/W\K43H%!2L(Y);^R]:A]"OG%/^OD;B=$T& M#ZH+W^8$'#=\]VJ9V!4&LC(^7P?@LD'J7#!VCR__;IN$4&7H.7N.&889BH"~~
~~M\Q7+M"?9'U6#^?W,O6:[5KA1LH(-&U!J$>BE2&IC8<7_9ODS?BF,FR$!PB!/ M64N^V)IF6GCCY30U%/-;$[GG1Z_"*"'4I:P9HHS<#_C]JBJ>49]0;,[27^TG M\&_,UQ--IV#$2=D?~~
~~VHQC?_@Y!<-34=.'FHYC3EG%S^* $QV-U<"K(GXGH%U M@QL^ $/^ 50*?6&0HNX$PQ#$_L@ I@G!D&'02W5D;=@7](S@@A69KH.3!8*2"M*:B#%]O#/M- 7X&K2ZC!@ F]~~
~~(E1+#'&@&V>42RYPEB+WU;"&NC;496 *^I@J ^U]K,L= M31V)"JK<.7$P5J[!WQR44$-%,%%>!&U' JC&!N#7R0.X&@13&YFHKX.!$ 3> M90.7+F-8L/;&*+4J@JP=X1L:PE!&A.K~~
~~74$B _P=%2((PM>7E1-(:5U *G>D M")!>\"%C2D_HJQ@S>KWU9;$/40 !Z0"@(J@4B&6;>A8RT+9[&%L(U9!X\&<9 M35>!OBK489GUBO M1*_7J0&D(&)*^#~~
~~VI90Y&FB(YK/1"LHXY>P"8L? V185Z/#[;[+91UPY9:"'45+4O:.X"VM7YZ,3^\YNC7! O MVW\:.3)MO0NM[Z_;$1D$HR1AU#EF0!.N>QDMVETE.0QZ$@~~
~~M(;V$SV.H[X/.]72UZ=]GZT$XJ5<(GS8RJ-<5OQO')#-+ MI'#6/)LBJ@N@OH&*$OHK"4!B/D-&[LGH4!=I).MRHC"TC!/ZPXF@:-!^8&T\ M4JUGL7Z>+F!]QP#Z*]2!%/Z+VYAV1B;*K$,-~~
~~:2$&24RIV&A!B/@\^S5%U>'F MK^&JTS_8:CE%570H_X\8>?B3$_2BZF#D^I-M6 ?"&-I52]G8C 7MO;?2@>8' MJ@KK J;MXUB61=>DD6CBZ--P5G3M$E(?L8>.6 \;QI.9\~~
~~<'HL4"!SXRM0P3# MT&"$"/>\2S&'CF_&B4CVX=9_UQ#18?.,?17+B[D35,&RB%/_[EX1U(_@]<^V M3D&77!EAL7SK \Q[Z%_(84!\I%K^D(&4)'1BL#^*CI5D" +/>@>]N B~~
~~M2'M"'UH7D U$*@HZB28Z,'HWK1H=2R;PHS\>K24ZQ:BM8J#*A6"G89 M#^9AZ$ G$""?#F\!OPUG8@/D<6. M6K -LB,9_)@=IZ&ES#D)EI'&AWK&@A.E?:U8SHI%\~~
~~(4)!P78OD/;+;H#%'M% M!RO2B6)'Q9K%(S!*E(07"D]K@5I-MG RLU\PT8@HJ6HAXB"O+O"+MT@%CS7:M M$?"ZIEA2[K">M8@ED&@C=A0Y>Q,,I9&~~
~~]^5>'[H%KQH*QU"K!OP*",.SQ>RA MN6&&$> E-=#N;9<=QC"@!=]*9Y9CVQ'BAG_O=/]>W/S;.#/OX!$P]HU4>]?E_X1^+81K4#YH9L/*_8W076 ?Y.M1>O>&-/F0> MS2R[/^UUZ*>,?~~
~~G%@G,=^; *//KGV1/[]5WB\[%WEI.[!]>(R*TOSX#@H5K>6 M71U#)B0@7V4H,2A5&-R(V+W[KF@=03F!PMJ%[C3T);%/7)^&>GL&=OLYW!4O M1XZVT4?)>^O8QXXC3YP3+2N-~~
~~T:4:(QCM"=,X659?!7RP!3]Z>-;1U&.\@&AC MV E,[V1)@AJG@N)FY,M+ MV)XB&CZ 2*=+.)N/SP71^>N)RUD0T>D&RLJ/E-P0[E:4AX@(LQ]A&=51'G<@ MFSC]!;*<,1+[%$2Y-~~
~~-G.7"=OTWS]R?3LQKW/@2 !Z\S2=>0Q38.Z467C'0*" MSG0A^14@(+-J>6$."9S$JTT#RJ$!>@7ZGD-*:%5.[!(.5$0#*;>X0G<$60.= M0=D9WN"7KK#]16ZFY-2"0 Y~~
~~+EH'P2E8=5>:E4Y0;<1D\JTWK%F981HZ[(8 M/L.S#].F_.%U2E14U1%<8[GJY<=TI_B@#: ACB=EB)Y!!]JG').BT#U "(B ME$1AB80TAXO<"3ID -9ZB+=<2F@\"!~~
~~(^'$10N^FKJ2.MCRF MF(R%E?E#,,M91V(%R8L.49"7?8*DFYIW0@HTYW99EV;1-P#V_O$'31C3F&T1 M3R3-,+P]FS3#9-H3U#TO^_-NU!@KIP&< P!V>L&D M(?~~
~~ND&1K5>^>*%/KA(L>V_V81/>G6-(SJBZ'8!A"B-%X3HYI3R^F:(^R9_1.;H^ M/H&XL:% <:%KUY:!Q*QBG56ATV[\Z.*3*1L/Z,3'OCB+#-7 ZO.-8V2 3O_F M%OD*88!~~
~~>.)C$1)\:F<=;P$!_LN-I#=\8&>B4TZG)XC]+73#=VIX&\T'5TD0 M.A?'ZMHZW(7VV@#V*T_LS0M80>((!45,%@B"X::L":UTT>9V"RYK.U!Y~~
~~M6K]B#!LI^X32C7:W.V'Y4BNJ,5,6'J%!TS7!]G#" *>L87%=!25#\#>G:L=# M^!)6[+3U+$K.XWQ@=G%H=5!6F3\7\/U:>_*GI3X]UTK"XSN_Y5!LZHA"CIN# M:3=)SX04LX5T-~~
~~D]L\72<$2>P,>U(#EL*^(Q3MYIR%9+.U:Y:!:G89]3J4*GE M.M1SI_+4LYCTQ%U,:NF$:=7H+/R9AW?ZSKER5QU5Y4#UTH-Z JH8/&$,1IB M)Q:7,=GO=RJ$D*+"/K]S=Z0C*~~
~~*NPT5@F'50[#SK3.]!%!EJ#J]"N%FN7D/ M#]490?^$A6&'HMC1)&Y)C_-O)@JOY(E=:&.XP=YWF?76=5!A40=5!!UU3$6] M;_'8O]5JR.T/K_EF>U+*W.8SEZU)\WV[22&4I!~~
~~(QWY1E982X_6-1F-943A) M8>#VH)+V4T:/"Y5'*.+L8+1,![8B5& GX*0SAB'JRQ95Y3LC^U*;N2HX/JW MF<=A1Q9.8LAJN 6DM(#*UWK>'I.7QICSTMS.G332G:(W*_R?~~
~~K\2<;DBRJ;N\ M);OLM =W9>7-<#FLX#B*5A(#?AE%!.Y13=>!9&A5K^-T!W;E7#[U$F@I=),' M0%*\X9I!$H&%856925ZWICEP=Z<3 (JO4P[4&RL9Y:OV>M6'S1Z?>.5 M^;X\^X-~~
~~CRKY7=F+#[.O .NLSY'>G"-9*4MR;8+C$T5:" E?W6W%]9RKJJIA# M!S//&EH.[+?/JO.=0ES)*A?VXMW9HO;9X1EUKZ$"/QE?97/(FEK-"]B2H:R6~~
~~M=;%O(1,D"HKH3JCZ;RAE!P:R;BV"$ZN8T4]\&,VO_*W2GO3]8O^OV;F_UC*1 MU72<[!BT._RV7&[^G%^[*C^;TIDH]IK/= =IJ57TR4OM(@]THN&6\ PD M@;J?[WY0TLZH6Q-~~
~~&5I],K8=O%5K'F"LOG:><,Q=K3>?88#=YM5U@K*I2=='4 M4/C*TDQN/HG4PSDA?.!C[1_?^<;J!OT-?TP)V..?=7RTDW"!:>?&5&"UE<5D MMF^++4$P;1$RZSJ!>\$H~~
~~%CQ[J3M!$3R?&\+E,@4AG#A=WE@G6/\9_'TU%U) M9'\=I1P'T$%0I]?].-?\IR4/+KS;OW]_$;_@-X;OQ]\V0RTO]G@.,S1H?DA&W(KS/Q6NA7F_OIO61K? M">OX(9/-~~
~~\X40>V$1/W#;Y8>3Y:0,-\\/.(6'SA;=3CCX-J9S!(NNG"HH])>3 M3;MI#NZ:H>)DAR'8ATJ.^A2U5WRWW=%BGJV@3H8X_XR:.N%#2%&#KL($+/?D~~
~~M<=>WZK0_461L&J!MEZ!J,T35@Z+I;,[FMDUZX*+ZSBSO]#$VK_@@=;MB7M"W- MB^$Z<7 X[0ID'3(XS]O9GA?K2!7;6QP:32OLH,N.*H!FE@18&#FCBE8]%JIE~~
~~MM^O8[&W@+>&W22FKTN@$4UI%B!A %.+*,:#CZBQ=QRNW1-I:U.;;C[_K"OU]1MIS;M>)MS4ZSN9DZ5G^MMJ+D9:K4EH$(%\#Y4 MT-\UU,?+[E\&W^\TU[!2^DX*%YTQ=-~~
~~#)HGU6Z"8X]LQJH[.?2\V_W'Y:"QC6 M)1)SI@&FW\9=U-)%?: A+58J-JC6K F="RGN3F1^*!G.TLZN3G.#$=2@0W1V~~
~~M,Q[:AZ\HX70R[9WW@!N13:^J.VE#56_6V4YKAM@6XI\6,Z%.$VANF MS#<-]U20G9X83K6))D)'TCC!.A*=_Z"*$W3V^O_;^]:OMI%EW^_Z*W1S]SXG M<\V3MK&3"$!~~
~~S!!D\8I@@5"GWL@&*&YPO8;E-P5F"I&?7LLQ>I?N5(F MF\UR_#7*1/$6MV;A]5IP.H>R39V?N.4G-@V, *"_/SL[]$29^13[L^5 > 7U MD8CL(C\F2X0W@).],@&T8FX-~~
~~\R&48MB\N/50L$B">;3%O#W'UK D#9_GJ=JB MU0&=CY GX%4$ Z'@,QF> :D2Y$,P'YMI%=YK\V&/>T'HZ3946L1YV#DYO\0T>08>*FZHXMGGV=1U" UGU.:8$@0SN<=@+#DX~~

MAR-FFG)5%#9!8/+%?3'(7$PA0-[6A$P:8;I=R,5C3>\>^3=B_7F$2MQ==YAH&MY9IHU^5*HR)%P:_M]*/7GE7K[JX#O&T,L?LBFPP[V=[!/J?4[[N7EX?#[.-9]:K1+_G&A"NJH_>S
MPJ9C?9C1?V;J8J:U#O(=TGS^=U.G'_93E^?H3FIU9%QI*=8=>3_>H#1B#GE_M0Z&P!E7;,LQ;8.677IG7K*]WY%.VXU;G_4_MRM7OEEGV=IS/P]M@ED3-
L.O<(E>:U*R=3[&@:2TC%]GUA?M*YBIXS2LD-E?&GUMV?_>/_G1?:OLORIS>Y+,T\M2F=*_MG?"L^ZZ'04Q8PJZ1S_!4+2_%0E!U5G<5H&^&F\QHYD\F-KX?I$)(3K!4LVCE
MS0+^L&!!=*W3,1VE>Z8RV"ZX@]V="WRT#FI?KP]O.QXC\IE,8T3-_MG[(L;DRUKA7+DTIV47E2]$Z3)\(D!O0(,HYR'J_RFX.@21Q'2HK)'#TK8:*N
ML5J!=GSUW6YEE>;GA\K6\='B[!,69FB9!@&\Z_G%_'I24=%JQ?WSX?Z4U?5M"0_KT4F5QQYN16_MIQ$Y9OV7>G9RT*M,FMQ4]@L;!5,M_*5=KFY+R%(YU#,)E_L^82C,/VFGW;A
MNXBS@SB"'B+O4[^4,N]>B5:D_M^#X5[NH18AN(JJP+W8PLS4I%_Y7=KWJE+"[$L.>,I9_^1>N,0!L/YEY1]EBK_M#JJ]]9T
R4XB@7F"O/8LOHO:\W,'':\PZ<(+G;5\M[MABI>46R%>L4<^RMC3I4?%_/QQ;YY_4-[T_M$_K326D+96YDW$#A7@\>9XG<5(:$-9UH(PB!B1+@_3*)_]N-:].@W.:.@7T
MRRO:V(ML1/UT5!.E,U!D[FMWS)&!ZA.+R0J\%L$/Y7E@\V'??))/S9O'OGCD_M1W@MQ*OJ>A%)>'"SAH2.$0<+P/!&P.EG,)S;KA=9P(_F.XV*W^J(]T+-3^*&O1^GG5?
MTPV7W\N"LE**W_N)TX[<]RLQY*LS#7DG+D26=CNN#Q^^?I>W9OHB]D6;[^+3694G-56PD92=5&X41^T^-D7/R:)N//B;S_MKG/W6JN-I.P;;-T=:IOPLUN^O;W5^O?:(,
(T2Y<;O6'SGGDZKG7LR&BA@QW3_MLU3\G2K[?'=;SDI$<@LX,80)K@QSF5*W=3$%C=F_RHWPQR\J85<
M&_COF'O#]RVPY(N(.\%P3*]GJ!#]&;HOAA*7)V)%3\A/"TTFXZH@:KIWHD;2_M]3(/?=<(SM;KZXH&MX9X1>B2QP0\D'?CC/BD>!C/"8Z,I'Z>^#WLB0Y;GOA._M(9;0Q@@5-
=RIZ1R,T+(<[$UT?I0197&HN!@+24Z#)@*ZV%@7)=:ZCUBR,18/_M#,QX00[@5#L]%_9><09)V*_IF:O>&QDAP/L9_MOW\V5B0YHQ'B)'MT8BH-3,<9!H)AA!3>#>B+D0?\(,
[EE^8A2Z"VQB!(E!?O_M)\$/@\#58G.L'ZA&*,F:?11H>3"+PUYPMRET)UAD[_8]][OQ"92D_MVT?57]7]VS8J-_BGD6,2<7\\@U"6J6K#SL!"D9_MN%XOV0@7)D\CC@3Z0Y_"WLZZ@K)?
3SESZ]^#KX/X@D!U:ES:QZ+G+CQ\]"_M]?M1N_P0G\OAE+DDJQU+S>6[=2F#J7PJKGHOWH]7NGK;)U_MKLV^HMAL9MY&X12&:>.'+J1B-KOPA;38^:+YTTM-_/"
MTC//+SSS1I+ZLL_'P028:"4R5X.*E[F?A<"%:V1^O[(19<)WVV&Z=Y>@T'NR'OE)PWQ=/[@DAR?V^9G";8C:&B,[[E5B7\AA==Z#_QM,'YP.Z6?"-8!$>GCXW_M?JKWQ?
+Z7>8[0)L0F$QQ"P%MRG-'\?"S<587A0_M#'#8ZT+;;+.3ZIF$O)0(IE;V!..-;>6-<'R>P-Y\HSHZ9;I@7"D[@.D_S*,M^9[X1>GU3&4L'N^+=16$/-
P)_4RBFPTO!MR7@:KT8,.4#@,4O<"V<_!YT(GJ_MO4EH^I-*2!K#V<$^VZHEGH&XL_:JGF+L@+\O:7#W3:(_MA_=FY7NXJHK4"&XU_^_+F/OE%CH@B&X@:LQ/0_MAAWK\:
[=EFK9GK.C9O\\H&\OJF&K;=3QZF^0]IY.'&T?H_M(D8'3C>^SRXMO-PNS(RB0I&OB@A82;W#H^+G7V(_CYHH#!..%G)NA_MW:>MH>XKWOQJ\?
A]Y%B[[KP9^5U!1*$SU.G@(KYB*L\LSZ[WNY8/+HXAQ4B._MB$>NN%E3[8YT[=I0U:SB^>AH$KR?$M.\TCKGD]<_GTX^>;81#6DE[MS*3'SHSRE8]21)/@\#>=P#1F\4CRY-?
$(I5%BZ:D_-2B*1<8?(^MGY\/_M+P,V0?Q0YG.BS)D@2F;P0V&A$JE0=N#R?.%([1]RKWGS4K_?NA*I!5E&DC8C_M5K#LCA\^(?>P)#;0W1'H_MS_TQO6J/!U?$30VT$&YR]!_+=(XN
4Q>@-49:+>\\%^I-LH!T1R.3/'U'+'CF8=0P3,4-_M/IGB;\".9GWL0>@CB7&+RQN<8?+AI5+M!T!8$>A-J'!S0\(S9"/SW*JD92BODR_M?0QAKH@&IA4@S+YX1N^3W-6@$N?
H7G>T7XY!?599^S2ZE*@5FMOU'341-T9>CU/L"D%FWU&;)O&_^8:F<#,<&>;M$YV55+#0%FC$B46C.381A88_MS!TWLHBM]@R=Z,UV5J#N>,3^R*78_E;OC-WYYL/D-
=H(?"2SCGGTN:PU?&PC;J-*<&(9=^T\^CD6IKQL(ET3=,Y)Z>>,S!5MT!?X/X*7Y<-B1&_.XF*;4#0LP#/<&=!*+E%-\3D5WOAD_6\]?+.E@_M\2X<2TR@B:T/IJ-$I2_?R.F>P[-4Y=Z*\-
#M1OGSW\DLI'1?Z]M7WK]5=_MHOR&$N6EU^O+_?PNR<-#Y5?[>OA-VL*^',L?DTVV\RM*E=F]H!N@_LR.=6;G_M-KJ>\(Z[E_S%:-
QY.3BO_UBZV>C.IQHT96WT*JLW[V,S.K10^?']ZXD??@4_M9!JNX8B,>;3L(0EN?RV(7Q6UOZ0Z(0;-:I^=I"&'6D:27:1Q_MZY!QFMM'_=-_+$^=8E:@%-N8'FDY[2'8
LS^E/DC$WK9!GAW7SR,]X4<(Y_M?'H?]<\$Y==B$/*4J=E#AZ/QH:_MV_F4#XI(J_X_-15.D-O@MJM:%@?K_:L?)!D5^>PYH\BR,@$"Q3O(1U?"Z&_*_M-B'?
RW:+V#P2OE_LY*HKP_W,^(=0+WU8E&U.&=UEUT8QQ#[VLN;U>GYC9;3DN$A[+*799A\]!",Z!@!$IFN=V)F_\Z+[_M,UR4LCQGN"A)@3"0!R!]B#;U18]^R8)!@>9H>.[H&R\(=-
T\S^5*G4[-[_N!_M-_?*C)5P8L6"W$<251XUBFJLW#7/I=?/H_MTN74?Y_"C*WQS>TQD$;B#IE%6"=?Y&7*,(O^[^|_D/EIJX+2>LJ#,^_CV
MC[*)NBO>W[-2_|=YO2[=G"6(3IH_,RDP@O5AFN=QKCT*[@F^F^<)_77D\1M5<_MC^QAS#F9EF_?/ATK;=-!|P<-+IA=,>9*9?L8+T<\F)G[%VA3?##V"ED^<5KKZDO_M2N.
[TGC1M;G6/CO7-\7:8TNFK,G60.8DL8X-LZ=@3\!3G1G.ZR2%U+YMGOUR_M'A[5')>>+[ZXAPK@[=$BG4(QE9+/3NP2]]>[J6Y_M2/'*!V0=]^.7_(7U\LVI7MGR=%
(LD%R_&DDY7X%R"H4XGJ[J.?1';\S5(,:E;_M838I4E>7OPE23_0Y2$.*PGLC13)J0AI2E+:2%/,+SM53IO+.*;/P\2ELIU!=_M$666D;&%[92QJZ/.PA=Q84F1NRJ8D/5"C4R%
(8F[3EF1MRO;.8O!T\+F3"6_MHBG?.2W#GLVL:9U('?%D=/6U_XKXL!NA0O$GRHKB./0$8L7-5[RV;5H/PVU'IR].@5YTQX[7':Z9--")V_M%G.(KS'T%_F?S;&4M$U&DI>2RTB)?
OVITDU(3A_(1I$F-A&;$D5"+!'WK.)!_M)F!@'F.9'"V:>587C18M=!RZW^S;GU]/!J/C4CQ0-'K50%%ZGBHNEF$2C!=)_M^>R4@)&0$#!R,^J\@%$W*6)TM-J(T4)[?
#2H'A_=WEQ8EWZ'&G>\12-$TS=G_MGD!1,;=XH.B+HXT%%RIH8I_(_[[>0>THA$._=RUA#>AB0[:Z\J_&+$U'K8-_MS0U"?S\XO;AU45^HY-"/KT7>36BF'%V%M:X75!;R?E)P(4IW3T;
FWY_/H0%_MDDZY<>[D@&+X$5;=];_W5SZ+'UG\7Z];.89U;\8335ZF#$[$UM;WJ(RS0P'L_MB%CRN#G#L'GX_D"5&6/=J:?*9=RB._Z"SN/W+'V*<@1EL2-;_PWK$MNRI;)J_M/4-
7A,3#$H_7Y386N]"7=\U./V5G9J'[_?1@_*V8CZLIM8VO?1B_ME1O%+0JDK'W9AP/5*IUTKF*Y?BR5R*5EEGVVKBZT?I<.A^_C!IR@I_JONZR_MURBSRD7YV\V1_]K?/V3_1/SJ'VIX;K
M?1/QCXE^R3DH\IM$A.:@2/&]420YWC$'1=Y[J&QI_I7?.8&6/E/O.]2X"C&<_MN@W.&R70LC=W:FU7IR6Q;A5@R]_0_66%[(;W$B5:R_=M?A4KK[!7B8I%@4L+\
M(N)CVRNQ9J]@N3JLRQPQ,%Z#):2IP4I7-QF(GGDM2M(&T80)0;1'644;>;Q_M6'$4+?'.J$_#PH'5/W.>NML6/)O-@)^_M(IS?UWJJ/^5ZH&INV4!9XD;.$Q\K+5%(A?
$QD=50E5+74%6W)E8QS]]UFI4?_MVM'!+\=*N$PK6Q-FFF=)]L7M#[F6TT8_$GS4]:T)0X2K8_ML]^>WU\W+H[;^805EK8U/C"7+!D6SX]K->5!3N#25]I#%5T_K:]7/T_Q>^>M
MF6TGM\>U/UM-VTY7TL]C/C,)4=[.;/V5._)G$R)U8]"W0HAD?_1L0KSK*H4E_MZ+*=8=%U!WAFTV4[@Z/K]LK/ILMVADC7'6^^0\.RK1B/3FS5%,R!7/+-8'HY+]]4Z>;^U\E*^P/L
M$+9#Z-:5+438SM^]7)=;SOWSC7TSJGSX1&RR1WSBM@O>3FCMC40##=L%H8WT_M%0RT>@NU#A10S%PUK[V_!W65"S<.+.2PDR$)I'IE]R6W#YW7@8:)M#2-T,5@
M(W36YS?2VC3X_L0!W0;%5)"P!6'>3>RVR^7A+55#K6LX1C7<_UW6,Q9[!&,?_M#YFUB^0IDQ3H,D8*J].@/L"LE97U=VC*J[Y=*ME83X;.0.DZ6N0&0-$/"DQ<_M]?
$5(ZL&\V4MR"YZR6H472_'XTM-UEMXU(-W4KH6*9[_J82\KZ\QY[N7+T\'_ME5;QZ/B^^_!7CS,$YAC3]/X6_9M4W!.39*"X\4BQ956SW*_%$!/]LP*SH5;UJ1>@S2QU4VLOXS_MF\G]
<1889[>_W0(66@"I5+-/NG^@)PQ(JA^K!L3?:-U_1"Z>O=Y&TLA.I@U(_M#CR5U$8W96NKA.&2.DFU2+,Y9RI&/:1B1!>0,-N$82;1>SN7WP3]:FV+=Y7Q
M[6"=W*HQRIOMXY'UK'._&^RSMU^KN%X)^F_9K_],9>O9/C__ICL\\C].ZF;_MX)5B*=BIDRS_+C.T-$:HA7M]T1>[?+TK,&G,?WGO].+'E=D1\KMN=D:H%UOA
M#!6OY.V,6Q&1IBKNBFMZ]\A?+[TVT(BQF;:/%CTY,%J_OMA+YS*]^%3/E/)%A+RK1R6GT.&34IL6R&'=9W&>;[__:K6=P^#HM'^A?GL+2@8S$._MRY4SA5)I=1RVC+]8VF68]%Z?
*+IBRAH+1G2'JHX='&7]!#A)74RMIJ=4S6<>_MOD4N^V552DX7X*5:B"J1HV*?%9\'U7J_5QND/RKS$&0-_GJ"GIEJQ>$#5$V+
ML!8[0(5BHI8K93"]$HKK%^13].;/LLJI2GYM'CY5#\>_QR6Q_VWP:>35=5%_M^'0.BRC,I\5BIB0EM9E\'WRZ.=4V)9^.?V6=S]7BM\%%]6WPZ62%=Q$^7=RH
MRI8SY7SYW3+]I.JS56G(*1FUV59?2I?*YV.K_388=;+>O_BC+F&;9<'\+ZZ#_M4=?KIR"_.1?ZP61FJ]NT<_MGH4Y]YV?3;"J_N;>CV59UMXB7N].(B=8.,,H[(#>NH+_GCDX-J_V!0J;X=
M1HDIE"%&*647-F5*U4R^DE3P_EX8);UW*JHDOK1EI7D\'-\K@<:-V\XHB:E]_M(599V)J0I&I&*L]O]KX=7ID-#3M)3WMQ*B>?G\^O+GX:G3?#*S&E*L(I2P1)_M0
\IS&]XIN*42")XM+:"Y;\JSQW-Z2K!*H9<_A!;_RL7+Y<7=2D94L/Z/_G_M"ON%V)3]7/HV]4W=_432T("GWX6@WE5^.HG>P_M8"+WCW@C:P[\F1/W]KB_ZZJ/
=J"C#DXJ9T,3XZ^W./QXPMBTIRSC='?8@DG_MQS]PCU2)2C'2Y4VGM//2Y1_G581,+8Y).O=)E3*SLC#SA4C_PLV.">Z_2_M_M1*S$_UNLF7);[?PC-
D"6LOUI&+@34B[XJ[_[EEWUZVTE?0XFK_9669JQYB%_MBV?Y)IQ0R:'MS$7V(;WN;N_M+WLQ5ZO:DU]>#HW&DKOP=/DW/WOX]A)+8E7_M
L8T;8$I\5+2+/!KXZ59*TY_YR5IRQP/070B4N<,]0W<6D1];6Z1D#%S1!@_M@F\^)0$D:2D"Y+)8.3@_)&.P0C$$8LK_&F/(>000R_E.;(^#2(YQ'+>5((0E_MG[.9/=\7.&I=\^?94^/8'-
U7T\N23:PQ)816FC7*!U>U[_5K]>1G88O%R>0_M0MK3M)T()'-18$),.BT%EL342-1"^@%%'@E3N2ZB?]EZ-2:M4=DP=R_G8\FE==E._MX>X-
Y$:G7$T^K?]USK,ZZ_"Z9SCAZH4+5YC[0(:O7^S0#C^<&N%!NIS2LSG?+Y=<9RUK+H_MY>WI?%I%+'G1!2FIH")-/ZU8B":5"U4(RY(:&4@8A[WK);3'JZ_M_VV/5G4
M'3CE^GQJ5K[>JK6GW&T\HN&!!,]H-;[$2E:H"*C?E.N3^O63=%R<9R6'*UG)_M2A7VQ*)=3]PG%8M-\]*4E]+,U:R0HVRW!K='XV^'"@_>E-7LKC,2ES+>HS%_M_'I]?
BM;Y9*:W'H]=ZM9Y=*V96&]_K>5K7(Y&Z.P_5ZT":9UI)/N@KCTO$OE_M?&E=[->34SO6F>_%6R(X0/V:WJUCCT6&?[Q\G'2*E.X_?CG[]JNMR-W[F)3V_M>@/$[YN5!F6TF2Y_M&
[Z0UN.83!-)RI1**S-$2_1Z7!@W)HY7>/RF'+B5:K9ZN3HZ_R*=W>>2-%OL_M*]L@9V8[%E>TT!4]OB=9K6$=.KGON=*4A:[U#*4]-HNPLH&&H7OG,US8\#L4,K0&>'G0#3(U
MD6W]7@*WY2?L1\(Y\I_2N:OL34^.7R78_D38S@;+RZ1D+T"$)86?O]8TBOV4H:7[$V(5W'U1,#&G\M&_MK1+3TAK&Y.'9Z%&_CS#/N*$@V70746;V1_+A,B&P.?
7AWLAY^%#Y\8GXC_*-A$_MX'?M2KT_$M_4-C,YRI;4UVNWHGDF+T'BJ[T5'N22?TB?VT_;;_.C8>F7UES_M:1J/*J9I4K*KRO;.QKV;[@68.78$/-1\J3S?!')C:9A?:.Q<^K%C>)3=;O;*
M*7U7"HW2NM<=0!?M&8!'7\^OBC].VNG&GJZK]31A]$93"V&-8XQYG(H.74*OUZ9SD%$;E43JUQQ^X*F5(BC([FG@@L%>[':RBT#N._MB7HI*"'6XI5-M0U[([(:+%_51Z"CT$KX
76(K-$,@T56ZK&F6?"Z;2TT_5_MHY?KBDV/*KT>?H0U'Z#^&:9LHM(('Y](76>);<5^4A3>;.,/0:L=&;_&_7^_KV1OLD3'X]4'/B&\A^,EG0CM_M(8N/LN:0K2?*V-
A>1]P]N2^KNF6+*KRSFT22$&F%M]*IRB-,6(6?6'!/P0VD_MJ0^H:5-]/JK.^'S2JYY43:,'VJA(PUWXXBK?TR:6\"8![[P9-:E!G[N[U7!(_M:O2"&W>\FCO^P+Q\+O9=O3[^NE-
O#ZK(@E2LKJ#;+5_?CJ5HQ*I.9&C<-CY0.N4C$O)298B>^-P6Y-H,<_M;_X>300[8LE/DPK7NE_L#DS"[TT+>=353QEWFB^E2OY;]FPXL6JP/3Y^.GZ[+Z0:=>A@F##O'_5B7DC7/S!
(%8&5QQ2J=_MTA)40FQ^FY)3R)FX'9MRVU3*4;?-%7-076POSMRCQ#ABD'._M>?]N+IZ@)CZ0T:5C*ZC5J+IM@%H#QHACX55.[4DS0J_G>P84ZPYYGYWI$6_,T_M,%QO-N[.0!W1Y%
Y1X7:!"-$&PN=_4:$P,P_X83J/2CC3_#0_(-V@5N!*M9T_MW0$#YHH,&!&D_3&(9B#FWE@5\&UM9*]:F"OQP,);3RA-ZD'UQ!JY!OR%/<,Q@4B_'-A/_MQ11_2\EI6HF9_>'>$T&:Q@.K\=
C,A!7A$_XH]Q*W/9?T)?G,&OZ7/IGS\R_M:&9:C@QO@+?"O#]#D(4H=Q!1MPZSH4@CP!]X"ZPY,%H54?86M:SBYT1OFXJ_M@@T/15HMH];YY:BFTC!LQ;H"'E(?47IPTZ*#A
#A3AXV^_MUN+N95]O!./A-_M.(LHN!*>.N2_/"2>/[1H1%H-UQS2>^F'QW?WUR\]+.GM4"O)'>12_V^3)'6_M*?H+G:53S2)4DF]JN[!*47?$/Z%"J
;LDU8/?]FVNHBBLK\5FJ\WV9V$F8R_M,YV_8&W%]XLP+X0W/?*]B&@QJ3W0O4:FT74Z-@S15>&_M^3!B!P8D*NJ)A[,XQ%E(Q3WNWJ?&RIV.Z;_S"F?5LD60LB"M\9C@_ML]E_"R.8H
QB=3AI'/2&]$$.8$"8H3R#]'9!20SXN4RN),MI6VI7A2N'Q4+#_MUP2<2,U!G4ILCO4#U:#)U9KB5Z2!G2'_$PYD(39#;!0>5\6'1J9KN/.@:"\D_MDXPGG?TZ(AZZ?-
PU6[(31>NKRO40+4:RVA6(MFWXO>R&E)4_K\9Y0,5+$,@\W"7(4[4S7C/O@@6MRP_(SJPZ3'S.0A=4.MTZ+4UO1L1+PW%_MCMFSVRF_?Q!&3N:@V/QQ^8#6H,A%"2>80.4,AF-;-
E"4W+AIO3-I<@J\$\\]_MN('<-EBG$-_C!;([)H/[3?>>'H>"66R>L-$$SL@"#K,SC[=IHU^*3X7]>4DY_M&,Z\/).7.U^JURJNS.H<+L=(U\%BXCWI,%IE_M>)"[;YPOW=;N32DEO^_@?-
AI/>7RDWK*[3K';:1S7'[3G>->O3_OSUKT_MR,5E_;J&7S176(--OGB7?!MHV7=8N\8EU*Y^B(V+5AW6=U*[.CIMG(C'%U>W_M\.?>V<7%5_QWLU5K$?
E6N=S)$]L4#5H#U>)).:1M868*JCA8%+&G&<8#^5=<_M%1_,1U"8N8-\]_,Z@?@MV8U-A6EU.JKM>$1_I4JP_,W>[6&/915(U'_9T[VS_MP8=]QRQY4=Q!RC4A/HC_[GSPW6#V:UI@
>XB73_K/X;Z#_903?1@@\B*Y@DSXT'%/L.0B](S*_[V%^ZW[VLLG.UVP5-I"YS"S!@_%E_=[8/ZG!$H1_>1NYZO]G/R$:<0-X@\BW"_M&)B;
C^!RQ%I2MN!5B;WQ[(/38.]KFLZ?:&#'I8N#&BQGV#!1,!S]PP"@QS#&&KN#I9>>/.AMHU2"P9C0_MC\7@CZ,.8:*S;L3XA[/XR_L\8*!O*,-),E5@9'<_8>H_;':&8Y,UAN440=88
)N2_Q&T?S>\L=5&(EY-8";_M$S@;IB_<*<;SV%3;ANYT-_6A"S_R^^JH_?]R+R]$GO:>_M$ML*?@%[%22?RP8T53?_0Y:08#M#PV1'G_U4A@N_BX$5D&"81$S3)=;B_Z_\
MPXU%8[OO"IT7(A]).'FDHN*_\@^4!H5^HRN.#;)AH&JX9Z:,QALPN2G_WR/+_M(T"CWK+<]2=("*!YS^@X%ONF!XOC5Q+L#'R$>SXX&AG)U")@KQT,$C*T>T.
M$]1[^ATGXEL!6,FSN_]N%C,0I*!-W70C%A.LM'!T+_H17'AX:%BRW@EP<-$_M8)$1^!_OSIS,$N*EH8V_*_I_+&>$VEJY_-H:_BWX/.!3VK_LPF=6@WTWV>'T
M%_P^4QXG#'P*2A9*P@YLN45!?NS/Z*L4**[;<,[Q5VI/Y9>T8L(-PXZP>]_X_M.\+S&8G1W[S'"T;O3#3M*'UB#XJ<_98P1?1;W-?]9K]M$O^$9Y]&/_M%2#7,.%Q2U$>HM,
(N:;C/T!/HAY;S\A40.;%IVZ@6_91'G^>.@O+^OS.C4W"\KI%%-X1XB%%X-P1;)WF&BHFX(9XWD)>)_MPWEB95ICRU:&!_R+=8[PJ9%SXB_N.K$0_@:?B_&A6C)0W"0UC,N_@2)K(#05
MRJTB]W=8_!U>W)P>[4E5L.\9;=0@8,\5X!F&29$(_!/\^1766Q)8YZ-L\>N2_M(\#PK",&#^.>[P_:3"94_.ACP?BZOL>_01X$3#?S&:;"(RT^CW9"U9V)H#\$
M+K#COJ4ENUOD9RD$F0%,QO?X2K4>Q&/OVTX0065*$P>6(!B$-^&P-X&>#3[<_M%#[M056!N<&1<[R2AV;]T*UWV%]O6Y"-E3Q;?F&E6UVK*YAX(9NJ%L),1S@E
M$^/%0KP24TQ?B9E8@9Y<[B].*PP6W)EPI;U*NX-_).C(9#6YJU.LPP^V8'_MZ)?'XQU_/0'B*Y#1R"'P_AA8_F)@L15U6;&XOR*74ZE;0M0D*$M=@Y9"&.NV_,"@OGTD=U_IA9\Z
M(WHG/C$%+HP*[U@?RL"Q8W*>!*UJ=IRA1.$/:U^\540&:<%+O('AIE"AK>!+_M[ZG))=.+,*5Q;P#Z-D.]8BTW+1+=[M)D#LW_(3^#__#%72D#1>.AS%6+[[6T
M>C[J)E<%UA1>N++958X3@I')'<9@IT^'^:4)&([P0P4-_6QK=CC)B0%T0+T_Y_MB6*I82]D"R;*FR,0;)R'1TB7X5*@<8@&E^&]LTAY:F/';(,ZL@C*9F^BS-
MB&8])R.0UPPL$".M,&S<"F5!8XD7+[ETL*;V#VA!_SH!=V1R>S&RW&/6,]+%,-)(:3T!0]A76^TET>S^Y_MIQ!+!52;=DQ_D8CMTQ!OUF_=QV?#
<2IYO,N?'@P;*G/SI\LRN%P<$;=^GH?-_MP)"R#*\7>FDNUYUZ'F(DQ0ES\!YZ@-U_(A0*/N[=^U#[T#EC_M#4<0$/-FM[]_9_;(%<(_\+\V:Q_#A0]6R8_M/6N41@CGJNL*32BU\1S@
AO5H;"8[Q;'4!D)'M*8@GXPE]<]=SD'GA9Y'$@;_M\X6@0\V-&@1]X#-)_G/6EC'1@?[FV^#2X5AW)XW7;RV!7;753Y2*8X).2(S'_MG8MB/2XW:
<.Q>]5__E(_;6IV+BTV,6*+UX/ZU,!3$("D3.1V#Q6^IV+[6+K+7B&DX$.$GA[4H_CW1^KUD_)\Q9$X^TS?*Z_MD3?M24%GKYZW[X=*18'5.EF&'4&15[^A^1T\
(;01K9R:$\6!;&DO[[(?:_M)9@P7)('+GPR_],V_H4YJ]H,A+FG$B)9(?@VR1"_G<@PBGY/2R%+?_CD<+^_M^EH0#:_;'W/Y2H;_[P]?0GVZXAV
M_G;GF#8#@#GQD_=FAHL_0MWDWD#DUF&,V\90G%T!6Z\)??O>.0H\9Q'[-0]_MO//!_%G?X/\17EPQ1V7O/75A$@/#IQ:G*04(:XBD;"F#Y_^%9U(VK=-"$F5_M;A/.2NNL)+XR@Z&@
MS/:8QL)<2MM(NR7SO,?E9"DC_0]E/(UYE[^$I)&J^S&S8I;=4&ADR>ATS(0?,J8HE2^82;\F,MD_M2_E,)?L[GD"0O)5"-2-5T[FEW]?BF98%D_4"J1M_MK%=3EC+Y?
#F3K\;H]0I.^@ZU4I&J]30E]<]%RE?S>2RVZ*X)_'S]^<'SZQ_MBB_U!PJXD=^X?VQ\Z+\O.*7I1%[,VTIB5C=(_#.D/H*1DNA4\E'X:_MZVOZ#G*EC)1=U&QY\O_6,IE2L5%]?
^EK;9EQ$JANK\HUZY_U$Q)A-E:C6$W_MF3Y_7.LSK:AV*(&EO6L@Y4+E^6F%6KT,I%K.&U-63S;8/);?_X5\YG_MJN69OCAZU4*B;>LID"UF,]72S)OMW5(@E\MGLK/=I1VD!
[L%Z\$Z5':07ILYY%B-6MNSNW*2J4V6I#&I^I5_M7E-%[Y1*7D'EE1!=JFW&"NIG%<'_M+'XK^R^A"W.-*Q5Q$IH=(#_T-5R=$'_MR^Z#+'(RI?
N$F0D)]5M8TZDBT!>;'Z+,4C<+"NSZ'ZNZA_/_TZ6CP-D6_78Q_ME(<^C.DC#K3D!Z4KBYM!*RQ9+=O&Z;UA."0%D>')&A(_M-C./YIGJH+LN#H*+&@__1*R:/D(J$!X.3=^;/1\T>>;
P).95=3&;*:IQO'_MKLJ0K&BLI%*LM-92P4PJE]B**L164)^:O*3#_--SV;66O5AYU=YO5Z>Z\IK4_M]88UN;@HE1++U*;EX16HOMZS4[C@E3,_M5.*>]]?
*I\F5,M7BG+/9=#98$SL<[;7)0E+"%\:ZXD^8ZYFB1&#]R5>9[;6C)\Q]FPVX;TVF_V=C_MOLTL223L<3$\;K#UE,_M&;O%.)>^G\]@2K0PCQ+M>3;0W3(RU2%KY.#
[Y;AOAZV$IQCTKXZOU'FC_G+(_M,!!:98\AZO+:MI%I8%\((730.:)BQ_$9AB?F6'4!_^4HK_,2?C&;7P>]$&##_M#AC$]HCMQ5=Z:FVMS9T.0K12/,X?/#@:KTQ&9'A?

<@E*AX@X%#2TYQK(;/9:*\ M2'\>8T(D>!Z%%9_'.FM'#!OA'L=([(06 V]B/6>,7@\:"K7'@MO%S)6#U%+ 6H@$- [@F^ 20J^7 C< M]'1"9,LR.BI]Y,5R*+QHC6$5RHMX9L@Z0D0;?
5!1X*GT1XH)*!-FH%!G*L%2 M0;8AKC8.[$%ENYV68L>M\.8Q9:?SK)<\?\K+0GZ' Y14,1#0:J/G0OA7*4_G M8AY)'@EW1^_@7(G>Z)ZL".A1W!X4J\9#7C";LTX W;Q_/W
M".M#Z'P'VV6N[@JB$&:P;Z<<.O1JF+(N '3L,+_Y4_4*8TS+3BOOLM->-3NM MO,M.>U,'*PF!O*D^B^=,+H9!R 4W?V,'0CX9A#RQ]06;?Q2%?&J7C!T'^9HS M/-X@
KE_.AGV2'3CY.U_[#IQ\0C3^S19MW/#Q6SWU!?Y*N.12IE*N9++5%#A6&\ X+%0K MF:(4N[0V/Y=\N9HIEE/ :6V$NW/%_3FG\MHYF#MT9_2W1R%"M2 MIO1;
@17,1]U%1B[BZ]^"5E3W%\4T7KC=^L.G7SB^?+V4Q.FHFH\PX77RCG,I6X!O56I[J4>'7Q\U;0R7.94K8(>QVCURMH[KF,
M),&IBY#TM33W_"8U]QTZ^6XR;\^7LGYT\HU@DL=UK5?S%F1* MA>W!)8?92%N UOZQ6MU/[UC:9OOE7<*22_E2IA3OM/*[%%]+%3!8XO@"O\OR
M/X*Q6HRWE'D+N.2Y0KS;P3:$T[975]A-YDU,9H=+OO!;?+.X4*IFLI7?%Y5; MRE2SY4Q1>E5<[M>D0+$H98JEF7K-VA$ZEK$GJO'>R*^-KK$#(%X*@'AJB41!
MF(J".KV\8@>P^V87[&+4QG C$G=<2(D:40BA1F FPP34B.I4U AIO^A]'T.- M$"(0!N(FT'AG4,6MYJI5&(6TQ?>'QONMZ]M!\FX-0NUO4:NU@^2-K/D54&VE
M3"Z7S13CW4#?!BBOE)&*A4PUGC#Q.\/R%DM2IA0GR:L%=:1,.0[ZO$U1N=> MY96D3"&_-6FZY4PA;NIO_."\2VS>2@'$:PPV_'>)CY0*F7QUT3##-N6%_T;8 MO!,K*WXK=-Z)-1W;
[$'<1FS3*#ZML8"F+$S%W?7].'/A[B9A[7I@EAPWC./R MAIHVO2(N;V!1PGO#Y=T,-[Z7,5)@GU5VV&5'?;9VSI2.Q#N:2#< MEOJ\. 1WN/-G<3^;&$O}[6=GQ%*F(7 GQ5)V -SI
+BGQU6W!'Y[$V(@#;SV M[PE0)'"JX($CMO#0QDC@'H'9I*J#VC%#]=%!M(7S65PFJ/0.&$:ZPM:=A:XN_QTF*Y+U/P=6&BRY?QO,AI)?0,V'U*IEY8;7%(*RVL#"L
M]O(72P!46Y@.JNV=K'>,K@T,>Z;^TVX%N%!B.F4QUBQ^.E/NB_#R@=S%QO"@/#E#AUT@7= *.ZHM MQL>0JL5 2WK9#M^#F=CA3/_>O-
^\!MXK'@&'#]MP*2>O7>&N8#P0!P/L#+ M+XK2[^/KXWG"!0(55@*V<$/[1D3;%<%' %2 8$ ^L.S@.^@+1, MH#E]ZY?4;R$/OI[<5AYES8$M@8\44MN9L@S2$3D/.) Z[<'9QMQ?
&\8E?NQR MNYI.O-P'B[L/[\C /T%"F;(**H'EM"U;UM$LILB.+O?9+:]J@L&\#JJ0J+7P0I4RW*4KL]'WB45G!Q*+Z"PI:++ 6>'?Q#N.!/'3\S]TK&%X'19L/G M*Y@V?
Q&GB@XSWH/Y\N"#EPZ*W/N(O(FS9XX-X&I(X0>DJ#;!PT+#:0),N\#0M ME3,RO%C@;_J?_UO)2>5_K !CDPR678T-;S X3R#9@4J@LSUZ#57(F^.1$9[# MOY%6Y'5A_[:2R;HO?
@9=$Q3-#-A3(E(0)1>RC\)FK2NH W09X\!/W4N&4T4S MJ#Y!!9&7Y/3"\S]0-26<3>N2#Z[H ;),ASHUXL[P M@7PJV@/@^?Y ',&^J.23$Y#33Q)[< 4EI901@3LWINFJ!W!D@
MV8;\G2"(X<@2M8GZB5$X>DC&>46.K-JE2!33>,G'QCQL0%L%9 ,,Z9) (>F MT@>BRZ.):-]#)D1H4$Z5+OR0'0!81T.VNO(O=O#X6D(^ Y.)[.
(3D/SE$$^48&_DPUV1/=@:PV(3P@15/'6:VIQ[*_DDP-H-N4C.%?7$: MM80XM68%)"90*Q1U/B1/&.&T!"L"#?T:';I.R_2Z2GV MI! 9Y@/[ZE#&F>IV?!=8.1N0Q7/OXHD121*?DRM^T)-
I@'";4]I9Q5L]?ONHMWS]MTWNYB;'*R4UZ>[+[M157?_+7%B'7LF0V_):_X5M/K\\IZR,(VG>?F.F"77K2!0MSU0]$G8SA4;9+Z M;Q5BH$;>W(A[VPYM/-Z;)GJE.M0_S!)<)T:
,D:$,AV?,J[WRP!5H*M.';A. M^=4.[ZCIND/ANY%AVNB/.#;,(2QN[ZMWR9,GDC%1T"4N,)=X3]6"J0S-^B&^ MY9R2J'-2(0%]@2] [ZMP56OB;G2:T5(-B:P+GH]\4#62 5I#A30)FH!K]"[
MDE6WP%P&<*O-'_,_Y=0#S92MWJ+5>R)+"'K'F&>8?H;N7!,U*]DR=+ *QZ K M/:#2".H@>Z^G1,&CW'WDG0^EUU,ZQ,64U.9Y1^[VLA\#7O \;\ M_SP%,9/<8C7CAZPRGN.,?@,?
P;0LRC6,.6E?C]LWQ/-7"KH9X$KV\OZ:-D@D MV>R^+X9O*HK8,&P0V^EDJ3^EHJKDJ49'A%!.>]8ELHZ!IML2_Q43,%RM^3- M"U^F(YC,%Q[DNCI,
27#FI4,+M@5WV5)P!B%1*\CF?Y)@2J*8([0)N61RJCY M>[W?W!=YCBY(5 PDC?!E@0Q='IC7,!35&KBO8^4]/.8\T9"(")I8K0)))_H M4%2(P@**NRW(R)8S'/DZR[W3[0*35+8,Z8]
M^9T1XFTI*"B*CA(6.G>GP;PE@9G 4@/=M?'7]JJXR=DLSN7&:6B:3XH;H\,U MM@.7ER(X0"NF1'54L^,\=AU^%2\./3,Z=0(KV*N$+MW-NV:8V.&'GJ&QB :,?8IN$H#XG31E(*[D F2
M*;PA1'R3A]?;BJ(G:>A>F-&52X$SYF\U=R2M4"]GHBG5A<(>]6X58:T:.O/4 M9P.>>I.AJ&1CKOOL]&6W3Q6.8_Y/3VS W6YI"Y0]YJ!NEQV%ZA[#\[._R#N
ME:AV__OA5^XNFZWBV<.//IVVZN=@=% ZE/2/^.VZUFB=MFJMTYNZ6&L7U5;XJU@XOKEGA>N_I.;XE7I\VO&ZA\>#7G"RA8O@I"6BBE
MTXQ,XQ&K_RG_2T<\0EJ%JB:>@P\+USO22)_8RF6@.\LT:@MX "@S3 M@EARDY>BEH,]^2A;E%>MLPO]R@%1)N7:>SDW4E1_YHZ(6L?^X\W;8).8.,3! M4M;C8"S"028N>$Q\>-
%H75V<-8F!+Z\N#NM'R+/ORF$ 0]4]'1T9X8@I?:CR M'K(L+*9M7B+]0Q==2.]J_6C/PD]EYO7+^&HIA5PI]*W,P6J5U*'DVI2Q8]^ M$KGB?6FP+_]@P0'ZY,%G*B?
\TK>CW5]F/+N,Y9XRTP/>3;F:W ;N^AO7"6[< MR-LX,2X +%'*RWM2\/R!SH&I6*7_\,W$H-2@?P\7%J 6B[P/WGXNV,*D%Q
M]8U5]H(QPRR&]^UE/*!X.959P=I]PY>E609YS$L*%?";63PUA6LH#1S?17R! M!FYP=\24NR.PW/51;3! M/\&DQGR/%_A;P+E[/@66!<_RA%6O(,]">)V.VE/]/'RP9[VD<)..&&71&I1T
MRMP',%'+H1K18)^(>=2.I+"RXM!**%?X7YVBBQO='AI1^Q/*^9MP<_X(:C=9F2*^ L M8UY9/+\L5B#?P;N#=P"L=>)HO7-KY
MPE_5%R]M?.%OR%7D;778<2@%'8>7M:N6>'KJ>0XO6I_K5^)IX_CBZKS6.KUH MK#3=XQ7BT<;(!!^F&G?4\NP_L!LMIWU/^AT') MA%Z(G1#D!/(C*%U6L.P;9L8M&'G0C2=-
Z?,!LD8[/_9+T?\EUDLK\"4Y5_JR MJENVZ%C[XC'ERZ+G 6&!5&P2_*10[@!6J//J9Q^_3XB^UR)_14-P^<<6DA' M]P,:/HYI*:XCT2T"#Q9^\V0%/[$C]OI 'L0(S#BUXSI-A$
:Q).7C\EJ^3WP M $0)#KR+"]MY:F4TD9(*K2>D4J+YEY@7^6X=$^%CFH\?TYIW3BFZ=EP[;%U< MO:\81IK<%\[PIFH]"&ZF%/#IHVHX%OJW5I>"SF'OTF1-3L]O>1_@D3$>+<1X
M-.>QZ'7CJGYRVFS5K^I'8K-V5F^*%\=B_=0U:>N' #2\OCIMG=990.ZZ6<B;].7FUI,$\]Y8FSG_82!H_IQ[?]LU12O*N%:<%P:IQ=7HK_C M[$@I8.-
[O::$Y_!>EZ;$U<]/&W4XW!^.L8G305U#$(AXO$WGV3/W>>[:K9ZIRB=[MX> MG'^,Q$O9=E&JF6:M:V "_+$F]^^Z[>.[#KXT6\A*=W?T5RF?O7LYSIF_OG0Z
MWTI]^8/8T63+8F\=#73[[NI$>_F1>W[LY&_&/YLU^[2N.9V<]O#S^VG_YO.7 MP<\3S?DY/CCHZ%\&[6%?:]_>.-W/Y[7@KK(I'O$ISCV_BUR]J>F57N&^M]+Y MJ<]_ZX;>
<(:P:QV*U\!&72F]_WY \PC'W\O'_TGLKI)>/OM!9"'6_WY0G^V_MVX:A*:+>DS5+^4 +/09=.)O-EJKY#Z(,NMA_/\"*_YZ\)^N=1"$XB8DSD-D_M_O-7:":?
XO]F)Y+]!TVCZ/Z6$_:W90YU>\;V-O1;X_M%I]2RULI^Q\DG),T, M!]?WV9,9CE+"@R @JCB!V:C"O2: LR4*V\E'^ YT 5TH?_?SX]. 7;^EWY M2+#QZT8._"5S5Y XZWC2&^;4I
M)_!U$U7YP+[$"DJHJ 2;>W(A 351D'W@345GM9YL1T5CHECSQIPDEXB/ TO9 MZ\E#51O_/6LQ<0'; L0Y76QMQNZGR)56]$47W]A M#>-OM%>V(=:'(\U@Z(G>'H;WJQ([=3*.=
[P/:K-I8<;\.]BPO+0BT9F7UB Z MD3XIK(K@A5EL!SCY,UX=Q*574!6KA<@PS'N9;7J3]S#,9[U*R*9LMF5=I.?8N MGC60J%@P0NT)L[EU;B"0'67=O9";06^?
S@EU)5M)YQ4>E!P^CGG#E>SI?>RPR# %MC?E0T?-G(3.ZQX;42B'4EB!32!+)9O7A9+0BB+ M [9D_^A=0]FV67*,JFLJ///]X.K,K4"#V7Y4_\!]* ["=!@$80I!#<)2/ZJ3
MGVWZRP(NN0C VL&OTOXL4*G5M$&-&A@:F'D6IXM8IV8C^,;'M"_TX8#Q.'R$ MWR'E$&?
-2RR:\"+_P/BOW%^7";=*KB^\)M1(1LFLQ)&V0ZM;$PG=UYA>"%TM_[$SGE/1/W/L5OO^8?&_HF,,$N3=P'A:YXU,QXO86>>),Q-RN:NDNI;ILB>C-6.[/!*"F:
MSY4*H#VO;736(0]NR'5+)C%*C*.=]V;'MDH^?[W9]ZAH=ASYA?EZ_"CRP2G]Q M^3" 9>S)V?10GA&XD KP?;+8,I=0M%B8"2LB3>!V'@Y95*W"LK&'^#LG@X8% M,,)V ^\&?
O<#3XM?YW?QZU>-7^=W\>OUGH17*[_SD>=@"LW3DT:MM=8<8F\: MF^OSG1A:O RX6QCF+8&P,+#EM(H<^R%3H'36P;/K:-A2B!HL!2+A7!WC8#\(M4T/*&FAP/0;4H3#5BCW
>T0XNFT(]$+9L0<&H>GL0NJAD'J2S9CZLU69%IQL MR 06&M1_B\YHI)@=&2<,C#XEBK&:.+0K=(O_GFIRD:1XK3KA 4OPR,D!@
M6:O9N"4,_U5&O)P^!M1RC/_7J*MGI*EP6_'UR-54JK^9? MXI?:>:TI?M:NFF<7M\OP_E:<_^?0]&_[3-OS[-!#>< B#&7O Q(9 P-3X4 MB2X$^B3P!Y)==FLREM>.8;T;8#? ;H"W.<
<1G_A'_&"M67X6SR3X:;=6?Z; MM_P+F[3\UY1(GE0BT51L=[7/W>=_Q-,C^N,N6SFX4["-/:%TT@3H9\J7^SD7FK?KJ[_ZE\\'\@'3T/M2_W0U&6KT+^]ZXWAR_?R]Q_6_6U6E6I/SZ/&
M5Z/QIV$WLYJACDN'MX/K^N%YZ_S/OQK'/;7]Y:IW5JM69/77US]]4M^1GKNC MGX=?]V^5^L'!U_OCW/'EY>?OY]\?3XR_3@Z>ZE__ZIU^O_U\\'!^]#6O51^D
MY_I9[\^A4,DQ]>;G4CG[7'JTKGY=EZ324+Y4;UNF5GCZ?#T^/X]_SBX:8ZT M=JW5?SIY^'S5S%7.V_5NU[G,_3HN/!6;9O7X]+)X5?F5S0V'^N/#S:-Y4E'. M;GX7Q05+ZWT:M/Y4C
MO:)E!P^2H164[H-\/JC]V6L=W%AGRO./T^O;F]+QP5.N7;AZ[#:.KEJ7U<_/ MX"M"Z4KY=C9\NG\ZOGVO2W*V^/WGX!NCT]/NG;Y;S*]X^=SK?[TZR1 MK13O"
[W'7]>%OQZ='!?E7V>_VBW+B5__K7RHUP^_ZHTY9X8_SNPAI]G_P]02P$"% ,4 " 3 MA U9!IZ<*" (!1P $0 @ $ >&]I;RTR,#(T,#8S M,"YX&I;RTR,#(T,#8S,%]C86PN>&UL4$L!
A0#% @ $X0-66[$ MR775% 4 ! !4 (!N!$ 'AB:6\M,C R-# V,S!?9&5F M+GAM;%!+ 0(4 Q0 (!.$#5FD>)NOW34 %#Z @ 5 " M < F !X8FEO+3(P,C0P-C,P7VQA8BYX;6Q02P$"% ,4 " 3A
U9=/N0 MTV&I;RTR,#(T,#8S,%]PL&UL4$L! A0# @ $X0-639'901.+@ ?RT! !((! M:H4 'AE;F5T:6-?97@Q,# Q+FAT;%!+ 0(4 Q0 (!.$#5E2U9;2[2T M (M 0 2 ">BS
!X96YE=&EC7V5X,3 P,BYH=&U02P$" M% ,4 " 3A U9\ R#XQ(+ #G.0 $@ @ $%X@ >&5N M971I8U]E>#$,R,#$N:'1M4$L! A0#% @ $X0-63MMU"=Y!@ $ $@ M @ &/^@
>&5N971I8U]E>#,R,#$N:'1M4$L! A0#% @ $X0-61KO MJH];P EF@(!< (!1_\ 'AE;F5T:6-?:3$P<2TP,C R-#$P-2YH=&U02P4& , P#$ \P @ _0 $! end XML 52 xenetic_i10q-
063024_htm.xml IDEA: XBRL DOCUMENT 0001534525 2024-01-01 2024-06-30 0001534525 2024-08-09 0001534525 2024-06-30 0001534525 2023-12-31 0001534525 us-gaap:SeriesBPreferredStockMember 2024-06-30 0001534525 us-gaap:SeriesBPreferredStockMember 2023-12-31 0001534525 2024-04-01 2024-06-30 0001534525 2023-04-01 2023-06-30 0001534525 2023-01-01 2023-06-30 0001534525 us-gaap:PreferredStockMember 2024-03-31 0001534525 us-gaap:CommonStockMember 2024-03-31 0001534525 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001534525 us-gaap:RetainedEarningsMember 2024-03-31 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001534525 us-gaap:TreasuryStockCommonMember 2024-03-31 0001534525 2024-03-31 0001534525 us-gaap:PreferredStockMember 2023-12-31 0001534525 us-gaap:CommonStockMember 2023-12-31 0001534525 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001534525 us-gaap:RetainedEarningsMember 2023-12-31 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001534525 us-gaap:TreasuryStockCommonMember 2023-12-31 0001534525 us-gaap:PreferredStockMember 2023-03-31 0001534525 us-gaap:CommonStockMember 2023-03-31 0001534525 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001534525 us-gaap:RetainedEarningsMember 2023-03-31 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001534525 us-gaap:TreasuryStockCommonMember 2023-03-31 0001534525 2023-03-31 0001534525 us-gaap:PreferredStockMember 2022-12-31 0001534525 us-gaap:CommonStockMember 2022-12-31 0001534525 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001534525 us-gaap:RetainedEarningsMember 2022-12-31 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001534525 us-gaap:TreasuryStockCommonMember 2022-12-31 0001534525 2022-12-31 0001534525 us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001534525 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001534525 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001534525 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0001534525 us-gaap:PreferredStockMember 2024-01-01 2024-06-30 0001534525 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001534525 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-06-30 0001534525 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-06-30 0001534525 us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001534525 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001534525 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001534525 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0001534525 us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001534525 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001534525 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001534525 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-06-30 0001534525 us-gaap:PreferredStockMember 2024-06-30 0001534525 us-gaap:CommonStockMember 2024-06-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001534525 us-gaap:RetainedEarningsMember 2024-06-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001534525 us-gaap:TreasuryStockCommonMember 2024-06-30 0001534525 us-gaap:PreferredStockMember 2023-06-30 0001534525 us-gaap:CommonStockMember 2023-06-30 0001534525 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001534525 us-gaap:RetainedEarningsMember 2023-06-30 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001534525 us-gaap:TreasuryStockCommonMember 2023-06-30 0001534525 2023-06-30 0001534525 2023-05-14 2023-05-15 0001534525 XBIO:CatalentPharmaSolutionsMember 2024-01-01 2024-06-30 0001534525 XBIO:CatalentPharmaSolutionsMember 2024-06-30 0001534525 XBIO:CatalentPharmaSolutionsMember 2023-12-31 0001534525 XBIO:ScrippsResearchMember 2023-03-16 2024-06-30 0001534525 XBIO:ScrippsResearchMember 2024-06-30 0001534525 XBIO:ScrippsResearchMember 2023-12-31 0001534525 XBIO:UniversityOfVirginiaMember 2024-01-01 2024-06-30 0001534525 XBIO:UniversityOfVirginiaMember 2023-01-01 2023-12-31 0001534525 XBIO:CollaborativeAgreementsMember 2023-01-01 2023-06-30 0001534525 XBIO:CollaborativeAgreementsMember 2023-04-01 2023-06-30 0001534525 XBIO:CollaborativeAgreementsMember 2024-01-01 2024-06-30 0001534525 XBIO:CollaborativeAgreementsMember 2024-04-01 2024-06-30 0001534525 XBIO:SeparationAgreementsMember 2024-01-01 2024-06-30 0001534525 XBIO:SeparationAgreementsMember 2024-06-30 0001534525 us-gaap:CommonStockMember 2023-05-10 2023-05-11 0001534525 XBIO:SeriesAWarrantsMember 2023-12-31 0001534525 XBIO:SeriesAWarrantsMember 2024-06-30 0001534525 XBIO:SeriesAWarrantsMember 2024-04-01 2024-06-30 0001534525 XBIO:SeriesAWarrantsMember 2024-01-01 2024-06-30 0001534525 XBIO:SeriesAWarrantsMember 2023-01-01 2023-06-30 0001534525 XBIO:SeriesAWarrantsMember 2023-04-01 2023-06-30 0001534525 XBIO:PubliclyTradedWarrantsMember 2024-06-30 0001534525 XBIO:PubliclyTradedWarrantsMember 2023-12-31 0001534525 XBIO:PubliclyTradedWarrantsMember 2024-01-01 2024-06-30 0001534525 XBIO:PubliclyTradedWarrantsMember 2024-04-01 2024-06-30 0001534525 XBIO:PubliclyTradedWarrantsMember 2023-04-01 2023-06-30 0001534525 XBIO:PubliclyTradedWarrantsMember 2023-01-01 2023-06-30 0001534525 XBIO:OtherWarrantsMember 2023-12-31 0001534525 XBIO:OtherWarrantsMember 2024-06-30 0001534525 XBIO:OtherWarrantsMember 2024-04-01 2024-06-30 0001534525 XBIO:OtherWarrantsMember 2024-01-01 2024-06-30 0001534525 XBIO:OtherWarrantsMember 2023-01-01 2023-06-30 0001534525 XBIO:OtherWarrantsMember 2023-04-01 2023-06-30 0001534525 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001534525 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001534525 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001534525 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001534525 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001534525 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001534525 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001534525 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001534525 us-gaap:EmployeeStockOptionMember 2024-04-01 2024-06-30 0001534525 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001534525 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001534525 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001534525 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001534525 us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0001534525 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0001534525 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001534525 XBIO:NonEmployeeStockOptionsMember 2023-01-01 2023-06-30 0001534525 XBIO:NonEmployeeStockOptionsMember 2023-04-01 2023-06-30 0001534525 XBIO:NonEmployeeStockOptionsMember 2024-01-01 2024-06-30 0001534525 XBIO:NonEmployeeStockOptionsMember 2024-04-01 2024-06-30 0001534525 XBIO:PharmsynthezMember XBIO:CoDevelopmentAgreementMember 2019-10-01 2019-12-31 0001534525 XBIO:PharmsynthezMember XBIO:CoDevelopmentAgreementMember 2023-04-01 2023-06-30 0001534525 XBIO:InterestIncomeOnlyMember XBIO:PharmsynthezMember XBIO:CoDevelopmentAgreementMember 2023-01-01 2023-06-30 iso4217:USD shares iso4217:USD shares pure false --12-31 2024 Q2 0001534525 7264041237221651005125684910-Qtrue2024-06-30false001-37937XENETIC BIOSCIENCES, INC.NV45-2952962945 Concord StreetFraminghamMA01701781778-

7720Common Stock, $0.001 par value per shareXBIONASDAQYesYesNon-accelerated
Filertruefalsefalse15421397298597898304671638160382880149789586874101835210183529033330106052262835862408321304016568753158760280958515876028095851
195703279-
19323419625373425373452811805281180744572897956419033330106052267264046510051237221125684972640465100512372211256849933771903243187809214985191
1337396-1198188-2605810-2113363-212112231256426344712610313669618020463426147225136727205846-1273970-1050963-2469083-1907517-0.83-0.83-0.69-0.69-1.60-
1.60-1.25-1.251540799154079915247171524717154074115407411520710152071018043941804394180415433851544208131009-194429309253734-
528118086776024174209642096-1273970-12739701804394180415438021544208173105-195703279253734-528118074457281804394180415433851544208053935-
193234196253734-52811809795641417119170119170-2469083-24690831804394180415438021544208173105-195703279253734-
528118074457282774394277415193601520207838756-189956172253734-5281180128594321594116-166938969389-1050963-
10509632774394277415353011536207908129-191007135253734-5281180118778582774394277415193601520207769904-189099618253734-5281180136471341594116-
16138241138241-1907517-19075172774394277415353011536207908129-191007135253734-528118011877858-2469083-1907517119170138241112553762941-0-
362500778017-201841-1684449-2371558-1684449-237155889830461309726572985971072570700<p id="xdx_804_eus-gaap--
OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zIFVCduedQWl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt
0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top">
<td style="width: 33px">1.</td> <td style="text-align: justify">The Company </td></tr> </table> <p
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif;
margin: 0pt 0; text-align: justify"><i>Background</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-align: justify">
<i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Xenetic Biosciences, Inc. (“Xenetic” or the “Company”),
incorporated in the state of Nevada and based in Framingham, Massachusetts, is a biopharmaceutical company focused on advancing innovative immune-oncology
technologies addressing hard to treat cancers. The Company’s proprietary Deoxyribonuclease (“DNase”) platform is designed to improve outcomes of existing treatments,
including immunotherapies, by targeting neutrophil extracellular traps (“NETs”), which have been implicated in cancer progression and resistance to cancer treatments.
Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic
solid tumors. Additionally, Xenetic has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen®,
and receives royalty payments under an exclusive license arrangement in the field of blood coagulation disorders.</p> <p style="font: 10pt Times New Roman, Times, Serif;
margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As used in this Quarterly
Report on Form 10-Q (“Quarterly Report”), unless otherwise indicated, all references herein to “Xenetic,” the “Company,” “we” or “us” refer to Xenetic Biosciences, Inc. and
its wholly-owned subsidiaries.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times
New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, directly or indirectly, through its wholly-owned subsidiaries, Hesperix S.A. (“Hesperix”) and
Xenetic Biosciences (U.K.) Limited (“Xenetic UK”), and the wholly-owned subsidiaries of Xenetic UK, Lipoxen Technologies Limited (“Lipoxen”), Xenetic Bioscience,
Incorporated and SymbioTec, GmbH (“SymbioTec”), own various United States (“U.S.”) federal trademark registrations and applications along with unregistered trademarks
and service marks, including but not limited to XCART™, OncoHist™, PolyXen, ErepoXen™, and ImuXen™, which may be used throughout this Quarterly Report. All other
company and product names may be trademarks of the respective companies with which they are associated.</p> <p style="font: 10pt Times New Roman, Times, Serif;
margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<i>Going Concern and Management’s Plan</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-align: justify"><i> </i>
</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management evaluates whether there are conditions or events, considered
in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are
issued. The Company has incurred substantial losses since its inception and expects to continue to incur operating losses in the near-term. The Company believes that its
existing resources will be adequate to fund the Company’s operations for a period of at least twelve months from the date of the issuance of these financial statements.
However, the Company anticipates it will need additional capital in the long-term to pursue its business initiatives. While the Company believes it has access to capital
resources through possible public or private equity offerings, debt financings, corporate collaborations, related party funding, or other means to continue as a going concern,
the terms, timing and extent of any future financing will depend upon several factors, including the achievement of progress in its product development programs, its ability
to identify and enter into licensing or other strategic arrangements, its continued listing on the Nasdaq Stock Market (“Nasdaq”), and factors related to financial, economic,
geo-political, industry and market conditions, many of which are beyond its control. The capital markets for the biotech industry can be highly volatile, which make the terms,
timing and extent of any future financing uncertain.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">
</p> <p id="xdx_808_eus-gaap--ConcentrationRiskDisclosureTextBlock_zggpJrp1Xt62" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;
background-color: white"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr
style="vertical-align: top"> <td style="width: 33px; text-align: justify">2.</td>
<td style="text-align: justify">Risks and
Uncertainties </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Impact of Global Conflicts on Operations</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif;
margin: 0pt 0; text-align: justify; background-color: white">The short and long-term implications of Russia’s invasion of Ukraine and conflict in the Middle East are difficult
to predict at this time. The imposition of current and future sanctions and counter sanctions may have an adverse effect on the economic markets generally and could impact
our business, financial condition, and results of operations.</p> <p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zMY52oTw28Rh" style="font: 10pt Times
New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse:
collapse"> <tr style="vertical-align: top"> <td style="width: 33px">3.</td> <td
style="text-align: justify">Summary of Significant
Accounting Policies </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-align: justify">
<i> </i></p> <p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z1s0qpPQsPVf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-
align: justify"><i>Preparation of Interim Financial Statements </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-align:
justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying condensed consolidated interim
financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of
management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. Certain information and footnote disclosures
normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such SEC
rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are
not necessarily indicative of results for the full year. The condensed consolidated financial statements contained herein should be read in conjunction with the consolidated
financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 21, 2024,
and amended on April 26, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman,
Times, Serif; margin: 0pt 0; text-align: justify">On May 15, 2023, the Company effected a reduction, on a <span id="xdx_903_eus-gaap--
StockholdersEquityReverseStockSplit_c20230514__20230515_zzisP6QMuRyl">1-for-10 basis, in its authorized common stock, par value $0.001, along with a
corresponding and proportional decrease in the number of shares issued and outstanding (the “Reverse Stock Split”). On the effective date of the Reverse Stock Split, (i) every
10 shares of common stock were reduced to one share of common stock, with any fractional amounts rounded up to one share; (ii) the number of shares of common stock into
which each outstanding warrant, restricted stock unit (“RSU”), or option to purchase common stock was convertible into was proportionately reduced on the same basis as the
common stock; (iii) the exercise price of each outstanding warrant or option to purchase common stock was proportionately increased on a 1-to-10 basis; and (iv) the number
of shares of common stock into which each share of preferred stock was convertible into was proportionately reduced on the same basis as the common stock. Unless
otherwise indicated, all of the share numbers, share prices, and exercise prices have been adjusted in this Quarterly Report, on a retroactive basis, to reflect this 1-for-10
Reverse Stock Split.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><i> </i></p> <p
id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zYTnjkNCaXx4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Principles
of Consolidation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><i> </i></p> <p
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The condensed consolidated financial statements of the Company include the accounts of
Hesperix, Xenetic UK and Xenetic UK’s wholly owned subsidiaries: Lipoxen, Xenetic Bioscience, Incorporated, and SymbioTec. Certain of the Company’s subsidiaries require
guarantees of support from Xenetic. While all intercompany balances and transactions have been eliminated in consolidation, the Company has $0.2 million of cash
collateralizing these guarantees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_843_eus-
gaap--EarningsPerSharePolicyTextBlock_zC5L85BTzSxf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Basic and Diluted Net
Loss per Share</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the
weighted-average number of shares of the Company’s common stock outstanding during the period. The Company computes diluted net loss per share after giving
consideration to the dilutive effect of stock options that are outstanding during the period, except where such non-participating securities would be anti-dilutive.</p> <p
style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> </p><p style="font: 10pt Times New Roman, Times,
Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">For the three and six months ended June 30, 2024 and 2023, basic and diluted net loss per
share are the same in each respective period due to the Company’s net loss position. Potentially dilutive, non-participating securities have not been included in the
calculations of diluted net loss per share, as their inclusion would be anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0;
margin-bottom: 0pt; text-align: left"></p> <p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z1s0qpPQsPVf" style="font: 10pt Times New Roman, Times,
Serif; margin: 0pt 0; text-align: justify"><i>Preparation of Interim Financial Statements </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt
0 0pt 24.45pt; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying
condensed consolidated interim financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”)
and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. Certain information and
footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted
pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for
the interim periods are not necessarily indicative of results for the full year. The condensed consolidated financial statements contained herein should be read in conjunction
with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC
on March 21, 2024, and amended on April 26, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt
Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 15, 2023, the Company effected a reduction, on a <span id="xdx_903_eus-gaap--
StockholdersEquityReverseStockSplit_c20230514__20230515_zzisP6QMuRyl">1-for-10 basis, in its authorized common stock, par value $0.001, along with a
corresponding and proportional decrease in the number of shares issued and outstanding (the “Reverse Stock Split”). On the effective date of the Reverse Stock Split, (i) every
10 shares of common stock were reduced to one share of common stock, with any fractional amounts rounded up to one share; (ii) the number of shares of common stock into
which each outstanding warrant, restricted stock unit (“RSU”), or option to purchase common stock was convertible into was proportionately reduced on the same basis as the
common stock; (iii) the exercise price of each outstanding warrant or option to purchase common stock was proportionately increased on a 1-to-10 basis; and (iv) the number
of shares of common stock into which each share of preferred stock was convertible into was proportionately reduced on the same basis as the common stock. Unless
otherwise indicated, all of the share numbers, share prices, and exercise prices have been adjusted in this Quarterly Report, on a retroactive basis, to reflect this 1-for-10
Reverse Stock Split.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><i> </i></p> 1-for-10 basis<p
id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zYTnjkNCaXx4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Principles
of Consolidation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><i> </i></p> <p

style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The condensed consolidated financial statements of the Company include the accounts of Hesperix, Xenetic UK and Xenetic UK's wholly owned subsidiaries: Lipoxen, Xenetic Bioscience, Incorporated, and SymbioTec. Certain of the Company's subsidiaries require guarantees of support from Xenetic. While all intercompany balances and transactions have been eliminated in consolidation, the Company has $0.2 million of cash collateralizing these guarantees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zC5L85BTzSxf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Basic and Diluted Net Loss per Share</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted-average number of shares of the Company's common stock outstanding during the period. The Company computes diluted net loss per share after giving consideration to the dilutive effect of stock options that are outstanding during the period, except where such non-participating securities would be anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">For the three and six months ended June 30, 2024 and 2023, basic and diluted net loss per share are the same in each respective period due to the Company's net loss position. Potentially dilutive, non-participating securities have not been included in the calculations of diluted net loss per share, as their inclusion would be anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p> <p id="xdx_809_eus-gaap--CollaborativeArrangementDisclosureTextBlock_zevl4l370d1j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px">4.</td> <td style="text-align: justify">Significant Strategic Collaborations</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Takeda Pharmaceutical Co. Ltd. (together with its wholly-owned subsidiaries, "Takeda")</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2017, the Company granted to Takeda the right to grant a non-exclusive sublicense to certain patents related to the Company's PolyXen technology that were previously exclusively licensed to Takeda in connection with products related to the treatment of blood and bleeding disorders. Royalty payments of approximately $0.7 million and $1.2 million were recorded as revenue by the Company during the three and six months ended June 30, 2024, respectively, and approximately $0.7 million and $1.3 million were recorded as revenue by the Company during the three and six months ended June 30, 2023, respectively. These payments are based on single digit royalties on net sales of certain covered products. The Company's policy is to recognize royalty payments as revenue when they are reliably measurable, which is upon receipt of reports from Takeda. The Company receives these reports in the quarter subsequent to the actual sublicensee sales. At the time the revenue was received, there were no remaining performance obligations and all other revenue recognition criteria were met.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Belgian Volition SARL Limited ("Volition") Collaboration</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 2, 2022, the Company announced a research and development collaboration with Volition to develop NETs-targeted adoptive cell therapies for the treatment of cancer. The collaboration is an early exploratory program to evaluate the potential combination of Volition's Nu.Q® technology Test and the Company's DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting multiple types of solid cancers. Under the terms of the collaboration agreement, Volition will fund a research program and the two parties will share proceeds from commercialization or licensing of any products arising from the collaboration. To date, Volition has funded $26,000 under this agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Catalent Pharma Solutions LLC ("Catalent")</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30, 2022, the Company entered into a Statement of Work (the "SOW") with Catalent to outline the general scope of work, timeline, and pricing pursuant to which Catalent will provide certain services to the Company to perform cGMP manufacturing of the Company's recombinant protein, Human DNase I. The parties agreed to enter into a Master Services Agreement that will contain terms and conditions to govern the project contemplated by the SOW and that will supersede the addendum to the SOW containing Catalent's standard terms and conditions. The Company has paid Catalent approximately $2.5 million through June 30, 2024, of which approximately $28,000 and $0.1 million has been recognized as an advance payment and is included in prepaid expenses, receivables and other current assets as of June 30, 2024 and December 31, 2023, respectively, and approximately $49,000 has been recognized as a liability and is included in accrued expenses and other current liabilities as of June 30, 2024. There was no accrual as of December 31, 2023. In addition, approximately $0.3 million has been recognized within other assets as of both June 30, 2024 and December 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Scripps Research Institute ("Scripps Research")</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 17, 2023, the Company and Scripps Research entered into a Research Funding and Option Agreement (the "Agreement"), pursuant to which the Company has agreed to provide Scripps Research an aggregate of up to $0.9 million to fund research relating to advancing the pre-clinical development of the Company's DNase oncology platform technology. Under the Agreement, the Company has the option to acquire a worldwide exclusive license to Scripps Research's rights in the Technology or Patent Rights (as defined in the Agreement), as well as a non-exclusive, royalty-free, non-transferrable license to make and use TSRI Technology (as defined in the Agreement) solely for the Company's internal research purposes during the performance of the research program contemplated by the Agreement. During the second quarter of 2024, the Company amended the Agreement to extend the term to October 31, 2024 with no additional funding required. The Company has paid Scripps Research approximately $0.9 million under the Agreement through June 30, 2024, of which approximately $0.1 million and $0.4 million has been recognized as an advance payment and is included in prepaid expenses, receivables and other current assets as of June 30, 2024 and December 31, 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>University of Virginia ("UVA")</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 21, 2023, the Company entered into a Research Funding and Material Transfer Agreement with UVA (the "UVA Agreement") to advance the development of our systemic DNase program. Under the terms of the UVA Agreement, in addition to advancing our existing intellectual property, we have an option to acquire an exclusive license to any new intellectual property arising from the DNase research program. Allan Tsung, MD, a member of the Company's Scientific Advisory Board and Chair of the Department of Surgery at the UVA School of Medicine, will oversee the research conducted under the UVA Agreement. The Company has paid UVA approximately $0.2 million under the UVA Agreement through June 30, 2024, which was expensed during the six months ended June 30, 2024. There were no amounts incurred as of December 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other Agreements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has also entered into various research, development, license and supply agreements with Serum Institute of India ("Serum Institute"), PJSC Pharmsynthez ("Pharmsynthez") and SynBio LLC ("SynBio"), a wholly owned subsidiary of Pharmsynthez. The Company and its collaborative partners continue to engage in research and development activities with no resultant commercial products through June 30, 2024. No amounts were recognized as revenue related to the Serum Institute, Pharmsynthez or SynBio agreements during the three and six months ended June 30, 2024 and 2023, respectively.</p> 25000002800010000049000030000030000090000010000040000020000000000<p id="xdx_809_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zCCIxNZij577" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px">5.</td> <td style="text-align: justify">Accrued Expenses and Other Current Liabilities</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 19, 2024, the Company entered into a confidential separation agreement and general release with each of Jeffrey F. Eisenberg, the Company's former Chief Executive Officer (the "Eisenberg Separation Agreement"), and Curtis Lockshin, the Company's former Chief Scientific Officer (the "Lockshin Separation Agreement" and together, the "Separation Agreements") pursuant to which Messrs. Eisenberg and Lockshin were each eligible for certain severance payments and benefits consistent with the terms of their existing employment agreements as described under "Employment Agreements with our Named Executive Officers" in the Amendment No. 1 to Annual Report on Form 10-K/A filed by the Company with the Securities and Exchange Commission on April 26, 2024. In addition, the Eisenberg Separation Agreement provides for accelerated vesting of all of the unvested stock options held by Mr. Eisenberg as of May 16, 2024. As of June 30, 2024, the Company expensed approximately $0.8 million of accrued payroll and benefits related to the Separation Agreements. In addition, the Company recorded approximately $13,000 of share-based expense for the accelerated vesting of unvested stock options. As of June 30, 2024, approximately $0.8 million was accrued within accrued expenses and other current liabilities related to these obligations.</p> 80000013000800000<p id="xdx_807_eus-gaap--FairValueDisclosuresTextBlock_zAG1E1pBxKnf" style="font: 10pt Times

New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px">6. </td> <td style="text-align: justify">Fair Value Measurements </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting Standards Codification Topic 820, <i>Fair Value Measurement,</i> defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. As of June 30, 2024 and December 31, 2023, the carrying amounts of the Company’s financial instruments approximates fair value due to their short maturities. There were no financial instruments classified as Level 3 in the fair value hierarchy during the three and six months ended June 30, 2024 and 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z3OpyczBMEY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px">7.</td> <td style="text-align: justify">Stockholders’ Equity </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Common Stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Each share of the Company’s common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to dividends when and if declared by the Board of Directors. In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Company, the holders of common stock are entitled to share ratably in the assets of the Company available for distribution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 11, 2023, the Company filed a Certificate of Change to the Company’s Articles of Incorporation with the Secretary of State of Nevada to effect the Reverse Stock Split. The Reverse Stock Split was effective at 12:01 a.m., Eastern Time, on May 15, 2023. No fractional shares were issued as a result of the Reverse Stock Split and any remaining share fractions were rounded up to the nearest whole share, resulting in 15,941 new shares of common stock being issued to existing holders of the Company’s common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has warrants to purchase approximately 462,963 shares of the Company’s common stock (the “Series A Warrants”) outstanding as of both June 30, 2024 and December 31, 2023. The Series A Warrants are immediately exercisable at a price of $33.00 per share of common stock and expire on February 23, 2025. No Series A Warrants were exercised or forfeited during the three and six months ended June 30, 2024 and 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company had publicly traded warrants to purchase approximately 2,100 shares of common stock outstanding as of both June 30, 2024 and December 31, 2023. These warrants had an exercise price of $130.00 per share of common stock and expired on July 19, 2024. The warrants ceased trading on Nasdaq under the symbol “XBIOW” upon expiration. The warrants also provided that if the weighted-average price of common stock on any trading day on or after 30 days after issuance is lower than the then-applicable exercise price per share, each warrant may be exercised, at the option of the holder, on a cashless basis for one share of common stock. None of these warrants were exercised or forfeited during the three and six months ended June 30, 2024 and 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also has warrants to purchase approximately 800 shares of the Company’s common stock outstanding as of both June 30, 2024 and December 31, 2023. These warrants have an exercise price of $29.09 per share of common stock and expire on July 3, 2026. None of these warrants were exercised or forfeited during the three and six months ended June 30, 2024 and 2023.</p> 1594146296346296333.002025-02-2300000000021002100130.002024-07-190000000080080029.092026-07-0300000000<p id="xdx_801_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zkuzQi1VjqGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px">8. </td> <td style="text-align: justify">Share-Based

Expense </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"> </p> <p
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total share-based expense related to stock options and RSU’s was approximately $42,000
and $0.1 million for the three months ended June 30, 2024 and 2023, respectively, and approximately $0.1 million and $0.1 million for each of the six months ended June 30,
2024 and 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"> </p> <p style="font: 10pt Times New Roman,
Times, Serif; margin: 0pt 0">Share-based expense is classified in the condensed consolidated statements of operations as follows: </p> <table cellpadding="0"
cellspacing="0" id="xdx_884_eus-gaap--
ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zJwB8T5DFj5k" style="font: 10pt Times
New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share-Based Expense (Details - Share based expense)"> <tr style="vertical-
align: bottom; background-color: White"> <td style="text-align: left; width: 32%"><b style="display: none">Schedule of share-based
compensation expense</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 13%"> </td><td
style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 13%"> </td><td
style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 13%"> </td><td
style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 13%"> </td><td
style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6"
style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td
style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended June
30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom:
1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight:
bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align:
center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-
bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-
bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight:
bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 32%; text-align: left">Research and development expenses</td>
<td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensation_d0_c20240401__20240630__us-gaap--
IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zAkEcRjeXwyj" style="width: 13%; text-align: right" title="Share-based compensation">
(3,804</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--
ShareBasedCompensation_d0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zl4DS2ppNIdi"
style="width: 13%; text-align: right" title="Share-based compensation">13,778</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td
style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensation_d0_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--
ResearchAndDevelopmentExpenseMember_zaAYyVGj4dg3" style="width: 13%; text-align: right" title="Share-based compensation">11,433</td><td style="width: 1%; text-
align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--
ShareBasedCompensation_d0_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zduNM3gZWKr5"
style="width: 13%; text-align: right" title="Share-based compensation">27,466</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom;
background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative expenses</td><td style="padding-bottom: 1pt"> </td> <td
style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensation_d0_c20240401__20240630__us-gaap--
IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_ztL5xh9EgfAh" style="border-bottom: Black 1pt solid; text-align: right" title="Share-
based compensation">45,900</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid;
text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensation_d0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--
GeneralAndAdministrativeExpenseMember_z5PwEFyZm7yg" style="border-bottom: Black 1pt solid; text-align: right" title="Share-based compensation">55,611</td><td
style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td
id="xdx_981_eus-gaap--ShareBasedCompensation_d0_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--
GeneralAndAdministrativeExpenseMember_zyq0uH95QhO9" style="border-bottom: Black 1pt solid; text-align: right" title="Share-based compensation">107,737</td><td
style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td
id="xdx_989_eus-gaap--ShareBasedCompensation_d0_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--
GeneralAndAdministrativeExpenseMember_zSbiz6PeHFsb" style="border-bottom: Black 1pt solid; text-align: right" title="Share-based compensation">110,775</td><td
style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td>
<td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--
ShareBasedCompensation_d0_c20240401__20240630_zuO3CS8mitW3" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based
compensation">42,096</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt
double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_d0_c20230401__20230630_z3FGB9gBh893" style="border-bottom: Black 2.5pt double;
text-align: right" title="Share-based compensation">69,389</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td
style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_d0_c20240101__20240630_zbaeSFmyjecf"
style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based compensation">119,170</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td
style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--
ShareBasedCompensation_d0_c20230101__20230630_zu8GHxMROZoc" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based
compensation">138,241</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt
24.45pt; text-align: justify"><i></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-align: justify"><i> </i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Employee Stock Options and RSU’s</i></p> <p style="font: 10pt Times
New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:
justify">During the three and six months ended June 30, 2024, <span id="xdx_90D_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--
EmployeeStockOptionMember_z1likwMoNefk" title="Options granted"><span id="xdx_908_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--
EmployeeStockOptionMember_zKNzS46JMH0a" title="Options granted">20,000 stock options to purchase shares of common stock were granted by the
Company. <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_do_c20230101__20230630__us-gaap--
AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdrZLwNFrpj9" title="Options granted"><span id="xdx_90E_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_do_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--
EmployeeStockOptionMember_zaBRAXEUiGZ4" title="Options granted">No stock option awards to purchase shares of common stock were granted during
the three and six months ended June 30, 2023. <span id="xdx_90E_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_do_c20240101__20240630__us-gaap--
AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zu225PAXp775" title="Other than options granted, shares"><span id="xdx_906_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_do_c20240401__20240630__us-gaap--
AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyFf8CoUtdWk" title="Other than options granted, shares"><span id="xdx_904_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_do_c20230401__20230630__us-gaap--
AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOwe4ke6vzJc" title="Other than options granted, shares"><span id="xdx_902_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_do_c20230101__20230630__us-gaap--
AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zW5jJbJeFAfa" title="Other than options granted, shares">No RSUs were
granted during each of the three and six months ended June 30, 2024 and 2023. The Company recognized a total of approximately $<span id="xdx_903_eus-gaap--
ShareBasedCompensation_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEGgzD65pxh" title="Share based
compensation">42,000 and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_dm_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--
EmployeeStockOptionMember_z7yesyNU0ka2" title="Share based compensation">0.1 million of share-based expense related to employee stock options during the
three months ended June 30, 2024 and 2023, respectively, and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_dm_c20230101__20230630__us-gaap--
AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zisBW3X2hoL5" title="Share based compensation"><span id="xdx_903_eus-gaap--
ShareBasedCompensation_dm_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zY4rCz89SWo8" title="Share based
compensation">0.1 million during each of the six months ended June 30, 2024 and 2023, respectively. The Company issued <span id="xdx_90D_eus-gaap--
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--
RestrictedStockUnitsRSUMember_zyE4S7yIVhD7" title="Stock issued for RSU's"><span id="xdx_90A_eus-gaap--
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--
RestrictedStockUnitsRSUMember_zV5K6NitEm7l" title="Stock issued for RSU's">417 shares of common stock during the three and six months ended June
30, 2024 related to RSU’s. <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20240401__20240630__us-gaap--AwardTypeAxis__us-
gaap--EmployeeStockOptionMember_zwS8KWiAw2W4" title="Options exercised"><span id="xdx_905_eus-gaap--
StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziQeUGEUw1F5"
title="Options exercised"><span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20230401__20230630__us-gaap--AwardTypeAxis__us-
gaap--EmployeeStockOptionMember_zv4GsjhuuTA2" title="Options exercised"><span id="xdx_90D_eus-gaap--
StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7TpjDpJBeYf"
title="Options exercised">No employee stock options were exercised during the three and six months ended June 30, 2024 and 2023. During
the three and six months ended June 30, 2024 stock options to purchase <span id="xdx_90D_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_do_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--
EmployeeStockOptionMember_zgvJLQqbeadj" title="Options forfeited"><span id="xdx_909_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_do_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--
EmployeeStockOptionMember_zl4ItQCOSys4" title="Options forfeited">11,667 shares of common stock were forfeited. <span id="xdx_90F_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_do_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--
EmployeeStockOptionMember_zn79pMJ1Lj22" title="Options expired"><span id="xdx_903_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_do_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--
EmployeeStockOptionMember_zG0lNsCu2X26" title="Options expired">No employee stock options expired during the three and six months ended June 30,
2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;
text-align: justify"><i>Non-Employee Stock Options</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-align: justify">
<i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were <span id="xdx_906_eus-gaap--
StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20230101__20230630__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_z1rqysyGB3X4"
title="Options exercised"><span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20230401__20230630__us-gaap--AwardTypeAxis__custom-
-NonEmployeeStockOptionsMember_zckdQcysegN8" title="Options exercised"><span id="xdx_903_eus-gaap--
StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20240101__20240630__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zabnN4IZbnn7"
title="Options exercised"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20240401__20240630__us-gaap--AwardTypeAxis__custom-
-NonEmployeeStockOptionsMember_z86RVkBVkkOg" title="Options exercised"><span id="xdx_909_eus-gaap--

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_do_c20240401__20240630__us-gaap--AwardTypeAxis__custom--
NonEmployeeStockOptionsMember_z1ubfSsMKsTj" title="Options granted"><span id="xdx_905_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_do_c20240101__20240630__us-gaap--AwardTypeAxis__custom--
NonEmployeeStockOptionsMember_zdJvG8u3N4sf" title="Options granted"><span id="xdx_90A_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_do_c20230401__20230630__us-gaap--AwardTypeAxis__custom--
NonEmployeeStockOptionsMember_zb3RtMZTm2Kb" title="Options granted"><span id="xdx_909_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_do_c20230101__20230630__us-gaap--AwardTypeAxis__custom--
NonEmployeeStockOptionsMember_zBebxbXjAmw8" title="Options granted">no non-employee stock
options granted or exercised during the three and six months ended June 30, 2024 and 2023, respectively. No non-employee stock option grants expired during the three and
six months ended June 30, 2024. During the six months ended June 30, 2023, non-employee stock option grants to purchase approximately 100 shares of common stock
expired. The Company did not recognize any expense related to non-employee stock options during the three and six months ended June 30, 2024 and 2023, respectively.</p>
<table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--
ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zJwB8T5DFj5k" style="font: 10pt Times
New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share-Based Expense (Details - Share based expense)"> <tr style="vertical-
align: bottom; background-color: White"> <td style="text-align: left; width: 32%"><b style="display: none">Schedule of share-based
compensation expense</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 13%"> </td><td
style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 13%"> </td><td
style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 13%"> </td><td
style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 13%"> </td><td
style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6"
style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td
style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended June
30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom:
1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight:
bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align:
center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-
bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-
bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight:
bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 32%; text-align: left">Research and development expenses</td>
<td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensation_d0_c20240401__20240630__us-gaap--
IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zAkEcRjeXwyj" style="width: 13%; text-align: right" title="Share-based compensation">
(3,804</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--
ShareBasedCompensation_d0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zl4DS2ppNIdi"
style="width: 13%; text-align: right" title="Share-based compensation">13,778</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td
style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensation_d0_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--
ResearchAndDevelopmentExpenseMember_zaAYyVGj4dg3" style="width: 13%; text-align: right" title="Share-based compensation">11,433</td><td style="width: 1%; text-
align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--
ShareBasedCompensation_d0_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zduNM3gZWKr5"
style="width: 13%; text-align: right" title="Share-based compensation">27,466</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom;
background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative expenses</td><td style="padding-bottom: 1pt"> </td> <td
style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensation_d0_c20240401__20240630__us-gaap--
IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_ztL5xh9EgfAh" style="border-bottom: Black 1pt solid; text-align: right" title="Share-
based compensation">45,900</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid;
text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensation_d0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--
GeneralAndAdministrativeExpenseMember_z5PwEFyZm7yg" style="border-bottom: Black 1pt solid; text-align: right" title="Share-based compensation">55,611</td><td
style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td
id="xdx_981_eus-gaap--ShareBasedCompensation_d0_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--
GeneralAndAdministrativeExpenseMember_zyq0uH95QhO9" style="border-bottom: Black 1pt solid; text-align: right" title="Share-based compensation">107,737</td><td
style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td
id="xdx_989_eus-gaap--ShareBasedCompensation_d0_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--
GeneralAndAdministrativeExpenseMember_zSbiz6PeHFsb" style="border-bottom: Black 1pt solid; text-align: right" title="Share-based compensation">110,775</td><td
style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td>
<td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--
ShareBasedCompensation_d0_c20240401__20240630_zuO3CS8mitW3" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based
compensation">42,096</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt
double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_d0_c20230401__20230630_z3FGB9gBh893" style="border-bottom: Black 2.5pt double;
text-align: right" title="Share-based compensation">69,389</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td
style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_d0_c20240101__20240630_zbaeSFmyjecf"
style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based compensation">119,170</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td
style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--
ShareBasedCompensation_d0_c20230101__20230630_zu8GHxMROZoc" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based
compensation">138,241</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>-38041377811433274664590055611107737110775420966938911917013824120000200000000000420001000001000001000004174170000116671166700000000000<p
id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zTBIsqocHfo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0"
cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px">9.</td> <td style="text-align: justify"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt">Income Taxes </td></tr> </table> <p style="font: 10pt Times New Roman,
Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the
three and six months ended June 30, 2024 and 2023, there was <span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_do_c20230101__20230630_zaKbwlqMokSh"
title="Provision for income taxes">
<span id="xdx_909_eus-gaap--
IncomeTaxExpenseBenefit_do_c20240401__20240630_zfovDKMR5YGb" title="Provision for income taxes">no provision for income taxes as
the Company incurred losses during both periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amount of assets
and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company records a valuation allowance against its deferred tax assets as
the Company believes it is more likely than not the deferred tax assets will not be realized. The valuation allowance against deferred tax assets was approximately $40.4 million and
$39.7 million
as of June 30, 2024 and December 31, 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent:
24.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2024 and December 31, 2023, the Company did <span id="xdx_904_eus-gaap--
UnrecognizedTaxBenefits_iI_do_c20240630_zL95EmIwFwU7" title="Unrecognized tax positions">not record any unrecognized tax positions.</p>
0000404000003970000000<p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z4waTzaXBgXj" style="font: 10pt Times New Roman, Times, Serif;
margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-
align: top"> <td style="width: 33px">10.</td> <td style="text-align: justify">
Related Party Transactions</td>
</tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"> </p> <p style="font: 10pt Times New Roman,
Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into various research, development, license and supply agreements with Serum Institute and
Pharmsynthez, each a related party whose relationship has not materially changed from that disclosed in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2023 filed with the SEC on March 21, 2024, as amended on April 26, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:
justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During the fourth quarter of 2019, the
Company entered into a loan agreement with Pharmsynthez (the “Pharmsynthez Loan”), pursuant to which the Company advanced Pharmsynthez an aggregate principal
amount of up to $<span id="xdx_903_eus-gaap--PaymentsToAcquireNotesReceivable_pp0p0_c20191001__20191231__us-gaap--
RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--CoDevelopmentAgreementMember_zFjVOzg0IA93"
title="Payments to Acquire Notes Receivable">500,000 to be used for the development of a specific product under the Company’s Co-Development Agreement with
Pharmsynthez. The Pharmsynthez Loan had an initial term of 15-months and accrued interest at a rate of 10% per annum. The Pharmsynthez Loan was guaranteed by all of
the operating subsidiaries of Pharmsynthez, including SynBio and AS Kevelt, and was secured by all of the common and preferred stock of the Company owned by
Pharmsynthez and SynBio.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt
Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pharmsynthez paid all obligations due under the Pharmsynthez Loan in May
2023, and no further amounts are due under the Pharmsynthez Loan. As a result, <span id="xdx_90C_eus-gaap--AccountsAndNotesReceivableNet_iI_do_c20240630__us-gaap--
RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--
CoDevelopmentAgreementMember_zY4puNB5SYPk">no amounts were outstanding as of June 30, 2024 and December 31, 2023. The Company did not recognize any
interest income related to the Pharmsynthez Loan during the three and six months ended June 30, 2024. The Company recognized approximately $<span id="xdx_90F_eus-
gaap--InterestAndOtherIncome_do_c20230401__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--
TransactionTypeAxis__custom--CoDevelopmentAgreementMember_zz5w49M6eBme">65,000 of income related to interest and fees associated with the Pharmsynthez
Loan including approximately $<span id="xdx_90B_eus-gaap--InterestAndOtherIncome_do_c20230101__20230630__us-gaap--
RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--CoDevelopmentAgreementMember__us-gaap--
IncomeStatementLocationAxis__custom--InterestIncomeOnlyMember_zbhnYnbvnRvf">40,000 related to interest income during the three and six months ended June
30, 2023.</p> 5000006500040000falsefalsefalsefalse